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ABSTRACT 
Osteosarcoma is the most common form of primary bone cancer in humans and well as dogs. The 
treatment options for OS include a multi-agent induction chemotherapy and radical excision of the tumor 
followed by adjuvant chemotherapy. Despite the aggressive treatment course, the survival rates are poor. 
In patients with localized disease, 5-year survival rates are approximately 65%. However, for metastatic 
disease at diagnosis or recurrence, the 5-year survival rates have plateaued to only 20%. Although progress 
has been made towards improving treatment options, the early detection and subsequent control of 
metastasis have been challenging in OS. This work is aimed at discovering the various proteomic and 
lipidomic biomarkers in metastatic and non-metastatic osteosarcoma as well as development of lipid 
mediators as potential therapeutics. 
We take a high-throughput approach towards identifying specific membrane proteins and lipids that are 
differentially expressed in normal osteoblasts, non-metastatic and metastatic osteosarcoma. As described 
in chapter 2, a high throughput peptide fingerprinting enabled us to identify various membrane proteins 
that are differentially expressed in metastatic versus non-metastatic osteosarcoma. Membrane proteins are 
the largest class of drug targets and this study identifies proteins that can targets for drugs without having 
to overcome the delivery of drugs across the plasma membrane. However, the functional study of 
membrane proteins is complicated by the fact that they exist in an amphipathic environment and lose their 
structure in aqueous buffers. Thus we stabilize the membrane proteome of osteosarcoma cells in nanodiscs 
(chapter 3). Nanodiscs are lipid bilayers surrounded by membrane scaffold protein and provide the 
amphipathic environment for membrane proteins. In this study we showed that lipid composition affects 
the protein composition incorporated.  
Since lipid composition affects protein incorporation and lipid-protein interactions are important for cell 
signaling processes, we investigated the global cellular lipidome of osteosarcoma and osteoblast cells 
through a high throughput lipidomics approach (chapter 4). We identified that several lipid classes and 
lipid species are differentially regulated in normal cells versus non-metastatic cells vs metastatic cells. 
These include both structural lipids as well as signaling lipids. Since signaling lipids play an important 
role in various physiological functions, we chose to further explore the role of a specific class of signaling 
lipids, known as endocannabinoid epoxides, in osteosarcoma (chapter 5). Endocannabinoid epoxides are 
metabolites of omega-3 fatty acids that arise from a cross-talk of phospholipase D and cytochrome P450 
epoxygenase enzymes. They have previously been shown to have anti-inflammatory and anti-angiogenic 
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properties. In this study, we show that they also possess anti-tumorigenic activity. Furthermore, we 
synthesize novel analogs of specific endocannabinoid epoxides that show reduced susceptibility to 
biological enzymes, making them better therapeutic candidates. 
Therefore, we have performed a thorough proteomic and lipidomic characterization of osteosarcoma that 
can serve as biomarkers as well as initiate the development of novel therapeutics. The lipid mediators 
synthesized in chapter 5 show promise in cellular studies and can be taken forward into mice models for 
osteosarcoma and bone cancer pain. These will likely show similar effects in other cancers and studies 
can be expanded to carcinomas and other cancers as well. 
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CHAPTER I: OSTEOSARCOMA INTRODUCTION AND DISSERTATION 
OVERVIEW 
1.1 OSTEOSARCOMA OVERVIEW 
Osteosarcoma is the most common form of primary bone cancer in pediatric patients as well as 
dogs (1, 2). Every year there are 3.1 incidences per million or 3-5% of all newly diagnosed 
childhood cancers, making it the most common malignancy in pediatric patients after leukemia 
and lymphoma (1). It occurs in the long bones of the limbs, near the metaphyseal growth plate. 
Common sites include the femur, the tibia and the humerus, and less commonly the skull, the jaw 
or the pelvis. Limb sparing surgeries are the most common treatment for OS. However, the survival 
rate with surgery alone is 15-17% (3, 4). Thus current therapeutic approaches incorporate surgical 
resection and combinational chemotherapy, which cures ~70% patients. In patients with localized 
disease, the response to chemotherapy before surgery is the strongest predictor of survival (5). 
However, in patients with metastatic disease, the 5- year survival rate has stagnated to about 20% 
in the past 30 years (4, 6). Therefore, there is a need for novel biomarkers for early diagnosis of 
metastasis, as well as development of therapeutics for these biomarkers.  
1.2 PROTEIN BIOMARKERS IN OS 
Biomarkers are measurable cellular, metabolic or molecular alterations in a diseased state that can 
be identified in tissues, blood or other biological media. The traditional approach towards 
biomarker discovery relied on discovery of dysregulated genetic factors (7) as well as differential 
transcriptomics (8). These discoveries have led to a deeper understanding of the underlying 
mechanisms of cancer pathways as well as drug discovery (9). Recently, various efforts have 
focused on the discovery of protein biomarkers. While proteins are traditionally more challenging 
to handle than their nucleic acid counterparts (REF), proteins are the final target of drugs, making 
them directly relevant to the process. Additionally, the fact that RNA levels do not always 
correspond to the protein levels, due to processes like post transcriptional degradation of mRNA 
(10), has made proteomic biomarkers very relevant.  
Functional proteomics has provided a rapid route towards discovery of biomarkers associated with 
tumors. Various techniques have been employed in the discovery of proteomic biomarkers 
including 2D-SDS PAGE (11), LC-MS (12, 13), MALDI-TOF (14, 15), antibody arrays (16) and 
tissue microarrays (17, 18). While most of these techniques are rapid and often semi-quantitative, 
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LC-MS or liquid chromatography followed by mass spectrometry, has been shown to be a very 
high throughput technique, allowing analysis of hundreds of proteins in a given sample in a short 
amount of time (19). LC-MS has also been coupled with various other proteomic approaches, like 
SDS-PAGE (20), to identify specific proteins. Two different approaches have been taken towards 
LC-MS analysis of proteins- bottom up approach or peptide fingerprinting and top-down approach 
or intact protein analysis. In the top down approach, single proteins are separated and then intact 
proteins are identified using electrospray ionization (ESI) (21). Although top down proteomics has 
several advantages, including the ability to identify post-translational modifications (PTMs), it is 
a relatively new technique and has been largely restricted to model systems and availability of 
specialized instrumentations. In the bottom up approach, the protein mixture is initially digested 
by trypsin or similar enzymatic agent, and the peptide fragments are then analyzed by liquid 
chromatography (22). The LC-MS procedure generates a list of peptides, which can then be 
matched to existing databases to generate a list of proteins. Bottom up proteomics is well 
developed and is routinely performed in many laboratories. 
As such, majority of the biomarker discovery processes in osteosarcoma and other cancers have 
relied on bottom up proteomics. Bottom up proteomics or simply referred to as proteomics from 
this point, has been utilized for whole cell (23) as well as for identifying the proteome of cellular 
fractions (24). The subcellular fractionation can be facilitated via various biochemical processes 
including sucrose gradients (25) or aqueous two phase extractions (26). Specifically, plasma 
membrane proteomics has been the focus of recent studies since the plasma membrane hosts the 
largest class of druggable targets as it is the first target presented to the drug and drugs do not have 
to cross the plasma membrane to perform their action (27). The plasma membrane hosts a variety 
of proteins including seven transmembrane receptors known as G-protein coupled receptors 
(GPCRs) and other transmembrane receptors. The plasma membrane is also associated with 
peripheral membrane proteins, both on the cytoplasmic side as well as the extracellular side that 
perform important cellular functions like signal transduction processes. Keeping these vast number 
of targetable proteins, several efforts have focused on osteosarcoma proteomics for identification 
of novel targets. 
An LC/MS/MS based differential plasma membrane proteomics of human OS cell line MG63 and 
osteoblast cell line hFOB revealed 342 non-redundant proteins out of which 68 were differentially 
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expressed at a 1.5 fold difference (28). This work further revealed that CD151 was overexpressed 
in osteosarcoma by immunohistochemistry. In a separate work, using a combination of 2D SDS 
PAGE and LC/MS, it was shown that NDRG1 was a biomarker for osteosarcoma (29). Similarly, 
high throughout proteomics was also employed to show that EPHA2, an ephrin type receptor was 
a biomarker for OS (30). Proteomic profiling of OS cell lines MNNG/HOS, MG63, and U2OS and 
osteoblast cells hFOB also showed nine up‐regulated proteins – FAS, CNOT1, ACACA, LRPPRC, 
FAK, ASNS, HMGCS1, PHGDH, and EFHD2 and two down‐regulated proteins – MX1 and 
TAGLN (31). All these studies utilized a high throughput proteomic screening, followed by 
validation of target by biochemical methodologies like flow cytometry, western blotting and 
immunohistochemistry.  
As mentioned above, several biomarkers for osteosarcoma have been identified using proteomics. 
However, a key challenge in OS is the metastasis of the disease. Thus, studies are required that 
focus on the proteomics of metastatic and non- metastatic osteosarcoma to understand the factors 
underlying metastasis as well as find markers specific to metastasis. Currently, only one such study 
exists comparing the proteomics profile of metastatic and non-metastatic canine osteosarcoma. 
This study utilized canine non-metastatic cell line POS, metastatic line HMPOS, and a normal 
canine osteoblast cell line CnOB to identify that thrombospondin-1, CD44, Plexin-B2, Notch-2 
and CYR61 were differentially regulated (32). 
Therefore, a study examining the plasma membrane proteomic profile of human metastatic and 
non-metastatic osteosarcoma is lacking. Additionally, since osteosarcoma affects pet dogs, it 
provides us a wonderful opportunity to extend the proteomic profiling to canine cell lines similar 
to the work by Milovancev and coworkers. It has been shown that human and canine osteosarcoma 
are genetically identical (33). Thus the identification of common proteomic profiles through 
comparative profiling of the human and canine membrane proteome will lead to the simultaneous 
development of therapies for both species and has been described in Chapter 2 of this thesis. 
1.3 NANODISCS FOR STABILIZATION OF MEMBRANE PROTEOME 
The utilization of membrane proteins for the drug development has faced several challenges. 
Membrane proteins are embedded in an amphipathic environment of lipids and proteins. Isolating 
them from their natural environment for biochemical studies, which are typically performed in 
aqueous buffer systems, results in denaturation of the protein. Thus, membrane proteins are 
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typically stabilized in a lipid based system for downstream assays. Detergents, liposomes, micelles 
and vesicles have all been used for incorporating a stabilizing membrane proteins (34). However, 
all these methodologies have major drawbacks. Detergents help solubilize membrane proteins but 
are often charged or zwitterionic and charged interactions are not favorable for many biochemical 
assays. This has been circumvented to an extent by utilizing uncharged detergents like β-maltoside. 
Furthermore, liposomes and micellar systems have to be prepared and used on the same day and 
all these systems do not provide long term stability to the protein.  
In the light of these drawbacks, nanodiscs have emerged as model membrane systems which are 
stable over a longer period of time and can survive several freeze thaw cycles. Nanodiscs are lipid 
bilayers surround by membrane scaffold proteins (MSP), providing an amphipathic environment 
to the embedded protein (35). The assembly of nanodiscs is accomplished by equilibrating the 
desired lipids, MSP and detergent briefly before detergent removal by Bio-beads® or by dialysis 
(36). Typically, the choice of lipids is POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine), 
a neutral lipid containing one unsaturated bond. However, as the technology has progressed, 
various different lipids including POPS (1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine), an 
anionic lipid and even cholesterol have been incorporated (37). A major advantage of the nanodisc 
system is the ability to control the size using a different MSP variant (38). The two most commonly 
used nanodisc variants are MSP1D1 and MSP1E3D1, which generate nanodiscs of sizes 10nm and 
13 nm respectively. However, MSP variants have been generated for nanodiscs as large as 50 nm 
(39) and as small as 7 nm (40). Additionally, nanodisc systems have been optimized to be 
compatible with many biochemical and biophysical assays including NMR, surface plasmon 
resonance, and others (41).  
Typically, membrane proteins are overexpressed in simplified systems like bacteria or yeast, 
purified and then incorporated into nanodiscs (36). This is very useful for studying specific 
proteins for deducing their structure, specific known interactions as well as calculating binding to 
ligands. However, not all proteins are amenable to overexpression and purification. Additionally, 
this approach is not suitable for detecting novel protein-protein or protein-small molecule 
interactions. Therefore, a library approach to membrane protein stabilization is required for 
stabilizing and studying membrane proteins that have low expression.  
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The first effort towards the formation of a nanodisc library utilized bacterial protein in POPC based 
nanodiscs (42). The authors verified the incorporation by SDS PAGE analysis and specific proteins 
from the inner and outer membrane were identified by excising specific bands from the gel 
followed by peptide fingerprinting. In a separate work, the membrane proteome of synapses was 
incorporated into a nanodisc library (43). The incorporation was verified by SDS PAGE followed 
by western blotting of several specific proteins associated with the synaptic membrane. The 
incorporated proteins were then utilized for functional assays to identify binding sites for 
alzheimer’s associated Aβ oligomers. The first fully characterized mammalian protein nanodisc 
library was established from osteosarcoma cells as described in chapter 3 of this dissertation (37). 
This work expanded the nanodisc library to incorporating various different lipids, which affected 
the population of incorporated nanodiscs as evidenced by peptide fingerprinting. Finally, the 
membrane proteome of HEK239 cells, erythrocytes and platelets was incorporated into PEG-PE 
discs (44).  
1.4 LIPID BIOMARKERS IN OS 
The other important component of the plasma membrane are the lipids. The plasma membrane 
consists 50% of lipids (45). Lipids also form a significant component of organellar membranes as 
well as vesicles trafficking pathways.  Lipids serve various important functions in living systems. 
First, they are used for energy storage. Second, as they comprise of a hydrophobic and hydrophilic 
portion, they tend to self-assemble into amphipathic structures like the plasma membrane and form 
a barrier for the cell. Finally, they compartmentalize the various organelles to allow for discrete 
functional units in the cell (46). 
Lipids show a large diversity in structure including their backbone, chain length, and number and 
position of unsaturated bonds. Based on their backbone, lipids are classified into phospholipids, 
glycolipids, sphingolipids and steroids.  Phospholipids constitute of the largest class including 
neutral lipids like phosphatidylcholine, negatively charged phosphatidylserine and positively 
charged phosphatidylethanolamine among others. Sphingolipids comprise of sphingomyelins and 
ceramides. Steroids comprise of molecules like cholesterol with a steroid core. These molecules 
are differentially distributed in the various membranes and contribute to specific functions. Lipid 
rafts are a popular example of how lipids segregate into various functional domains (47). 
Specifically, lipid rafts are rich in cholesterol and sphingolipids and various receptors are known 
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to partition into lipid rafts for signaling activities. Thus, lipids and their synthesis and metabolism 
has emerged as a ripe area of exploration to be able to gain an integrated picture of the cellular 
physiology. 
Historically, cellular lipids have been extracted using an organic extraction method. Bligh and 
Dyer devised a two-step organic extraction that is still in use today (48). However the separation 
and identification of lipids is a complicated process due to their structural diversity. Thin layer 
chromatography was initially used to separate out lipid classes and further analysis (49). This 
allows for separation of the various classes and analysis, but finer details like chain lengths and 
location of unsaturations, etc. are still not detectable by this method. With the development of mass 
spectrometry (MS), the separation and analysis of lipids has become more convenient and high-
throughput (50). MS based lipidomics can be targeted, focusing on a single class of molecules or 
global where the aim is to quantify all lipids in the system. The application of liquid 
chromatography (LC) in combination with MS/MS has been a popular approach for high 
throughput untargeted lipidomics. Also known as shotgun lipidomics, the various lipid classes are 
first separated by their polarity, followed by ESI (electrospray ionization) of the individual 
components of the classes. A normal phase column is used to separate the various classes. However 
this is often coupled with a reverse phase column to separate minor molecular species. The spectral 
data obtain post ESI analysis is then processed by specific softwares to generate a list of lipids in 
the sample (51, 52). 
This high-throughput shotgun lipidomics has been utilized to identify differentially regulated lipids 
as biomarkers in various diseases including cancer (53), cardiovascular health (54), 
neurodegenerative disease (55) and others. Specifically in cancer, recent work has focused on the 
differences in normal cells versus tumorigenic cells. Cancer cells are known to reprogram their 
lipid machinery to sustain their uncontrolled growth and proliferation (56). Early literature 
demonstrated that cancer cells increase their production of lipids significantly (57). This was 
further supported by studies that showed that fatty acid synthase is upregulated and is a biomarker 
in various cancers (58) and that increased fatty acid synthesis is an initial step in tumor 
development (59). Increased cholesterol biosynthesis has also been shown to be a biomarker for 
prostate cancer (60). While the role of increased lipid production in cancer is not fully understood, 
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there are various studies that provide interesting insight into their role beyond providing more 
lipids for the rapidly proliferating cells. 
An increase in specific lipids can could result in increased formation of lipid rafts that result in 
higher signaling activity from cancer cells (61).  Lipids are also involved in autophagy (62) and 
the mobilization of lipids from intracellular stores has consequently been termed macrolipophagy 
(63). This is interesting in light of the fact that autophagy is thought to be a pro-survival pathway 
in cancer (64). Lipid biosynthesis has also been linked to disruption of normal cellular architecture 
(65) as well as tumor cell dissemination (66). A difference in the pattern of lipid synthesis is also 
observed.  The shift from lipid uptake in normal cells to de novo lipogenesis in cancer cells leads 
to increased lipid saturation, resulting in higher levels of saturated and monounsaturated 
phospholipids, potentially protecting cancer cells from oxidative damage by reducing lipid 
peroxidation (67). Increase lipid saturation has also been associated with increased membrane 
fluidity and has been associated with breast cancer cells (68). Therefore, a high throughput 
profiling of cancer cells and their comparison to non-tumorigenic cells has been pursued to identify 
lipid biomarkers as well as to identify specific lipid synthesis or metabolism pathways that are 
dysregulated in cancer cells.  
A phospholipid analysis of breast cancer cell lines revealed that phosphatidylethanolamines (PE) 
was highest in non-malignant cells while phosphatidic acid was present with highest relative 
abundance in metastatic cells (69). A similar profiling of isogenic metastatic and non-metastatic 
adenocarcinoma cells showed increased PC and triglyceride lipid levels, decreased PE lipids, 
decreased C-16 containing sphingomyelin and ceramide lipid levels, and a dramatic increase in 
the abundances of total cholesterol ester and triglyceride lipids in the primary cells compared to 
their metastatic counterparts (70). In leukemia cell lines 14 classes of lipids- TG, DG, PS, PG, PI, 
PA, LPC, LPE, LPS, LPG, LPI, Cer, Sa, and Cer1P were upregulated and 3 classes- ChE, PC, and 
LPA were downregulated (71). 
To gain a more holistic view of the tumorigenesis process, lipidomics has been correlated with 
transcriptomic data from the same cells or tissues. In renal cell carcinoma, lipidomic analysis of 
affected tissue versus normal surrounding tissue revealed that the cancerous tissue was 
distinguished by higher levels of ether-type phospholipids, cholesterol esters, and triacylglycerols, 
as well as by lower levels of phospholipids (except for phosphatidylcholines) and polyunsaturated 
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fatty acids (72). Furthermore, an mRNA analysis indicated that changes in the levels of mRNAs 
and metabolites suggested that the phosphatidylethanolamine (PE) synthesis pathway is 
suppressed in renal cell carcinoma and is therefore associated with cell proliferation. Analysis of 
prostate cancer tumor and non-tumor tissue showed that cholesteryl esters are most accumulated 
in the tumor samples and cholesteryl oleate as a biomarker for prostate cancer (73). Furthermore, 
it was shown that overexpressed scavenger receptor class B type I (SR-BI) may contribute to CEs 
accumulation. As evidenced by these examples, high throughput lipidomics has enabled the 
identification of various differentially regulated cancers including breast cancer, prostate cancer 
and adenocarcinoma. However, a similar study is lacking for cancers of mesenchymal origin like 
osteosarcoma. In light of the fact that the lipidome of the cell greatly affects the cellular 
polarization and the lipid composition (74), the lipidomics of osteosarcoma is an important area of 
research and is described in Chapter 4 of this dissertation.  
1.5 LIPID MEDIATORS AS THERAPEUTICS IN OS 
 Beyond serving as structural components of cellular membranes, lipids also act as primary and 
secondary messengers in various signaling pathways. The omega-6 membrane lipid arachidonic 
acid (AA) gets metabolized to form various signaling molecules (75). The main pathways of AA 
metabolism are the cyclooxygenase (COX) pathway, the lipoxygenase (LOX) pathway and the 
epoxygenase (EPOX) pathway, collectively giving rise to eicosanoids.  The COX pathway 
metabolizes AA into prostaglandins, which interact through prostaglandin receptors and affect 
various factors like cell growth, constriction of vasculature, platelet aggregation and others (76). 
The LOX pathway metabolizes AA into leukotrienes, which act through GPCRs and are 
responsible for inflammation and smooth muscle constriction (77). The EPOX pathway 
metabolizes AA into EETs or epoxyeicosatrienoic acids, which act through an unknown receptor, 
but also have roles in inflammation and other physiological effects (78). A fourth metabolite of 
AA is anandamide (AEA), which arises in a two-step synthesis (79). First AA converts to N-
arachidonoyl phosphatidylethanolamine (NAPE). Furthermore, NAPE converts to AEA through 
cleavage by phospholipase D. Anandamide is an endocannabinoid, which acts through the 
cannabinoid receptors found throughout the human body. It has anti-cancer (80), anti-pain (81) 
and anti-inflammatory effects (82).  
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Similar to derivatives of omega-6 fatty acids, the body also metabolizes omega-3 fatty acids that 
are obtained through diet. Omega-3 fatty acid EPA (eicosapentaenoic acid) and DHA 
(docosahexaenoic acid) are found in fish, chicken eggs and various nuts and have been shown to 
have various beneficial (83). These molecules are similar to structure to arachidonic acid and are 
metabolized by similar classes of enzymes. The EPOX pathway enzymes, cytochrome P450s 
(CYPs) metabolize EPA and DHA into their corresponding epoxides (84). Additionally, both EPA 
and DHA are converted into the ethanolamide derivative DHEA and EPEA, which have been 
shown to be endocannabinoids. Both these metabolites have shown to have physiological activities 
including anti-cancer properties. 
The epoxide derivatives of EPA and DHA will be referred to as EEQs and EDPs respectively. 
EEQs have shown to inhibit proliferation in endothelial cells by p28 MAP kinase activation and 
cyclin D1 downregulation (85). Furthermore, EDPs have also been shown to be anti-angiogenic, 
and restrict tumor growth and metastasis in mice (86). The ethanolamide derivatives also have 
anti-tumorigenic activity. It has been shown in prostate cancer cells that both EPEA and DHEA 
have anti-proliferative activity (87). It is hypothesized that the beneficial effects of DHA and EPA 
are due to their downstream metabolites including their epoxides and amide derivatives. 
While the exact mechanism of action of these molecules I unknown, there are several hypotheses. 
The epoxide derivatives are thought to mediate their effects through a variety of receptor-mediated 
signaling pathways and ion channels including a putative GPCR (g-protein coupled protein 
receptor), whose identity remains unclear in the CYP450 epoxygenase literature (88). 
Additionally, their action maybe mediated through peroxisome proliferator-activated receptor 
gamma (PPARγ) (89) as well as transient vanilloid receptor 4 (TRPV4) (90). The receptor binding 
of endocannabinoids is better understood. Endocannabinoids like anandamide traditionally are 
thought to bind to the cannabinoid receptors 1 and 2 (CB1 and CB2) (91). CB1 and CB2 are also 
GPCRs which have relatively distinct distributions in the body. CB1 is mainly expressed in the 
central nervous system and CB2 is expressed on immune cells. However, the role of CB1 and CB2 
in the anti-proliferative activity of DHEA and EPEA is not clear (87). 
A new class of molecules known as endocannabinoid epoxides have recently been discovered (92). 
These molecules have both the ethanolamine conjugation as well as the epoxide moiety. 
Endocannabinoid epoxides of both EPA and DHA known as EEQ-EA and EDP-EA were found 
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to be endogenously expressed in rat organs. They were further shown to be anti-inflammatory, 
anti-angiogenic as well as anti-aggregatory in platelets. Finally, these molecules were shown to 
bind to both cannabinoid receptors. The literature precedence of epoxides and endocannabinoid 
derivatives of DHA being anti-tumorigenic, and the anti-inflammatory and anti-angiogenic 
activity of endocannabinoid epoxides (eCBs), taken together, indicate that eCBs could possess 
anti-tumorigenic activity against various cancers including osteosarcoma. 
Furthermore, endocannabinoids also possess anti-nociceptive activity (93). Since bone cancer pain 
is one of the most debilitating side effects of OS as well as metastasis of other cancers to the bone, 
various pain management therapies have been employed to combat this. Cannabinoid receptor 
agonists, like the endocannabinoid anandamide and other synthetic agonists, have also been used 
for the attenuation of such pain (81). Therefore, the endocannabinoid epoxides provide promise 
that in addition to their anti-inflammatory effects, they could possess anti-tumorigenic and anti-
nociceptive activity against OS. 
However, these molecules contain two hydrolytically susceptible groups which reduce their 
endogenous effects. First, the epoxide group is susceptible to hydrolysis by soluble epoxide 
hydrolases (sEH). Additionally, the amide group is labile to fatty acid amide hydrolase (FAAH). 
Efforts to increase their biological activity has been made by employing inhibitors of sEH and 
FAAH (81, 86) in addition to the bioactive molecule. A second approach to increasing their 
biological lifetime has been to synthesize derivatives that retain biological function but due to 
steric and electronic factors have reduced hydrolytic susceptibility. Towards the epoxide 
functional group, substitution by heteroatoms like nitrogen and sulfur (94) as well as replacing it 
with bioisosteric groups has been employed (95). Towards attenuating the hydrolysis of the amide 
group, the 1’ position of the amide results in increased metabolic stability of AEA due to the steric 
bulk reducing hydrolysis, while affecting the CB1 binding ability (96). A variety of other 
functional groups have been conjugated to the nitrogen of the amide group including straight 
chains, saturated and unsaturated cyclic structures, heterocyclic groups and even bulky groups like 
adamantane (97). These groups affect hydrolysis by FAAH to varying degrees as well as receptor 
binding. Modest increase in steric bulk assists in FAAH inhibition and increasing CB1 binding. 
However, very large groups reduce both. Majority of the literature has focused on derivatives of 
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anandamide. It can be postulated that similar modifications can be employed for EPA and DHA 
metabolites to reduce their hydrolytic susceptibility. 
Thus the anti-tumorigenic activity of these eCBs has been explored in Chapter 5 of this dissertation 
in cell models for OS. Additionally, since these molecules are labile to enzymatic hydrolysis, 
derivatives have been synthesized to reduce their hydrolytic susceptibility and also tested for their 
pro-apoptotic and anti-migratory activity. 
1.6 SUMMARY 
Osteosarcoma is the most common form of primary bone cancer in humans and dogs. Despite 
progress in biomarker discovery and personalized therapeutics in various other cancers like breast 
cancer and leukemia, including drugs like Herceptin and Imatinib, the approach for OS treatment 
remains traditional surgery including amputation. Therefore, there is a necessity for biomarker 
discovery in OS for the early discovery and development of therapeutics of OS. In this chapter are 
summarized the various efforts that have been directed towards proteomic and lipidomic 
investigations in biomarker discovery in OS and other cancers exhibiting the deficiency of 
preliminary work on OS biomarker discovery. Therefore the second and fourth chapters of this 
thesis focus on preliminary biomarker discovery in OS. 
Furthermore, since this work focuses on the membrane proteome for biomarker discovery, we 
further attempt to stabilize the membrane proteome in nanodisc libraries in chapter three to avoid 
complications of unfolding and denaturation that is faced by membrane proteins in aqueous 
buffers. Finally, we explore the anti-tumorigenic activity of a novel class of bioactive lipids known 
as endocannabinoid epoxides towards therapeutics for OS. 
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1.7 FIGURES, TABLES AND LEGENDS 
 
Figure 1.1: A representation of bottom up proteomics approach. Proteins extracted from cells or 
tissue are enzymatically digested and then subject to LC-MS/MS separation. The peptide spectra 















                                                 
1 Figure has been reproduced and modified from “Large-scale production and protein engineering of G protein-coupled 
receptors for structural studies” Dalibor Milic and Dmitry Veprintsev. Front. Pharmacol. 2015, 6, 66. The work is 





Figure 1.31F2: Figure represents synthesis of a nanodisc library. Membrane proteins are equilibrated 









                                                 
2 Figure has been reprinted with permission from John Wiley and Sons License. “Recent Advances in Nanodisc 
Technology for Membrane Protein Studies (2012‐2017)” John Rouck, John Krapf, Jahnabi Roy, Hannah Huff, Aditi 



















Figure 1.52F3: Figure shows the various endocannabinoid epoxides originating from omega 6 
membrane lipid arachidonic acid and the dietary omega 3 lipids EPA and DHA. The metabolites 
AEA, EPEA and DHEA, respectively get metabolized by cytochrome P450 epoxygenase enzymes 





                                                 
3 Figure has been reprinted from “Anti-inflammatory ω-3 endocannabinoid epoxides” Daniel R. McDougle, Josephine 
E. Watson, Amr A. Abdeen, Reheman Adili, Megan P. Caputo, John E. Krapf, Rodney W. Johnson, Kristopher A. 
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CHAPTER II: HIGH-THROUGHPUT PROTEOMICS TO IDENTIFY 
MEMBRANE PROTEIN BIOMARKERS IN OSTEOSARCOMA3F4 
 
2.1 ABSTRACT 
Osteosarcoma is the most common bone cancer in dogs and people. In order to improve clinical 
outcomes, it is necessary to identify proteins that are differentially expressed by metastatic cells. 
Membrane bound proteins are responsible for multiple pro-metastatic functions. Therefore 
characterizing the differential expression of membranous proteins between metastatic and non-
metastatic clonal variants will allow the discovery of druggable targets and consequently improve 
treatment methodology. The objective of this investigation was to systemically identify the 
membrane-associated proteomics of metastatic and non-metastatic variants of human and canine 
origin. Two clonal variants of divergent in vivo metastatic potential from human and canine origins 
were used. The plasma membranes were isolated and peptide fingerprinting was used to identify 
differentially expressed proteins. Selected proteins were further validated using western blotting, 
flow cytometry, confocal microscopy and immunohistochemistry. Over 500 proteins were 
identified for each cell line with nearly 40% of the proteins differentially regulated. Conserved 
between both species, metastatic variants demonstrated significant differences in expression of 
membrane proteins that are responsible for pro-metastatic functions. Additionally, CD147, CD44 
and vimentin were validated using various biochemical techniques. Taken together, through a 
comparative proteomic approach we have identified several differentially expressed cell 
membrane proteins that will help in the development of future therapeutics.   
2.2 INTRODUCTION 
Osteosarcoma (OS) is the most common form of primary bone cancer among children and young 
adults. The treatment options for OS include a combination of multi-agent induction 
chemotherapy, and radical excision of the tumor followed by adjuvant chemotherapy. Despite the 
aggressive treatment course, the survival rates are poor. For instance, in patients with localized 
disease, 5-year survival rates are approximately 65%; however, in the case of metastatic disease at 
                                                 
4 This work has been previously published as “Comparative proteomic investigation of metastatic and non-metastatic 
osteosarcoma cells of human and canine origin.” Jahnabi Roy, Kathryn L. Wycislo, Holly Pondenis, Timothy M. Fan 
and Aditi Das. PlosOne, 2017, 12(9), e0183930. The work is allowed to be republished under the Creative Commons 
Attribution license (https://creativecommons.org/licenses/by/4.0/) 
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diagnosis or recurrence, the 5-year survival rates are only 20% [1,2]. Although progress has been 
made towards improving treatment options, the early detection and subsequent control of 
metastasis have been challenging in OS.  
The current approach towards the discovery of drug targets has focused on using high throughput 
peptide fingerprinting techniques to identify plasma membrane (PM) biomarkers in various 
cancers. Cell membranes are a dynamic and selective gatekeeper that controls the influx and efflux 
of multiple signaling molecules, and is responsible for multiple functions including adhesion, 
proliferation, migration and intercellular communication. Given their key roles in diverse, yet 
critical cellular functions, perturbations in plasma membrane proteins are associated with 
pathological states including cancer. Hence, the characterization of the membrane proteins in the 
cell surface of tumor cells can aid not only in early diagnosis, but also lead to the development of 
novel therapeutics. Recent evidence demonstrates the fluidity of cancer cell proteomic profiles 
with distinct classes of proteins being differentially expressed by tumor cells during metastatic 
progression [3]. Therefore, the current approach in this work is to identify and characterize the 
differential PM biomarkers of metastatic OS. This will be facilitated through the use of high 
throughput peptide fingerprinting that has been employed to identify targetable receptors in 
various cancers [4,5] as well as to identify differentially regulated markers in OS [6,7]. The 
thorough annotation of PM proteins differentially expressed by metastatic and non-metastatic OS 
cells holds promise to identify surrogate biomarkers of aggressive OS leading to earlier disease 
detection, as well as illuminate the biochemistry of metastasis. 
A major limiting factor in the development of novel therapeutics in OS is the lack of suitable 
comparative animal models. While mouse models are commonly used for studying OS, they lack 
the degree of genetic heterogeneity as humans, making the study of OS oversimplified. Dogs are 
companion animals, which share the same environment with their human counterparts and have a 
greater genetic diversity than mice bred for research. Importantly, pet dogs also spontaneously 
develop OS that is genetically indistinguishable from human OS [8]. Hence dogs are more reliable 
comparative animal models that can aid in the discovery of novel OS therapeutics that can benefit 
both human and dogs. Currently there are no studies that show the correlation in cell surface 
receptors between human and canine OS. The identification of receptors that are upregulated in 
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both humans as well as dogs, will allow for the development of novel therapeutics for both species 
in a parallel manner.  
This will provide an opportunity to employ high throughput peptide fingerprinting to profile the 
global membrane proteome of human and canine OS and perform a cross-species analysis. For our 
study, we chose isogenic human and canine metastatic and non-metastatic cells. The availability 
of these cell lines allowed us to examine the differences in proteomic profiles that affect a 
metastatic phenotype without a significant genetic difference. Additionally, the comparison of 
metastatic versus non-metastatic cells, as opposed to tumorigenic and non-tumorigenic species, 
provides additional insight into factors that not only promote initial tumor formation but also those 
that promote metastasis.  
Herein, we isolated the plasma membrane proteins and characterized the proteins by high-
throughput peptide fingerprinting. We identified membrane proteins that were differentially 
regulated in both canine and human OS cell lines. We validated several targetable receptors using 
biochemical methodologies and immunohistochemistry studies in paired canine primary and 
metastatic tissues. Finally, overall changes in GPCR activity were measured that corroborated with 
the changes in the GPCR distribution in metastatic and non-metastatic samples as identified from 
the peptide fingerprinting data. Taken together, in this work we identify cross-species trends in 
expression of cell surface receptors between metastatic and non-metastatic OS that were consistent 
between both human and canine species. Several of these receptors are known targets in various 
cancer types and therefore drugs targeting of these receptors can be repurposed to develop OS 
therapeutics. 
2.3 MATERIALS AND METHODS 
Materials: Antibodies- CD44 (Santa Cruz Biotechnology sc-18849), Vimentin (Abcam ab16700) 
and CD147 (Abcam ab108317). Secondary antibodies for confocal microscopy and flow 
cytometry- Goat anti-Rabbit IgG (H+L) Secondary Antibody, Alexa Fluor® 488 conjugate 
(ThermoFischer Scientific  A-11034) and    Goat anti rat (Santa Cruz Biotechnology sc-2011). 
Image IT Fx Signal Enhancer (R37107), ProLong Gold Antifade Mount (P10144), 4’, 6-
diamidino-2-phenylindoleg (DAPI) were obtained from Thermo Fischer Scientific. IHC- all IHC 
reagents, except primary antibodies and 61-9520 are from Biocare Medical (biocare.net). 61-9520 
is from Fisher Scientific (thermofisher.com) 
27 
 
Cell culture: Human cell lines HOS and 143B and canine cells POS and HMPOS were cultured in 
DMEM (Gibco, Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum 
(FBS) and 1mgml–1 penicillin–streptomycin (Gibco, Invitrogen) at 37 °C and 5% CO2 in a 
humidified incubator. All cell lines were verified via STR analysis. The human cell lines HOS and 
143B were verified at The University of Arizona Genetics Core and the canine cell lines POS and 
HMPOS were verified at Colorado State University Flint Animal Cancer Center. 
Extraction of plasma membranes: Membrane extraction was done as previously published (7, 58). 
All steps were carried out at 4°C. Briefly, about 60 million adherent cells were washed with 
phosphate-buffered saline (PBS), scraped using a plastic cell lifter, and lysed in 1 mL solution 
containing 0.2 mM EDTA and 1 mM NaHCO3 and 20 µL protease inhibitor (Nacalai USA, Inc.), 
using a glass homogenizer. The nuclear and unbroken cells were removed through centrifugation 
a 200×g, and the supernatant was collected and centrifuged for 30 min at 25,000 rpm. The cell 
pellets were resuspended in 1 mM NaHCO3 in an approximate ratio of 1 mL per 5×108 cells and 
used for PM separation by two-phase systems. Suspended cell pellets were added to the top of 14 
g of the dextran–poly (ethylene glycol) mixture (6.6% Dextran T500, 6.6% PEG 3350, 0.1 M 
sucrose, 5 mM K3PO4, pH= 7.2). After mixing up and down for 40 times, the tube was centrifuged 
for 5 min at 750×g. The PM-enriched up phase was collected and purified again as described 
above. The up phase was diluted with 1 mM sodium bicarbonate and centrifuged at 100,000×g for 
2 h in a SW32 rotor. 
Peptide fingerprinting:  
Protein Identifications using CID mass spectrometry:  
Sample preparation: Sample cleanup was done using G-Biosciences (St. Louis, MO) Perfect Focus 
according to manufacturer’s instruction. 1-100μl of protein solution (containing 10μg protein per 
sample) was transferred into a 1.5ml microfuge tube. 300μl of reagent UPPA-I was added and 
mixed well. This was incubated at 4°C for 15 minutes. 300μl of reagent UPPA-II was added to the 
protein mixture and the tube was vortexed. The tube was then centrifuged at 15,000x g for 5 
minutes to form a protein pellet. Carefully, without disturbing the pellet, a pipette tip was used to 
remove & discard the entire supernatant. The tube was centrifuged again for 30 seconds. A pipette 
tip was used to remove the remaining supernatant. 40μl of FOCUS-Wash was added on top of the 
pellet. The tube was centrifuged again for 5 minutes and the wash was discarded. 25μl of milliQ 
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water was added on top of the pellet and the tube was vortexed. 1ml OrgoSol Buffer, pre-chilled 
at –20°C, was added to the tube containing protein suspension. The tube was vortexed to suspend 
the pellet. The tube was incubated at –20°C for 30 minutes. Periodically the tube was vortexed for 
20-30 seconds. The tube was centrifuged at 15,000xg for 5 minutes to form a pellet and the 
supernatant was removed and discarded. The pellet was air dried and the white pellet turned 
translucent on air drying.  
Digestion with trypsin: Sample was digested with MSG-Trypsin (G-Biosciences, St. Louis, MO) 
at a w/w ratio of 1:10 using a CEM Discover Microwave Digestor (Mathews, SC) at 55 ˚C and 
maximum power of 60 watts for 30 minutes. Digested peptides were lyophilized in a Virtis -55 
lyophilizer to dryness.  The digested peptides were dissolved in 5% acetonitrile + 0.1% formic 
acid for LC/MS. 
LC/MS: LC/MS was performed using a Thermo Dionex Ultimate RSLC3000 operating in nano 
mode at 300 microliters/min with a gradient from 0.1% formic acid to 100% acetonitrile + 0.1% 
formic acid in 120 minutes. The trap column used was a Thermo Acclaim PepMap 100 (100 µm 
x 2 cm) and the analytical column was a Thermo Acclaim PepMap RSLC (75 µm x 15 cm). 2 
micrograms of the digested peptides were loaded per injection. 
Mass spectrometry was performed on a Thermo LTQ Velos ETD Pro Mass spectrometer using 
data dependent MS/MS analysis on the top five most intense ions detected in the precursor scan 
mode.  Previously detected ions were automatically excluded for 60 seconds to allow deeper 
coverage of the less abundant ions.  
Data Analysis: The Xcalibur raw file was converted by Mascot Distiller into peaklists that were 
submitted to an in-house Mascot Server and searched against specific NCBI-NR protein databases. 
The list of proteins obtained was filtered by a p < 0.05 for a 95% confidence value. Additional data 
about peptide fingerprinting parameters can be found in SI. The peak lists have been uploaded into 
external repository as indicated at the end of this section. This list of proteins was then classified 
by their subcellular location (to filter out non- membrane contaminants) and plasma membrane 
candidates were classified into various functional classes. The emPAI values were normalized to 
the total emPAI value and compared as a percentage to the overall composition. 
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Quantitation: emPAI protocol: The Exponentially Modified Protein Abundance Index (emPAI) 
offers approximate, label-free, relative quantitation of the proteins in a mixture based on protein 
coverage by the peptide matches in a database search result. Developed by Ishihama and 
colleagues, Exponentially modified protein abundance index (emPAI) is a quantification unit for 
estimation of absolute protein amount in proteomics as calculated from the number of sequenced 
peptides per protein [9].  
Unlike the other quantitation protocols, the information required for emPAI is always present in a 
search result, and there are no parameter settings, as long as the MS/MS search contains at least 
100 spectra.  
emPAI=〖10〗^(Nobserved/Nobservable)-1 
Where Nobserved is the number of experimentally observed peptides and Nobservable is the 
calculated number of observable peptides for each protein. The tricky bit is deciding what to 
include and what to exclude in these two counts. 
Western Blot: Based on protein concentration measurements, equal amounts of plasma membrane 
preparations generated from all cells were resolved by 4–20% SDS-PAGE (Pierce) and transferred 
onto a PVDF membrane. The membranes were blocked in PBS, 0.1% Tween 20, 5% nonfat dry 
milk powder for 1 h at room temperature and incubated with primary antibody for 16 h at 4 °C 
followed by washing and incubation with HRP-conjugated secondary antibody for 1 h at room 
temperature. All antibody incubations and washing steps were carried out in PBS, 0.1% Tween 
20. The immunoreactive bands were visualized using an ECL Western blot kit (Amersham 
Biosciences). The western blots were normalized by Ponceau staining [10]. 
Confocal Microscopy: Cells were grown in 8 well chamber slides (Ibidi, Verona, WI), overnight. 
The cells were washed with warm phenol red free DMEM free of FBS. The cells were fixed with 
warm phenol red free DMEM free of FBS containing 4% methanol free paraformaldehyde at room 
temperature for 10 minutes. The wells were washed 3X with PBS, and permeabilized with 0.1% 
Triton-X 100 in PBS for 5 minutes. The cells were then blocked with 5- drops of IT signal FX 
solution (SFX kit, Invitrogen) for 30 min. at room temperature. After 3 washes with PBS, the slides 
were blocked with 3% BSA in PBS for 30 min at room temperature. The primary antibody, which 
was diluted in PBS containing 3% BSA (1:100), was added to the cells, and samples were 
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incubated overnight at 4 °C. Cells were rinsed 3X with PBS, secondary antibody was added in 
PBS containing 3% BSA (1:200), and cultures were incubated for 1 hour at room temperature. 
After 3 washes with PBS, nuclei were counterstained with DAPI for 15 minutes at room 
temperature, samples were washed 3X with PBS, and cells were mounted with 5 drops of ProLong 
Gold solution and allowed to dry in a chemical fume hood for 24 hours before imaging. Imaging 
was performed through the bottom of the chamber slides in a Nikon A1R confocal laser 
microscope system. The data was analyzed using ImageJ and NIS Elements Confocal Microscope 
Imaging Software. Laser power and other parameters indicated in Supporting Information. 
GPCR activity assay: Intracellular cAMP levels were measured as an indicator of GPCR activity 
by a competitive immunoassay based on time-resolved fluorescence resonance energy transfer 
(TR-FRET) between the fluorescent reporter cAMP-d2 and anti-cAMP-cryptate using a cAMP 
dynamic 2 kit (Cisbio Bioassays). Cells were cultured in 96-well cell culture plates with a 
concentration at 26000 cells/well overnight at 37 °C with forskolin or with DMSO control. The 
medium was removed and lysis buffer (50 μl/well) supplied in the kit was added to lyse cells in 
the presence of 3-isobutyl-1-methylxanthine (IBMX- phosphodiesterase inhibitor). Then, 10 μl 
cell lysate/well was transferred to 384-well microplates followed by the addition of cAMP-d2 and 
anti cAMP- cryptate (5 μl each). Each cell line was measured in triplicate to account for variability 
as well as two separate experiments weeks apart to ensure no batch-to-batch variability. Incubation 
for 1 h at room temperature was followed by a read out with Analyst HT (Molecular Devices, 
LLC). Data processing and quantification of cAMP were performed according to the 
manufacturer’s instructions. 
Flow cytometry: Cells were washed with PBS, scraped and pelleted at 2000 RPM for 5 min and 
divided into flow cytometry tubes. 0.1 mL of Fixation/ Permeabilization solution was added to the 
cells (BD Bioscience Fixation/Permeabilization Solution Kit catalog no. 554714) and pulse 
vortexed. The cells were incubated for 1h at room temperature. Cells were washed with 0.1 mL of 
Permeabilization/Wash Buffer followed by centrifugation and decanting of supernatant. Cells 
were suspended in 0.2 mL of Permeabilization/Wash Buffer and the primary antibody was 
incubated (1:100) overnight at 4 °C. The cells were pelleted and washed 3X with 0.2 mL of 
Permeabilization/Wash Buffer and secondary antibody was incubated (1:200) at room temperature 
in the dark for 1h. The cells were pelleted and washed 3X with 0.2 mL of Permeabilization/Wash 
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Buffer and resuspended in Permeabilization/Wash Buffer for flow cytometry in Accuri C6 
instrument. 
Immunohistochemistry in cell pellets: Confluent cell cultures were collected, washed in PBS, and 
pelleted by centrifugation.  Supernatant PBS was discarded and the washed cells were suspended 
in 1 mL of 10% formalin for 1 hour, followed by centrifugation and formalin removal.  1 mL 4% 
melted agarose gel was then added to the fixed, pelleted cells, which were immediately vortexed 
to create a uniform cell suspension and then briefly centrifuged to create an agarose-embedded 
cell pellet.  
Canine tumor samples: Immunohistochemistry in paired metastatic and primary canine tumor 
samples: All tissue controls for antibody optimization and specificity of staining were obtained 
from canine necropsy specimens at the Veterinary Diagnostic Lab at the College of Veterinary 
Medicine, University of Illinois, Urbana-Champaign. The skin samples (negative control) were 
taken from a necropsy specimen without skin disease.  The kidney samples (positive control) were 
taken from a necropsy specimen without kidney disease. Canine appendicular OS tissue blocks 
and their corresponding lung metastases tissue blocks were also retrieved from the University of 
Illinois Veterinary Diagnostic Laboratory for immunohistochemistry (IHC). Formalin-fixed, 
agarose-embedded cell pellets from the previously utilized cell lines were also processed into 
paraffin-embedded tissue blocks for IHC.  Slides cut from the tissue blocks were deparaffinized in 
xylene and rehydrated in ethanol.  Antigen retrieval was performed using Diva Decloacker 
(DV2004).  Endogenous peroxidase activity was blocked using Peroxidazed 1 (PX968) for 5 
minutes, followed by blocking of non-specific background staining using Background Punisher 
(BP974) for 10 minutes.  Blocked slides were incubated with either anti-human CD147 (ab108317) 
for 1 hour and 15 minutes or anti-mouse CD44 (sc-18849) for 1 hour at dilutions of 1:100 and 
1:50, respectively.  CD147 slides were then incubated with a rabbit-on-canine horseradish 
peroxidase (HRP) secondary antibody (RC542) for 30 minutes and CD44 slides were incubated 
with a rabbit-on-rat HRP secondary antibody (61-9520) for 30 minutes at 1:100.  The chromogen 
3-3’-diaminobenzidine (DAB) (IPK5010) was applied for 5 minutes to develop slides, followed 
by counterstaining with Cat hematoxylin (CATHE).  All steps were followed by washing in either 
wash buffer or DI water, as appropriate.  Negative controls for the samples were processed 
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identically in the absence of primary antibody.  Using ImageJ software, immunohistochemical-
staining positivity was expressed as normalized pixel intensity per positive cell. 
2.4 RESULTS 
We chose two human and two canine isogenic cell lines for proteomic profiling. The human cell 
lines HOS (non-metastatic) and 143B (metastatic) have been established as clinically relevant 
orthotopic models for human OS [11]. Both HOS and 143B cells were derived from parent TE-85 
cells through methylnitronitrosoguanidine (MNNG) or Ki-ras transformation respectively. The 
canine cells POS (non-metastatic) was derived from spontaneous canine osteosarcoma and 
HMPOS (metastatic) were established from five subcutaneous implantation cycles of lung tumor 
deposits [12]. We choose cell lines over tumor tissue in order to avoid heterogeneity in tissue 
samples obtained from tumor tissue [13]. The cell lines chosen here have been previously shown 
to be appropriate models for OS [11,12]. Additionally, since the cell lines are isogenic, it reduces 
the possibility of differential proteomic patterns arising due to different cellular origins. Finally, 
to avoid differences due to nutritional treatment, all cells were harvested at 80-90% confluency, 
and the samples utilized for different methods of detection as described below.  
The overall workflow is outlined in Figure 2.A. Briefly, the cells were scraped instead of 
trypsinizing to maintain the integrity of cell surface proteins. The plasma membrane fraction was 
enriched by aqueous two phase extraction protocol in order to remove cytoplasmic contaminants 
that may overwhelm the signal from low-population PM proteins. Subsequently peptide 
fingerprinting was done that provided a list of proteins that was then classified by function to 
identify global proteomic changes (Table ST1- ST4 in Appendix II).  
Proteomic profiles from peptide fingerprinting:  
Peptide fingerprinting is a high throughput method that provides a list of proteins and their relative 
abundances. For each sample set, 10 µg of protein from each set was taken to analyze as indicated 
in the materials and methods section to remove any differences that may arise due to different 
quantities of proteins used for each sample. This is the first control towards standardizing the 
protein abundance. Peptide fingerprinting provided a list of over ~500 proteins per cell line. It is a 
semi-quantitative technique and provides the relative amount of specific proteins in a given 
mixture through a measure of the exponentially modified protein abundance index (emPAI) [9] as 
explained in the materials and methods section. Other similar measures include spectral counts 
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and peptide counts. The emPAI value can help understand the overall protein composition of the 
membrane.  However, it is not a consistent measure across various samples. Thus, two different 
methods were used for standardizing the emPAI aside from loading the same amount of protein 
initially. Each proteins individual emPAI was normalized to the total emPAI of that set.  
Furthermore, trends of proteomic distribution can be compared in the human and canine sets across 
the two species. It is important to note that many proteins were undetectable as they present in low 
abundance and is below p value of 0.05, which was set as a significance cut-off for matching the 
peptide fingerprinting results to the MASCOT database. The analysis of the peptide fingerprinting 
data, as seen in Figure 2.1, revealed various interesting trends that are discussed below. The 
corresponding calculations are represented in Table 2.1. The peptide fingerprinting protocol was 
used only to generate a list of potential candidates and therefore not replicated. Statistical 
significance from peptide fingerprinting was only utilized to filter out targets that have 
questionable peptide match and therefore may not be valid targets. The candidates of interest were 
taken forward for downstream validations where each biochemical validation was replicated for at 
least n=3.  
Structural proteins: The structural proteins form the largest class of proteins in the membrane 
proteome (1 and Table 2.1). They play various roles including maintenance of cell shape, adhesion, 
and migration. In our proteomic data, we observed several different structural proteins that are 
differentially regulated as discussed below.  
Intermediate filaments: We observe a significant increase in the total content of intermediate 
filaments (Figure 2.2 and Table 2.1), which comprises of mainly keratins and vimentin. Vimentin 
is a marker for the epithelial to mesenchymal transition in various epithelial cancers and has been 
discussed in further detail in the validation of targets section below.  
Collagens: Collagens are important constituents of the extracellular matrix. The increase of 
collagen expression in the tumor microenvironment has been correlated with tumor progression 
[14]. We observed an overall increase in the amount of collagens in both metastatic cell lines as 
compared to the non-metastatic cell lines. In human cells, there was a 48% increase in the collagen 
content of metastatic cells versus non-metastatic cells. Likewise, in the canine cell lines, the 
metastatic cells expressed 46% more collagen than the non-metastatic cells (Figure 2.2).  
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Annexins: Annexins A1, A2 and A5 have been found on the cell surface and are involved in 
membrane scaffolding and are responsible for anchoring several membrane proteins.  In our 
studies, in both cell lines the metastatic cells produce only about half the annexin A1 as the non-
metastatic (Table 2.2). This agrees with previous literature where reduced Annexin A1 expression 
was significantly associated with advanced breast cancer [15]. 
Annexin A2 is a calcium-dependent, phospholipid-binding protein. It plays multiple roles in 
regulating cellular functions, including angiogenesis, proliferation, apoptosis, cell migration, 
invasion and adhesion. It has been implicated in several cancers [16-19]. The upregulation of 
annexin A2 in various cancers is 5.74, the metastatic HMPOS show values of 8.63 (Table 2.2). 
However, with the human cell lines, a reverse trend is observed. The non-metastatic HOS line has 
an emPAI value of 36.85, whereas the metastatic 143B cells show 17.11 emPAI (Table 2.2).  
Immune markers: Immunological eradication of cancer is an important function of the immune 
system. This is evident from literature that indicates that cancer cells downregulate their immune 
markers to evade this response [20]. The major histocompatibilty complex (MHC) is a key 
component of the immune system. Our findings through peptide-fingerprinting mass spectrometry 
show a significant change in the expression levels of MHCs and immunoglobulins within the 
metastatic and non-metastatic human cells. The overall expression of immune-related proteins 
reduces approximately 80% in human metastatic cell line and about 50% in the canine metastatic 
cell line (Figure 2.3B). A much lower density of MHC class I is also observed in the metastatic 
versus the non-metastatic cells. In the human lines, 143B expresses only 0.10 times MHC Class I 
than HOS, and in the canine lines the expression of MHC Class I in HMPOS was not detectable 
for p<0.05 whereas POS expression was detected. The down regulation of MHC class of molecules 
has been intrinsically linked to cancer as it assists in tumor immune escape [21]. Specifically in 
OS, the down regulation of MHC class I has been shown in patient samples and it is suggested that 
it restricts cytotoxic T lymphocyte pathway, which plays a major role in immune surveillance of 
patients with OS [22].  
G proteins and GPCRs: G-protein coupled receptors (GPCRs) are a large family of cell-surface 
receptors that are responsible for signal transduction in a large number of cellular processes. 
Malignant cancer cells are known to hijack the normal physiological functions of GPCRs to 
survive, proliferate autonomously, evade the immune system, increase blood supply, invade their 
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surrounding tissues and disseminate to other organs. Increased GPCR expression has been 
observed in various cancers including breast cancer [23]. Herein we observe an overall increase in 
percentage of GPCRs from 7% of total proteins identified in HOS cells to 18% of total in the 
human metastatic143B cells (Figure 2.3A). A similar trend, albeit of smaller magnitude, is 
observed for the canine lines, where 11% of total proteins identified are GPCRs in POS cells and 
13% of total identified in HMPOS (expression difference in the human lines and canine lines is 
depicted in Figure 2.3A).  
A class of small G-proteins, the RAS family, has also been implicated in several oncogenic 
processes [24] and is the most common gene mutation observed in various cancers [25]. This is 
supported by our proteomics results where a significant overexpression of KRAS is observed in 
the metastatic cells versus the non-metastatic cells in both human and canine lines (Table 2.2). 
KRAS expression was also validated for the four cell lines by western blotting (Figure 2.4), which 
shows significant overexpression in the 143B cells versus the HOS cells. However, the differences 
between the canine cell lines in KRAS by western blotting were not significant.  
Finally, a specific class of GPCRs that has been aberrantly been linked to cancer are olfactory 
receptors (ORs). Initially thought to be an anomaly, genes responsible for ORs showing significant 
mutation have been observed in various cancers [26-28]. Our findings also suggest an increase in 
the overall expression of ORs in the metastatic cell line as compared to the non-metastatic cell 
lines... In our peptide fingerprinting results OR7D2 and OR4N4 were observed in the 143B cell 
membrane proteome and OR4C11 and OR4C16 were identified in HMPOS membrane proteome. 
There were no ORs identified in the corresponding non-metastatic cells HOS and POS at p<0.05, 
which was set for our peptide fingerprinting data. 
GPCR activity assay: Peptide fingerprinting indicated that GPCR levels are overall upregulated in 
metastatic vs. non-metastatic cells. To investigate whether the expression levels correspond with 
a concomitant increase in activity, a GPCR activity assay was performed. Cyclic AMP (cAMP) is 
a secondary messenger of several GPCR pathways- the Gi and Gs, and thus cAMP levels were 
measured as an indicator of GPCR activity. Briefly, cells were stimulated with forskolin 
(stimulates Gs class of G-proteins) or DMSO and then lysed, and cAMP was measured by a TR-
FRET-based method. As seen in Fig 2.5, the overall levels of cAMP were significantly higher in 
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143B and HMPOS cells as compared to their non-metastatic counterparts, HOS and POS, 
respectively, indicating higher metastatic activity is accompanied by increase in GPCR activity. 
Receptors and Transporters: 
Integrin β1: Integrins are a family of transmembrane glycoprotein receptors that mediate cell-
matrix and intercellular interactions [29]. Integrins play a key role in the invasion process by 
inducing various matrix metalloproteinases (MMPs) and lead to the breakdown of extracellular 
matrix (ECM). We observed an increase in integrin β1 expression in the metastatic human cell line 
by nearly 1.5 times as compared to the non-metastatic line (Table 2.2). No integrin β1 was 
observed in the canine lines at p< 0.05 in the peptide fingerprinting data. CD98 is known to 
associate with integrin signaling and thereby increase cell growth and proliferation [30,31].  
CD147: Tumors interact with their microenvironment through enzymes known as matrix 
metalloproteinases (MMP). CD147, also known as Basigin, is an MMP inducer that is 
overexpressed and promotes tumor progression, invasion, and metastasis by stimulating MMP 
secretion [32,33]. Due to the pivotal role of CD147 in cancer, this molecule has been termed a 
cancer-associated biomarker [34] and serves as a target for cancer therapy [35]. In our studies we 
also observed an increase in CD147 expression in the metastatic lines for both species. In the 
human cells, there was a 1.6-fold increase in CD147 expression, whereas in the canine cells there 
was a greater than twofold increase in expression which was further validated by western blotting 
and confocal microscopy. Interestingly, CD147 is known to be associated with increased 
expression of monocarboxylate transporter (MCT) expression in various cancers including 
cervical carcinoma [33,36]. Our results corroborate this, with the increased expression of MCT1 
by over twofold for the human lines. In the canine lines, POS expression of MCT1 was not 
detectable for p<0.05; however, the metastatic HMPOS line shows expression. These insights can 
lead towards targeting not only specific proteins but also cellular pathways that are involved in 
increasing the metastatic potential of the cells. Due to potential implication of CD147 in therapy, 
this target was further validated by biochemical methods as indicated in the validation section. 
CD44: CD44 is a multifunctional cell surface glycoprotein involved in cell proliferation, cell 
differentiation and cell migration. The crucial involvement of this protein in cell processes makes 
it highly important in the pathologic state of cancer cells. In our studies, we observed CD44 to be 
upregulated in metastatic cell lines. In human cells, it was 1.3 times in 143B cells versus HOS 
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cells. In canine cells, while no CD44 was detected for POS at p<0.05, a value of 0.16 was observed 
for HMPOS cells. Previously in OS, a higher level of CD44 has been shown to correlate with poor 
prognosis (42).  
CD98: CD98 or 4F2 antigen is a large neutral amino acid transport protein that has been implicated 
in various cancers [37,38]. In our results, we observed a 1.2-fold increase in the metastatic human 
cell line for CD98 expression. In the canine lines, CD98 was not detected in the non-metastatic 
line but it was detected in the metastatic line indicating an increase. In OS, increased expression 
of CD98 has been observed in patient samples [39].  
Validation of selected targets using western blots and confocal microscopy: Several differentially 
regulated targets were further validated as seen in Table 2. Three targets that were validated by 
western blotting and confocal microscopy are: CD44, CD147 and vimentin. These targets were 
chosen due to their implications in various other cancers. For western blotting samples, since the 
samples are membrane fractions and not whole cells, housekeeping proteins like GADPH and beta-
actin do not present themselves as ideal controls. Thus Ponceau staining was used as a loading 
control as has been indicated in materials and methods. In general 5 µg of total protein was loaded 
for CD44 and CD147 in each trial and 1 µg was loaded for vimentin in each trial. A total of n=3 
was performed for all western blotting samples and n=2 was performed for confocal microscopy. 
The quantification for confocal microscopy images is shown in Figure 2.8.  
CD44: In our studies, we observed CD44 to be upregulated in metastatic cell lines. In human cells, 
it was 1.89 times in 143B cells versus HOS cells. In canine cells, while no CD44 was detected for 
POS at p<0.05, a value of 0.12 was observed for HMPOS cells.  We validated CD44 in both human 
and canine cells by western blotting and confocal microscopy. As observed in Figs 2.6A and 2.7A, 
a strong upregulation of CD44 is observed when evaluated using the two detection methods.  
CD147: In our peptide fingerprinting data we observed an increase in CD147 expression in the 
metastatic lines for both species. In the human cells, there was a 1.6-fold increase in CD147 
expression, whereas in the canine cells there was a greater than twofold increase in expression 
which was further validated by western blotting and confocal microscopy. As seen in Figs 2.6B 




Vimentin: Vimentin is an intermediate filament expressed in mesenchymal cells and is responsible 
for maintenance of cell shape and integrity, migration, and adhesion. In our results, we observed a 
1.2-fold increase in vimentin expression in the human cell lines and an over threefold increase in 
vimentin expression in canine metastatic cell lines. This target was validated by western blotting 
and confocal microscopy and as shown in Figs 2.6C and 2.7C, these results corroborate our 
findings from peptide fingerprinting analysis.  
Validation of selected targets using immunohistochemistry in paired primary and metastatic canine 
tumor samples: Using western blots and confocal microscopy, we validated the upregulation of 
three targets that can also observed to be upregulated-using peptide fingerprinting. Two of these 
targets, CD44 and CD147, were further investigated, as they are potential druggable targets. First, 
flow cytometry was performed. For each sample, flow cytometry was performed in triplicates for 
n=3. As observed from Figs 2.9A and 2.9B, in both human and canine cell lines, the metastatic 
cells showed higher levels of CD44 and CD147 as compared to the non-metastatic counterparts. 
Furthermore, immunohistochemical (IHC) analysis was performed for both CD44 and CD147 on 
formalin fixed cells for n=3. As observed in Fig 2.9C and 2.9D, the staining of CD44 and CD147 
is greater on the metastatic cell lines 143B and HMPOS as compared to their non-metastatic 
counterparts. This is in agreement with our western blotting, confocal microscopy and flow 
cytometry data. The quantification is shown in Figure 2.10. This also indicates that no changes in 
staining trends are observed due to formalin fixation, which was done for cell pellets in 
immunohistochemistry (IHC) but not for other biochemical techniques.  
The expression of these proteins was finally tested in paired primary and metastatic OS canine 
tissue samples to investigate whether the findings in cell lines corresponds with spontaneously-
arising osteosarcoma tumors in pet dogs. For each antibody to be tested two distinct sets of paired 
primary and metastatic tissue samples were evaluated for PM protein expressions. Furthermore, 
five sections of each tissue were stained to account for tissue heterogeneity. As observed in Figs 
2.11 A-B, for CD44 all the metastatic samples showed significantly higher staining intensity than 
their primary counterparts (A and B: p < 0.05). For CD147, the staining intensities in the patient 
samples also followed the trend as that of the cell lines. While samples from patient C did show 
higher CD147 expression in the metastatic (p<0.01), samples D showed metastatic staining greater 




The discovery of biomarkers and targetable receptors in osteosarcoma is key to improving 
therapeutic outcomes of metastatic OS disease. Herein we use high throughput peptide 
fingerprinting to identify potential protein level differences between metastatic and non-metastatic 
OS. While traditional investigations in biomarker discovery have focused on the comparison of 
tumorigenic versus non-tumorigenic samples, this study investigates the more subtle differences 
between metastatic and non-metastatic samples. Metastasis is a major challenge in OS therapy 
since non-metastatic OS can be treated by limb-sparing surgeries but metastatic disease has poor 
five-year survival rates and is often fatal. Thus, identifying metastasis biomarkers for potential 
therapeutics is of great importance. Additionally, the subtle changes in protein expression profile 
between metastatic and non-metastatic cells, provides a deeper insights into the factors that are 
responsible for promoting the metastasis of OS. 
Furthermore, we investigated the proteome of metastatic and non-metastatic canine OS cellular 
membrane and compared it to the proteome of human OS cellar membrane. Canine OS is 
spontaneously arising and could serve as closer animal model for human OS than mice in which 
the disease has to be induced. Additionally, a similar trend in metastasis biomarkers for both 
species can help advance parallel development of therapeutics. Furthermore, our cross-species 
study lends more support to the differentially regulated protein species that are identified through 
the peptide fingerprinting studies. 
The high-throughput capacity of proteomics method allows analysis of targets more rapidly than 
traditional biochemical methods like western blotting and flow cytometry. Herein, the semi-
quantitative peptide fingerprinting method provided us with several protein candidates that were 
differentially expressed in the metastatic versus non-metastatic OS cell lines. While, proteomic 
approaches have been utilized for biomarker discovery in various cancers, its use has been limited 
in OS due to difficulty in protein collection from bone tissues. To circumvent this problem, a few 
studies have performed peptide fingerprinting on cell lines, comparing tumor cells versus 
osteoblasts [6,7,40]. These studies have provided valuable insight into the membrane proteome of 
OS cells and identified key biomarkers including NDRG1 and EPHA2. In this study, the 




There are several important steps in metastasis including uncontrolled proliferation, motility, 
invasion and survival in vasculature that are mediated by interaction of signaling molecules with 
membrane proteins. Membrane proteins are known to be differentially regulated in cancerous 
states [41].  Membrane proteins are important components of the cell and form the largest class of 
drug targets. They form the gateway of the cells and control the influx and efflux of multiple 
signaling molecules. They are responsible for multiple functions including adhesion, cellular 
remodeling, proliferation and migration, several of which are significantly altered between normal 
and tumorigenic cells. Membrane proteins can be classified into various major classes including 
structural proteins, GPCRs, receptors (not including GPCRs), transport proteins, proteins 
responsible for immune responses and other smaller classes like enzymes.  
GPCRs are a large class of PM receptors. The aberrant overexpression of GPCRs and their 
autocrine and paracrine activation by agonists released by tumor cells is one of the most frequent 
strategies used by cancer cells to develop and maintain their metastatic phenotype. While GPCRs 
constitute over 50% of current drug targets [42], the GPCRs targeted for cancer therapy are very 
few [43]. Various GPCRs including KRAS have shown to dysregulate the MAPK pathway and 
result in uncontrolled proliferation [44]. In our studies, in both species the metastatic cell lines 
showed an overall increase in GPCR content and this was also reflected in our GPCR activity 
assay. In this assay, the Gs class of receptors when stimulated by forskolin showed heightened 
cAMP production for both metastatic cell lines as compared to the non-metastatic cells. 
Furthermore, proteins that formed an essential component of the ECM such as collagen were found 
to be differentially regulated, as degradation of the ECM and cell motility is a key step in the 
metastatic process. Overall collagens increased in both metastatic cell lines. Collagen regulates 
extracellular martrix (ECM) remodeling through matrix metalloproteinases (MMPs) [45]. It has 
been shown that in OS, the synthesis and activation of MMP-2 is affected by interactions between 
OS cells and collagen I. Proteins that promote the invasion of the vasculature, for example integrin 
β1, were also identified as upregulated. Interestingly, in OS, integrin α2β1 has shown to be 
correlated with increased invasion through its interaction with collagen 1 [46]. In the same study, 
cells forced to overexpress the α2 subunit was not sufficient to increase tumorigenesis implicating 
the involvement of the β1 subunit [46].   
41 
 
Proteins involved in the degradation of ECM, CD147 and MCT1, were also found to be 
upregulated in the metastatic cell lines. CD147 expression in the various cell lines was also 
validated through downstream biochemical techniques. Although no drugs are clinically available 
for targeting CD147, progress has been made towards the use of siRNA in targeting CD147 in 
human malignant melanoma [47].   
Finally, a downregulation of immune complexes was observed in the metastatic cell lines as 
compared to the non-metastatic cell lines was also observed in our results. As cancerous cells try 
to evade the immune response, there is downregulation of the major histocompatibility complex. 
Lower expressions of MHCs, specifically MHC class I, have indicated less-favorable prognoses 
of various cancers [48].  
In this work, we validated three proteins from different functional classes, by western blotting, 
flow cytometry, confocal microscopy and cell pellet IHC, as a representative set to show that 
results from proteomics hold true in low-throughput biochemical methods. CD147 has been 
discussed with respect to its importance in the metastatic process as well as possible therapeutic 
routes. CD44 and vimentin were the other two proteins which were significantly upregulated in 
both human and canine metastatic cells as compared to their non-metastatic counterparts. CD44 is 
a cell surface glycoprotein that has been implicated in various cancers. It is hypothesized that the 
poor prognosis to increased chemoresistance as mediated with its interaction with its ligand 
hyaluronic acid. However, the correlation of CD44 expression to prognosis and disease outcome 
has not been clearly established. Whereas in renal cell carcinoma a high expression level of CD44 
is related to poor outcome [49], in ovarian cancer overexpression of CD44 is related to favorable 
prognosis [50]. Moreover, in breast cancer CD44 has been related to both tumor suppression and 
promotion [51]. Vimentin overexpression, on the other hand, is a marker of epithelial to 
mesenchymal transition in cancers of epithelial origin, like breast cancer.  However, in sarcomas, 
the role of vimentin as a tumor marker has not been explored deeply due to its ubiquitous 
expression. Recent work has shown that Withaferin A targets vimentin in soft tissue sarcomas 
resulting in vimentin cleavage and apoptosis [52], increasing the promise for vimentin as a target 
in cancers of mesenchymal origin. 
Finally, the results were validated in spontaneously arising osteosarcoma tumors in dog. For these 
studies, paired primary and lung metastasized samples from canine patients were utilized. The 
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importance of using paired samples is to avoid any differences due to genetic differences in results. 
The results obtained show that in vitro cell culture proteomic studies followed by validation did 
correspond with the expression levels in canine patient samples. The CD44 results agreed very 
well with our small set of patient samples, the staining of CD147 in patient samples was not as 
intense as that in cell lines, although it was upregulated in the metastatic tumor as compared to the 
primary tumor.  
This work is a proteomic profiling of human and canine membrane proteome and indicates that 
the upregulation of specific proteins follows the same trend. This has been verified in a limited 
number of canine paired primary and metastatic samples. However future work will focus on the 
verification of these targets, and other targets in a greater number of paired primary and metastatic 
canine tissues as well as human tissue samples. While it is anticipated that the upregulation will 
not be the same fold across all samples, the trends are expected to remain constant.  
While cell lines only represent one part of the tumor microenvironment, tumors themselves present 
a significant level of heterogeneity. This microenvironment is also responsible for tumor 
development and progression through the interaction of the ECM, signaling molecules, immune 
system and other cell populations. The modeling of such environments to investigate their effects 
on the proteomic signature of cancer cells has been a subject of recent interest [53]. It is likely that 
these interaction will alter the proteomic profile of the tumor cells in both primary as well as 
metastatic tumors. Conversely, the presence of the tumor will also affect the environment and 
biomarker discovery from tumor microenvironment has also been explored [54]. 
To further explore the proteomic profile of cancer cells in orthotopic models, the study can be 
extended to animal models of the disease. While murine models are not the best models for 
osteosarcoma, since they do not develop spontaneous tumor and tumors have to be induced, they 
do provide a platform for testing out preliminary hypotheses. The cell lines used in this study have 
been previously shown to be a clinically relevant orthotopic model for human osteosarcoma 
because their tumor progression and metastasis development in mice, mimic the clinical scenario 
[11]. These studies will provide more evidence for the studies to be extended tocompanion animals 
that show more similar proteomic profile as humans, such as dogs, and will allow for a parallel 




This study describes a cross-species comparison of PM proteins of metastatic and non-metastatic 
OS. We have shown that the global membrane proteomes of canine and human OS show 
significant preferential regulation of various proteins, which agrees with results in genetic 
expression levels. Furthermore, the cross-species comparison allows greater confirmation that 
dogs can be utilized as a model for human OS. It also offers a platform for the development of 
therapeutics for both species. We identified various differentially regulated proteins that were 
validated downstream by biochemical techniques including western blotting, flow cytometry and 
confocal microscopy. CD44, CD147 and vimentin were identified as significantly upregulated in 
both human and canine OS. The results were also confirmed by IHC in spontaneously arising 
osteosarcoma tumors samples.  
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2.8 FIGURES, TABLES AND LEGENDS 
 
Table 2.1: Table shows the percentage of proteins in each category in each cell membrane. Table 
1 represents the calculations reflected in Fig 1. HOS and POS are the non-metastatic human and 
canine cell lines and 143B and HMPOS are the metastatic human and canine cell lines respectively. 
  
 
HOS 143B POS HMPOS 
Structure 63.48 56.68 49.11 56.01 
Transport 3.41 2.46 14.82 6.59 
Immune Complexes 15.69 11.09 2.26 0.62 
G protein and GPCRs 6.74 18.3 10.99 13.02 
Chaperones  1.6 1.47 3.61 5.89 
Receptors 3.19 4.88 2.57 3.24 
Enzymes 4.23 1.35 8.52 9.4 
Others 1.66 3.77 8.11 5.24 












Table 2.2: Table shows the relative emPAI of selected differentially regulated proteins in the 
human and canine osteosarcoma cells. HOS and POS are the non-metastatic human and canine 
cell lines and 143B and HMPOS are the metastatic human and canine cell lines respectively. 
emPAI of each protein is normalized to total emPAI. The ratios 143B/HOS and HMPOS/POS 
show fold change in expression.  
Protein HOS 143B 143B/ HOS POS HMPOS HMPOS/ 
POS 
Keratin Type 1 2.31 4.31 1.87 2.99 3.80 1.27 
Keratin Type 2 0.30 2.48 8.30 2.48 3.41 1.38 
Vimentin 6.06 7.20 1.19 4.34 13.69 3.16 
Annexin A1 0.86 0.45 0.52 1.91 1.01 0.53 
Annexin A2 36.85 17.11 0.46 5.74 8.63 1.50 
MHC Class I 2.73 0.28 0.10 0.15 0.00 0.00 
KRAS 0.40 1.53 3.80 0.05 0.24 4.48 
CD44 0.17 0.33 1.30 0.00 0.16 
 
CD 147 (Basigin) 0.42 0.67 1.6 0.22 0.46 2.12 
Monocarboxylate 
transporter I 
0.07 0.11 1.46 0.00 0.09 
 
CD 98 0.15 0.18 1.20 0.00 0.07 
 





Figure 2.1: Figure shows global membrane proteomic composition across various cell lines 
classified according to function. The colors are as mentioned in the key. HOS and POS are the 
non- metastatic human and canine cell lines and 143B and HMPOS are the metastatic human and 










Figure 2.2:  Relative expression of structural proteins in metastatic versus non- metastatic cells as 
observed by peptide fingerprinting. The percentage increase in the expression in the metastatic 








Figure 2.3: Change in expression of (A) Immune complexes and (B) GPCRs in metastatic versus 












Figure 2.4: Western blot showing overexpression of KRAS in 143B vs HOS. 143B shows greater 
















Figure 2.5: Figure shows the relative GPCR activity as measured by cAMP concentration. The 
experiment was performed in biological triplicates (and technical duplicates) with n=2 (total 














Figure 2.6: Western blot showing the expression of (A) CD44, (B) CD147 and (C) Vimentin. 
Lanes from left to right: ladder, HOS, 143B, POS and HMPOS. HOS and POS are the non-
metastatic human and canine cell lines and 143B and HMPOS are the metastatic human and canine 








Figure 2.7: Confocal microscopy images showing the expression of (A) CD44, (B) CD147 and 
(C) Vimentin. HOS and POS are the non- metastatic human and canine cell lines and 143B and 
HMPOS are the metastatic human and canine cell lines respectively. Blue staining of nuclei with 
DAPI and red staining of CD44 with phycoerythrin secondary and green staining of Alexa Fluor 








Figure 2.8: Fig shows the ImageJ quantification of confocal microscopy images. Quantification 
was performed by measuring staining intensity of 20 random cells each in 2 different slides. The 











Figure 2.9: Flow cytometry fluorescence levels showing the expression of (A) CD44 and (B) 
CD147. Cell pellet immunohistochemistry showing the expression of (C) CD44 and (D) CD147. 
HOS and POS are the non- metastatic human and canine cell lines and 143B and HMPOS are the 










Figure 2.10: Image shows quantification of cell pellet immunohistochemistry. Images were 
quantified by using ImageJ and Adobe Photoshop. The images corresponding are Fig 5C and D. p 
values are as follows: CD44 human (HOS and 143B) p=0.07, canine (POS and HMPOS) p=0.17. 














Figure 2.11: Immunohistochemistry of paired canine primary (left) and metastatic (right) in two 
different patient samples showing the expression of (A-B) CD44 and (C-D) CD147. p values for 














Fig 2.12: Image shows quantification of paired primary and metastatic tissue 
immunohistochemistry. Images were quantified by using ImageJ and Adobe Photoshop. The 
images corresponding are Fig 6. p values are as follows: CD44 primary and metastatic 1 p=0.01, 
primary and metastatic 2 p=0.03. CD147 primary and metastatic 1 p=0.003, canine primary and 
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CHAPTER III: DIRECT CAPTURE OF FUNCTIONAL PROTEINS FROM 
MAMMALIAN PLASMA MEMBRANES INTO NANODISCS 4F5 
 
3.1 ABSTRACT 
Mammalian plasma membrane proteins are the largest class of drug targets yet are difficult to 
study in a cell free system due to their intransigent nature. Herein, we perform direct encapsulation 
of plasma membrane proteins derived from mammalian cells into a functional nanodisc library. 
Peptide fingerprinting was used to analyze the proteome of the incorporated proteins in nanodiscs 
and to further demonstrate that lipid composition of the nanodiscs directly affects the class of 
protein that is incorporated. Furthermore, the functionality of the incorporated membrane 
proteome was evaluated by measuring the activity of membrane proteins – Na+/K+-ATPase and 
receptor tyrosine kinases. This work is the first report of successful establishment and 
characterization of a cell free functional library of mammalian mem-brane proteins into nanodiscs 
3.2 INTRODUCTION 
Plasma membranes (PMs) serve as a protective bilayer for cells by forming a permeability barrier 
for trafficking molecules into and out of the cell. These membranes are comprised of a diverse 
array of proteins and lipids that interact to form a complex superstructure with capacity to regulate 
various cellular processes. PM proteins are involved in cellular signaling, regulation, and 
homeostasis and serve as the largest class of druggable targets (1). These proteins can be classified 
into various functional groups, including receptors, transporters, and enzymes (2). Additionally, 
these membranes also contain various lipid components consisting primarily of different types of 
phospholipids, including POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine), POPS (1-
palmitoyl-2-oleoyl-sn-glycero- 3-phospho-L-serine), and sphingomyelin, and other lipids, 
including cholesterol (3-6). Furthermore, the PM contains microdomains such as lipid rafts that 
contain a percentage of cholesterol and sphingomyelin significantly higher than that of the regular 
plasma membrane that aid in protein signaling (4, 7). Taken together, the plasma membranes are 
highly ordered, and their complexity arises from the intricate interplay between membrane proteins 
                                                 
5  Reprinted with permission of the American Chemical Society Permissions. “Direct Capture of Functional Proteins 
from Mammalian Plasma Membranes into Nanodiscs.” Jahnabi Roy, Holly Pondenis, Timothy Fan and Aditi Das. 
Biochemistry 2015, 54, 6299−6302. 
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and a variety of lipids. The involvement of plasma membrane proteins in signaling processes and 
their importance in therapeutic development necessitate the discovery of innovative methods for 
interrogation of membrane proteins in a cell free medium (1). Here we use nanodiscs to efficiently 
capture membrane proteins directly from the mammalian cellular membranes (Figure 3.1). 
Previous studies show that nanodiscs can be used to preserve the structural and functional integrity 
of membrane proteins, including cytochrome P450s, G protein-coupled receptors (GPCRs), and 
other receptors (8-10). Additionally, they can be coupled to various downstream detection 
methodologies and assays such as SILAC and MALDI, nuclear magnetic resonance, and 
fluorescence microscopy (11). The application of nanodiscs has been predominantly limited to the 
incorporation of single purified proteins (8-10, 12-14). Recently, there have been studies to prepare 
membrane protein nanodisc libraries (MPNLs) by directly encapsulating proteins from the 
membranes of simpler organisms such as bacteria (15) and yeast (16). This work is the first report 
of a mammalian membrane protein nanodisc library with detailed characterization of the 
incorporated proteome. Furthermore, we demonstrate that the incorporated proteins also retain 
functional activity. The capacity to stably incorporate membrane proteins as a library in nanodiscs 
provides a cell free platform suitable for facile downstream functional analysis and drug binding 
studies. 
3.3 MATERIALS AND METHODS 
Materials:  β- octylglucoside, imidazole, ethylenediaminetetraacetic acid (EDTA), and Amberlite 
XAD-2 beads were purchased from Sigma-Aldrich (St. Louis, MO). Phenylmethanesulfonyl 
fluoride (PMSF) was obtained from Fisher Scientific (Pittsburgh, PA). Ni- NTA resin was 
purchased from Gold Biotechnology (St. Louis, MO). Sodium Cholate as obtained from 
Affymetrix (Maumee, OH). 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1-
palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine (POPS) were obtained from Avanti Polar 
Lipids (Alabaster, AL). MHC Class I antibody was obtained from Abcam (ab134189). Ras 
antibody was obtained from Upstate Cell Signalling (05-516).  Kinase assay kit was obtained from 




Cell culture: Human cell line 143B was cultured in DMEM (Gibco, Invitrogen, Carlsbad, CA, 
USA) supplemented with 10% fetal bovine serum (FBS) and 1mg ml–1 penicillin–streptomycin 
(Gibco, Invitrogen) at 37 °C and 5% CO2 in a humidified incubator. 
Extraction of plasma membranes: Membrane extraction was done as previously published(17, 18). 
All steps were carried out at 4°C. Briefly, about 60 million adherent cells were washed with 
phosphate-buffered saline (PBS), scraped using a plastic cell lifter, and broken in 1 mL solution 
containing 0.2 mM EDTA and 1 mM NaHCO3 and 20 µL protease inhibitor (Nacalai USA, Inc.), 
using a glass homogenizer. The nuclear and unbroken cells were removed through centrifugation 
a 200×g, and the supernatant was collected and centrifuged for 30 min at 25,000 rpm. The cell 
pellets were resuspended in 1 mM NaHCO3 in an approximate ratio of 1 mL per 5×108 cells and 
used for PM separation by two-phase systems. Suspended cell pellets were added to the top of 14 
g of the dextran–poly (ethylene glycol) mixture (6.6% Dextran T500, 6.6% PEG 3350, 0.1 M 
sucrose, 5 mM K3PO4, pH= 7.2). After mixing up and down for 40 times, the tube was centrifuged 
for 5 min at 750×g. The PM-enriched up phase was collected and purified again as described 
above. The up phase was diluted with 1 mM sodium bicarbonate and centrifuged at 100,000×g for 
2 h in a SW32 rotor. 
Assembly of 143B nanodisc:  All steps were done at 4 °C unless otherwise mentioned. Expression 
and purification of MSP1E3D1 was performed as previously described(19, 20). MSP from stock 
concentration of 75 µM was added in 1:132 ratio in POPC, dried under nitrogen and solubilized 
in 25% β- octyl glucoside and 0.1mM sodium cholate. Although solubilization of lipids in typically 
performed in 50 mM sodium cholate, precaution was taken to reduce the amount of total cholate 
to prevent any denaturation of mammalian proteins. The MSP and POPC mixture was equilibrated 
for 30 min. Simultaneously, the membrane protein (ratio of 1:10- MP: MSP) was equilibrated with 
2% β- octyl glucoside for 15 min. The MP was then added to the MSP- POPC mixture and 6 mL 
of 0.1 M phosphate buffer (pH 7.4) was added to dilute salts in the protein buffer and DTT to final 
concentration of 0.1 mM was added. The mixture was allowed to equilibrate for 30 min and 
Amberlite ® biobeads were added to the mixture to remove detergents and allow nanodisc 
formation. The biobeads were filtered off after 2.5 h and the nanodisc solution was loaded onto a 
Ni- NTA column (1.5 mL). The column was washed with 1.5 mL of 20 mM imidazole in 0.1 M 
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tris buffer (pH 7.4). The nanodisc was then eluted with 200 mM imidazole in 0.1 M tris buffer (pH 
7.4). 
Size exclusion chromatography: Size exclusion chromatography (SEC) was performed with a 
calibrated Superdex HR 200 10/300 size exclusion column (Amersham-Pharmacia Biotech, 
Piscataway, NJ) by a Waters Alliance System. Samples were filtered prior to analysis and injected 
using a 500 μL sample loop and a flow rate of 0.5 mL/min with 0.1 M phosphate buffer (pH 7.4).  
Disassembly of nanodiscs for peptide fingerprinting: The nanodisc preparation was loaded on to 
Ni-NTA column (1.5mL) and the flow through was removed. A solution of 200 mM sodium 
cholate (2 mL) was added to the column and pipetted up and down to mix. The column was allowed 
to stand in sodium cholate solution for 30 min and the sodium cholate solution was eluted 
containing the proteins liberated due to nanodisc dis-assembly. The MSP remained attached to the 
column due to its His-tag. 
Peptide fingerprinting:  
Sample preparation: Sample cleanup was done using G-Biosciences (St. Louis, MO) Perfect Focus 
according to manufacturer’s instruction. 
Digestion with trypsin: Sample was digested with MSG-Trypsin (G-Biosciences, St. Louis, MO) 
at a ratio of 1:10 – 1:50 using a CEM Discover Microwave Digestor (Mathews, SC) at 55 ˚C and 
maximum power of 60 watts for 15 minutes. Digested peptides were lyophilized and resuspended 
in 5% acetonitrile + 0.1% formic acid for LC/MS. 
LC/MS: LC/MS was performed using a Thermo Dionex Ultimate RSLC3000 operating in nano 
mode at 300 microliters/min with a gradient from 0.1% formic acid to 100% acetonitrile + 0.1% 
formic acid in 120 minutes. The trap column used was a Thermo Acclaim PepMap 100 (100 µm 
x 2 cm) and the analytical column was a Thermo Acclaim PepMap RSLC (75 µm x 15 cm). 
Data Analysis: The peptide fingerprinting Xcalibur raw file was converted by Mascot Distiller into 
peaklists that were submitted to an in-house Mascot Server and searched against specific NCBI-
NR protein databases. The list of proteins obtained was filtered by a p < 0.05 for a 95% confidence 
value. This list of proteins was then classified by their subcellular location (to filter out non- 
membrane contaminants) and plasma membrane candidates were classified into various functional 
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classes. The emPAI values were normalized to the total emPAI value and compared as a percentage 
to the overall composition. 
Western Blot: Based on protein concentration measurements, equal amounts of plasma membrane 
preparations generated from all cells were resolved by 4–20% SDS-PAGE (Pierce) and transferred 
onto a PVDF membrane. The membranes were blocked in PBS, 0.1% Tween 20, 5% nonfat dry 
milk powder for 1 h at room temperature and incubated with primary antibody for 16 h at 4 °C 
followed by washing and incubation with HRP-conjugated secondary antibody for 1 h at room 
temperature. All antibody incubations and washing steps were carried out in PBS, 0.1% Tween 
20. The immunoreactive bands were visualized using an ECL Western blot kit (Amersham 
Biosciences). The western blots were normalized by Ponceau staining(21). 
Na+/K+ ATPase assay:  Samples were incubated at various mentioned temperatures for different 
periods of time, as mentioned for the assay. For freeze thaw samples, the freezing was done as a 
flash freeze in liquid nitrogen for 1 min. The samples were thawed on ice for analysis before flash 
freezing again. The total Na+/K+-ATPase activity was assayed at 37°C in an incubation mixture 
containing 30 mmol/L Tris-HCl, pH 7.4, 0.1 mmol/L EDTA, 50 mmol/L NaCl, 5 mmol/L KCl, 
6 mmol/L MgCl2, and 1 mmol/L ATP in the presence or absence of ouabain (0.5 mM), as 
described previously (22, 23). Briefly, after preincubating the isolated membranes or nanodisc 
preparation, for 10 min at 37°C, the reaction was started by the addition of ATP and stopped with 
55 μL of ammonium molybdate in sulfuric acid after 20 min. The amount of inorganic phosphate 
released was determined by reduction of phosphomolybdate complex by 10% ascorbic acid 
solution and measuring absorbance at 820 nm. The Na+/K+-ATPase activity was calculated as the 
difference between the presence or absence of ouabain-sensitive Na+/K+-ATPase activity. 
Experiments were performed in triplicates. 
Kinase assay: The assay was performed according to manufacturer’s instruction. Briefly, the 
nanodisc preparation was incubated with imatinib (20 µM) or DMSO (control) for 10 min. To this 
ATP and coupling phosphatase were added and incubated for 10 min. The reaction was quenched 
with Malachite reagent A, water and Malachite reagent B and readout was measured at 620 nm. 
The absorbance of nanodisc incubated with imatinib was subtracted from that with DMSO control 
for final phosphate calculations and the readings were adjusted for total protein used in each 
preparation. Assay was performed in triplicates. 
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3.4 RESULTS AND DISCUSSION 
For the preparation of the MPNL, we utilized metastatic human osteosarcoma 143B cells17 in the 
study presented here to serve as a model of mammalian plasma membranes for the preparation of 
the mammalian protein nanodisc library (MPNL). The immortalized 143B cell line originates from 
the malignant osteoblast lineage and is characterized by a short doubling time in vitro and a 
spontaneous metastatic potential in vivo (24). The potential discovery of membrane biomarkers of 
osteosarcoma and drug discovery against identified receptor targets permit 143B cells to serve as 
a relevant and suitable mammalian cell model for this study. To capture the membrane proteins 
into nanodiscs, first, the membrane fraction from 143B cells was isolated using an aqueous two-
phase partitioning system (ATPS) (17, 25). This was followed by equilibration with mild, nonionic 
detergent, β-octyl glucoside, to extract the proteins from the membrane. Use of β-octyl glucoside 
has been previously shown to maintain the functional integrity of membrane proteins as compared 
to that of cholate or sodium dodecyl sulfate (26, 27). Detergent-solubilized lipids and membrane 
scaffold protein (MSP1E3D1) were added followed by removal of the detergents by Amberlite 
Biobeads to initiate nanodisc self-assembly (Figure 3.1). The ratio of these components was 
optimized and verified by using size exclusion chromatography (Figure 3.2). The following lipid 
compositions were chosen to make nanodiscs (NDs): 100% POPC (ND1), 20% POPS and 80% 
POPC (ND2), 20% cholesterol and 80% POPC (ND3), and 20% POPS, 72% POPC, and 8% 
cholesterol (ND4). Interestingly, the nanodiscs prepared from different lipid compositions had 
similar sizes except for the cholesterol nanodiscs that show a later elution time, indicating a smaller 
size (Figure 3.2). The rigid structure of cholesterol possibly increases the fluidity of the nanodisc 
as it disrupts the phospholipid packing (28). A similar reduction in size upon incorporation of 
cholesterol has been observed in molecular dynamics (MD) simulations of bilayers (29). For 
peptide fingerprinting analysis of the MPNL, the protein content of the nanodiscs was further 
characterized using peptide fingerprinting by mass spectrometry (30, 31). Prior to proteomic 
analysis, the MPNL nanodiscs were disassembled using sodium cholate followed by use of a Ni-
NTA to remove His-tagged MSP1E3D1 as the presence of MSP1E3D1 overwhelms the ion signal 
from the other membrane proteins. The proteins identified in the nanodiscs using proteomics were 
classified into the following functional categories: structural, GPCRs, enzymes, transporters, 
chaperones, immune complexes, and other receptors (Figure 3.3 and Appendix III). Herein, we 
use two parameters for data analysis. Figure 3.3 and Table 3.1 represent the percentage of a 
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particular functional class of membrane protein in the protein mixture. The second parameter is 
the incorporation of proteins into nanodiscs as compared to the initial membrane (Table 3.2) 
indicating the percentage incorporation Peptide fingerprinting of POPC nanodisc ND1 revealed 
that ∼55% of membrane protein species in the initial membrane fraction were incorporated into 
nanodiscs (Table 3.2). Although a majority of the protein categories were conserved in these 
nanodiscs, the percentage of structural proteins was only 19% in ND1 as compared to 56% in MP 
(Table 3.1). An important class of structural proteins, annexins, was completely absent in ND1 
(Appendix III), indicating that the protein−lipid electrostatic interaction that is important for 
annexin binding is lacking in the zwitterionic POPC lipid bilayer (15, 32). Typically, the plasma 
membrane of cells consists of ∼20% anionic lipids such as phosphatidylserine (6). Various 
proteins, including phospholipases and annexins that contain positively charged residues, 
preferentially associate with anionic lipids to perform their biological activities (33-35). Therefore, 
ND2 containing 20% POPS (Appendix III) was prepared. In these nanodiscs, the protein content 
recapitulated the initial membrane composition (Table 3.1) and achieved an overall incorporation 
of 70% of the initial mixture of membrane proteins into nanodiscs (Table 3.2). Unlike ND1, the 
structural proteins constituted the largest class of proteins in ND2 (Figure 3.3C and Table 3.1) as 
seen for the original MP fraction (Figure 3.3A and Table 3.1). Next we incorporated cholesterol 
into nanodiscs. Cholesterol is the primary lipid component of lipid raft domains in the plasma 
membranes that have been implicated in clustering of GPCRs and other signaling proteins (36, 
37). In vivo, these rafts contain a percentage of cholesterol (∼30%) significantly higher than that 
of the plasma membrane (8−14%) (4). Because of the rigid nature of the sterol group, cholesterol 
partitions preferentially into the lipid rafts where acyl chains of the phospholipids tend to be more 
rigid and in a less fluid state. The proteomic analysis of 20% cholesterol-containing nanodiscs, 
ND3 (Appendix III), surprisingly showed an incorporation efficiency of 15% (Table 3.1), and only 
a few protein classes were detected (Table 3.2 and Figure 3.3D). Similar to ND1, cholesterol 
nanodiscs demonstrated a lack of proteins binding preferentially to anionic lipids. Interestingly, 
the percentage of enzymes incorporated into ND3 was higher than in ND1 and ND2 (Table 3.1). 
However, the overall incorporation of membrane proteins in cholesterol ND3 was poor. MD 
simulation studies show that the volume of a bilayer decreases with an increase in cholesterol 
content (29). The smaller size is also evident from our size exclusion chromatography, which 
showed that ND3 was smaller than other nanodiscs (Figure 3.2). The smaller volume of the 
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nanodisc due to a high cholesterol concentration possibly results in a lower incorporation 
efficiency. Finally, ND4 nanodiscs that closely mimicked the composition of the plasma 
membrane [POPC (72%), POPS (20%), and cholesterol (8%)] were prepared. Results from peptide 
fingerprinting show that ND4 achieved >75% incorporation of proteins, the highest incorporation 
efficiency among the different nanodisc classes (Table 3.2). There was a dramatic enrichment of 
GPCRs and G proteins (Figure 3.3E and Tables 3.1 and Appendix III). ND4 contains significantly 
less cholesterol than ND3 and therefore an overall greater nanodisc size as evidenced by size 
exclusion chromatography (SEC). Additionally, the presence of cholesterol has been linked to 
GPCR signaling either directly by binding to the GPCR33 or by altering membrane physical 
properties (38, 39), or both. The significant enrichment of GPCRs in ND4 is probably due to 
favorable interactions of cholesterol with GPCRs. For the enrichment of selective membrane 
proteins in the MPNL, all the nanodisc libraries show enrichment of the membrane protein 
population (Appendix III). This led to identification of several low-abundance membrane proteins 
not originally detected in the membrane proteome. Therefore, nanodiscs preferentially capture and 
enrich membrane proteins and remove the soluble proteins and other cellular contaminants. For 
Western blot validation of selected membrane proteins in the MPNL, we further validated the 
incorporation of two specific membrane protein targets into nanodiscs using Western blot analysis. 
It was determined that both GTPase KRAS, a peripheral membrane protein, and major 
histocompatibility complex (MHC) class I, an integral membrane protein, identified via peptide 
fingerprinting were present in Western blot analysis in all the different nanodisc preparations 
(ND1− ND4) (Figure 3.4 A,B). For the functional assay of proteins in the MPNL, from the 
proteomics data, we see that ND4, which most closely resembles the lipid composition of the 
native plasma membrane, is able to capture more than 75% of the initial membrane proteins (Table 
3.2). The primary advantage of incorporation of proteins into nanodiscs as compared to detergent-
solubilized membrane preparations is the preservation of their function (10, 12). From the peptide 
fingerprinting analysis, we chose two representative classes of proteins to demonstrate that 
proteins are functionally active in nanodiscs: Na+ /K+ -ATPase and receptor tyrosine kinases 
(RTKs). The Na+ /K+ -ATPase transports sodium and potassium ions across their concentration 
gradient by hydrolyzing one molecule of ATP to ADP and inorganic phosphate (Pi). Ouabain is a 
specific inhibitor of Na+ /K+ -ATPase. The protein activity was measured by phosphate liberated 
in the absence and presence of ouabain (22, 23) (Figure 3.4C). It can be seen that Na+ /K+ -ATPase 
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incorporated into the MPNL retains functionality over 7 days at 37 °C. Furthermore, the functional 
assay was conducted at a variety of temperatures [4 °C and room temperature (23 °C)] over 
different periods of time (days 1−7) and using freeze−thaw conditions (Figure 3.5). Under all 
tested conditions, Na+ /K+ -ATPase activity was retained in nanodiscs over a broad range of 
storage durations and temperatures. Phosphorylation of proteins is a key process for signal 
transduction in enzymatic regulation. A major class of kinases is receptor tyrosine kinases (RTKs), 
which are involved in cancer, and there are various inhibitors that currently are available to target 
them (40). We measured the activity of RTKs in nanodiscs by using malachite green-dependent 
detection of phosphate released from kinase activity (41) in the presence and absence of imatinib. 
This inhibitor inhibits multiple RTKs, including platelet-derived growth factor (PDGF) receptor, 
an overexpressed receptor in osteosarcoma (42, 43). All four nanodisc preparations retained RTK 
activity as evidenced by the decrease in activity in the presence of imatinib, indicating functional 
kinases that are inhibited by imatinib (Figure 3.4D). Interestingly, the highest RTK activity was 
identified in POPC/POPS/cholesterol ND4. The activity of RTKs was lowest in the 20% 
cholesterol nanodisc, correlating with the absence of PDGF receptor and small amounts of RTKs 
detected by peptide fingerprinting. This demonstrates that the MPNL can be used for screening 
small molecules against a large variety of kinases in a model library. 
3.5 CONCLUSION  
In conclusion, this work establishes the formation of a functional mammalian nanodisc library 
from human osteosarcoma 143B cells and is the first to report a detailed analysis of Figure 3. (A 
and B) Western blot showing incorporation of MHC-1 and KRAS protein into the different 
nanodiscs: (1) ladder, (2) 143B membrane, (3) 100% POPC ND1, (4) 20% POPS ND2, (5) 20% 
cholesterol ND3, and (6) 8% cholesterol and 20% POPS ND4. (C) Na+ /K+ -ATPase activity in 
nanodiscs monitored at 37 °C by measuring phosphate produced in the presence and absence of 
ouabain (Na+ /K+ -ATPase blocker) relative to day 1. (D) Net kinase activity measured in the 
nanodiscs in the presence and absence of imatinib (RTK inhibitor) showing active RTK in 
nanodiscs is inhibited. Furthermore, it is shown that the change in lipid composition strongly 
influences the subpopulation of proteins incorporated into the nanodisc. This study can be further 
extended to other lipid compositions, including sphingomyelin, cardiolipin, etc. In ND4 containing 
both anionic lipids and cholesterol, there was more than 75% incorporation of membrane protein, 
including enrichment of certain GPCRs and G proteins. These MPNLs are functionally active as 
72 
 
shown by measuring Na+ /K+ -ATPase activity and RTK activity as proof-of-concept protein 
classes. This approach of using functional nanodisc libraries provides promise for stabilizing entire 
membrane proteomes in a cell free system that can be further utilized for evaluating protein 
interactions and drug binding studies. Notably, the methods used to prepare a functional MPNL 
from 143B cells can be broadly applied to other cell lines, including cancerous and noncancerous 
cells. 
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3.7 TABLES AND FIGURES 
Table 3.1: Percentage abundance of proteins of each class in membrane fraction or nanodiscs as 
identified by peptide fingerprinting (individual data in Appendix III). Abundance does not directly 
correlate with number of species in each class. emPAI or exponentially modified protein 




 Membrane ND1 ND2 ND3 ND4 
Structure 56.3  19.3 63.6 31.4 25.9 
Transport 2.4 10.0 2.9 7.6 3.2 
Immune 
complexes 11.0 38.0 16.2 23.3 20.0 
G proteins 
and GPCRs 18.1 20.2 10.8 1.2 43.8 
Chaperones 1.4 4.4 0.3 0.0 0.7 
Receptors 4.8 4.0 2.9 1.6 2.7 
Enzymes 1.9 3.8 2.2 22.5 2.3 












Table 3.2: Number of individual proteins identified in each class (data in Appendix III). Number 
of proteins identified in nanodisc can be higher than those identified in initial membrane due to 
improved signal to noise ratio on removal of non- membrane contaminant proteins.  
 
 
Membrane ND1 ND2 ND3 ND4 
Structural 56 35 52 9 41 
Transport 20 13 14 4 13 
Immune 
Complexes 
15 18 19 2 22 
G- proteins 
and GPCRs 
34 18 23 1 38 
Chaperones  8 5 2 0 4 
Other 
Receptors 
17 10 14 2 12 
Enzymes 20 11 8 7 11 
Others 31 0 8 4 9 
 







Figure 3.1: Schematic of nanodisc assembly. Membrane proteins in membranes were mixed with 
membrane scaffold protein (MSP), β- octyl glucoside, and lipids of choice. The detergent was 























Figure 3.2: Size exclusion chromatogram of various nanodiscs showing the formation of 
symmetrical nanodiscs. POPC (ND1) SEC is also representative of POPS (ND2) and 8% 
cholesterol+ 20% POPS + 72% POPC disc (ND4).  20% Cholesterol nanodiscs (ND3) formed are 












Figure 3.3: Schematics (left) of nanodiscs containing different lipid compositions. POPC lipids 
are colored white and POPS lipids orange, and cholesterol is colored pink. Phospholipid 
headgroups are colored purple, and membrane scaffold protein is colored blue: (A) MP, (B) ND1 
(100% POPC), (C) ND2 (20% POPS and 80% POPC), (D) ND3 (20% cholesterol and 80% 
POPC), and (E) ND4 (20% POPS, 8% cholesterol, and 72% POPC). Functional classification 
(right) of the membrane proteome. The percentage represents the ratio of one particular class of 
membrane protein in the mixture. The percentages of structural proteins (blue), immune complexes 




Figure 3.4: (A and B) Western blot showing incorporation of MHC-1 and KRAS protein into the 
different nanodiscs: (1) ladder, (2) 143B membrane, (3) 100% POPC ND1, (4) 20% POPS ND2, 
(5) 20% cholesterol ND3, and (6) 8% cholesterol and 20% POPS ND4. (C)Na+/K+ -ATPase 
activity in nanodiscs monitored at 37 °C by measuring phosphate produced in the presence and 
absence of ouabain (Na+ /K+ -ATPase blocker) relative to day 1 (details in Table ST8). (D) Net 
kinase activity measured in the nanodiscs in the presence and absence of imatinib (RTK inhibitor) 





Figure 3.5: Sodium potassium ATPase activity by measuring total phosphate produced in the 
presence and absence of ouabain over different temperature conditions over 7 days. (A) Freeze 
thaw cycles, (B) 4 °C and (C) room temperature (23 °C). Data shows no appreciable change in 
phosphate produced at any temperature over a period of 7 days. Data is average of three replicates. 
(ND1 (100% POPC); ND2 (20% POPS-80% POPC); ND3 (20% cholesterol- 80% POPC); ND4 
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CHAPTER IV: DIFFERENTIAL LIPID PROFILE OF METASTATIC 
OSTEOSARCOMA CELLS VIA LIPIDOMICS 
4.1 ABSTRACT 
Osteosarcoma (OS) is the most common form of primary bone cancer in humans. The early 
detection and subsequent control of metastasis has been challenging in OS. Lipids are important 
constituents of cells that act as signaling molecules, maintaining structural integrity as well as 
storage of energy, and are reprogrammed in cancerous states. Herein, we investigate the global 
lipidomic differences in metastatic (143B) and non-metastatic (HOS) human OS cells as compared 
to normal fetal osteoblast cells (FOB) using lipidomics. We detect fifteen distinct lipid classes in 
all the three cell lines that included ~1500 lipid species across various classes including 
phospholipids, sphingolipids and ceramides, glycolipids and cholesterol. The statistical 
significance in the class wise differences was ascertained using ANOVA and the individual species 
were analyzed using the non-parametric Wilcoxon rank sum test and the comparison was corrected 
by Benjamini-Hochberg false discovery rate (FDR). Finally, we identify a key class of lipids, 
diacylglycerols are overexpressed in metastatic OS cells as compared to their non-metastatic or 
non-tumorigenic counterparts. We show that blocking diacyglycerol synthesis reduces cellular 
viability and reduce cell migration in metastatic osteosarcoma cells. Thus, the differentially 
regulated lipids in this study can be targets for biomarker development and the synthesis and 
metabolism of specific lipids can be targeted for therapeutic development. 
4.2 INTRODUCTION 
Osteosarcoma (OS) is the most common form of primary bone cancer in humans. The treatment 
options for OS consists of multi-agent induction chemotherapy, and tumor excision and adjuvant 
chemotherapy. The survival rates remain poor despite aggressive treatment. In patients with 
localized disease, 5-year survival rates are approximately 65%; however, in the case of metastatic 
disease, the 5-year survival rates have plateaued to about 20% (98, 99). Although progress has 
been made towards improving treatment options in OS, the early detection and subsequent control 
of metastasis has been challenging. Lipids are important constituents of cells that act as signaling 
molecules, maintaining structural integrity as well as storage of energy, and are often 
reprogrammed in cancerous states (185). The discovery of metabolically altered pathways 
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especially those related to lipid synthesis can aid in understanding the mechanism of tumor 
formation and metastasis and can aid in the development of novel OS therapeutics. 
Lipids are an important component of the cellular machinery. They encompass a large class of 
biomolecules including diversity in backbone, chain length as well as number and position of 
unsaturated bonds (186, 187). While the functional consequences of lipid diversity are not fully 
understood, it is well characterized that lipids help regulate a variety of cellular functions including 
protein signaling in the membrane as well as homeostasis (188, 189). Thus, the dysregulation in 
lipid metabolism is linked to a variety of pathological conditions including immune disorders and 
cancer (190).  
Cancer cells are metabolically reprogrammed to sustain their uncontrolled growth and 
proliferation. An increased production of lipids, nucleic acids and proteins is required to drive 
downstream oncogenic processes (185). While significant research has delved into the 
transcriptomics and proteomics of various cancers, the lipidomic profiles of most cancers remain 
poorly understood Lipids form a major component of the plasma membrane and various cellular 
membranes, as well as in vesicles for inter- and intra-cellular transport. Altered lipid composition 
leads to changes in membrane fluidity and cellular polarization (191). Thus the lipidomic profiles 
of cancer cells can lead to the development of biomarkers, identify potential therapeutic targets 
and help understand the underlying mechanisms of the diseased state. 
Various analytical approaches have been taken towards understanding lipid profiles of cancer cells. 
The expression level and activity profiling of various lipid synthesis enzymes have been performed 
to identify increased fatty acid synthase activity and ATP citrate lyase activity in tumors (192, 
193).  Microarray profiling of metabolic genes has revealed altered cholesterol metabolism and 
LDL profile (194). Raman spectroscopy has also been employed for understanding cellular lipid 
profiles at the single cell level (195) as well as 31P NMR spectroscopy has been employed towards 
lipidomic profiling (196).  
The complexity in study of lipids arises from the similarity in structures of lipids accompanied 
with overlapping mass. Lipids are classified in various ways including classifications based on 
their chain length, backbone or saturation levels. Based on their backbone, lipids are classified 
mainly into phospholipids, glycolipids, sphingolipids and sterols (Figure 1). The saponifiable part 
of phospholipids, glycolipids and sphingolipids are free fatty acids. Thus mixtures of lipids are 
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highly diverse and numerous, based on combinations of fatty acids and the backbone. The 
development of mass spectrometric techniques has enabled the separation and identification of 
complex lipid mixtures. Soft ionization techniques including ESI and MALDI allow lipids to 
remain intact for mass spectrometric analyses. These techniques, in combination with highly 
specialized softwares, are also quantitative allowing a thorough and high-throughput analysis of 
the lipid mixtures.  
The use of mass spectrometry to study cancer lipidomics has precedence in breast cancer, prostate 
cancer and adenocarcinoma among others (69, 70, 197). Phospholipids are the largest class of 
structural lipids and have been widely explored in various cancers. It has been observed that 
lysophosphatidylcholine (LPC) levels are increased in aggressive breast cancer cell lines (198). 
Individual lipid species including palmitate-containing phosphatidylcholines are overexpressed in 
malignant cancers (68). Furthermore, data obtained from lipidomics has been compared to 
transcriptomic data to discover specific lipid markers like cholesteryl oleate (CE) for prostate 
cancer and correspondingly overexpressed scavenger receptor class B type I resulting in CE 
accumulation (73).  
Although, there are several examples of lipidomics in cancer types of epithelial origin, the 
lipidomic profiles of cancers of mesenchymal origin such as osteosarcoma (OS), has remained 
unexplored. In this work, we investigate the global lipidomic differences in metastatic and non-
metastatic OS cells as compared to normal fetal osteoblast cells in a high throughout manner. We 
identified over 1500 lipid species across various classes including phospholipids, sphingolipids 
and ceramides, glycolipids and cholesterol. Differences in lipid profiles between the classes as 
well as difference between specific lipids were observed in all the classes of lipid that were 
examined. The statistical significance in the class wise differences was ascertained using ANOVA 
and the individual species were analyzed using the non-parametric Wilcoxon rank sum test (199) 
and the comparison was corrected by Benjamini-Hochberg false discovery rate (FDR) in 
MATLAB, accounting for false discovery rates. Furthermore, the lipidomic signature of each class 
was identified using principal component analysis. Finally, we identify a key class of lipids, 
diacylglycerols as being preferentially upregulated in the tumorigenic cell lines as compared to the 
non-cancerous control cell line. We block the pathway of diacylglycerol synthesis and show that 
it induces apoptosis as compared to non-treatment control as well as reduces migratory potential 
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of the metastatic cells. Taken together, in this work we compare the global lipidomic profile of 
osteoblasts, and non-metastatic and metastatic osteosarcoma cell lines. We further identify several 
differentially regulated pathways including diacylglycerols, which can serve as biomarkers and 
targeted for potential therapeutics.  
4.3 MATERIALS AND METHODS 
Materials: Amplex red kit was obtained from Thermo Scientific catalog no. A12216. PLC inhibitor 
U73122 was obtained from Enzo catalog no. BML-ST391-0005. U73122 was obtained from Santa 
Cruz Biotechnology (sc-3574). 
Cell culture: Human cell lines FOB, HOS and 143B were cultured in DMEM (Gibco, Invitrogen, 
Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) and 1mgml–1 penicillin–
streptomycin (Gibco, Invitrogen) at 37 °C and 5% CO2 in a humidified incubator.  FOB cells were 
kindly provided by Dr. Avudaiappan Maran at Mayo Clinic, Rochester, Minnesota. 
Extraction of Lipids: Cells were grown to 80-90% confluency. Cells were detached using scraping 
and cell count was performed. The cell suspension was immediately diluted with PBS (1:1) and 
centrifuged 5 min at 1700 rpm. The cell pellet was washed three times with 1ml PBS, followed by 
centrifugation at 1700 rpm for 5 min, and cells resuspended in 1ml PBS. The cells were lysed 
using 6 freeze thaw cycles rapidly. Total lipids from all cell lines were extracted with the Bligh 
and Dyer method (200). Briefly, 3.75 ml chloroform/methanol 1:2 (v/v) was added to 1ml of cell 
sample, vortexed well for 15 min, and incubated on ice for 5 min. An additional volume of 1.25 
ml chloroform and 1.25 ml dH2O were added. Finally, following vigorous vortex for 5 min, 
samples were centrifuged at 1,000 rpm for 5 min at room temperature to obtain a two-phase 
system: aqueous top phase and organic bottom phase from which lipids were obtained. This was 
dried down and submitted for MS. 
Lipidomics Analysis:  
Sample preparation:  200 uL methanol, 100 uL chloroform, and 30 uL water were added into the 
dried sample.  After centrifugation, 150 uL of aliquot from aforementioned solution was spiked 
with 5 uL 50 ug/mL internal mixture (Cer 18:1/12:0; PC 12:0/12:0; PE 14:0/14:0; PG 14:0/14:0;PS 
14:0/14:0) before instrument injection.  
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Instrument analysis: The samples were analyzed by using the Thermo Q-Exactive MS system 
(Bremen, Germany) in the Metabolomics Laboratory of Roy J. Carver Biotechnology Center, 
University of Illinois at Urbana-Champaign.  Software Xcalibur 3.0.63 was used for data 
acquisition and analysis.  The Dionex Ultimate 3000 series HPLC system (Thermo, Germering, 
Germany) used includes a degasser, an autosampler, and a binary pump. The LC separation was 
performed on an Thermo Accucore C18 column (2.1 x 150 mm, 2.6 μm) with mobile phase A 
(60% acetonitrile: 40% H2O with 10 mM ammonium formate and 0.1% formic acid) and mobile 
phase B (90% isopropanol : 10% aceontrile with with 10 mM ammonium formate and 0.1% formic 
acid ). The flow rate was 0.4 mL/min. The linear gradient was as follows: 0 min, 70% A; 4 min, 
55% A; 12 min, 35% A; 18 min, 15% A; 20 -25 min, 0% A; 26-33 min, 70% A. The autosampler 
was set to 15°C and the column was kept at 45°C.  The injection volume was 10 μL.   Mass spectra 
were acquired under both positive (sheath gas flow rate, 50; aux gas flow rate: 13; sweep gas flow 
rate, 3; spray voltage, 3.5 kV; capillary temp,  263 °C; Aux gas heater temp, 425 °C) and negative 
electrospray ionization (sheath gas flow rate, 50; aux gas flow rate: 13; sweep gas flow rate, 3; 
spray voltage, -2.5 kV; capillary temp,  263 °C; Aux gas heater temp, 425 °C).  The full scan mass 
spectrum resolution was set to 70,000 with the scan range of m/z 230 ~ m/z 1,600, and the AGC 
target was 1E6 with a maximum injection time of 200 ms.  For MS/MS scan, the mass spectrum 
resolution was set to 17,500.  AGC target was 5E4 with a maximum injection time of 50 ms.  Loop 
count was 10.  Isolation window was 1.0 m/z with NCE of 25 and 30 eV.  
Data analysis:   Thermo software LipidSearch (v.4.1.30) was used for lipid identification.  The 
lipid signal responses were normalized to sample dry weight and the corresponding internal 
standard signal response (for those lipid classes without corresponding internal standard, positive 
lipid ion signals were normalized with the signal of internal standard Cer 18:1/12:0 and negative 
ion signals were normalized with the signal of internal standard PG 14:0/14:0. 
Statistical Analysis: The high dimensional lipidomic data of three cell lines with their three 
replicates were orthogonally transformed to a lower dimensional eigenspace using principal 
component analysis (PCA) in MATLAB.  The lower dimensional space is formed by three 
principal components (PC) that contain more than 85% of the data.  
In order to identify the details of separation in lipid profiles of three cell lines, a two sample 
statistical test was used to compare a cell line versus each of the other two, resulted in a total of 
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three comparisons. The non-parametric Wilcoxon rank sum test (199) implemented in MATLAB 
was used to calculate the p-values. The comparison was corrected by Benjamini-Hochberg false 
discovery rate (FDR) control [2] and FDR values were calculated in MATLAB. Moreover, fold-
change was jointly used with p-values to compare different levels in lipidomic profiles and 
determine significant regulations.  
This procedure of statistical testing was executed in a global analysis among 17 lipid classes as 
well as an analysis of individual lipid profiles. Moreover, a third analysis was accomplished to 
characterize different lipid levels in treated versus untreated 143B cell lines. The global lipid 
profile is presented by lipid levels for all the 16 lipid classes in three cell lines with 3 replicates for 
each cell line. Therefore, a global lipid level value assigned to a lipid class in a replicate of one of 
the cell line is attained by adding up the profiles of all lipids belonging to that class and measured 
in the same replicate of the corresponding cell line. Finally, the global lipid profile is fed to the 
statistical testing procedure to identify significantly regulated lipids. In all three lipidomic 
analyses, the significance is assigned if fold-change > 2-fold or fold-change < 0.5-fold. Moreover, 
as a second measure in global and individual lipid analyses, significance is assigned if FDR < 0.15 
and FDR < 0.13 respectively. For the third analysis between treated and untreated 143B cell lines, 
FDR < 0.07 was used to assign significance.  
Identification of differentially expressed genes (DEGs) was carried by same statistical testing 
explained above. For gene expression analysis, significance is assigned if fold-change > 2-fold or 
fold-change < 0.5-fold and p-value < 0.05 (No significantly regulated genes were found for FDR 
< 0.35). 
Amplex red cholesterol assay: Lipids were extracted as outlined in the Bligh and Dyer protocol 
above. The lipids were suspended in reaction buffer and the protocol was followed as outlined for 
Amplex red cholesterol assay (Thermo Scientific catalog no. A12216). Briefly, 50 μL of lipid 
extract and 50 μL of the Amplex® Red reagent/HRP/cholesterol oxidase/cholesterol esterase 
working solution or working solution without esterase was added to the appropriate well and 
incubated in the dark at 37° C for 90 minutes. The plate was read using a spectramax II with 
excitation at 534 nm and emission at 590 nm. The samples were compared to cholesterol standard 
and normalized to cell number. 
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Cell titer blue assay: 20,000 cells were plated per well in 96 well plates and allowed to adhere 
overnight. In the morning, the cell media was aspirated and replaced with fresh 100 μL of cell 
media and incubated with compound or DMSO vehicle control (1 μL) and allowed to incubate at 
37 °C and 5% CO2 in a humidified incubator for 4 hours. 20 μL of cell titer blue reagent was added 
and the plate was incubated for 1 hour before the fluorescence was read using a plate reader with 
excitation at 534 nm and emission at 590 nm. 
Wound healing assay: Cells were grown to a confluent monolayer in 12 well plates and a scratch 
was made across the center of the plate with a pipette tip and images were taken. The media was 
replaced with fresh media and treatment or vehicle control was added to the wells. The cells were 
maintained at 37 °C and 5% CO2 in a humidified incubator and images were taken every two 
hours. The images were processed using ImageJ via the wound healing plugin and normalized to 
100% area at time 0.  
4.4 RESULTS 
Global lipidomics profile of osteosarcoma cells: To evaluate the lipidomic differences in 
osteosarcoma as compared to non-tumorigenic cells, we compared human osteoblast cells (FOB) 
to HOS osteosarcoma cells which are non-metastatic and with 143B cells which are highly 
metastatic (105). The total lipid was extracted from roughly 90% confluent cell plates using Bligh 
and Dyer method (200) for three separate experiments (n=3). Total lipid extract was subjected to 
LC-MS/MS analysis by Thermo Q-Exactive Hybrid Quadrupole-Orbitrap Mass Spectrometer and 
the data was searched against LIPIDSEARCHTM (Thermo Scientific) software to identify specific 
lipid species. The lipids were then normalized to respective internal standards and cell count from 
that sample to avoid instrument errors as well as errors due to different amounts of cells in each 
sample.   
Greater than 1000 species of lipids were identified in each of the cell lines (Appendix IV). The 
highest number of species was identified in phosphatidylcholines (PC) followed by 
phosphatidylethanolamines (PE) and cardiolipin (CL). The global data was statistically analyzed 
using single factor ANOVA and Tuckey post-hoc test. Figure 4.2 shows the global lipidomic 
changes by ANOVA. Furthermore, to gain more rigorous and specific information, the different 
classes as well as single lipid species were tested by the non-parametric Wilcoxon rank sum test 
(199) and the comparison was corrected by Benjamini-Hochberg false discovery rate (FDR) 
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control in MATLAB. A secondary analysis yielded finer details of what specific species within a 
class were upregulated and downregulated. The various class wise differences are represented in 
figure 4.3. A similar treatment of individual species is represented in figure 4.4 which shows the 
significantly upregulated species in each class. The data corresponding to figure 4.4 is given in 
Appendix IV. We note that in classes with low number of individual species, the results typically 
appear amplified and therefore results for MG (7 species), Pet (7), PA (6) and LPE (4) are not very 
as reliable as classes with higher totals species. Therefore, we focus on the lipid classes that are 
significantly upregulated or downregulated and discuss them further.  
Finally, a principal component analysis (PCA) was performed on the lipidomes of the different OS 
cell types (FOB, HOS, 143B) to distinguish the normal osteoblast cells (FOB) as compared to the 
non-metastatic and metastatic cells (HOS, 143B). As seen in figure 4.5A, in the PCA score plot, 
the OS cells (HOS and 143B) are separated in a different ellipsoid space from the normal osteoblast 
cells. This is also reflected in the two dimensional plot in figure 4.5B. The various classes and the 
specific species that were differentially regulated have been discussed below. We have discussed 
both total lipid content in each class and the type of lipid species in each class.  
Phosphatidylcholines (PCs) and Lysophosphatidylcholine (LPCs) 
Phosphatidylcholines (PCs) are the largest class of membrane phospholipids. LPC are 
phosphatidylcholines that arise from partial hydrolysis of PCs. PCs and LPCs were analyzed in 
positive ion mode. 130 species of PCs and 21 species of LPCs were detected (Appendix IV). 
Overall, similar levels of PC species were found in all three cell lines. The levels of PC in normal 
osteoblast FOB cells was slightly higher than HOS and 143B cells albeit insignificantly as 
analyzed by ANOVA and Wilcoxon tests.  
Figure 4.4 represents the upregulation in specific species. As indicated in the labels, the three 
different colors represent the differential regulation in a class versus another. As seen in figure 4.4, 
about 20% species are differentially regulated in FOB vs HOS, about 60% between HOS and 143B 
and about 50% species are differentially regulated between FOB and 143B. PC (34:1) was the 
most abundant species in all three cell lines  
As PCs form a large class of structural lipids, significant alteration in PC levels is not expected. 
However, lysophosphatidylcholine (LPCs) and sub-class of PCs have been correlated with various 
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cancers (201, 202). Herein, we observed that the amount of LPC was significantly higher in FOB 
cells than in 143B cells (p= 0.015) by ANOVA. This corresponds to the non-parametric global 
analysis test where LPC is downregulated in 143B with respect to both HOS and FOB cells as 
shown in figures 4.2 and 4.3. The amount of saturated LPCs was higher in all three cell lines as 
compared to the unsaturated LPC counterparts. However, both saturated and unsaturated LPCs 
were significantly higher in FOB cells as compared to the tumorigenic cell lines 
Among specific LPC species higher plasma levels of LPC (18:0) have been related to lower risk 
of cancer (203). This was corroborated in our results where FOB cells had the highest amount of 
LPC (18:0) and was significantly higher than 143B cells (p= 0.014) and modestly higher than HOS 
(p= 0.099). Figure 4.4 shows the comparison of individual species in all cell lines.  About 20% 
species were different among FOB and HOS and about 30% differential regulation was seen 
between HOS vs 143B and FOB vs 143B. 
Phosphatidylethanolamines (PE) and Lysophophatidylethanolamines (LPEs)  
PEs are positively charged phospholipids that account for 25% of all phospholipids. LPEs are 
derived from partial hydrolysis of PEs similar to LPCs (from PCs). Both PEs and LPEs were 
measured in negative ion mode. 117 PE species and 4 LPE species were detected (Appendix IV). 
Overall, no significant changes were observed in PE levels among the three cell lines by ANOVA 
and Wilcoxon test (Figure 4.2 and 4.3). There was a slight gradient decrease on going from 
osteoblasts to non-metastatic to metastatic cells, but these differences were not statistically 
significant. These results are in agreement with literature in breast cancer cell lines where MCF-
10A non-malignant cell lines had higher abundance of PE than the corresponding cancerous cells 
(69).  
The most abundant species was PE (18:0) in HOS and FOB cells. However, PE (18:1) was the 
most abundant in 143B metastatic cells. As observed in figure 4.4, under 30% of the PE individual 
species were differentially regulated in FOB vs HOS, 60% between HOS vs 143B and about 40% 
between FOB and 143B.  
Similar to the trend observed in LPCs, the levels of LPEs were significantly higher in FOB versus 
143B cells (p= 0.009). LPEs were highest in FOB cells, followed by HOS and least in 143B cells 
(Figure 4.2). A moderate change in LPE levels was also observed on going from non-metastatic 
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HOS to metastatic 143B cells (p=0.072). Due to low number of LPE species detected, the statistical 
data for individual species as seen in figure 4.4 is unreliable for LPE> 
Phosphatidylserines (PS) 
Phosphatidylserines are negatively charged membrane proteins that are typically present in the 
inner cell membranes (204). However, in cells undergoing apoptosis they flip out to the outer 
membrane in cells undergoing apoptosis (205). 43 species of PS were detected in our studies in 
negative ion mode (Appendix IV). The differences between the three cell lines were not significant 
by ANOVA and Wilcoxon tests (Figure 4.2 and 4.3).  
However, specific lipid species were differently expressed. As seen in figure 4.4, there was less 
than 10% difference in the individual species between FOB and HOS. However, over 50% species 
were differentially regulated in HOS vs 143B and 30% species between FOB and 143B potentially 
suggesting a role for specific PS species in the metastatic process.  
Sphingolipids- Ceramides (Cer) and Sphingomyelins (SM) 
Sphingomyelins and ceramides are lipids with a sphingosine backbone. Ceramides were analyzed 
in positive ion mode and total of 124 individual ceramide species were detected (Appendix IV). 
Among these 20 CerG1, 14 CerG2 and 9 CerG3 ceramides of the simple Glc series (neutral 
glycosphingolipids) were detected. Overall ceramides were found to be significantly 
downregulated in HOS vs FOB cells by Wilcoxon test (figure 4.3). The tumorigenic cells showed 
slightly less amount of total ceramides than their osteoblast counterpart. Specifically, HOS cells 
had the least amount of ceramides followed by 143B with FOB exhibiting the highest amount 
(figure 4.2). 
Comparing the individual species in the three cell lines, as seen in figure 4.4, there is about a 45% 
difference between FOB and HOS, HOS and 143B and FOB and 143B.  
Sphingomyelins were analyzed in positive ion mode. 101 SM species were detected (Appendix 
IV) and overall the differences in SM content in all 3 lines remained relatively consistent (figure 
4.2). However, the levels of SM were slightly less in the metastatic 143B cells as compared to the 
osteoblast FOB cells and non-metastatic HOS cells (figure 4.2).  
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Specifically, several SM species were significantly lower in 143B cell lines and sometimes below 
the threshold of detection. These were SM(d18:1/19:0), (d40:4), (d42:5), (d44:4), (d44:7), (d46:7) 
and (d48:2). As seen in figure 4.4, all classes showed several differentially regulated species. A 
50-60% difference in individual species was observed in all three comparisons FOB vs HOS, HOS 
vs 143B and FOB vs 143B. 
Cardiolipins (CL) 
Cardiolipin is an inner mitochondrial membrane phospholipid constituting 20% of the membrane 
lipid composition (206). 142 CL species were detected in negative ion mode (Appendix IV). As 
seen from figures 4.2 and 4.3, CL expression in HOS cells is significantly more than in FOB and 
143B cell lines.  
As shown in figure 4.4, there is a 45% difference in individual species in FOB vs HOS, about 65% 
between HOS and 143B and about 30% between FOB and 143B. 
Cholesteryl Esters (ChE) 
Cholesteryl esters are fatty acid esters of cholesterol through the hydroxyl group of cholesterol. 
They are a biologically inert form of cholesterol storage and liberate cholesterol when it is required 
for membrane and lipoprotein formation (207). In our data, 38 distinct species of cholesteryl esters 
were detected in positive ion mode (Appendix IV). While the levels of ChE in FOB and HOS cells 
was relatively similar, the amount of ChE in 143B cells was significantly lesser (p= 0.045 HOS vs 
143B and p= 0.068 FOB vs 143B) by ANOVA (Figure 4.2). This is reflected in the non-parametric 
global analysis in figure 4.3 where 143B is downregulated as compared to both HOS and FOB 
cells. 
Several distinct species of ChE were downregulated in 143B vs HOS and FOB. These include 
18:1, 18:2, 20:3, 20:4, 20:5, 22:3, 22:4, 22:5, 22:6 and 24:4, 24:5, 24:6, 26:0, 28:1, 30:1 and 30:5 
(Figure 4.6B). Conversely however, three species were significantly higher in 143B vs FOB and 
HOS cells. These were 28:1, 30:1 and 30:3. As observed in figure 4.4, HOS and FOB have only 
10% species differentially regulated. However there are greater than 60% difference in species 
when 143B is compared to FOB or HOS. 
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Total cholesterol was not measured in our studies via high throughput lipidomics since the ESI-
MS platform is not well suited for detection of free cholesterol. However, as the interest in 
cholesterol and cholesterol metabolism and their correlation with cancer has increased in literature, 
we measured both total cholesterol as well as cholesteryl esters in our cells through amplex red 
measurement (208). The assay is based on the oxidation of cholesterol in the presence of 
cholesterol oxidase. The hydrogen peroxide so generated converts the amplex red to resorufin, 
which is a fluorescent molecule. The assay is further modified to convert cholesterol esters to free 
cholesterol first by using cholesterol esterase and thus gives a measurement of total cholesterol in 
the cells. In our assay, we performed the experiment with all three cell lines with and without 
cholesterol esterase to examine the amount of free cholesterol, cholesterol esters and total 
cholesterol in each cell line. As observed in figure 4.6A, the total cholesterol levels were greatest 
in FOB cells, followed by 143B cells and then HOS cells. However, none of these differences were 
significant. The amount of free cholesterol also followed the same pattern in levels. Finally, the 
difference between total cholesterol and free cholesterol was calculated to determine the amount 
of cholesteryl esters. As observed in figure 4.6A, the amount of ChE was greatest in FOB followed 
by HOS and very low in 143B, although these differences were not statistically significant. These 
values indicate that the levels of esterified cholesterol are lower in 143B cells as compared to FOB 
and HOS cells thereby confirming results found in our lipidomics data. 
MonoacylGlycerols (MG) 
Monoacylglycerols contain one glycerol moiety connected to a fatty acid through an ester bond. 
MGs are catabolized by monoacylglycerol lipase (MAGL) to form free fatty acid and glycerol and 
the overexpression of MAGL in cancers has generated recent interest in this pathway. In our 
studies we detected seven MG species in positive ion mode with four saturated and three 
monounsaturated species (Appendix IV). A significant overexpression of MG was observed in 
143B metastatic cells as compared to both non-metastatic HOS (p=0.0105) and osteoblast FOB 
(p=0.0069) cells by ANOVA and is also reflected by the results of the non-parametric global 
analysis (figure 4.2 and 4.3). However the difference between HOS and FOB cells was not 






Diacylglycerols contain two glycerol units esterified with a fatty acid backbone. DG levels in 
cancer cells has been shown to be dysregulated, signaling through the protein kinase C pathway 
(209). Additionally, the levels of DG have been shown to affect the effectivity of drugs such as 
fatty acid synthase inhibitors in cancer cells (210). In our studies, 54 DG species were detected in 
positive ion mode (Appendix IV).  
Different regulation of DG species was observed in 143B cells as compared to HOS cells 
(p=0.029) and FOB cells (p=0.07) by ANOVA (figure 4.2). Although the latter is not significant 
by ANOVA, both are reflected in the global Wilcoxon test as significant regulations (figure 4.3). 
 As seen in figure 4.4, over 60% species were differentially regulated in 143B as compared to FOB 
and HOS, making this class one of the hallmark characteristics of the 143B cell line. There was 
only a 30% difference between FOB and HOS.  
Phosphatidic Acids (PA) 
Phosphatidic acids are components of the membrane and generate DAGs as mentioned previously. 
DAG itself converts to PA in the presence of DAG kinases that are also targets for cancer drugs 
(211). In our studies six PA species were detected in negative ion mode (Appendix IV). While 
ANOVA indicated the differences in PA levels to be not significant (figure 4.2), global Wilcoxon 
test revealed that PA is downregulated in HOS as compared to FOB cells (figure 4.3).  
TriAcylGlycerols (TG) 
Triacylglycerols contain three esterified glycerols on a fatty acid backbone. Similar to MG and 
DG, TGs are also implicated in various cancerous pathways. Particularly, increased levels of TG 
are associated with enhanced apoptosis (212, 213). Our results show a similar trend. 163 species 
of TG were identified in positive ion mode (Appendix IV) and the levels of TG were most in FOB 
cells, followed by HOS and least in 143B cells (Figure 4.2). The difference between FOB and 
143B was significant with p=0.03 by ANOVA and was also reflected in the global Wilcoxon test 
(figure 4.3).  
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Specific species that were higher in FOB versus 143B cells were As observed in figure 4.4, there 
is a 20% difference in individual species levels in FOB vs HOS, 35% between HOS and 143B and 
about 50% between 143B and FOB. 
DG inhibition results in reduced cell viability and migration 
As identified in the previous section, diacylglycerols are a significantly upregulated population in 
the lipidome of 143B vs HOS and FOB cells. Therefore, we wanted to investigate if the inhibition 
of DG synthesis will result in reduced cell viability and migration. There are several different 
synthetic pathways for the formation of DGs. The chief pathway of synthesis is through the 
phospholipase C (PLC) catalyzed hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) in 
the membrane to form DG, which remains in the membrane and inositol-triphosphate (IP3), which 
acts as an intracellular signal transduction molecule. Alternately, DG can be produced from MGs 
by monoacylglycerol transferase and from phosphatidic acid through phosphatidic acid 
phosphatase (PAP). The inhibition of PLC to inhibit DG synthesis and its effects on various 
diseased states has been investigated (214, 215). In our studies, we used PLC inhibitor U73122 to 
block diacylglycerol synthesis and investigate its effects on metastatic 143B cells. First, 143B cells 
were incubated with 1 μM U73122 for four hours and lipids were extracted by the Bligh and Dyer 
method and analyzed by high-throughput lipidomics. As seen from figure 4.7A, the levels of DG 
were reduced in the treated samples as compared to the controls. Surprisingly, TG levels went up 
significantly after inhibitor treatment. We further looked at what percentage of individual species 
were affected by the inhibitor treatment. As seen in figure 4.7B, most classes of lipids were 
affected. This is expected, since DG synthesis is directly linked to most phospholipid synthesis 
(216).  
Furthermore, as seen from figure 4.8A, the cell viability is reduced in all three cell lines, but the 
change is greatest in 143B cells, the presence of 0.1 μM, 0.5 μM and 1 μM of U73122 using the 
cell titer blue assay (217). Finally, a reduction in cell migration is also observed in 143B cells in 
the presence of U73122 as indicated by the wound healing assay (218) in figure 4.8B-D but the 
effect is not observed in HOS cells (figure 4.6D). While a PLC inhibitor affects various pathways 
in the cancer cell, this study exhibits that the reduction of DAG levels is a contributor towards 
reducing cell viability and reduction of cell migration, two hallmarks of cancer cells. 
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Finally, we wanted to explore if the gene expressions for the synthesis and metabolism of 
diacylglycerols concur with our data. We studied a published microarray gene expression data 
(219) available in GEO database (accession number: GSE66673) containing the gene expression 
during the early and late passages of  HOS and 143B cells with three replicates (n=3) for all cell 
lines (219). This dataset contained 42545 probe sets that were mapped to either a known or a model 
RefSeq accession number and were grouped into 20724 unique genes. We used the data to identify 
differentially expressed genes in late passage 143B versus late passage HOS cells. Among all of 
the 20724 genes, 1415 genes passed our significance thresholds that gives a differentially 
expressed gene ratio of 0.068. In order to identify the differentially expressed genes in DG 
metabolism, we used KEGG database to obtain DG metabolic pathway. We identified 3 
differentially identified genes in DG metabolism that were found to be upregulated in 143B versus 
the HOS cells- AGPAT9, PPAP2C and MGLL as shown in figure 4.9.  
4.5 DISCUSSION 
The lipidomic profiling of cancer cells has become an important area of research that has been 
facilitated by the improvement of mass spectrometric techniques that can identify as quantify very 
small quantities of lipids in mixtures of hundreds of species. While the investigation of the 
lipidome of breast cancer and prostate cancer cells has been recently explored, the investigation of 
lipidomic profiles of bone cancers has remained unexplored. In this work, we investigate the 
lipidomic profile of human osteosarcoma cell lines and compared them to a human osteoblast cell 
line. We perform high throughput lipidomics of osteoblasts (FOB), non-metastatic (HOS) and 
metastatic (143B) cells. Various classes and hundreds of individual species in each class were 
identified in our results and several of them were found to be differentially regulated.  
Among the chief lipid classes, we found cholesteryl esters, cardiolipins, mono-, di- and 
triacylglycerols, lysophosphatidylcholines, lysophosphatidylethanolamines, as well as various 
individual lipid species to be significantly differentially regulated. In general, various patterns can 
be drawn from the global lipidomic changes represented in figures 4.2 and 4.3. Lipids that are 
differentially regulated in HOS or 143B vs FOB can be correlated with the process of 
tumorigenesis. Additionally, lipids that are differentially regulated in 143B vs HOS can be 
correlated with the metastatic process. As seen in figure 4.2 and 4.3, ceramides are downregulated 
in HOS cells and cardiolipins are upregulated in HOS cells as compared to FOB cells. Furthermore, 
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mono and diacylglycerols are upregulated in 143B vs HOS and LPC and LPE are downregulated 
in 143B vs HOS.  
Ceramides are bioactive sphingolipids that have come to the forefront of cancer research. 
However, the various ceramide species, depending on the fatty acid conjugated to them have 
shown various properties including their roles in cellular proliferation or cancer cell death (220). 
For instance, C18-ceramide treatment suppresses tumor growth in head and neck cancer cells 
(221), however, the C16- ceramides induce head and neck squamous cell carcinoma tumor 
proliferation (222). Thus, a cumulative evaluation of ceramide species will not be accurate in 
representing the correlation of lipid with osteosarcoma. In our results, the levels of C18 ceramides 
was significantly less in 143B and HOS cells as compared to the FOB cells, which is in agreement 
with literature results. C-18 ceramide has been recognized as a serum biomarker for monitoring 
chemotherapy response as its levels increase with improvement in diseased state for HNSCC 
(223).  
Conversely, cardiolipins (CL) maybe implicated in tumorigenesis. Indeed, CL has been found to 
impact prostate cancer cell proliferation (224). Specifically, C16 rich cardiolipin was found to 
stimulate proliferation and C18 cells were found to reduce proliferation. As observed from table 
ST1, C18 rich CL appear to have a higher expression in FOB cells as compared to 143B cells and 
C16 rich CL have a higher expression in 143B cells, therefore in agreement with literature 
observation. For example, CL(16:0/16:0/16:0/16:0) is not detected in FOB cells but is detected in 
both 143B and HOS cells and CL(18:4/18:2/18:2/18:2) is much lower in 143B cells as compared 
to FOB cells. 
The abundance of LPCs in non-tumorigenic cell line as compared to the tumorigenic OS cell lines, 
indicates a faster metabolism of LPCs in OS cells as compared to the normal cells. Indeed, in 
human colorectal cancer, it has been shown that lysophosphatidylcholine acyltransferase 1 
(LPCAT1), the enzyme that converts LPC to PC is overexpressed (225) and LPCAT1 expression 
has been investigated as a biomarker in prostate cancer as well (226). However, as the levels of 
LPC reduces in 143B cells as compared to HOS cells indicating that while they promote 
tumorigenesis, they may not be completely implicated in the process of metastasis.  
Cholesterol and cholesterol metabolism have been found to be highly dysregulated in cancer (227). 
However, the underlying mechanism of this is not very well understood. The accumulation of 
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cholesterol is usually correlated with higher cancer progression and metastasis. However, in our 
studies we observed that the level of cholesteryl esters in metastatic OS cell line 143B was 
significantly less than the osteoblast and the non-metastatic cell lines. On exploring this further 
via an Amplex red detection of total cholesterol as well as cholesteryl esters in all three cell lines 
we found that the levels of cholesterol, both free and esterified, were higher, albeit not 
significantly, in normal osteoblast cells than tumorigenic osteosarcoma cells. 
The other lipid signaling pathway of interest are acylglycerols. Mono-, di- and tri-acyl glycerols 
are important lipid components of the cell and all three were identified in our studies. While MGs 
and DGs increased in metastatic cells as compared to their non-metastatic counterparts, TGs 
reduced. While all three moieties are synthesized through various pathways, they also interconvert 
through various enzymatically facilitated pathways. Since the DG levels increase but no increase 
but the reverse trend is seen for TGs, it can be hypothesized that diacylglycerol transferase 
(DGAT), the enzyme responsible for the conversion of DG to TG is expressed less in metastatic 
cells. Conversely, it is possible that the lipase responsible for TG to DG conversion is 
overexpressed. Additionally, phosphatidic acid (PA) is converted to DAG by PAP (phosphatidic 
acid phosphatase) and it is possible that PAP is overexpressed resulting in high levels of DAG but 
similar levels of PA in the osteoblast versus osteosarcoma cells.  
In our work, we show that inhibiting PLC and therefore inhibiting the DG synthesis pathway 
results in reduced cell viability and migration. DG is an important membrane lipid and acts as a 
secondary messenger. DG is known to bind directly to protein kinase C and D family, as well as 
to the Ras family (228, 229). The DG related activation of PKC and PKD plays an important role 
in cancer as they signal through multiple pathways and control the expression of genes controlling 
cell cycle progression, tumorigenesis and metastasis (230). Therefore, it is not surprising that the 
reduction of DG accumulation in cells reduces the cellular viability. Finally, we identify genes 
associated with the DG pathway that are differentially regulated. AGPAT9 encodes for glycerol-
3-phosphate acyltransferase 3 (GPAT3). It catalyzes the conversion of glycerol-3-phosphate (G3P) 
to lysophosphatidic acid (LPA), which converts to phosphatidic acid and subsequently to 
diacylglycerol (231). The genetic upregulation of AGPAT9 in 143B therefore corresponds to the 
increased synthesis of diacylglycerol and thus higher levels of DGs in 143B cells than HOS. 
Interestingly, AGPAT9 is also known as metastasis associated gene 1 and activates the mTOR 
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pathway (232). PPAP2C gene encodes for lipid phosphate phosphohydrolase 2, which catalyzes 
the conversion of phosphatidic acid to diacylglycerol (233) and hence increases levels of DG 
overall. PPAP2C has been shown to be a potential anti-cancer drug target by genomic screening 
in transformed adult mesenchymal stem cells (234). Furthermore the knockdown of PPAP2C 
impaired anchorage-dependent in vitro growth of cancer cell lines and impaired the in vitro growth 
of primary mesenchymal stem cells but not differentiated human fibroblasts by delaying entry into 
S phase of the cell cycle and is transcriptionally regulated by p53.  
4.6 CONCLUSION 
This work compares the global lipidomic profile of normal osteoblast cells to non-metastatic and 
metastatic osteosarcoma cell lines. We show that various different lipid pathways and specific lipid 
species are differentially regulated in the diseased state. Furthermore, we identify that 
diacylglycerols are significantly upregulated in metastatic 143B cells as compared to HOS and 
FOB cells. We block the synthesis of DG though PLOC inhibition and exhibit that this reduces 
cell viability as well as cell migration in 143B cells. Finally, we identify 2 genes involved in DG 
synthesis pathway that are significantly upregulated and therefore can be potential therapeutic 
targets in osteosarcoma. 
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4.8 FIGURES, TABLES AND LEGENDS 
 
Figure 4.1: Figure shows the various classes of lipids. The major classes of biological lipids are 
phospholipids, sterols, acylglycerides and sphingolipids. Phospholipids are further classified into 
phosphatidylcholines (PC), phosphatidylethanolamines (PE), phosphatidylserines (PS), 
phosphatidylglycerols (PG), cardiolipin (CL) and phosphatidylinositols (PI). The major human 
sterol is cholesterol which is often stored as cholesteryl ester (ChE). Acylglycerols can be 
monoacylglycerols (MG), diacylglycerols  (DG) and triacylglycerols (TG) based on the number 







Figure 4.2: Figure represents the fifteen major classes of lipids detected in three cell lines- 
osteoblast FOB (green vertical striped), non-metastatic HOS (purple horizontal striped) and 
metastatic 143B (yellow dots) as analyzed by ANOVA. The various lipid classes are 
phosphatidylcholines (PC), phosphatidylethanolamines (PE), phosphatidylserines (PS), 
phosphatidylglycerols (PG), phosphatidylinositols (PI), cardiolipin (CL), cholesteryl ester (ChE), 
monoacylglycerols (MG), diacylglycerols (DG), triacylglycerols (TG), sphingomyelins (SM) and 
ceramides (Cer), lysophosphatidylcholines (LPC) and lysophosphatidylethanolamines (LPE). All 








Figure 4.3: (A) Figure shows the global analysis of lipid classes by Wilcoxon rank sum test and 
comparison correction by Benjamini-Hochberg false discovery rate. The heat map represents 
classes that are upregulated (green), downregulated (red) and those where no significant 
differences were found (grey) in each lipid class for HOS when compared to  FOB (left panel), 
143B when compared to HOS (middle panel) and FOB when compared to 143B (right panel). (B) 










Figure 4.4: Figure shows the number of individual species that are significantly different among 
the three cell lines. Differences between FOB and HOS represents differences in lipids between 
normal and non-metastatic state (yellow). Differences between 143B and HOS represents 
differences in lipids between non-metastatic and metastatic state (blue). Differences between FOB 













Figure 4.5: (A) Figure shows principal component analysis on all three cell lines, osteoblast FOB 
(red), non-metastatic (green) and metastatic 143B (blue) cells as represented in a three dimensional 
space.  (B) The same PCA plot with osteoblast FOB (red), non-metastatic (green) and metastatic 
143B (blue) cells as represented in a two dimensional space. As seen in figure, all three cell lines 












Figure 4.6: (A) Figure shows the levels of total cholesterol (vertical lines), free cholesterol 
(horizontal bars) and cholesteryl ester (dots) in FOB (green), HOS (purple) and 143B (yellow) 
cells as measured by the Amplex red detection methodology. (B) Figure shows shows specific 
cholesteryl ester species significantly differentially regulated in the three cell lines FOB (green), 












Figure 4.7: (A) Figure represents differences in total lipidomic content of 143B cells on treatment 
with PLC inhibitor U73122. Solid bars represent the lipidomic composition before treatment and 
striped bars represent composition after treatment with PLC inhibitor. (B) Figure represents 
percentage changes in individual lipid species in treated vs untreated cells that are downregulated 








Figure 4.8: (A) Figure represents reduction in cell viability in all three cell lines on treatment with 
PLC inhibitor as measured by cell titer blue assay. (B) Figure represents cell migration in 143B 
and HOS cells over time at different concentrations of PLC inhibitor U73122. (C) Figure 
represents cell migration in HOS cells at 0 and 8h time points with 1 µM concentration of U73122. 
(D) Figure represents cell migration in 143B cells at 0 and 8h time points with 1 µM concentration 






Figure 4.9: Figure shows differentially regulated genes associated with the diacylglycerol 
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CHAPTER V: ANTI-TUMORIGENIC PROPERTIES OF OMEGA-3 
ENDOCANNABINOID EPOXIDES 
5.1 ABSTRACT 
Dietary omega-3 fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) have been shown to suppress tumor growth and progression as they are converted into 
downstream lipid metabolites that exert anti-inflammatory, pro-resolving and anti-tumorigenic 
effects. Recently, a new class of omega-3 lipid metabolites known as endocannabinoid epoxides 
(eCB epoxides) were found to have potent anti-inflammatory and anti-angiogenic properties. 
Herein, we show that a novel class of omega-3 eCB epoxides and their stable derivatives exhibit 
anti-inflammatory (28), anti-angiogenic, anti-tumorigenic and anti-migratory properties in 
osteosarcoma, the most common bone cancer in human. We find these molecules are 80% more 
in osteosarcoma metastatic lungs. We synthesized more stable analogs of these molecules, which 
are less hydrolytically susceptible to fatty acid amide hydrolase (FAAH) while retaining their anti-
tumorigenic activity. Furthermore, we investigated whether the endogenous molecules as well as 
the synthetic analogs affect the cell cycle of osteosarcoma cells as well as whether they have an 
effect on the angiogenic properties of endothelial cells. Taken together, we show that a new class 
of biological metabolites of omega-3 fatty acids have beneficial anti-cancer effects and have 
therapeutic potential with respect to bone cancer pain and inflammation. 
5.2 INTRODUCTION 
Recent studies in cancer have focused on understanding the role of inflammation in tumor 
initiation and malignant progression. It has been shown previously that inflammatory conditions 
can promote oncogenic transformation, and in turn the carcinogenic environment can also generate 
an inflammatory microenvironment that can further support tumor progression (1-3). Dietary 
omega-3 fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have 
been shown to suppress tumor growth and progression as they are converted into downstream lipid 
metabolites that exert anti-inflammatory, pro-resolving (4) and anti-tumorigenic effects (5) (6) (7). 
As inflammation dictates tumor initiation, progression and growth, it is hypothesized that omega-
3 fatty acid derived lipid metabolites will contribute towards preventing tumor formation and 
metastasis (5). Hence, it is necessary to discover potential omega-3 fatty acids based lipid 
metabolites that possess anti-tumorigenic and anti-inflammatory properties.  
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In one particular physiological pathway, omega-3 fatty acids such as EPA and DHA are converted 
to their corresponding epoxides by cytochrome P450 (CYP) epoxygenase that have shown to 
exhibit have anti-cancer properties. The epoxide derivative of EPA known has been shown to be 
anti-proliferative (8). It was observed that the terminal epoxide of EPA, 17,18-EEQ 
(epoxyeicosatetraenoic acids), decreased endothelial cell proliferation, interrupted the cell cycle 
in S-phase and down-regulated the cyclin D1/cyclin-dependent kinase (CDK)-4 complex. The 
corresponding DHA epoxide, epoxydocosapentaenoic (EDP) inhibits metastasis and tumor growth 
(9). Furthermore, the action of the DHA and EPA epoxides are attenuated in the absence of a 
soluble epoxide hydrolase (sEH) inhibitor, indicating that the functional epoxide moiety is key for 
their anti-tumorigenic properties.  
Omega-3 fatty acids such as DHA and EPA are also converted non-oxidatively into 
docosahexaenoyl ethanolamide (DHEA) and eicosapentaenoyl ethanolamide (EPEA) through the 
N-acyl ethanolamine synthesis pathway similar to the conversion of arachidonic acid to 
arachidonoyl ethanolamide (AEA, anandamide) (10, 11). These ethanolamide derivatives are 
collectively termed as endocannabinoids (eCB) as they elicit similar physiological effects as 
cannabinoids found in marijuana. The endocannabinoid system consists of the eCBs and 
cannabinoids receptors 1 and 2 (CB1 & CB2) (12, 13). While, CB1 is predominantly found in the 
central nervous system (CNS), CB2 is found in immune cells (14). These receptors interact with 
various eCBs to exert their physiological activities (15). Interestingly, these receptors also interact 
with the active ingredients in cannabis, or marijuana and are responsible for their psychoactive and 
anti-inflammatory properties. Phytocannabinoids, Δ-9-THC and cannabidiol (CBD), are major 
components of marijuana has been shown to induce apoptosis in hepatocellular carcinoma, breast 
cancer as well as colon cancer (16). Phytocannabinoids and eCBs have been shown to play an 
important role in cancer cell proliferation, apoptosis, inflammation and immunomodulation and 
form the basis of medical marijuana use in cancer (17, 18).   
The most studied eCBs in the human body are AEA and 2-arachidonylglycerol (2-AG) that are 
derived from the omega-6 fatty acid arachidonic acid (AA). Anandamide was shown to be anti-
tumorigenic in breast cancer, colorectal cancer as well as osteosarcoma (19-21). 2-AG has been 
shown to induce apoptosis in prostate cancer (22). Omega-3 derived eCBs, DHEA and EPEA have 
shown greater anti-proliferative efficiency than their parent counterparts in prostate cancer cells 
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(11). Additionally, it was also shown that the activity of eCBs in cancer cell was increased in the 
presence of a fatty acid amide hydrolase (FAAH) inhibitor, indicating that the ethanolamide 
endocannabinoids, AEA DHEA and EPEA contributes to the increased pro-apoptotic and anti-
proliferative activity.  
Recently, we showed that a novel class of eCB epoxides are generated from the cross-talk of the 
NAPE-PLD pathway and CYP epoxygenase pathways that are anti-inflammatory in nature and 
were found in multiple tissues (23) (Figure 5.1A). As separately both the endocannabinoid and 
epoxyeicosanoid pathway have been implicated in cancer as described above (8, 9) we wanted to 
evaluate their anti-tumorigenic properties of dual functional eCB epoxides in a cancer model. 
These lipid metabolites termed as EPEA epoxide (a.k.a. epoxyeicosatetraenoic-ethanolamide 
(EEQ-EA)) and DHEA epoxide (a.k.a. epoxydocosapentaenoic-ethanolamide (EDP-EA)) are 
synthesized from EPEA and DHEA by cytochrome P450s. More importantly, our analysis of the 
metastatic lung tissues show that there is almost ~77% increase in these eCB epoxides in metastatic 
lungs (Figure 5.1B and Appendix V) as compared to normal lungs of mice indicating that they 
play a physiological role in cancer metastasis.  
Herein, we investigate the anti-tumorigenic role of the different regioisomers of omega-3 eCB 
epoxides of DHEA on osteosarcoma. Osteosarcoma (OS) is the most prevalent primary bone 
cancer in humans and presents high rates of invasion and metastasis. The cannabinoid receptor 
agonist WIN-55212 has been shown to potentiate the anti-tumorigenic properties of drugs like 
Adriamycin in OS (24). Additionally, the administration of cannabinoid receptor agonists have 
shown to reduce bone loss in bone tumor model and cannabinoid receptor mediated nociceptive 
pain (25, 26). Taken together, herein we test our hypothesis that DHEA epoxide regioisomers and 
their stable derivatives will exhibit anti-tumorigenic activities in osteosarcoma and will potentially 
reduce bone cancer pain through receptor selective activation.  
In order to examine the anti-tumorigenic properties of DHEA epoxides, we first tested the 
apoptotic potential of the different regioisomers of DHEA epoxides using annexin V staining assay 
in three different OS cell lines - metastatic OS cell lines MG63 and 143B and the non-metastatic 
cell line HOS, and identified the most potent DHEA epoxide regioisomer. We further tested the 
anti-migratory potential of the DHEA epoxides via a wound healing assay in all three cell lines 
(27). Interestingly, we observed significant differences between the different DHEA epoxide 
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regioisomers tested with respect to their pro-apoptotic and anti-migratory properties that were 
uniform across the different cell lines chosen for the studies. This indicates common signaling 
pathways being triggered in the different cell lines by specific isomers of these lipid metabolites.  
Furthermore, we synthesized stable derivatives of the most pro-apoptotic regioisomer of DHEA 
epoxide (10,11-EDP-EA)  to reduce its hydrolytic susceptibility to fatty acid-amide hydrolase 
(FAAH) and increase binding to cannabinoid receptor 1 (CB1). The action of the most potent 
regioisomer and its stable derivatives were further tested towards their anti-tumorigenic, anti-
migratory and FAAH hydrolysis.  
Herein, we report a novel class of eCB epoxides and their stable derivatives that exhibit anti-
inflammatory (28), anti-angiogenic, anti-tumorigenic and anti-migratory properties and by virtue 
of their ability to bind cannabinoid receptors will also exhibit anti-nociceptive bone pain activities. 
As osteosarcoma is accompanied by inflammation and pain, these molecules will aid in alleviating 
both. Moreover, as they are naturally occurring increasing their levels using FAAH and sEH dual 
inhibition will be effective adjuvant therapy for osteosarcoma (29, 30). 
5.3 MATERIALS AND METHODS 
Materials: Annein V/ PI kit was obtained from BD biosciences (556547). HUVEC cells were 
obtained from ThermoFisher (C0035C) and endothelial cell media was obtained from Lonza 
(EGM2 bullet kit CC-3162). Angiogenesis kit was obtained from Abcam (ab204726). 
Isolation of endocannabinoids from tissue samples: K7M2 Experimental Metastasis Tumor 
Models. All animal experimental procedures were reviewed and approved by the University of 
Illinois Institutional Animal Care and Use Committee (Protocol 15120). 1,000,000 K7M2 cells 
were prepared in HBSS and intravenously injected into the tail vein of 6−8 week old female 
BALB/c mice (day 0) in a 200 μL volume. After x days the mice were sacrificed and lung tissue 
was isolated, weighted and total endocannabinoids were extracted. The tissue was mechanically 
homogenized on ice with a BioHomogenizer (BioSpec) in a 1:1 ratio with PBS supplemented with 
sEH inhibitor 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA) (Cayman Chemical) (30 
μm) and FAAH inhibitor PMSF (1 mM) till a homogenous slurry was formed. For 1 g of each 
tissue was homogenized, 40 mL of ethyl acetate/hexane (9:1) was employed with a 
BioHomogenizer (BioSpec) at room temperature and then was sonicated for 1 min. The resulting 
solution was washed with a 30% volume of water and centrifuged for the layers to separate. The 
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organic layer was removed, and the aqueous layer was extracted with an equal volume of ethyl 
acetate/hexane (9:1) twice. The total organic layer was concentrated in vacuo using a Buchi 120 
rotary evaporator and was reconstituted in 1 mL of chloroform. The metabolites of interest were 
isolated by solid-phase extraction (SPE) using a 1-mL silica gel column (no. 214477; Sigma). The 
reconstituted samples were added to the silica column and washed in three column volumes of 
chloroform, and consequently eluted with four column volumes of methanol/chloroform (1:9). The 
eluent was dried, and samples were reconstituted in ethanol for analysis via LC-MS/MS. 
Liquid chromatography mass spectrometry analysis. The LC separation was performed on an 
Agilent Eclipse XDB-C18 (4.6 x 150mm, 5μm) with mobile phase A (0.1% formic acid in water) 
and mobile phase B (0.1% formic acid in acetontrile). The flow rate was 0.4 mL/min. The linear 
gradient was as follows: 0-2min, 90%A; 8min, 55%A; 13-25min, 40%A; 30min, 30%A; 35min, 
25%A; 40-47min, 20%A; 47.5-54min, 90%A. The autosampler was set at 5°C. The injection 
volume was 10 μL. Positive mass spectra were acquired with the ion spray voltage of 5500 V under 
electrospray ionization (ESI). The source temperature was 450°C. The curtain gas, ion source gas 
1, and ion source gas 2 were 32 psi, 60 psi, and 60 psi, respectively.  Multiple reaction monitoring 
(MRM) was used for quantitation: 19,20-EDP-EA and 7,8-EDP-EA m/z 388.1 →  m/z 62.1; 16,17-
EDP-EA, 13,14-EDP-EA, and 10,11-EDP-EA m/z 388.1 →  m/z 370.1; DHEA 372.4 à m/z 62.1; 
Anandamide m/z 348.3 à m/z 62.1.  Internal standards were monitored at: m/z 376.4 →  m/z 66.1 
for DHEA-d4.  
Cell culture: Human cell lines HOS, MG63 and 143B were cultured in DMEM (Gibco, Invitrogen, 
Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) and 1mgml–1 penicillin–
streptomycin (Gibco, Invitrogen) at 37 °C and 5% CO2 in a humidified incubator.  
CTB assay: 20,000 cells were plated per well in 96 well plates and allowed to adhere overnight. 
In the morning, the cell media was aspirated and replaced with fresh 100 μL of cell media and 
incubated with compound or DMSO vehicle control (1 μL) and allowed to incubate at 37 °C and 
5% CO2 in a humidified incubator for 4 hours. 20 μL of cell titer blue reagent was added and the 
plate was incubated for 1 hour before the fluorescence was read using a plate reader with excitation 
at 534 nm and emission at 590 nm 
Annexin V assay: Annexin V kit from BD biosciences -San Diego, CA) was used. Briefly, cells 
were scraped and collected with the dead cells. They were washed with ice cold 2X PBS twice and 
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resuspended in 1X binding buffer and incubated with annexin V-FITC and propidium iodide for 
15 mins, followed by flow cytometry by BD Accuri C6 instrument. Annexin V/PI assay was 
performed as per manufacturer’s instructions. Briefly, cells were trypsinized and collected for 
analysis. Dead cells in the media were collected for testing along with the rest of the sample. The 
total cell sample was washed twice with cold PBS and then resuspended in 100 μL of binding 
buffer. 5 μL of each annexin V and PI were added and the cells were vortexed and incubated in 
the dark for 15 mins. The cells were then diluted with 400 μL of binding buffer and analyzed by 
BD Accuri flow cytometer within an hour. The treated samples were compared with negative and 
positive stained samples both with vehicle control. 
Wound healing assay: Cells were grown to a confluent monolayer in 12 well plates and a scratch 
was made across the center of the plate with a pipette tip and images were taken. The media was 
replaced with fresh media and treatment or vehicle control was added to the wells. The cells were 
maintained at 37 °C and 5% CO2 in a humidified incubator and images were taken every two 
hours. The images were processed using ImageJ via the wound healing plugin and normalized to 
100% area at time 0.  
Synthesis of amine EDP-EAs and analogs: To a solution of epoxide in acetonitrile, we will add a 
solution of 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) (10 mg/mL in acetonitrile) 
and N-hydroxysuccinimide (NHS) (10 mg/mL in acetonitrile) in the ratio of (1:50:50) and incubate 
at 37 °C for 20 mins. To this is we will add a solution of amine (2 mg/mL in acetonitrile) in the 
ratio of 1:50 with epoxide and this will be stirred at room temperature overnight. The acetonitrile 
will be removed under reduced pressure and the residue will be dissolved in ethanol before 
purification via HPLC. Purification of 10,11-EDP derivatives will be performed using a reversed 
phase high-performance liquid chromatography (RP-HPLC), Sun Fire Prep C18 5 µm 19 x 50 mm 
(Waters, PN 186002566) and a mobile system composed of solvent A (H20/acetonitrile/acetic acid 
95:5:0.1) and solvent B (H20/acetonitrile/acetic acid 5:95:0.1) and a linear gradient from 50% A 
to 0% A in 50 minutes. 
Cell cycle analysis: 80% confluent cells in a 12 well plate were treated for 24 hours with 
appropriate treatment and harvested. Cells were washed twice with PBS and fixed with 70% 
ethanol in ice for 30 mins by vortexing to prevent clumping. The cells were washed twice with 
PBS and were incubated with a 50 µL of a 100 µg/ mL RNase solution for 30 mins on ice followed 
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by addition of 200 μL of 50 µg/mL propidium iodide solution before analysis by BD LSR II flow 
cytometer and analyzed by FCS software. 
FAAH hydrolysis: The preparation of pig forebrain membranes was achieved using dounce 
homogenization in buffer (50 mM Tris pH 7.4, 1 mM EDTA and 3 mM MgCl2) and membrane 
pelleting as previously described (31). Incubations contained 5 µg forebrain protein in a 0.5 mL 
reaction containing 50 mM Tris (pH 7.4), 1 mM EDTA, 3 mM MgCl2, and amide at 20 µM. At 
40 min reactions were quenched with methanol containing 1 mM PMSF and and centrifuged to 
pellet protein (10,000 g x 10 min). The supernatant was collected and analyzed via LC-MS/MS as 
outlined below. 
Analysis of 10,11-EDP by LC-MS/MS: LC-MS/MS method for quantitation of 17,18-EEQ and 
19,20-EDP. Analyses were performed using the 5500 QTRAP LC/MS/MS system (AB Sciex, 
Foster City, CA) in Metabolomics Lab of Roy J. Carver Biotechnology Center, University of 
Illinois at Urbana-Champaign. The 1200 series HPLC system (Agilent Technologies, Santa Clara, 
CA) includes a degasser, an autosampler, and a binary pump, and this system was used to separate 
the metabolites. LC separation was performed on an Agilent Eclipse XDB-C18 (4.6 x 150mm, 
5μm) with mobile phase A (0.1% formic acid in 20 water) and mobile phase B (0.1% formic acid 
in acetonitrile) at a flow rate was 0.4 mL/min. The linear gradient was as follows: 0-2min, 90%A; 
8min, 55%A; 13-25min, 40%A; 30min, 30%A; 35min, 25%A; 40min, 20%A; 45-47min, 15%A; 
48-54min, 90%A. The autosampler was set at 5°C. The injection volume was 10 μL. Negative 
mass spectra were acquired with the ion spray voltage of -4500 V under electrospray ionization 
(ESI). The source temperature was 450 °C. The curtain gas, ion source gas 1, and ion source gas 
2 were 32 psi, 50 psi, and 55 psi, respectively. Multiple reaction monitoring (MRM) was used for 
quantitation: 10,11-EDP m/z 343.0.  
Angiogenesis Assay: Angiogenesis in endothelial HUVEC cells was measured using abcam 
angiogenesis kit (ab204726). Briefly, HUVEC cells at passage 2 (p=2) were grown to 80% 
confluency. The matrigel provided was thawed overnight and 50 μL was put into each well of a 
96 well plate that had been chilled overnight in a -20 °C freezer. The plate was rocked slightly and 
then allowed to incubate at 37 °C for 1 hour. 15,000 HUVEC cells were then plated into the wells 
and were treated with vehicle control or 0.5 μM or 1 μM compound. A no matrix control and a 
control with vinblastine (inhibitor of angiogenesis) was also performed. All wells were performed 
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in duplicates. The plates were then incubated for 5 hours at 37 °C. The incubation medium was 
removed and cells were washed with 100 μL of wash buffer. 100 μL of staining dye was added to 
each well and incubated for 30 mins at 37 °C. The wells were imaged using a fluorescent 
microscope and analyzed using ImageJ with Angiogenesis Analyzer Plugin. 
Synthesis of 10,11-cyclopropylamideaziridine: To a stirred solution of sodium azide (2 
equivalents) and ammonium chloride (3 equiv) in water at room temperature a solution of 
ethanolamine epoxide (1 equiv) was added in MeOH and then the reaction was stirred at 80 °C for 
3 h. After the solution is cooled to room temperature, the excess of MeOH will be removed under 
reduced pressure and the residue will be diluted with EtOAc, washed with water, dried over 
anhydrous sodium sulfate and concentrated under reduced pressure to give a brown oil. Filtration 
on a pad of silica gel (hexane/EtOAc 4:1) gave the nitrile that is taken forward for the next reaction. 
A solution of nitrile in anhydrous acetonitrile was heated to reflux under nitrogen atmosphere. 
Next, triphenylphosphine (20 equiv), was added immediately and the reaction will be stirred under 
reflux for 3 h. After cooling to room temperature, the mixture was concentrated under reduced 
pressure and purified by column chromatography on silica gel (hexane/EtOAc 7:3). 
Synthesis of 10,11-cyclopropylamidethiirane: To a solution of 10,11-cyclopropylamine in 
methanol was added KSCN and oxalic acid and heated in a commercial microwave at power 1 for 
10 mins. The reaction mixture was cooled and concentrated in vacuo. The mixture was purified 
using normal phase HPLC using 90% hexane 10% isopropanol as the eluent. 
5.4 RESULTS 
DHEA epoxides are endogenously produced in osteosarcoma metastatic lung tissues. We have 
developed a targeted lipidomics method in the multiple reaction monitoring (MRM) mode to 
identify and quantitate DHEA epoxides (EDP-EA) regioisomers (19,20-, 16,17-, 13,14-, 10,11-, 
and 7,8-) (28). In order to estimate the basal levels of the endogenous EDP-EA regioisomers in 
metastatic and non-metastatic lungs, we measured the metabolites on osteosarcoma tumor in mice. 
Towards this, an experimental metastasis tumor model was prepared. 1,000,000 K7M2 cells 
(murine OS cells) were prepared in HBSS and intravenously injected into the tail vein of 6−8 week 
old female BALB/c mice in a 200 μL volume. Lungs from ten mice, five nude mice with lungs 
free of tumor and five with lung metastasized osteosarcoma tumors were isolated and the total 
endocannabinoids were extracted and quantified by LC-MS/MS as described in materials and 
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methods. As indicated in figure 5.1B and Appendix V, we can observe that both tumor-free lungs 
and lungs with tumors produced eCB epoxides with several fold difference compared to DHEA, 
the parent molecule. There was ~87% increase in the terminal DHEA epoxide (19,20-EDP-EA), 
66% increase in 16,17-EDP-EA, 72% increase 13,14-EDP-EA, 49% 10,11-EDP-EA and DHEA 
essentially decreases in lungs with metastasized tumors as compared to healthy lungs with no 
tumors. The high increase of these metabolites in the metastasized lungs warranted further 
investigation of their anti-tumorigenic properties.  
In order to investigate the effects of eCB epoxides on osteosarcoma, all five regioisomers were 
synthesized as described previously (23). Briefly, DHA was reacted with mCPBA, followed by 
separation using reverse phase HPLC and normal phase HPLC to separate the different 
regioisomers. The individual regioisomers were further coupled to ethanolamine and purified by 
reverse phase chromatography. The compounds were quantified and used for further studies.  
Effect of DHEA epoxides (EDP-EA) regioisomers on cell viability.  
To evaluate the effect of EDP-EA isomers on cellular viability of osteosarcoma cells, cell titer blue 
assay was performed on 143B metastatic OS cells at 5 μM concentration. As seen in Appendix V, 
only 13,14-, 10,11- and 7,8- EDP-EA reduced total cell viability. However, no change effect on 
cell viability was seen by action of similar concentration of 19,20-EDP-EA and 16,17-EDP-EA 
and no further studies were performed with these regioisomers. Next, we measured the cell 
viability as a function of the variable concentration of 13,14-, 10,11- and 7,8- EDP-EA. As seen 
in figure 5.1C, all three regioisomers reduced cell viability in a dose dependent fashion.  In order 
to evaluate if the decrease in cell viability of the three different DHEA epoxide regioisomers is 
due to cell death or check in cell migration, we performed apoptosis and cell migration assay.  
Induction of apoptosis in metastatic OS cells by DHEA epoxides (EDP-EA) regioisomers 
The apoptotic potential of 7,8-EDP-EA, 10,11- EDP-EA and 13,14-EDP-EA were tested in three 
different cell lines - HOS, 143B and MG63 cells using the Annexin V/ PI staining assay at 12.5 
μM concentration. This concentration was chosen to reflect a point in the CTB assay where cell 
viability is reduced but not completely diminished. As seen in Figure 5.1D, all three regioisomers 
induced apoptosis in all the cell lines at a concentration of 12.5 µM. Specifically, in 143B cell line 
(Table ST1), 7,8-EDP-EA induced 8.75 ±0.145% apoptosis. 10,11-EDP-EA induced 17.92 ± 
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3.32% apoptosis and 13,14- EDP-EA induced 9.95 ± 1.88% apoptosis. Similar to these results, in 
MG63 cells (Table ST2), 7,8-EDP-EA induced 16.4 ±1.4% apoptosis. 10,11-EDP-EA induced 
26.6 ± 3.5% apoptosis and 13,14- EDP-EA induced 16.9 ± 2.3% apoptosis. In HOS cells (Table 
ST3), the trend followed and 7,8-EDP-EA 17.1± 0.5% apoptosis. 10,11-EDP-EA induced 31.1 ± 
2.3% apoptosis (p=) and 13,14- EDP-EA induced 19.6 ± 3.5% apoptosis. 
In contrast to these results (Table ST4), treatment of all three different cell lines with AA, AEA, 
DHA and DHEA at 12.5 µM concentration showed little to no suppression of apoptosis as 
compared to no treatment control.  
DHEA epoxides inhibit cell migration of cancer cells determined using wound healing assay 
A wound healing assay or scratch assay has been shown to be an effective measure for directional 
migration of cells in vivo (32). A wound healing assay was performed for 7,8-EDP-EA, 10,11- 
EDP-EA and 13,14-EDP-EA at 5 μM . This concentration was chosen to reflect a concentration 
where the compounds are not significantly pro-apoptotic and the reduction in wound healing is 
because of the compound’s anti-migratory properties. Figure 5.1E shows the effects of 7,8-EDP-
EA, 10,11- EDP-EA and 13,14-EDP-EA on the wound closure in 143B cells as a representation. 
As seen from the data in Figure 5.1F, in HOS cells, all three compounds inhibit cell migration. 
However, for 7,8-EDP-EA and 13,14-EDP-EA the difference in wound closure at 10 hours is not 
significant. For 10,11-EDPEA, the wound closure at 10 hours tends to significance (p=0.08). In 
143B cells, Figure 5.1F (ii), 7,8-EDPEA and 13,14-EDPEA do not inhibit wound healing at 10 
hours. However 10,11-EDPEA inhibit wound closure significantly (p=0.05). In MG63 cell lines, 
Figure 5.1F, all three isomers restrict wound healing and at 10 hours and 10,11-EDP-EA prevented 
wound closure. Thus, while all three isomers are able to restrict wound healing and thereby show 
anti-migratory potential, the effect is greatest in 10,11-EDP-EA. 
Taken together, we found from the apoptosis assay and cell migration assay that 10,11-EDP-EA 
was the most potent regioisomer and this was partly mediated through cannabinoid receptor 1 as 
using CB1 receptor antagonist, the reduction of cell migration by 10,11-EDP-EA was completely 
abolished (Appendix V). 
Synthesis of amide derivatives of 10,11-DHEA epoxide (10,11-EDP-EA) 
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The eCB epoxides are dual functional molecules. As the amide bond is susceptible to fatty acid 
amide hydrolase (FAAH), we designed more stable analogs of 10,11-EDP-EA, which shows 
highest efficacy amongst the various epoxide derivatives of DHA. First, derivatives were made at 
the carboxylate end for different amide modifications, to reduce susceptibility to FAAH as well as 
better receptor binding to CB1 and CB2, which are the purported receptors for apoptotic activity 
(33-35).  
The current literature has mainly focused on anandamide or arachidonylethanolamine (AEA) 
derivatives, since AEA is the biological ligand of CB1 and CB2 receptors and thus is likely to be 
the receptor binding to DHEA and its analogs. It has been previously shown that introduction of a 
methyl group at the 1’ position of the amide results in increased metabolic stability of AEA, while 
affecting the CB1 binding ability (33). It was shown that the R isomer shows 4-fold higher CB1 
binding and the S isomers shows 2-fold lower binding as compared to AEA. Thus the R-1’-methyl 
isomer was the first modification made to 10,11-EDP (figure 5.2). Next, the cyclopropyl derivative 
of AEA has been shown to have modest FAAH inhibition with an IC50 value of 4.1 ±2.0 µM, with 
significantly increased CB1 binding (34). Finally, the n-propyl derivative was made to assess the 
effect of acyl chain length on FAAH hydrolysis. It has also been shown to have better affinity for 
CB1 than AEA (35, 36). 
The synthesis of these analogs is outlined in the materials and methods section similar to the 
synthesis of 10,11-EDP-EA. Briefly, 10,11-EDP was incubated with NHS and EDC in acetonitrile 
for 20 mins at 37 °C, followed by additional of the amine and stirring overnight at room 
temperature. The amines were purified by reverse phase HPLC chromatography and quantified 
similar to 10,11-EDP-EA.  
Susceptibility to FAAH hydrolysis of 10,11-DHEA epoxides and its amide derivatives 
Fatty acid amide hydrolase (FAAH) is a ubiquitously expressed protein in various mammals and 
the sequence of the protein has shown to be highly conserved in humans (36), mouse (36) and pig 
(37). For our studies, we used pig brain membrane preparations to analyze the effect of FAAH on 
10,11-EDP-EA as well as the three amino derived modifications. The details of membrane 
preparation from pig brains are mentioned in materials and methods. As observed from figure 
5.2B, there was significant reduction of hydrolytic potential in all three derivatives as compared 
to 10,11-EDP-EA. While 10,11-EDP formed from 10,11-EDP-EA was 1121.2 ± 11.2 ng min-1 
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mg protein-1, the same for 10,11-EDP-NA, 10,11-EDP-IA and 10,11-EDP-CA was 3.7 ± 2.3, ng 
min-1 mg protein-1 39.8 ± 1.7  ng min-1 mg protein-1and 198.6 ± 2.3 ng min-1 mg protein-1 
respectively. Since the three derivatives show significantly reduced hydrolytic susceptibility, they 
could have higher bioavailability and thus their apoptotic and anti-migratory potential was further 
evaluated.  
Apoptosis induced by amino modified derivatives of 10,11 DHEA epoxide (10,11-EDP-EA) 
All three amino-modified derivatives of 10,11-EDP were tested for their apoptotic activity. All 
three compounds showed increased apoptotic potential as compared to the no treatment control 
with variation in different cell lines. The cyclopropyl analog seemed to have the highest pro-
apoptotic potential among the three derivatives that were synthesized for the study. In HOS, MG63 
and 143B cells, it increased apoptosis to 27.19 ± 4.05%, 17.09 ± 4.4% and 21.3 ± 1.9% 
respectively.  The iso-propyl analog seemed to be the second most effective in HOS and MG63 
cells with apoptotic potentials of 20.15± 1.75% and 17.48 ± 2.8% respectively. In 143B cells it 
was only 18.8 ± 0.3% for the iso-propyl derivative as compared to 25.7 ± 0.4% for the n-propyl 
derivative. However, the n-propyl derivative was least effective in HOS and MG63 cells with only 
17.05 ± 1.4% and 15.15 ± 3.28% respectively. Overall, all the derivatives showed similar pro-
apoptotic potential to the parent compound without discernable differences.  
Would healing assay to determine the potential to inhibit cell migration by amino modified 
derivatives of 10,11 DHEA epoxide (10,11-EDP-EA) 
A scratch assay was performed to analyze the anti-migratory properties of the three derivatives. 
The data in Figure 5.2 D is represented as a ratio of the percentage area remaining in the wound 
by compound and the control. As seen in Figure 5.2D, in all the cell lines, all the 10,11-EDP 
derivatives restrict wound migration at 10 hours. Among the derivatives, the 10,11-cyclopropyl 
derivative shows significantly greater potency at the 8 and 10 hour time points inhibiting migration 
by 4.5- 6 times more than vehicle control.  
Similarly as seen in figure 5.2D, in the 143B cells, restriction in wound migration was 1- 1.9 times 
by 10,11-EDP-EA,  1- 1.47 times by n-propyl derivative, 1- 3.9 times by isopropyl derivative and 
1 to nearly 10 fold by the cyclopropyl derivative as compared to the control. Finally, in the MG63 
cell line (figure 5.2D), the restriction in wound healing was 1-2 times by 10,11-EDP-EA as 
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compared to the control. The 10,11-EDP-NA and 10,11-EDP-IA were slightly poorer than the 
control in restricting wound migration. And the 10,11-EDP-CA was comparable to 10,11-EDP-
EA for the MG63 cell line in restricting wound migration. 
As observed from the various results, it was concluded that the 10,11-EDP-CA was the most potent 
in inhibiting wound migration in 143B and HOS cells and comparable to the parent molecule in 
MG63 cells. It is interesting to note that the rate of wound closure is not constant in all the cases.  
Cell cycle analysis of 10,11-EDP-EA and its analogs 
The effects of 10,11-EDP-EA and its analogs was tested on cell cycle progression by treating cells 
with the compound for 24 hours, staining with propidium iodide and then analyzing with flow 
cytometry. As seen in Table 5.1, in 143B cells there does not appear to be a significant effect on 
the cell cycle except a slight suppression in the S phase with 10,11-EDP-NA. However, with the 
HOS cell lines there is an increase in G1 phase with all compounds but a suppression in the S 
phase with all the compounds. Finally, with MG63 there is an increase in the G1 phase and 
suppression in S phase with the 10,11-EDPIA. 
10,11-EDPEA and its analogs prevent angiogenesis in HUVEC cells 
Increased angiogenesis is one of the hallmarks of cancer. The development of neo-vascularization 
is key for the adequate supply of nutrients and oxygen to the site of metastasis (38). Endothelial 
tube formation on matrix has been established as a cellular model for angiogenesis (39). Briefly, 
endothelial HUVEC cells were grown on matrix and treated with vehicle control, 0.5 μM 
compound or 1 µM compound. The tube formation was assessed by Image J analysis. As seen in 
figure 5.3, 0.5 μM restricts tube formation significantly as compared to the vehicle control but 
does not completely restrict it. However, at 1 μM concentration, the tube formation is completely 
restricted. It was also verified that 1 μM concentration of treatment did not reduce cell viability in 
HUVEC cells as seen in appendix V. 
 
 
Expression of CB1 and CB2 receptors in model cell lines 
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Literature evidence suggest that DHEA is an agonist of CB1 and CB2 receptors (11). Therefore, 
we investigated whether the effect of DHEA is through CB1/ CB2 pathway mediated. 
Additionally, CB receptors have been shown to be overexpressed in various cancers including 
osteosarcoma (40). We first determined the expression of CB1 and CB2 receptors in all three cell 
lines HOS, 143B and MG63. Additionally, the expression of CB1 and CB2 was also significantly 
higher in 143B cells as compared to HOS cells.  
Apoptotic effect of DHEA epoxides in the presence of CB1 and CB2 antagonists 
As an initial investigation into the mechanism of action for these endocannabinoids, we assessed 
their apoptotic activity in the presence of CB1 and CB2 antagonists, rimonabant and AM 630 
respectively. As seen from Appendix V, rimonabant and AM 630 exhibit very limited apoptotic 
activity as compared to control. When CB1 and CB2 antagonist were incubated with 7,8-EDP-EA, 
a slight increase in apoptotic activity with 14.60 ± 1.82% and 10.12 ± 1.36% respectively. A 
similar result was seen for 13,14-EDP-EA where the treatment plus CB1 antagonist showed 13.03 
± 3.63%. The treatment plus CB2 antagonist showed no difference in apoptosis as compared to 
treatment alone at 9.2 ± 0.80%. The slight increase in apoptosis might be as a combinatorial effect 
of the treatment with the antagonist. Alternatively, since the molecules have two different reactive 
centers, the epoxide as well as the amide, they likely act through two different receptor classes- 
the cannabinoid receptor and the unknown epoxide receptor. It is possible that the blocking of the 
CB1 or CB2 receptors shuttle the molecule to the second epoxide receptor pathway thereby 
increasing the apoptotic activity. Finally, 10,11-EDP-EA showed a decrease in apoptotic potential 
with CB1 and CB2 antagonist at 7.44 ± 2.19% and 10.9 ± 0.08% indicating that this molecule 
mainly goes through the CB1 and CB2 receptors. 
5.5 DISCUSSION 
Lipid metabolites that are generated from omega-3 fatty acids such as DHA have been shown to 
exert anti-inflammatory, pro-resolving (4) and anti-tumorigenic effects through various 
mechanisms (5) (6) (7). In one mechanism, DHA is converted to DHA epoxides (EDPs) by CYP 
epoxygenase that have shown to exhibit have anti-tumorigenic properties. Alternatively, DHA is 
converted to DHEA, an endocannabinoid that have shown anti-proliferative efficiency in prostate 
cancer cells (11). Previously, we have shown that CYPs convert DHEA into DHEA epoxides 
(EDP-EA) that have both ethanolamide and epoxide moiety (23) (Figure 5.1A). Herein we 
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evaluated the anti-tumorigenic properties of all the different regioisomers of DHEA epoxides as 
both the endocannabinoid and epoxyeicosanoid pathway have been separately implicated in cancer 
(8, 9) and the terminal DHEA epoxide was shown to exhibit anti-inflammatory properties (23).   
In order to execute our studies, we induced tumor in mice by injecting metastatic K7M2 
intravenously into the tail vein. The mice were sacrificed and lung tissues were collected and the 
endocannabinoids were extracted. We showed that the DHEA epoxides were increased 20-80% 
depending on the regioisomers (Figure 5.1B) in the metastatic mice with osteosarcoma tumors as 
compared to the normal lungs. We further show that the EDP-EAs show a reduction of migratory 
potential of the cancer cells and moderately increased apoptosis in osteosarcoma cell lines. We 
hypothesized that the increase production of DHEA epoxides (EDP-EA) in the metastasized lungs 
are due to the immune response that is trying to reduce inflammation, cell migration and 
angiogenesis and promote apoptosis.  
We tested all the five epoxide regioisomers of EDP-EAs towards their ability to do apoptosis in 
three human osteosarcoma cell lines- 143B and MG63, which are metastatic and HOS, which is a 
non-metastatic cell line. In all the three cell lines, the various regioisomers show an apoptotic effect 
and an anti-migratory affect. However, this effect is differential among the various EDP-EA 
regioisomers. For instance, 10,11-EDP-EA emerges as the most potent regioisomers in reducing 
cell migration. Interestingly, this effect was mediated via the CB1 receptor as using a CB1 
antagonist, the anti-migratory potential of 10,11-EDP-EA was significantly reduced (Appendix 
V). 
Since 10,11-EDP-EA showed the greatest potency in our assays, we wanted to characterize the 
molecule and explore its therapeutic potential in vivo. However, EDP-EAs has two hydrolytically 
susceptible groups. The amide functionality is hydrolyzed by fatty acid amide hydrolase. And the 
epoxide group is hydrolyzed by soluble epoxide hydrolases. Thus, the approach was to modify the 
molecules such that they retain their efficacy while being less susceptible to hydrolysis. Based on 
literature, modifications at the amide end of anandamide can reduce hydrolytic susceptibility as 
well as increase cannabinoid receptor binding (96). Thus, the R-1’-methyl isomer was the first 
modification made to 10,11-EDP. Next, the cyclopropyl derivative of AEA has been shown to 
have modest FAAH inhibition, with significantly increased CB1 binding (97). Finally, the n-propyl 
derivative was chosen for examination to assess the effect of acyl chain length on FAAH 
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hydrolysis. It has also been shown to have better affinity for CB1 than AEA (235, 236). We made 
similar analogs of 10,11-EDP-EA. All the analogs demonstrated similar apoptotic potential (Figure 
5.2C) as compared to parent 10,11-EDP-EA, but markedly reduced susceptibility to FAAH 
hydrolysis (Figure 5.2B). Next, we performed a cell cycle analysis of 10,11-EDP-EA and analogs 
in all three cell lines. The data suggests that there is an increase in the G1 phase and a lowering of 
the S phase thus implying that the G1 to S phase transition is being blocked.  
Next, we wanted to ascertain whether these molecules are acting through the cannabinoid receptors 
1 and 2. We show that all three cell lines express both CB1 and CB2 (Appendix V). From the 
apoptosis assay in the presence of CB receptor antagonists, we conclude that the apoptosis is not 
mediated through cannabinoid receptor. However, the reduction of cell migration by 10,11-EDP-
EA was abolished using CB1 antagonist. Taken together, these results suggest that in addition to 
CB1, 10,11-EDP-EA mediates its effect through other receptors including the uncharacterized 
epoxide receptor, PPAR and TRPV as their anti-tumorigenic effects cannot be completely 
abolished using CB1 agonists.  
Thus, we show that a novel class of eCB epoxides and their stable derivatives exhibit anti-
inflammatory (28), anti-angiogenic, anti-tumorigenic and anti-migratory properties. By virtue of 
their ability to bind CB receptors, these molecules will also exhibit anti-nociceptive bone pain 
activities. As osteosarcoma is accompanied by inflammation and pain, these molecules will aid in 
alleviating both conditions. As pointed out in the introduction, as these molecules are naturally 
occurring and their levels increase ~80% in osteosarcoma metastatic lungs, increasing their levels 
in vivo using FAAH and sEH dual inhibition will be effective adjuvant therapy for osteosarcoma 
(29, 30). 
5.6 CONCLUSIONS 
Omega-3 fatty acids and their biological metabolites have numerous physiological activities. In 
this work we show that a new class of omega-3 fatty acid metabolites known as endocannabinoid 
epoxides (eCBs) exert pro-apoptotic and anti-migratory effects in osteosarcoma cell lines. We 
show that the various regioisomers of eCBs have differential effects on the anti-tumorigenic 
effects. Furthermore, we develop synthetic analogs that are more hydrolytically stable to fatty acid 
amide hydrolase while maintaining their anti-apoptotic and anti-migratory effects. Thus, we show 
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5.8 FIGURE, TABLES AND LEGENDS 
 
 
Figure 5.1:  (A) Figure shows the synthesis of five structural isomers of DHEA-epoxide- 19,20-, 
16,17-, 13,14-, 10,11- and 7,8- EDPEA from DHA and DHEA. (B) Figure shows the percentage 
fold change in endocannabinoid epoxides synthesized found in normal lung tissue and lung tissue 
with metastasized OS tumor. (C) Figure shows percentage cell viability as measured by cell titer 
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blue assay at 5 different concentrations of 13,14-EDPEA (orange), 10,11- EDPEA (blue) and 7.8- 
EDPEA (pink). (D) Apoptosis induced in HOS, 143B and MG63 cells at 12.5 μM concentration 
of 13,14-EDPEA (criss-cross), 10,11- EDPEA (checkered) and 7,8- EDPEA (dots). (E) Wound 
healing scratch shown at 0h and 10h in 143B cell lines by 13,14-EDPEA 10,11- EDPEA and 7,8- 
EDPEA at 5 μM concentration. (F) Wound healing represented as a percentage of original wound 
over 10 hours in three cell lines (i) HOS, (ii) 143B and (iii) MG63 by 5 μM concentration of 13,14-





















Figure 5.2: (A) Figure shows synthetic scheme for EDP-EA analogs. (B) Figure shows the Fatty 
Acid Amide Hydrolase (FAAH) dependent hydrolysis of amide derivatives. (C) Figure shows the 
apoptotic potential as shown by 10,11-EDPEA, 10,11-EDPNA, 10,11-EDPIA and 10,11EDPCA 
as compared to control as measured by Annexin V apoptosis assay. (D) Figure shows the anti-
migratory properties of 10,11-EDPEA, 10,11-EDPNA, 10,11-EDPIA and 10,11EDPCA as 
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Figure 5.3: Figure shows the restriction of tube formation in endothelial HUVEC cells on matrigel 
















Table 5.1: Table shows cell cycle analysis of 10,11-EDPEA, 10,11-EDPNA, 10,11-EDPIA and 
10,11-EDPCA as monitored by propidium iodide staining in all three cell lines. All experiments 
were done in triplicates. * p<0.05, **p<0.01 as compared to untreated, # p<0.05, ##p<0.01 as 





10,11-EDPNA 10,11-EDPIA 10,11-EDPCA 
143B 
     
G1 56.17 ± 2.67 50.74 ± 2.03 52.21 ± 0.13 50.09 ± 0.03 54.23 ± 0.75 
S 26.61 ± 0.42 28.18 ± 3.90 24.04 ± 0.28* 41.84 ± 3.74 22.87 ± 0.32 
G2 17.22 ± 2.25 21.08 ± 1.87 23.74 ± 0.41 8.07 ± 3.70 22.85 ± 0.42 
      
HOS 
     
G1 47.81 ± 0.66 67.23 ± 
0.62**# 
62.17 ± 0.42** 55.75 ± 5.03 54.37 ± 1.41*# 
S 37.08 ± 1.62 20.33 ± 0.88* 20.73 ± 2.07* 24.28 ± 1.36* 30.49 ± 1.76# 
G2 15.11 ± 0.97 12.44 ± 0.25 17.09 ± 1.65 19.96 ± 3.66 15.13 ± 0.35# 
      
MG63 
     
G1 62.91 ± 1.75 67.71 ± 2.23 63.46 ± 0.81 76.71  ± 0.06* 59.61 ± 0.25 
S 20.17 ± 1.76 17.89 ± 2.07 19.00 ± 0.42 10.84 ± 0.28* 23.05 ± 0.39 
G2 16.92 ± 0.01 14.4 ± 0.15** 17.54 ± 0.4# 12.45 ± 
0.35**# 
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CHAPTER VI: CONCLUSIONS AND FUTURE WORK 
6.1 SUMMARY 
In summary, this work investigates various proteomic and lipidomic profiles in osteosarcoma. The 
second chapter performed a comparative proteomic profiling of the membrane proteome of 
metastatic and non-metastatic osteosarcoma in human and canine cell lines by peptide 
fingerprinting. While several proteins were identified as differentially regulated, three proteins- 
CD44, CD147 and vimentin were taken forward for biochemical validation by western blotting, 
flow cytometry, confocal microscopy and immunohistochemistry in cell pellets and paired primary 
and metastatic samples from canine patients. The results from biochemical validation confirmed 
those from peptide fingerprinting. A major conclusion of this work was that canine and human OS 
cell lines show similar proteomic profiles. Thus, dogs are an appropriate model for human OS and 
there can be development of parallel therapeutics for metastatic disease in both species. 
Furthermore, we established the first fully characterized mammalian membrane protein nanodisc 
library. This allows stabilization of membrane proteins that cannot be overexpressed as well as to 
preserve protein-protein interactions. A major finding in this study was that lipid composition 
affects the proteomic incorporation and this could be exploited to the user’s goal. Furthermore, we 
showed that the activity of the incorporated proteome is preserved in all nanodisc compositions by 
two different activity assays. 
Next, a lipidomics composition change was investigated in normal osteoblasts, non-metastatic OS 
as well as metastatic human OS cells. Several different lipids were found to be differentially 
regulated in the three cell lines. Most notably diacylglycerols were upregulated in metastatic vs 
non-metastatic or normal cells and cholesteryl esters followed the reverse trend. 
Finally, we investigated the anti-tumorigenic effects of endogenous lipids known as 
endocannabinoid epoxides (eCBs). We determined that endogenous eCBs show modest pro-
apoptotic and anti-migratory activity in OS cell lines. This was followed by synthesis of analogs 
designed to reduce the hydrolytic susceptibility of the endogenous molecules. These molecules 
showed slight reduction in hydrolytic susceptibility as well as similar anti-migratory and pro-
apoptotic activity as the endogenous molecules making them better targets for therapeutic delivery 
since they are likely to have longer bioavailability, while retaining similar activity.  
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6.2 FUTURE DIRECTIONS 
As summarized in the previous section, four aspects relating to biomarkers and therapeutics in 
osteosarcoma. Each aspect has its own future direction. In the first section, several different 
biomarkers were identified in OS. The next steps towards this would be to evaluate if these 
proteomic profiles are conserved in tissue samples beyond what has been shown in our work with 
immunohistochemistry of tissue samples. This is especially in light of the fact that processing the 
primary tissue sample of bone cancers involves several steps including decalcification and fixing. 
These steps can significantly alter the epitopes exposed on the tissue surface and a better picture 
of the protein expression can be obtained by peptide fingerprinting. Furthermore, the proteomic 
study can be extended both in cell lines by employing top-down proteomics (1). Top-down 
proteomics will allow differentiation in post translational modifications that in themselves can be 
targets for therapeutics. The ultimate goal of this project is to develop therapeutics towards the 
differentially regulated proteins identified. For CD44, various peptides that affect hyaluronic acid 
binding to CD44 (2) as well as antibody conjugates (3) have been explored in various cancers. 
These could provide a starting point towards exploration of anti-CD44 therapy. Towards CD147, 
limited efforts have been with antibodies (4). Therefore there is potential for peptide as well as 
small molecule therapeutic development for CD147. 
Towards the stabilization of the membrane proteome in nanodisc libraries, there are two main areas 
of exploration following the work described in chapter three. First, a systematic study of varying 
lipid composition instead of a few discrete compositions can be performed to see how the changing 
lipid profile affects the incorporated proteome. This would be beneficial towards optimizing the 
incorporation of proteins in the desired ratios. This could be furthered to incorporating other lipids 
including sphingomyelin, as well as lipids like DOPC (1,2-Dioleoyl-sn-glycero-3-
phosphocholine) and DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine).  The second direction 
is the biophysical characterization of the synthesized nanodiscs by techniques like small angle X-
ray scattering (SAXS) (5). Techniques like SAXS could help understand why cholesterol results 
in smaller disc size as well as how the lipid distribution changes in the disc- whether they have a 
uniform distribution or form discrete units. Towards this I have performed some initial phase 
transition studies by incorporating fluorescent molecule laurdan in the nanodisc and measuring the 
change in fluorescence polarization with increase in temperature.  
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The lipidomics study for OS is the first study deciphering the lipidomic composition for OS and 
identifies the diacylglycerols as an upregulated class in the lipidome. While in this study, the DG 
synthesis is blocked by a PLC inhibitor in a proof of concept study to show that DG reduction 
lowers the cell viability as well as migration in metastatic OS cells. However, PLC inhibition 
affects a variety of lipid syntheses and is not a viable therapeutic approach for specifically blocking 
DG synthesis. Therefore, more specific pathways need to be identified for inhibiting DG synthesis. 
One probable pathway could be from monoacylglycerol (MG) to DG synthesis through MGAT 
(monoacylglycerol tansferase) (6-8). Furthermore, an interesting find was the lowering of 
cholesteryl esters in the metastatic cells. It is known that cells store energy as esterified cholesterol 
(9) and since cholesterol is known to increase in metastasized disease in various cancers (10), it 
would be interesting to investigate what factors are lowering the conversion of free cholesterol to 
esterified cholesterol, and if this is specific to osteosarcoma or prevalent in all cancers. 
Finally, in chapter five we have shown that endocannabinoid epoxides are moderately anti-
tumorigenic in osteosarcoma cell lines. This study should be followed by pharmacokinetic studies 
in mice and mice models of osteosarcoma to see the effects of the eCBs on the tumor size in lung 
metastasized tumors (11). Finally, these compounds can be employed to measure reduction in 
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APPENDIX A: DEVELOPMENT OF POLY UNSATURATED FATTY 
ACID DERIVATIVES OF ASPIRIN FOR INHIBITION OF PLATELET 
FUNCTION 5F6 
A.1 ABSTRACT 
The inhibition of platelet function is a key step in prevention of myocardial infarction and ischemic 
stroke. Aspirin is the most widely used drug for the inhibition of platelet aggregation. However, it 
suffers from several key drawbacks including its poor permeability across biological membranes 
due to its ionic state at physiological pH. In this work, we propose new aspirin anhydride molecules 
for the inhibition of platelet function where aspirin is conjugated to dietary omega-3 and omega-6 
fatty acids. Omega-3 fatty acids themselves have shown inhibitory effects on platelet function and 
thus this approach employs a “hybrid-drug” strategy of combining selected unsaturated fatty acids 
with aspirin. The molecules are tested for their effectiveness towards inhibiting platelet 
aggregation in washed platelets and platelet-rich plasma. Furthermore, they are examined 
biochemically for their effect on the COX-1 thromboxane synthase pathway for platelet 
aggregation, as well as COX-1 activity. Finally, hydrolysis studies on these molecules indicate 
release of aspirin and free fatty acids from these conjugates at a controlled rate in both buffer and 
plasma.  
A.2 INTRODUCTION 
Platelet adhesion and aggregation is important for maintaining normal hemostasis and is an 
essential component in the morbidity and mortality associated with cardiovascular disease 
including myocardial infarction and ischemic stroke. Therefore, the ability to modulate platelet 
function is of significant clinical importance. Aspirin is currently the most widely used therapeutic 
for inhibition of platelet activation. Aspirin functions via irreversible acetylation of platelet COX-
1, resulting in inhibition of platelet-derived TXA2 formation. It has poor permeability across 
biological membranes at physiological pH due to the presence of free carboxylic acid, which is 
significantly ionized at physiological pH. The result is poor absorption of drugs with carboxylic 
acid moieties through lipid membrane barriers. Typically, NSAIDs also cause gastric toxicity as 
                                                 
6 Reprinted with permission of the American Society for Pharmacology and Experimental Therapeutics. Development 
of poly unsaturated fatty acid derivatives of aspirin for inhibition of platelet function. Jahnabi Roy, Reheman Adili, 
Richard Kulmacz, Michael Holinstat, and Aditi Das. J Pharm Exp Ther 2016, 359(1), 134-141.  All rights reserved. 
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they inhibit COX-1 which is involved in maintaining the integrity of gastrointestinal epithelium. 
The general approach to solve these side effects is to esterify the carboxylic acid to produce 
lipophilic pro-drug forms. However, several aliphatic or aromatic esters of carboxylic acid drugs 
are not sufficiently labile in vivo to ensure a suitably high rate and extent of conversion from the 
esterified form. Additionally, esters are highly susceptible to enzymatic hydrolysis in plasma and 
thus have differential rates of aspirin liberation in different individuals. Moreover, aspirin has two 
major functional groups, the carboxylate end and the O-acetyl end. As the O-acetyl end is the 
pharmacophore for the activity of aspirin, for an aspirin ester derivative pro-drug to be effective, 
it must hydrolyze at the carboxylate end faster than the O-acetyl end (238). Therefore in this work, 
we synthesize aspirin anhydride derivatives with lipids and evaluate their platelet aggregation 
function.  
Recent work has focused on the modification of drug molecules with lipids or lipid derivatives as 
a means to overcome their side effects as well as to facilitate their delivery. Specifically, addition 
of a hydrophobic lipid tail allows the drug molecule to cross the hydrophobic plasma membrane 
and enter the cell (239). Herein we combine the two approaches of derivatizing aspirin with poly-
unsaturated fatty acids in order to keep aspirin in a unionized form so as to achieve facile transport 
across the plasma membrane. The “hybrid-drug” approach of combining two drugs with similar 
therapeutic properties but different mechanisms has been gaining interest (240). For instance, there 
are several reports in literature indicating the inhibition of platelet aggregation by dietary fatty 
acids, chiefly omega-3 fatty acids EPA and DHA and omega-6 fatty acid linoleic acid (LA) (241). 
The action of these lipids is thought to be through competitive inhibition of COX-1-mediated 
arachidonic acid metabolism. The metabolism of EPA and DHA by COX-1 leads to the formation 
of alternative thromboxane-like molecule that are less potent than TXA2 with regard to platelet 
aggregation.  
In our studies, we synthesize anhydride conjugates of dietary fatty acids- LA, EPA and DHA with 
aspirin for the inhibition of platelet aggregation. We hypothesized that if the omega-3 fatty acids 
and aspirin are reducing platelet aggregation separately then the conjugated moiety itself will have 
anti-platelet aggregatory properties through a synergistic or co-drug effect. Additionally these 
aspirin-lipid conjugates will prevent the deleterious effects of the free aspirin carboxylate group. 
The aspirin-lipid anhydride bond will be more susceptible to hydrolysis compared to O-acetyl end. 
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Therefore the compound will decompose to its carboxylic acid counterpart at a predictable rate 
and pattern depending on the conjugated molecule, as shown previously with related compounds 
(242). Furthermore, anhydrides are typically less sensitive to enzymatic cleavage than esters or 
amides (243). Thus the use of lipid anhydride conjugation is likely to increase bio-availability, be 
released in a controlled manner, and reduce gastric and mucosal toxicity.  
In summary, this work is the first report on application of aspirin anhydride using polyunsaturated 
fatty acids– LA, EPA and DHA for reduction in platelet aggregation. We demonstrate that 
anhydride conjugates of aspirin with dietary omega-3 fatty acids are potent inhibitors of platelet 
aggregation. Furthermore, we biochemically examine their effect on the COX-1 mediated TXA2 
formation since the focus of current literature in dietary lipids has focused on dietary 
supplementation in controlled trial groups (241). Finally, we exhibit through hydrolysis studies, 
that the conjugates release aspirin and free fatty acids at a controlled rate in both buffer and plasma.  
A.3 MATERIALS AND METHODS 
Materials: Human TXAS gene was obtained from Origene. Ampicillin, arabinose, 
chloramphenicol, isopropyl β-D-1-thiogalactopyranoside (IPTG) and Ni-NTA resin were bought 
from Gold Biotechnology. δ-Aminolevulinic acid (δ-ALA) and hematin were obtained from 
Frontier Scientific. 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) was purchased 
from Avanti Polar Lipids. Aspirin was purchased from Sigma Aldrich.  Arachidonic acid, EPA, 
DHA and LA were obtained from Cayman Chemicals. PAR4-AP (AYPGKF) and PAR1-AP 
(SFLLRN) were purchased from GL Biochem (Shanghai, China). Thrombin was purchased from 
Enzyme Research Laboratories (South Bend, IN). Collagen and ristocetin was purchased from 
Chorology Cooperation. U46619 and ADP were purchased from Sigma Aldrich. University of 
Michigan Review Board approved studies and written informed consent was obtained from all 
participants prior to blood collection. 
Synthesis of aspirin chloride: Aspirin chloride was synthesized as previously mentioned (244). 
Briefly, to a 250 mL round bottom flask charged with stir bar was added aspirin (500mg, 2.77 
mmole) and dissolved in benzene (69.5 mL, 0.04 M in aspirin) and thinoyl chloride (805 µL, 11.1 
mmoles) was added. The mixture was refluxed for 8 h and the resulting solution was cooled down. 
The solution was concentrated in vacuo to yield a white solid that was taken into future reactions 
without further purification. Yield: 435 mg, 79%.  
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Synthesis of anhydrides: To a 7 mL vial charged with stir bar was added aspirin chloride (10 mg, 
0.05 mmoles) and fatty acid (DHA- 16 mg, 0.05 mmole, EPA- 15 mg, 0.05 mmole, 14 mg, 0.05 
mmole) and dissolved in DCM (1 mL, 0.04 M). To this was added pyridine (4 µL, 0.075 mmole) 
and the solution was stirred at room temperature for 4 h. The reaction was then quenched with 1 
mL of 1 N HCl solution and vortexed. The organic layer was removed and the aqueous layer was 
re-extracted with 1 mL DCM. The combined organic layers were dried over sodium sulfate and 
concentrated in vacuo. The residual solid was recrystallized in diethyl ether to yield a white solid. 
Yields: DHA anhydride- 3.5 mg, 20%, EPA anhydride- 6 mg, 26%, LA anhydride- 17.5 mg, 79%.  
Platelet purification: Human whole blood was drawn from the antecubital vein of healthy donors. 
PRP was obtained from whole blood by centrifugation at 200g for 10 minutes. Leftover blood 
samples were centrifuged at 200g for 10 minutes to obtain Platelet-poor-plasma (PPP). Washed 
human platelets were isolated from whole blood and platelet aggregation studies were performed 
as previously described (245). Whole Blood was drawn from the antecubital vein of untreated 
healthy donors or healthy donors who were orally given 81mg/day aspirin for 7 days.  Platelets 
were pelleted from PRP in the presence of ACD (2.5%) and apyrase (0.02 U/mL) by centrifugation 
at 2000g for 10 minutes then resuspended in Tyrodes buffer (12 mM NaHCO3, 127 mM NaCl, 5 
mM KCl, 0.5 mM NaH2PO4, 1 mM MgCl2, 5 mM glucose, 10 mM HEPES) to a final 
concentration of 3.0 x 108 platelets/mL. Washed platelets (250μL) were separately incubated with 
2.5, 5, 10 μM or with same volume of DMSO for 5 minutes.  
Washed human platelet aggregation:  platelet aggregation was induced by 5 μM AA, Thrombin 
(1nM), PAR4-AP, PAR1-AP (SFLLRN), ADP (1μM) or U46619 (1μM) and change in light 
transmission was recorded by eight channel platelet aggregometer (Chronolog) under stirring at 
1200 rpm at 37°C.  
Platelet aggregation in PRP: Platelet concentration in PRP was adjusted to 3.0 x 108 platelets/mL 
using PPP from same donor. 10 μM of C1, C2, C3 compounds or DMSO in same volume was 
separately incubated with 250uL of PRP for 5 minutes. Platelet aggregation was induced by adding 
AA (5 μM) ADP (1 μM), collagen (2 μg/mL), Ristocetin (1 μM) or U46619 (1 μM) and change in 
light transmission were recorded by platelet aggregometer as described above.   
Expression and purification of cyclooxygenase 1 (COX-1) 
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An 8- 10 g of Sf9 cell pellet from a 2L cell culture expression COX-1 was suspended in 40-45 ml 
of Buffer A (25 mM NaPO4 / 20 mM imidazole, pH 7.4 / 1 mM phenol) and 5 ml of 10x Sigma 
protease inhibitor (P2714) was added. Cell clumps were resuspended by magnetic stirring. This 
resuspension was homogenized by sonication and centrifuged at 100,000 × g for 1 hr and 
supernatant was removed. The pellet was resuspended in ~45 ml of Buffer B (25 mM NaPO4 / 
100 mM NaCl / 20 mM imidazole / 0.1 mM phenol, pH 7.4) using with a Dounce homogenizer. 
10% Tween 20 solution was added to a 1.5% final concentration and stirred for 1-2 hr followed by 
centrifugation at 100,000 x g for 1 hr. The supernatant (S1) was removed and the pellet was 
resuspended in ~20 ml Buffer B. S1 was mixed with 2.5-3 ml of Ni-NTA Agarose (Qiagen) 
prewashed with Buffer C (25 mM NaPO4 / 100 mM NaCl / 20 mM imidazole / 0.1 mM phenol, 
pH 7.4 / 0.1% Tween 20) and rocked in cold room for 2 hours. The mixture was poured into column 
(~1.5 x 10 cm) and the flow though was allowed to drain out. The column was washed with 10- 
15 mL of Buffer C and then with 10-15 ml of Buffer D (25 mM NaPO4 / 300 mM NaCl / 20 mM 
imidazole / 0.1 mM phenol, pH 7.4 / 0.1% Tween 20). The protein was eluted with 10 x 0.75 ml 
aliquots of Buffer E (25 mM NaPO4 / 100 mM NaCl / 200 mM imidazole / 0.1 mM phenol, pH 
7.4 / 0.1% Tween 20). The active fractions were pooled and concentrated.The buffer was 
exchanged on a 10DG column eluted with 50 mM KPi, pH 7.2 / 50 mM NaCl / 0.01% NaN3 / 
0.1% Tween 20 and collect 0.25 ml fractions. COX- 1 activity each fraction was assayed and active 
fractions were pooled. Protein was stored at -80 °C with ¼ vol of glycerol. 
Expression and purification of thromboxane synthase: TXAS was expressed and purified as 
previously mentioned (159). Briefly, the cells were grown in terrific Broth (TB) and were induced 
with 1 mM IPTG and 0.5 mM δ-ALA and 4 mg/L arabinose at O.D 1.2. They were grown for 44 
hours at 26°C and 160 rpm. The harvested cells were resuspended in Buffer A (0.1 M potassium 
phosphate pH 7.4, 10% glycerol, 0.1 M sodium chloride) containing 2 mM magnesium chloride, 
1 mM PMSF, 1 mg each of DNase and RNase for 1 hour and lysed 5 times for 1 min each using a 
sonicator. The solution was then centrifuged at 35 K rpm for 1 hour and the pellet was resuspended 
in Buffer A containing 2% Lubrol to solubilize TXAS. The re-suspended sample was centrifuged 
at 35 K rpm for 1 hour and the supernatant was loaded onto a Ni-NTA column. The column was 
incubated for 2 hours with 5X column volume of buffer A containing 10 mM Histidine, 5 mM 
ATP, 10 mM MgCl2 and 150 mM KCl to separate any co-purifying GroEL (246). TXAS was 
eluted using Buffer A containing 0.2% Lubrol and 100 mM Histidine.  
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Assembly of TXAS -Nanodiscs: TXAS-Nanodiscs were assembled from a mixture of TXAS, 
membrane scaffold protein (MSP1D1), cholate and POPC lipids by removing the detergents using 
Amberlite (164). MSP1D1 was added to POPC (solubilized using sodium cholate) in a ratio of 
65:1 (lipids: MSP1D1) and the solution was incubated at 4oC for 1 hour on a shaker. We thank 
Sligar laboratories for giving the MSP1D1 gene. TXAS was then added in a ratio of 1:15 (TXAS 
: MSP1D1) and incubated another 1 hour. Amberlite was added to remove detergents and initiate 
the formation of Nanodiscs.  The TXAS-Nanodiscs were then purified using size exclusion 
chromatography as previously mentioned (159).  
Coupled assay with secondary lipids: TXAS converts PGH2 into TXA2, and HHT (12(L)-
hydroxy-5,8,10-heptadecatrienoic acid) and MDA (malondialdehyde) as a side reaction (247). To 
measure overall effect of a secondary lipid on the metabolization of AA, a coupled enzymatic 
assay was performed. Briefly, to COX-1 (10 nM) incubated with hematin (0.5 µM) in tris buffer 
(0.1 M, pH= 7.4) was added TXAS (50 nM). To this was added AA (20 µM) and secondary 
substrate (20 µM) and rate of MDA formation was monitored over 3 minutes at 268 nm and HHT 
at 234 nm. Absorbance was then measured and the reaction mixture was quenched in 300 µL of 
ethyl acetate. The amount of TXB2 formed was determined using TXB2 EIA ELISA Kit 
(Cayman). 
A.4 RESULTS  
Synthesis of aspirin anhydride derivatives: The synthesis of the fatty acid-aspirin derivatives was 
performed as shown in Scheme A.1. The free carboxylic acid in aspirin was first converted to its 
corresponding acid chloride by reacting with thionyl chloride in the presence of amine base by 
refluxing in benzene for 8h. The activated acid chloride was taken, without further purification, to 
react with the carboxylic acid in EPA, DHA and LA to form a mixed anhydride. The mixed 
anhydride was purified by recrystallization in diethylether to give >99% purity by 1H- NMR and 
HR-ESI mass spectrometry (Figure A.1-A.3).  
Lipid- aspirin conjugates inhibit AA induced platelet aggregation: The effect of fatty acid- aspirin 
derivatives compounds C1, C2 and C3 on platelet function was studied in vitro using platelet 
aggregation at differing concentrations from 2.5µM to 10 µM. As shown in Figure A.4, 
arachidonic acid-induced (5 µM) platelet aggregation was inhibited by all three compounds in a 
dose-dependent manner. However, these compounds varied in potency of inhibition with C3 being 
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the most potent followed by C2 and C1. As seen from the aggregation curves, as compared to the 
DMSO control, compound C1, LA anhydride, shows a slight decrease in platelet aggregation with 
a significant decrease at 10 µM concentration (p= 0.0158). In contrast C2, the EPA anhydride, 
shows a greater inhibition at lower concentrations with a significant decrease at 5 µM (p= 0.0176) 
and a further decrease at 10 µM (p ≤ 0.0001). Compound C3, DHA anhydride, shows most 
significant inhibition of platelet aggregation with a significant inhibition at 2.5 µM (p= 0.0049) 
and 5 µM (p= 0.0011) and almost complete inhibition of aggregation at 10 µM (p= 0.0002). Similar 
results were observed for platelet rich plasma (PRP) (Figure A.5). As seen in Figures A.5A and 
A.5B, at 10 µM concentration, compounds C2 and C3 show a significant decrease in platelet 
aggregation (p= 0.1006 for C2 and p= 0.0003 for C3). However, C1 did not show a significant 
decrease in aggregation in PRP.  
In addition to AA, compounds C1, C2 and C3 attenuated platelet aggregation induced by various 
platelet agonists including thrombin, PAR4-AP, PAR1-AP, ADP or 46619. As seen in Figure A.6 
and 7 a slight allbeit insignificant decrease was observed in platelet aggregation induced by 
thrombin, PAR4-AP and PAR1-AP for all three compounds at 10 µM concentration. No notable 
inhibition in platelet aggregation was observed in PRP stimulated with ADP, collagen, ristocetin, 
or U46619 (Figure A.6 (D), (E) and 7 (B), (C), (D)). Collectively, these observations indicated 
that the aspirin-lipid conjugates are acting through the inhibition of the COX- thromboxane 
synthase pathway. 
In order to understand the potency of inhibitory effects of fatty acid-aspirin derivatives compounds 
on human platelet function, we compared the effectiveness of compound C3 against aspirin treated 
controls. As seen in figure A.5C, washed platelets with AA induced aggregation, as compared to 
DMSO controls, with 20 µM of compound C3 shows a similar level of inhibition as aspirin treated 
controls, of platelet function in response to AA (p< 0.0001). The inhibition values are similar to 
aspirin treated controls where a treatment of 81 mg/day of aspirin was administered for 7 days. 
Thus, compound C3 at 20 µM concentration displays similar effectiveness to aspirin  
Inhibition of COX-1-thromboxane synthase activity by lipid-aspirin conjugates: Platelet 
aggregometry data shows that the inhibition by these compounds is effective only when induced 
by AA. Thus, the mechanism of action of the derivatives is likely through the COX-1-TXAS 
pathway. To confirm the effects of the derivatives and their parent compounds on the COX-1- 
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TXAS enzyme system, a coupled activity assay was performed. In this assay, COX-1 converts AA 
to prostaglandin H2 that is further converted by TXAS to thromboxane A2. TXA2 is a pro-
aggregatory molecule that initiates platelet aggregation. However, TXA2 is quickly converted to 
TXB2 by hydrolysis of the endoperoxide bond to the diol form. TXB2 can be subsequently 
measured.  
We utilized nanodiscs to stabilize TXAS is a membrane protein, which tends to lose functionality 
in aqueous buffers typically used for protein assays. Therefore it was incorporated into nanodiscs, 
lipid bilayers surrounded by membrane scaffold protein (MSP) (Figure A.8A). Previously we have 
shown that TXAS facilitates robust biophysical studies in nanodiscs as compared to naked protein 
in detergent solution (248). 
The anhydrides and their parent molecules were subjected to the coupled activity assay in a 1:1 
ratio with the substrate molecule AA. As observed in Figure A.9A, the EPA and DHA anhydrides 
were potent in inhibiting the thromboxane formed in a coupled assay system to a similar extent. 
The perceived reduction in TXA2 formation in both cases was about 30-35% of the control. 
However, the LA anhydride did not show any significant decrease in the formation of 
thromboxane. These observations are in agreement with the results obtained in the aggregometry 
studies that LA did not reduce platelet aggregation in washed platelets (Figure A.1). 
Furthermore, the parent molecules- LA, EPA and DHA, by themselves did not show any decrease 
in TXA2 formation (Figure A.8B). It is hypothesized that LA, EPA, and DHA compete with AA 
for metabolism by COX-1 and thereby reduce the ability of AA to be converted to TXA2, inducing 
aggregation. EPA is metabolized to PGH3 and subsequently TXA3 (249). However, our results 
indicate that the rate of metabolism of any of these fatty acids is not sufficient to result in 
competitive inhibition of AA metabolism by COX-1-CYP5A1. Therefore, it is evident that the 
effect of dietary unsaturated fatty acids on the COX pathway of platelet aggregation is not 
significant. 
Direct inhibition of COX-1-thromboxane synthase activity by lipid-aspirin conjugates: 
Observations in the coupled assay indicated that the EPA and DHA anhydride conjugates reduce 
platelet aggregation by inhibiting the COX-1 -TXAS pathway. Since both aspirin and PUFAs are 
thought to affect COX-1 directly, we wanted to test the effects of these anhydrides on COX-1 
activity. COX-1 converts AA into PGH2, which as previously stated is highly unstable and 
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decomposes to PGF2α. Thus a second reaction converting PGH2 into PGF2α, via action of tin (II) 
chloride was performed to completely convert it to PGF2α, a more stable species, and was 
subsequently measured by ELISA to determine the inhibition of COX activity by reduction in 
product formation. The inhibition of product formation by COX was measured at concentrations 
from 0-50 μM and the product formation relative to a no inhibitor control was fitted using non-
linear regression analysis. As seen in Figure A.9B, all three anhydrides show a dose-dependent 
decrease in PGF2α formation, showing less than 10% product formation, as compared to the 
absence of inhibitor at 50 μM. However, the trend in decline of product formation varied for the 
three derivatives. While for the LA anhydride the decrease in product formation was gradual, it 
was more dramatic initially for the EPA ad DHA anhydrides. The EPA anhydride shows an initial 
decline to 50% activity at 2.5 μM and then gradually declines to >10% at 25 μM concentration. 
The DHA anhydride shows an initial drop to less than 40% of total activity at 2.5μM and then 
slowly declines to ~10% at 25 μM. Interestingly, both EPA and DHA anhydrides show similar 
effects above 10 μM concentrations. The IC50 values for the compounds were calculated to be 7.5 
μM, 5.8 μM and 2.1 μM respectively for the LA anhydride, EPA anhydride and DHA anhydride. 
Direct buffer hydrolysis of the lipid-aspirin conjugates: To test the lability of the anhydrides in 
buffer, the rate of hydrolysis was measured by analyzing the remaining anhydride in PBS at 37°C 
at different time intervals. In all three cases, HPLC analysis of the aliquot indicated the presence 
of the original parent compound, aspirin and the corresponding fatty acid, indicating the release of 
the aspirin active moiety and not of salicylic acid. As observed in Figure A.10A, all three 
compounds show pseudo-first order kinetics of decomposition. The LA-aspirin anhydride shows 
a gradual decomposition over 30 mins, leading to decomposition of about 60% of the drug species 
into its individual components. In contrast, the EPA-aspirin anhydride shows a sharp 
decomposition in the first 5 mins and plateaus around 60% decomposition after the initial 
hydrolysis. This provides an explanation to the significant differences in the activities of EPA and 
LA anhydrides in the COX activity assay as well as the COX-thromboxane synthase coupled 
activity assays that are carried out over shorter incubation times. The LA anhydride being liberated 
more slowly has a lesser effect on the inhibition of COX-1 than the EPA anhydride, which releases 
the active species much faster. The DHA anhydride shows hydrolysis trends similar to LA 
anhydride whereby it is more gradual over the initial 5 mins and plateaus to about 55% at 60 mins.  
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Plasma hydrolysis studies: To investigate the release of aspirin from the aspirin-fatty acid mixed 
anhydride in plasma, plasma buffered with phosphate buffer (pH=7.4) was equilibrated at 37°C 
and the anhydride was added. At various time points aliquots were withdrawn and the extracted 
products were analyzed by HPLC. Figure A.10B represents the plasma hydrolysis patterns of all 
three anhydrides. Similar to the buffer hydrolysis, pseudo-first order kinetics can be observed in 
all three cases. All three compounds show a gradual decomposition over 2 hours plateauing to 
about 35- 40% decomposition. Note that the plasma hydrolysis of DHA is at a comparable range 
as EPA.  
A.5 DISCUSSION  
Platelet aggregation is triggered by a number of primary activators leading to positive feedback 
and potentiation of the activation signal. The Cyclooxygenase-1 (COX-1)-thromboxane synthase 
(TXAS) pathway is a well-established positive feedback signal in the platelet. In this pathway, 
arachidonic acid (AA) is metabolized by COX-1 to prostaglandin H2 (PGH2) followed by 
conversion of PGH2 to thromboxane A2 (TXA2), which is a pro-aggregatory molecule (250). 
Activation of the platelet either through primary activation or feedback activation via COX-1 leads 
to activation of the integrin GPIIb/IIIa resulting in platelet clot formation. The inhibition of platelet 
aggregation both ex vivo and in vivo can be aided by molecules inhibiting the COX-1-dependent 
feedback pathway as well as by directly blocking GPIIb/IIIa integrins (245) . 
Aspirin is the most popular NSAID for reducing pain, fever and inhibition of platelet function. The 
free carboxylate group in aspirin stays as an ionized species at physiological pH, which is poorly 
absorbed across lipid bilayers. Hence, the derivatization of the free carboxylic acid, to form more 
lipophilic species can facilitate transport across bio-membranes. Herein, we have derivatized the 
carboxylate end of aspirin through anhydride formation with dietary fatty acids including EPA and 
DHA (omega-3 fatty acids) as well as LA (omega-6 fatty acid) that have been shown to reduce 
platelet aggregation through dietary supplementation in platelet aggregometry studies. As 
compared to esters, anhydrides show more controlled patterns of hydrolysis and decomposition 
that are not enzyme dependent. Therefore we report the design of aspirin-poly unsaturated fatty 
acid mixed anhydrides that would exist in a unionized, lipophilic state as well as allow for a facile, 
more controlled release of the active species in plasma. Additionally, recent studies on 
polyanhydrides as drug carriers show that anhydrides degrade in a controlled fashion and are 
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biocompatible with human body tissues, including the brain (251). One of the rationale for the 
design of the hybrid co-drug is that the aspirin-fatty acid-anhydride pro-drug would hydrolyze to 
release not one but two active species, which could both inhibit the enzyme.  
The synthesis of the mixed anhydrides were tested in platelet aggregometry studies to analyze their 
anti-aggregatory effects. All three compounds displayed a concentration dependent decrease in 
platelet aggregation. However, the DHA anhydride was most potent, almost completely inhibiting 
aggregation at 10 µM concentration, followed by EPA anhydride and, finally, LA anhydride, 
which showed marginal decrease in the inhibition of aggregation. As expected from the 
mechanism of inhibition of platelet aggregation studies, the decrease was only observed in AA-
induced platelet aggregation and not observed for ADP, collagen, U46619 or thrombin, indicating 
that these molecules did not affect those pathways for platelet aggregation. Furthermore, 
comparing the inhibition of the DHA anhydride with aspirin-treated species showed comparable 
inhibition potentials.  
To understand the biochemical mechanism of action of these molecules, an activity assay was 
performed on the COX-1 -thromboxane synthase system. It was observed that while the reduction 
in TXA2 for EPA and DHA anhydride was significant, LA anhydride did not show significant 
reduction, thereby following the similar trend of the platelet aggregometry studies. More 
interestingly, however, the parent fatty acids showed no inhibition in thromboxane formation 
(Figure A.8). Thus, it appears that while LA, EPA, and DHA may be able to compete for 
metabolism against AA, this is likely not the chief mechanism of their action to prevent platelet 
aggregation. Literature reports have suggested that omega-3 fatty acids reduce platelet aggregation 
by signaling through other pathways (252). Furthermore, a meta- analysis of the effect of omega-
3 fatty acids on the inhibition of platelet aggregation suggests that the effect is sufficiently short-
term to hinder significant changes in plasma lipid or lipoprotein composition (253, 254). 
Additionally it is possible that this inhibition is mediated through collagen induced pathways 
(255). 
Next, we determined the effect of the compounds on COX-1 activity and derived IC50 values for 
the anhydrides. The values for the LA, EPA, and DHA anhydrides were obtained to be 7.1, 5.8 
and 2.1 μM respectively. Literature reports suggest that the IC50 values of COX-1 inhibition for 
linolenic acid, EPA, and DHA are 93 μM, 13 μM and 15 μM, respectively. Furthermore, the IC50 
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value of aspirin on COX-1 in purified enzyme system is 8 μM (256). The culmination of these 
results suggests a greater effect of the mixed anhydrides in comparison to their parent molecules.  
Finally, the molecules were characterized by their hydrolytic decomposition patterns as it is the 
key step in releasing both the species. It was observed that the only species resulting from the 
hydrolysis of the fatty acid- aspirin anhydride were aspirin and the corresponding fatty acid. This 
is important since in several aspirin formulations it has been observed that the O-acetyl group of 
aspirin hydrolyzes before the aspirin moiety is released from the pro-drug thereby only being as 
effective as salicylic acid and not aspirin. Furthermore, we observed that all three molecules show 
pseudo-first order decomposition kinetics in both buffer and plasma. Additionally, the extents of 
hydrolysis in buffer and plasma were comparable, indicating that enzyme hydrolysis is not a 
significant pathway for the release of aspirin. It appears that EPA hydrolyzes faster than DHA, 
which hydrolyzes more rapidly than LA. This can be partly explained by the hydrophobicity of the 
species attached to the aspirin moiety. It is known that LA > DHA > EPA in terms of 
hydrophobicity. In general, the more hydrophobic a species, the slower the rate of hydrolysis. This 
observation can be further extended to control the rate of hydrolyses of these species by carefully 
tuning the anhydride partner.  
A.6 CONCLUSION  
We have synthesized anhydrides of aspirin and dietary fatty acids to explore a “hybrid- drug” 
approach. Both aspirin and the fatty acids in this study are inhibitors of platelet aggregation and 
this conjugation addresses the side effects of aspirin in addition to the synergism between the two 
species. We observed that all three compounds individually inhibit platelet aggregation in a dose-
dependent manner in the effectiveness order of C3, C2 then C1. Additionally, we show that C3 is 
comparable to aspirin-treated samples. Furthermore, we show that while all three molecules act 
through the COX-thromboxane synthase pathway by inhibiting COX-1, the parent fatty acids do 
not act via that pathway. Finally, hydrolysis studies of the drugs in buffer as well as plasma 
conditions confirm the release of aspirin and fatty acid separately, instead of the salicylate moiety 
as is the case with several aspirin pro-drugs. 
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A.8 FIGURES, TABLES AND LEGENDS 
 
 
Scheme A.1: Synthesis of anhydrides. Aspirin (acetylsalicylic acid) is first converted to the 
activated acyl chloride by refluxing with thionyl chloride (SOCl2) in benzene. This further reacts 
with the carboxylate on dietary fatty acids in the presence of pyridine in DCM to give LA 




































Figure A.4: Effect of anhydrides on platelet aggregation in washed platelets by arachidonic acid. 
The plots show the transmission of light versus time for various concentrations (2.5 μM, 5 μM and 
10 μM) of (A) LA anhydride (C1) (B) EPA anhydride (C2) and (C) DHA anhydride (C3), and 
DMSO control. The reduction of light transmission indicates the inhibition of aggregation. All 
compounds show a concentration dependent decrease in aggregation in the order of effectivity LA 
anhydride<EPA anhydride<DHA anhydride. The results show data from n=5. (* p< 0.05, ** p < 






Figure A.5: (A) Effect of 10 μM anhydrides on platelet aggregation as indicated by light 
transmission in platelet rich plasma by 5 μM arachidonic acid. (B) All compounds show a 
concentration dependent decrease in aggregation in the order of effectivity LA anhydride (C1) < 
EPA anhydride (C2) < DHA anhydride (C3). The results show data from n=5. (C) Comparison of 
the inhibitory effect of C3 compound with Aspirin. 20 μM C3 compound completely inhibited the 










Figure A.6: Inhibition of platelet aggregation in washed platelets by anhydrides (10 uM) in the 
presence of (A) 1nM Thrombin (B) 50 μM PAR4-AP (C) 1 μM PAR1- AP (D) 1 μM ADP (E) 1 
μM U46619 (thromboxane analog).  Results show no significant decrease in platelet aggregation 












Figure A.7: Inhibition of platelet aggregation in platelet rich plasma by anhydrides (10 uM) in the 
presence of (A) 1 uM ADP (B) 2 μg/mL Collagen (C) 1 μM ristocetin (D) 1 μM U46619 
(thromboxane analog).  Results show no significant decrease in platelet aggregation using alternate 
agonists. Results show no significant decrease in platelet aggregation. The results show data from 










Figure A.8: (A) Schematic of coupled assay. Arachidonic acid (AA) converts to Prostaglandin H2 
(PGH2) in the presence of enzyme COX-1 (cyclooxygenase-1). PGH2 converts to Thromboxane 
A2 (TXA2) in the presence of TXAS (thromboxane synthase) that is stabilized in nanodiscs. (B) 
Thromboxane formed in the presence of LA, EPA and DHA in a coupled assay and AA control 
with no inhibitor. Results show that while no significant reduction in thromboxane formation is 











Figure A.9: (A) Thromboxane formed in the presence of LA anhydride, EPA anhydride and DHA 
anhydride in a coupled assay and AA control with no inhibitor. Results show that while no 
significant reduction in thromboxane formation is observed in the presence of LA anhydride, 
significant thromboxane reduction is seen in the presence of EPA anhydride and DHA anhydride. 
(B) Effect of LA anhydride (solid square, solid line), EPA anhydride (solid circle, dashed line) and 
DHA anhydride (open square, dashed and dotted line) on COX activity from 0- 50μM. All 




Figure A.10: (A) Buffer hydrolysis of anhydrides. (B) Plasma hydrolysis of anhydrides: DHA 
anhydride (dashed line, solid squares), EPA anhydride (dotted line, solid circle) and LA anhydride 
(solid line, open square). The extent of hydrolysis is in the order EPA anhydride > DHA anhydride 
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APPENDIX B: TABLES OF PROTEINS IDENTIFIED BY PEPTIDE 
FINGERPRINTING OF HOS, 143B, POS AND HMPOS CELL LINES 
Parameters for Proteomics Classifications 
Taxonomy Homo sapiens 
(human) (287,757 
sequences) 





Mass values Monoisotopic 


























emPAI or exponentially modified protein abundance index is a parameter indicating relative 
abundance of proteins in the mixture 




ST1-1.  Overall proteomic profile 
 
emPAI Percentage 
Structure 67.86 63.48 






G protein and 
GPCR 
7.21 6.74 
Chaperones  1.71 1.60 
Receptors 3.41 3.19 
Enzymes 4.52 4.23 
Others 1.77 1.66 
Total 106.9 100 
 




gi|11935049 66027 2.07 keratin 1 [Homo sapiens] 
gi|11961705
7 
57772 0.83 keratin 8, isoform CRA_a [Homo sapiens] 
gi|11961703
2 
59874 0.44 keratin 6B, isoform CRA_a [Homo sapiens] 
gi|11939575
4 
62340 0.32 keratin, type II cytoskeletal 5 [Homo sapiens] 
gi|11958114
8 
57526 1.3 keratin 9 (epidermolytic palmoplantar keratoderma) [Homo 
sapiens] 
gi|12653819 48003 1.26 Keratin 18 [Homo sapiens] 
gi|1195531 51206 0.4 type I keratin 16 [Homo sapiens] 
gi|181402 65825 0.7 epidermal cytokeratin 2 [Homo sapiens] 
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gi|7106439 49639 1.2 tubulin beta-5 chain [Mus musculus] 
gi|11960877
5 
48794 1.04 tubulin, beta 2C, isoform CRA_b [Homo sapiens] 
gi|340021 50120 0.68 alpha-tubulin [Homo sapiens] 
gi|62421087 11517 0.44 actin-like protein [Homo sapiens] 
gi|4501885 41710 9.89 actin, cytoplasmic 1 [Homo sapiens] 
gi|63055057 41976 1.53 beta-actin-like protein 2 [Homo sapiens] 
gi|24119203 29015 0.56 tropomyosin alpha-3 chain isoform 2 [Homo sapiens] 
gi|17986258 16919 1.13 myosin light polypeptide 6 isoform 1 [Homo sapiens] 
gi|5031573 47341 0.2 actin-related protein 3 isoform 1 [Homo sapiens] 
gi|2605594 19694 0.55 myosin regulatory light chain [Homo sapiens] 
gi|5031595 19654 0.55 actin-related protein 2/3 complex subunit 4 isoform a [Homo 
sapiens] 











0.23 alpha-actinin-1 isoform a [Homo sapiens] 
gi|16788775
1 
49623 6.48 vimentin variant 3 [Homo sapiens] 
gi|12667788 22639
2 
0.02 myosin-9 [Homo sapiens] 





35984 3.78 Chain A, Human Annexin V With Proline Substitution By 
Thioproline 
gi|71773329 75826 0.99 annexin A6 isoform 1 [Homo sapiens] 
gi|11958295
2 
40057 0.72 annexin A1, isoform CRA_c [Homo sapiens] 
gi|53791219 27733
2 





0.07 filamin-B isoform 2 [Homo sapiens] 
gi|34234 31774 0.5 laminin-binding protein, partial [Homo sapiens] 
gi|18760933
8 




66564 0.92 moesin, isoform CRA_b [Homo sapiens] 
gi|16974825 8483 0.63 Chain A, Solution Structure Of Calcium-calmodulin N-
terminal Domain 
gi|7656991 53215 0.18 coronin-1C isoform b [Homo sapiens] 
gi|19920317 65983 0.3 cytoskeleton-associated protein 4 [Homo sapiens] 
gi|4826898 15045 1.32 profilin-1 [Homo sapiens] 
gi|3212355 11064 3.53 Chain A, P11 (s100a10), Ligand Of Annexin Ii 
    
gi|641958 22879
8 
0.02 non-muscle myosin B [Homo sapiens] 
gi|15778914 42189 0.11 Parvin, alpha [Homo sapiens] 





0.02 envoplakin [Homo sapiens] 
gi|57879833
0 
64316 0.07 PREDICTED: afadin- and alpha-actinin-binding protein 
isoform X6 [Homo sapiens] 
gi|44889481 12487
2 
0.04 unconventional myosin-Ib isoform 2 [Homo sapiens] 
gi|1846005 33298
7 
0.01 collagen type XII alpha-1 [Homo sapiens] 
gi|11958523
5 
84713 0.05 SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily c, member 1, isoform 
CRA_a [Homo sapiens] 
gi|4235275 26966
1 
0.02 talin [Homo sapiens] 
gi|306896 57790 0.08 intercellular adhesion molecule-1 precursor [Homo sapiens] 
gi|11958466
5 











0.02 PREDICTED: FERM and PDZ domain-containing protein 4 
isoform X1 [Homo sapiens] 
gi|6912534 29088 0.16 BMP and activin membrane-bound inhibitor homolog 
precursor [Homo sapiens] 
gi|50897294 51245 0.09 POTE ankyrin domain family member A isoform 1 [Homo 
sapiens] 
gi|14149805 38735 0.12 enkurin domain-containing protein 1 [Homo sapiens] 
176 
 
gi|4503375 56594 0.08 dihydropyrimidinase [Homo sapiens] 





0.03 uveal autoantigen with coiled-coil domains and ankyrin 
repeats, isoform CRA_a [Homo sapiens] 
 
 






69258 0.06 PREDICTED: two pore calcium channel protein 2 isoform 
X4 [Homo sapiens] 
gi|62088088 85811 0.94 transferrin receptor variant [Homo sapiens] 
gi|11957495
4 




0.07 plasma membrane Ca2+ pumping ATPase [Homo sapiens] 
gi|1478281 56585 0.17 neutral amino acid transporter B [Homo sapiens] 
gi|11959567
9 
95691 0.05 potassium voltage-gated channel, KQT-like subfamily, 
member 2, isoform CRA_c [Homo sapiens] 
gi|11558368
5 





0.03 cache domain containing 1 [Homo sapiens] 
gi|98986321 58920 0.08 gliomedin [Homo sapiens] 
177 
 




13223 0.38 Chain A, Crystal Structure Of The Px Domain Of Sorting 
Nexin-17 (Snx17) 
gi|15012080 17190 0.28 ACAT1 protein [Homo sapiens] 
gi|549988 81597 0.05 sulfate transporter [Homo sapiens] 
gi|34794849
2 
8529 0.62 Chain A, Complex Of Cambr And Cam 
gi|3882215 11978
3 
0.04 KIAA0747 protein [Homo sapiens] 
 
ST 1-4: Immune Complexes Identified 
Accession Mass emPAI Description 
gi|161376703 31480 0.51 MHC class I antigen [Homo sapiens] 
gi|47564005 31489 0.73 MHC class I antigen [Homo sapiens] 
gi|358423242 21090 0.84 MHC class I antigen [Homo sapiens] 
gi|333036593 21139 0.84 MHC class I antigen [Homo sapiens] 
gi|34222512 40410 0.54 RecName: Full=HLA class I histocompatibility antigen, B-73 
alpha chain; AltName: Full=MHC class I antigen B*73; 
Flags: Precursor 
gi|55415712 10828 0.47 MHC class II antigen [Homo sapiens] 
gi|371448219 14569 0.34 immunoglobulin G heavy chain variable region, partial 
[Homo sapiens] 
gi|26801098 8458 0.63 immunoglobulin heavy chain variable region [Homo sapiens] 
178 
 
gi|371447513 13673 0.36 immunoglobulin G heavy chain variable region, partial 
[Homo sapiens] 
gi|62871150 17043 0.28 immunoglobulin alpha heavy chain variable region [Homo 
sapiens] 
gi|304562592 13044 0.38 immunoglobulin gamma 1 heavy chain variable region 
[Homo sapiens] 
gi|388777938 13723 0.36 immunoglobulin heavy chain variable region, partial [Homo 
sapiens] 
gi|177216 58041 0.16 4F2 heavy chain antigen [Homo sapiens] 
gi|179531 26172 0.18 IgE-binding protein [Homo sapiens] 
gi|220702506 54199 0.9 Chain A, TapasinERP57 HETERODIMER 
gi|7161035 10423 0.49 immunoglobulin heavy chain [Homo sapiens] 
gi|886258 65091 0.07 alcam [Homo sapiens] 
gi|19909527 38169 0.57 DERP12 (dermal papilla derived protein 12) [Homo sapiens] 
gi|19747283 12346 0.41 X antigen family member 2 [Homo sapiens] 
gi|627493 2788 2.82 interferon alpha (component g) - human (fragment) 
gi|70913399 2021 4.89 T cell receptor alpha variable 7 [Homo sapiens] 
 




gi|4504041 40425 0.38 guanine nucleotide-binding protein G(i) subunit alpha-2 





39680 0.39 guanine nucleotide binding protein (G protein), beta 
polypeptide 2-like 1, isoform CRA_h [Homo sapiens] 
gi|29766022
0 
16459 0.3 Rho GTPase activating protein 26 variant 3 [Homo sapiens] 
gi|1770396 42266 0.11 G-protein coupled receptor (putative) [Homo sapiens] 
gi|6680045 37353 0.12 guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit 
beta-1 [Mus musculus] 
gi|1174072 42116 0.23 G alpha-q [Homo sapiens] 
gi|52353947 34995 0.13 olfactory receptor 51F1 [Homo sapiens] 
gi|187281 77555 0.4 M4 protein [Homo sapiens] 
gi|54034458
4 
37576 0.12 guanine nucleotide-binding protein subunit alpha-12 isoform 
3 [Homo sapiens] 
gi|62088744 29577 0.16 regulator of G-protein signalling 11 isoform 1 variant [Homo 
sapiens] 




51201 0.09 septin 11, isoform CRA_a [Homo sapiens] 
gi|58257741 17136
9 
0.03 KIAA1219 protein [Homo sapiens] 
gi|4505675 68448 0.07 high affinity cGMP-specific 3',5'-cyclic phosphodiesterase 
9A isoform a [Homo sapiens] 
gi|4456467 77101 0.06 TM7XN1 protein [Homo sapiens] 
gi|3002951 15512 0.31 breakpoint cluster region protein 1 [Homo sapiens] 







0.04 Rap guanine nucleotide exchange factor (GEF) 1, isoform 
CRA_b [Homo sapiens] 
gi|21928311 35019 0.13 seven transmembrane helix receptor [Homo sapiens] 
    
gi|13569962 22157 1.17 ras-related protein Rab-1B [Homo sapiens] 
gi|11962032
9 
28129 0.85 RAB1A, member RAS oncogene family, isoform CRA_f 
[Homo sapiens] 
gi|4506413 20974 0.5 ras-related protein Rap-1A precursor [Homo sapiens] 
gi|20147713 23971 0.43 Ras family small GTP binding protein RALA [Homo 
sapiens] 






0.07 IQ motif containing GTPase activating protein 1 [Homo 
sapiens] 
gi|508285 23553 0.44 Rab5c-like protein, similar to Canis familiaris Rab5c protein, 
PIR Accession Number S38625 [Homo sapiens] 
gi|763130 24559 0.19 YPT3 [Homo sapiens] 
gi|35980705
9 
20502 0.23 TBC1 domain family member 1 isoform 4 [Homo sapiens] 
ST 1-6: Chaperone Proteins Identified 
ACCESSION MASS EMPAI DESCRIPTION 
    
GI|431822408 82269 0.89 heat shock protein HSP 90-beta isoform c [Homo 
sapiens] 




GI|4502643 57988 0.08 T-complex protein 1 subunit zeta isoform a [Homo 
sapiens] 
GI|5453603 57452 0.08 T-complex protein 1 subunit beta isoform 1 [Homo 
sapiens] 
GI|48762932 59583 0.08 T-complex protein 1 subunit theta isoform 1 [Homo 
sapiens] 
GI|48145555 59291 0.08 CCT7 [Homo sapiens] 
GI|671527 60292 0.07 gamma subunit of CCT chaperonin [Homo sapiens] 
 
ST 1-7: Receptors Identifed 
ACCESSION MASS EMPAI DESCRIPTION 
GI|19743813 88357 0.22 integrin beta-1 isoform 1A precursor [Homo sapiens] 
GI|11958159
1 
46372 0.45 basigin (Ok blood group), isoform CRA_g [Homo sapiens] 
GI|11961028
6 
18642 1.5 progesterone receptor membrane component 1, isoform 
CRA_b [Homo sapiens] 




26154 0.18 membrane-associated progesterone receptor component 2 
[Homo sapiens] 
GI|62089372 30214 0.15 FK506 binding protein 5 variant [Homo sapiens] 
GI|483831 30384
4 
0.01 type 3 inositol 1,4,5-trisphosphate receptor [Homo 
sapiens] 




GI|703110 17307 0.28 thyroid receptor interactor, partial [Homo sapiens] 
GI|62088916 26594
3 
0.02 Insulin-like growth factor 2 receptor variant [Homo 
sapiens] 
GI|62089376 70414 0.06 complement component 1, q subcomponent, receptor 1 
variant [Homo sapiens] 





0.02 PREDICTED: peripheral-type benzodiazepine receptor-









GI|33946291 59113 0.08 lysophosphatidylcholine acyltransferase 1 [Homo sapiens] 
GI|29146338
2 
17983 1.58 Chain A, Free Acetyl-Cypa Trigonal Form 
GI|181250 22597 1.13 cyclophilin, partial [Homo sapiens] 
GI|33946291 59113 0.08 lysophosphatidylcholine acyltransferase 1 [Homo sapiens] 
GI|6331328 11510
3 
0.08 KIAA1280 protein [Homo sapiens] 
GI|53039052
8 






24546 0.42 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, beta polypeptide, isoform CRA_b [Homo 
sapiens] 




9922 0.53 Chain A, Crystal Structure Of Phospholipase C Beta 3 In 
Complex With Pdz1 Of Nherf1 
GI|38202211 14353
1 
0.03 N-acetylglucosamine-1-phosphotransferase subunits 
alpha/beta precursor [Homo sapiens] 
GI|57035982
4 
37730 0.12 Chain A, Crystal Structure Of The Human Cyclin G 
Associated Kinase (gak) 
GI|68051721 49031 0.09 neutral cholesterol ester hydrolase 1 isoform b [Homo 
sapiens] 
 
ST 1-9: Other Proteins Identified 
ACCESSION MASS EMPAI DESCRIPTION 
GI|1665773 78230 0.06 KIAA0253 [Homo sapiens] 
GI|178775 28944 1.1 proapolipoprotein, partial [Homo sapiens] 
GI|4505893 16680 0.29 proteolipid protein 2 [Homo sapiens] 
GI|1374813 23368 0.2 SNAP-23 [Homo sapiens] 
GI|28376621 46614 0.1 SEC14-like protein 4 isoform a [Homo 
sapiens] 





ST2: Proteomics data of plasma membrane protein from 143B 
 




Structural 87.73 56.68 




G- proteins and 
GPCRs 
28.33 18.30 




Enzymes 2.09 1.35 
185 
 
Others 5.84 3.77 
Total  154.78 100 
 
 
ST2-2. Structural proteins detected 
Accession Mass emPAI Description 
 
gi|435476 62092 2.89 cytokeratin 9 [Homo sapiens] 
gi|12803709 51619 1.26 Keratin 14 [Homo sapiens] 
gi|12653819 48003 0.3 Keratin 18 [Homo sapiens] 
gi|11935049 66027 6.72 keratin 1 [Homo sapiens] 
gi|62414289 53619 9.57 vimentin [Homo sapiens] 
gi|47132620 65393 2.88 keratin, type II cytoskeletal 2 epidermal [Homo sapiens] 
gi|119617032 59874 0.76 keratin 6B, isoform CRA_a [Homo sapiens] 
gi|119395754 62340 0.84 keratin, type II cytoskeletal 5 [Homo sapiens] 
gi|119617057 57772 0.79 keratin 8, isoform CRA_a [Homo sapiens] 
gi|28173564 58887 0.15 keratin, type II cytoskeletal 73 [Homo sapiens] 
gi|73909156 40503 26.66 Annexin A2 [Homo sapiens] 
gi|62897671 41694 8.17 beta actin variant [Homo sapiens] 
gi|7106439 49639 1.77 tubulin beta-5 chain [Mus musculus] 
gi|119608775 48794 1.81 tubulin, beta 2C, isoform CRA_b [Homo sapiens] 




gi|34234 31774 0.7 laminin-binding protein, partial [Homo sapiens] 
gi|16974825 8483 10.06 Chain A, Solution Structure Of Calcium-calmodulin N-
terminal Domain 
gi|5031635 18491 2.07 cofilin-1 [Homo sapiens] 
gi|4502101 38690 0.92 annexin A1 [Homo sapiens] 
gi|12667788 226392 0.18 myosin-9 [Homo sapiens] 
gi|24119203 29015 1.06 tropomyosin alpha-3 chain isoform 2 [Homo sapiens] 
gi|17986258 16919 1.67 myosin light polypeptide 6 isoform 1 [Homo sapiens] 
gi|179976 75857 0.48 calelectrin [Homo sapiens] 
gi|37492 50126 0.52 alpha-tubulin [Homo sapiens] 
gi|321400138 46537 0.31 CD44 antigen isoform 6 precursor [Homo sapiens] 
gi|119593154 263754 0.08 filamin A, alpha (actin binding protein 280), isoform 
CRA_e [Homo sapiens] 
gi|530393410 236464 0.07 PREDICTED: myoferlin isoform X1 [Homo sapiens] 
gi|7656991 53215 0.08 coronin-1C isoform b [Homo sapiens] 
gi|3282771 278018 0.06 actin-binding protein homolog ABP-278 [Homo 
sapiens] 
gi|4826898 15045 0.73 profilin-1 [Homo sapiens] 
gi|119584665 9744 0.52 ankyrin repeat domain 28, isoform CRA_d [Homo 
sapiens] 
gi|186837 197937 0.02 laminin B1 [Homo sapiens] 
gi|41322910 512292 0.03 plectin isoform 1d [Homo sapiens] 
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gi|205831092 68253 0.06 RecName: Full=Putative IQ motif and ankyrin repeat 
domain-containing protein LOC642574 
gi|641958 228798 0.02 non-muscle myosin B [Homo sapiens] 
gi|3287188 127296 0.03 ankyrin-like protein [Homo sapiens] 
gi|120660098 163133 0.03 CAMSAP1 protein [Homo sapiens] 
gi|444738793 5129 1.16 alternative protein CEP350 [Homo sapiens] 
gi|8885790 287292 0.03 filamin 2 [Homo sapiens] 
gi|762885 81583 0.05 Plakoglobin [Homo sapiens] 
gi|578821687 271519 0.02 PREDICTED: spectrin beta chain, non-erythrocytic  2 
isoform X3 [Homo sapiens] 
gi|438056 342550 0.01 laminin M chain (merosin) [Homo sapiens] 
gi|4507115 54496 0.08 fascin [Homo sapiens] 
gi|119576069 394840 0.01 myosin XVA, isoform CRA_c [Homo sapiens] 
gi|6563228 43212 0.1 rap2 interacting protein x [Homo sapiens] 
gi|4757944 25792 0.18 CD81 antigen [Homo sapiens] 
gi|1107687 505963 0.02 homologue of Drosophila Fat protein [Homo sapiens] 
gi|578837838 423562 0.01 PREDICTED: dystrophin isoform X5 [Homo sapiens] 
gi|578823153 93390 0.05 PREDICTED: tastin isoform X1 [Homo sapiens] 
gi|119574344 91877 0.05 ankyrin repeat domain 30B, partial [Homo sapiens] 
gi|2996006 70660 0.06 outer dense fiber protein 2/2 [Homo sapiens] 
gi|34226 288131 0.01 laminin A chain [Homo sapiens] 




gi|186964 177492 0.02 laminin B2 chain [Homo sapiens] 
gi|578819318 310817 0.01 PREDICTED: ankyrin-3 isoform X17 [Homo sapiens] 
gi|55743096 193394 0.02 collagen alpha-1(XIV) chain precursor [Homo sapiens] 
 
ST 2-3: Transport Proteins detected 
Accession Mass emPAI Description 
gi|119574954 34459 0.84 voltage-dependent anion channel 2, isoform CRA_a 
[Homo sapiens] 
gi|198443050 31818 0.3 Chain A, Solution Structure Of Human Vdac-1 In Ldao 
Micelles 
gi|61744477 68059 0.28 4F2 cell-surface antigen heavy chain isoform b [Homo 
sapiens] 
gi|4505893 16680 0.28 proteolipid protein 2 [Homo sapiens] 
gi|51094709 10252
3 
0.04 tweety homolog 3 (Drosophila) [Homo sapiens] 
gi|48255951 13678
9 
0.03 plasma membrane calcium-transporting ATPase 2 isoform 
1 [Homo sapiens] 
gi|5733504 27630 0.16 voltage-dependent anion channel VDAC3 [Homo sapiens] 
gi|1478281 56585 0.16 neutral amino acid transporter B [Homo sapiens] 
gi|5730102 10625
8 
0.04 short transient receptor potential channel 6 [Homo sapiens] 
gi|4502281 31492 0.14 sodium/potassium-transporting ATPase subunit beta-3 
[Homo sapiens] 





0.02 ATP-binding cassette sub-family A member 2 [Homo 
sapiens] 
gi|38516 20468 0.23 caveolin [Homo sapiens] 
gi|347948492 8529 0.61 Chain A, Complex Of Cambr And Cam 
gi|62087606 50068 0.09 sorting nexin 1 isoform a variant [Homo sapiens] 
gi|2337920 29827 0.15 syntaxin 7 [Homo sapiens] 
gi|25777643 59949 0.07 small conductance calcium-activated potassium channel 
protein 1 [Homo sapiens] 
gi|51339295 12684
3 
0.07 cation channel sperm-associated protein subunit beta 
precursor [Homo sapiens] 
gi|4507297 68692 0.06 syntaxin-binding protein 1 isoform a [Homo sapiens] 
gi|169790839 59534 0.07 excitatory amino acid transporter 1 isoform 1 [Homo 
sapiens] 
 
ST 2-4 :  Immune Complex proteins detected 
Accession Mass emPAI Description 
gi|432139040 12890 0.38 immunoglobulin heavy chain variable region, partial [Homo 
sapiens] 
gi|290560013 11815 3.04 Chain B, Crystal Structure Of Mhc Class I Hla-A2.1 Bound 
To A Photocleavable Peptide 
gi|4324088 10594 0.47 immunoglobulin lambda light chain variable region [Homo 
sapiens] 
gi|307496 1390 9.07 T cell receptor beta chain [Homo sapiens] 
gi|333036593 21139 0.22 MHC class I antigen [Homo sapiens] 
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gi|151188217 40719 0.11 killer-cell Ig-like receptor [Homo sapiens] 
gi|17986005 29943 0.15 major histocompatibility complex, class II, DR beta 3 
precursor [Homo sapiens] 
gi|611962048 10753 0.46 immunoglobulin heavy chain variable region, partial [Homo 
sapiens] 
gi|247425243 13679 0.35 immunoglobulin heavy chain variable region [Homo 
sapiens] 
gi|15680023 27975 0.16 B-cell receptor-associated protein 31 [Homo sapiens] 
gi|4038122 4086 1.57 T-cell receptor beta chain [Homo sapiens] 
gi|226316189 21056 0.22 MHC class I antigen [Homo sapiens] 
gi|224962016 21226 0.48 MHC class II antigen [Homo sapiens] 
gi|119573139 39827 0.11 SLAM family member 9, isoform CRA_a [Homo sapiens] 
gi|26985944 13046 0.37 immunoglobulin IgG1 heavy chain [Homo sapiens] 
    
ST 2- 5: GPCRs and G- proteins detected 
Accession Mass emPAI Description 
gi|4506413 20974 0.81 ras-related protein Rap-1A precursor [Homo sapiens] 
gi|327195100 33961 0.45 UBE2L3/KRAS fusion protein [Homo sapiens] 
gi|119574084 39680 0.53 guanine nucleotide binding protein (G protein), beta 
polypeptide 2-like 1, isoform CRA_h [Homo sapiens] 
gi|508285 23553 0.43 Rab5c-like protein, similar to Canis familiaris Rab5c protein, 
PIR Accession Number S38625 [Homo sapiens] 
gi|13569962 22157 1.56 ras-related protein Rab-1B [Homo sapiens] 
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gi|33946329 23552 0.43 ras-related protein Ral-A precursor [Homo sapiens] 
gi|1174149 23447 1.04 small GTP binding protein Rab7 [Homo sapiens] 
gi|14249144 24473 0.67 ras-related protein Rab-11B [Rattus norvegicus] 
gi|5729850 40506 0.37 guanine nucleotide-binding protein G(k) subunit alpha [Homo 
sapiens] 
gi|21361884 24199 0.19 ras-related protein Rab-2B isoform 1 [Homo sapiens] 
gi|5031703 52132 0.18 ras GTPase-activating protein-binding protein 1 [Homo 
sapiens] 
gi|5031703 52132 0.18 ras GTPase-activating protein-binding protein 1 [Homo 
sapiens] 
gi|297660220 16459 0.29 Rho GTPase activating protein 26 variant 3 [Homo sapiens] 
gi|311697329 3564 1.93 KRAS protein [Homo sapiens] 
gi|4885287 7314 0.73 guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit 
gamma-5 precursor [Homo sapiens] 
gi|540344584 37576 0.12 guanine nucleotide-binding protein subunit alpha-12 isoform 
3 [Homo sapiens] 
gi|3292965 1071 15.8 m1 muscarinic acetylcholine receptor protein [Homo sapiens] 
gi|53828729 34724 0.13 olfactory receptor 7D2 [Homo sapiens] 
gi|334278900 35700 0.12 olfactory receptor 4N4 [Homo sapiens] 
gi|19338916 36399 0.12 G protein-coupled receptor SNSR5 [Homo sapiens] 
gi|2500069 21555 0.21 RecName: Full=Ras-related protein Rab-31; AltName: 
Full=Ras-related protein Rab-22B [Homo sapiens] 
gi|3327062 221821 0.02 KIAA0624 protein [Homo sapiens] 
gi|4139784 24393 0.19 Chain A, Canine Gdp-Ran Q69l Mutant 
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gi|390635651 110782 0.04 ras-related protein Rab-44 [Homo sapiens] 
gi|21928341 34874 0.13 seven transmembrane helix receptor [Homo sapiens] 
gi|530416765 113467 0.04 PREDICTED: ras-interacting protein 1 isoform X1 [Homo 
sapiens] 
gi|62088744 29577 0.15 regulator of G-protein signalling 11 isoform 1 variant [Homo 
sapiens] 
gi|359807059 20502 0.22 TBC1 domain family member 1 isoform 4 [Homo sapiens] 
gi|4836765 77704 0.06 G-protein-coupled receptor [Homo sapiens] 
gi|13122463 37605 0.12 G protein-coupled receptor [Homo sapiens] 
gi|9625037 21295 0.22 rho-related GTP-binding protein RhoG precursor [Mus 
musculus] 
gi|51036603 8001 0.66 guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit 
gamma-12 precursor [Homo sapiens] 
gi|15293749 23836 0.19 olfactory receptor [Homo sapiens] 
 
ST 2-6: Chaperone proteins detected 
Accession Mass emPAI Description 
gi|431822408 82269 0.95 heat shock protein HSP 90-beta isoform c [Homo sapiens] 
gi|153792590 98099 0.47 heat shock protein HSP 90-alpha isoform 1 [Homo 
sapiens] 
gi|62089036 57725 0.16 chaperonin containing TCP1, subunit 6A isoform a variant 
[Homo sapiens] 




gi|1136741 58465 0.16 KIAA0002 [Homo sapiens] 
gi|5453607 59329 0.15 T-complex protein 1 subunit eta isoform a [Homo sapiens] 
gi|671527 60292 0.07 gamma subunit of CCT chaperonin [Homo sapiens] 
gi|36796 60356 0.15 t-complex polypeptide 1 [Homo sapiens] 
 
ST 2-7: Other Receptor proteins detected 
Accession Mass emPAI Description 
gi|1477388 132282 0.07 metabotropic glutamate receptor 1 alpha [Homo sapiens] 
gi|119581591 46372 0.2 basigin (Ok blood group), isoform CRA_g [Homo 
sapiens] 
gi|187609338 20107 0.51 Chain A, Crystal Structure Of The Extracellular Portion 
Of Hab18gCD147 
gi|19743813 88357 0.47 integrin beta-1 isoform 1A precursor [Homo sapiens] 
gi|124942 129214 0.14 RecName: Full=Integrin alpha-2; AltName: Full=CD49 
antigen-like family member B; AltName: Full=Collagen 
receptor; AltName: Full=Platelet membrane 
glycoprotein Ia; Short=GPIa; AltName: Full=VLA-2 
subunit alpha; AltName: CD_antigen=CD49b; Flags: 
Precu 
gi|6424942 96019 0.05 ALG-2 interacting protein 1 [Homo sapiens] 
gi|5729875 21658 0.21 membrane-associated progesterone receptor component 
1 isoform 1 [Homo sapiens] 
gi|4530577 65546 0.07 LISCH protein [Homo sapiens] 
gi|21928311 35019 0.13 seven transmembrane helix receptor [Homo sapiens] 
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gi|62089376 70414 0.06 complement component 1, q subcomponent, receptor 1 
variant [Homo sapiens] 
gi|119611708 110644 0.04 protein tyrosine phosphatase, receptor type, C, isoform 
CRA_c [Homo sapiens] 
gi|47077659 72805 0.06 FLJ00268 protein [Homo sapiens] 
gi|1374813 23368 0.43 SNAP-23 [Homo sapiens] 
gi|20072835 59945 0.07 ACSL1 protein, partial [Homo sapiens] 
gi|5360115 89012 0.05 NY-REN-45 antigen [Homo sapiens] 
gi|257743046 43424 0.1 C-C chemokine receptor type 3 isoform 2 [Homo 
sapiens] 
gi|70913399 2021 4.89 T cell receptor alpha variable 7 [Homo sapiens] 
 
ST 2-8: Enzymes detected 
ACCESSIO
N 
MASS  EMPAI DESCRIPTION 
GI|18909593
8 
11754  0.42 Chain A, Crystal Structure Of E60a Mutant Of Fkbp12 
GI|53037506
5 
51152  0.09 PREDICTED: neutral cholesterol ester hydrolase 1 
isoform X1 [Homo sapiens] 
GI|22209028 31786  0.3 Thioredoxin-related transmembrane protein 1 [Homo 
sapiens] 




56246  0.08 PREDICTED: death-associated protein kinase 2 isoform 





 0.03 phosphorylase b kinase regulatory subunit beta isoform 
a [Homo sapiens] 
GI|1666423 16149
3 
 0.03 FMI protein [Homo sapiens] 
GI|1486363 41988  0.11 extracellular signal regulated kinase [Homo sapiens] 
GI|35360 65350  0.07 PDC-E2 precursor (AA -54 to 561) [Homo sapiens] 
GI|516516 11732
0 
 0.04 neuronal kinesin heavy chain [Homo sapiens] 
GI|181944 10818
5 
 0.04 protein-tyrosine kinase [Homo sapiens] 
GI|16306598 15353
3 














31726  0.14 Chain A, Crystal Structure Of Human Pyridoxal 5'-
Phosphate Phosphatase 
GI|837261 88581  0.05 ERK5 [Homo sapiens] 
GI|62897321 34328  0.13 steroid dehydrogenase homolog [Homo sapiens] 




73247  0.06 RecName: Full=Heparan-alpha-glucosaminide N-
acetyltransferase; AltName: Full=Transmembrane 
protein 76 [Homo sapiens] 
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GI|13242866 31413  0.14 type 3 iodothyronine deiodinase [Homo sapiens] 
 
ST 2-9: Other membrane proteins detected 
Accession Mass emPAI Description 
gi|13129092 26194 0.38 transmembrane protein 109 precursor [Homo sapiens] 
gi|5821140 40308 0.37 ASY [Homo sapiens] 
gi|345198270 23750 0.69 tumor protein D54 isoform j [Homo sapiens] 
gi|337930 27386 0.84 scar protein [Homo sapiens] 
gi|23712 45220 0.32 myoblast antigen 24.1D5 [Homo sapiens] 
gi|1160963 83616 0.29 transmembrane protein [Homo sapiens] 
gi|662994 72707 0.06 GPI-anchored protein p137 [Homo sapiens] 
gi|5729718 46003 0.1 trophoblast glycoprotein precursor [Homo sapiens] 
gi|578830259 58187 0.08 PREDICTED: brain-specific angiogenesis inhibitor 1-
associated protein 2 isoform X11 [Homo sapiens] 
gi|7767178 19180 0.24 Chain A, Apolipoprotein E3 (Apoe3) Truncation Mutant 165 
gi|6912582 30361 0.15 peflin [Homo sapiens] 
gi|6002678 45242 0.1 colon carcinoma related protein [Homo sapiens] 
gi|19923969 25820 0.18 coiled-coil domain-containing protein 124 [Homo sapiens] 
gi|39725636 27260 0.17 transmembrane emp24 domain-containing protein 9 
precursor [Homo sapiens] 
gi|19920317 65983 0.14 cytoskeleton-associated protein 4 [Homo sapiens] 
gi|1161384 384046 0.01 BRCA2 [Homo sapiens] 
gi|40789001 108477 0.04 KIAA0964 protein [Homo sapiens] 
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gi|4240313 149996 0.03 KIAA0912 protein [Homo sapiens] 
gi|30089664 575806 0.01 ABC A13 [Homo sapiens] 
gi|27735113 50114 0.09 EF-hand calcium-binding domain-containing protein 3 
isoform b [Homo sapiens] 
gi|28680 21594 0.21 amphiglycan [Homo sapiens] 
gi|235397 24680 0.18 HMFG, partial [Homo sapiens] 
gi|15012003 17359 0.27 Family with sequence similarity 162, member A [Homo 
sapiens] 
gi|1616918 46323 0.1 membrane protein with histidine rich charge clusters [Homo 
sapiens] 
gi|6331328 115103 0.04 KIAA1280 protein [Homo sapiens] 
gi|29648540 14892 0.32 MLL5 [Homo sapiens] 
gi|20521880 198894 0.02 KIAA1305 protein [Homo sapiens] 
gi|7706322 28051 0.16 UPF0568 protein C14orf166 [Homo sapiens] 
gi|471270576 23424 0.2 Chain L, Crystal Structure Of Tnf-alpha In Complex With 
Infliximab Fab Fragment 
gi|71891687 139575 0.03 KIAA0931 protein [Homo sapiens] 
gi|223462187 266458 0.02 SPG11 protein [Homo sapiens] 
 







ST3-1.  Overall proteomic profile 
 
emPAI Percentage 
Structural 36.45 49.11 







Chaperones  2.68 3.61 
Receptors 1.91 2.57 
Enzymes 6.32 8.52 
Others 6.02 8.11 
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Total 74.22 100 
 
ST 3-2 Structural Proteins Identified 
 
Accession Mass emPAI Description 
gi|4501885 41710 6.01 actin, cytoplasmic 1 [Homo sapiens] 
gi|6755901 50104 1.56 tubulin alpha-1A chain [Mus musculus] 
gi|73997851 49990 0.54 PREDICTED: tubulin alpha-8 chain [Canis lupus 
familiaris] 
gi|61740600 57676 1.83 keratin, type I cytoskeletal 10 [Canis lupus familiaris] 
gi|545510666 54047 0.27 PREDICTED: keratin, type I cytoskeletal 42 [Canis lupus 
familiaris] 
gi|62122767 76308 0.12 keratin, type I cytoskeletal 9 [Canis lupus familiaris] 
gi|50950177 38630 4.26 annexin A2 [Canis lupus familiaris] 
gi|7106439 49639 2.65 tubulin beta-5 chain [Mus musculus] 
gi|5174735 49799 2.06 tubulin beta-4B chain [Homo sapiens] 
gi|345803407 49835 0.54 PREDICTED: tubulin beta-6 chain isoform 3 [Canis lupus 
familiaris] 
gi|50979272 63751 1.4 keratin, type II cytoskeletal 1 [Canis lupus familiaris] 
gi|345791904 62778 0.41 PREDICTED: keratin, type II cytoskeletal 5 isoform X1 
[Canis lupus familiaris] 
gi|545545102 63592 0.5 PREDICTED: keratin, type II cytoskeletal 2 epidermal 
isoform X1 [Canis lupus familiaris] 
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gi|359323093 54684 0.48 PREDICTED: keratin, type II cytoskeletal 8 [Canis lupus 
familiaris] 
gi|345791839 62832 0.23 PREDICTED: keratin, type II cytoskeletal 6A isoformX2 
[Canis lupus familiaris] 
gi|545545370 63946 0.22 PREDICTED: keratin, type II cytoskeletal 73 isoform X1 
[Canis lupus familiaris] 
gi|74008809 280450 0.26 PREDICTED: filamin-A isoform 2 [Canis lupus 
familiaris] 
gi|559098393 53565 3.22 vimentin [Canis lupus familiaris] 
gi|558695394 38602 1.42 annexin A1 [Canis lupus familiaris] 
gi|73953627 75842 0.87 PREDICTED: annexin A6 isoformX2 [Canis lupus 
familiaris] 
gi|160425231 226328 0.23 myosin-9 [Canis lupus familiaris] 
gi|345802274 223986 0.04 PREDICTED: myosin-11 isoformX29 [Canis lupus 
familiaris] 
gi|5031635 18491 0.98 cofilin-1 [Homo sapiens] 
gi|545558304 69724 0.54 PREDICTED: moesin isoform X3 [Canis lupus familiaris] 
gi|74005014 131810 0.14 PREDICTED: unconventional myosin-Ib isoformX2 
[Canis lupus familiaris] 
gi|50978940 129321 0.14 collagen alpha-2(I) chain precursor [Canis lupus 
familiaris] 
gi|73947726 104337 0.09 PREDICTED: alpha-actinin-4 isoformX6 [Canis lupus 
familiaris] 
gi|74005014 131810 0.14 PREDICTED: unconventional myosin-Ib isoformX2 
[Canis lupus familiaris] 
201 
 
gi|73969959 65382 0.58 PREDICTED: cytoskeleton-associated protein 4 [Canis 
lupus familiaris] 
gi|545494454 47490 0.72 PREDICTED: lactadherin [Canis lupus familiaris] 
gi|55742853 35790 0.13 annexin A4 [Canis lupus familiaris] 
gi|57106334 48209 0.09 PREDICTED: keratin, type I cytoskeletal 18 isoform 1 
[Canis lupus familiaris] 
gi|17986258 16919 0.28 myosin light polypeptide 6 isoform 1 [Homo sapiens] 
gi|359320831 269595 0.07 PREDICTED: talin-1 isoform X1 [Canis lupus familiaris] 
gi|157151714 342453 0.01 collagen alpha-3(VI) chain precursor [Canis lupus 
familiaris] 
gi|460417294 41977 0.11 actin-related protein 3 isoform 2 [Homo sapiens] 
    
gi|13937393 46861 0.1 actin-like protein 6B [Mus musculus] 
gi|545552032 114397 0.04 PREDICTED: SWI/SNF-related matrix-associated actin-
dependent regulator of chromatin subfamily A containing 
DEAD/H box 1 isoform X7 [Canis lupus familiaris] 
gi|545530710 68641 0.13 PREDICTED: LOW QUALITY PROTEIN: kinesin light 
chain 2 [Canis lupus familiaris] 
gi|545507020 59610 0.07 PREDICTED: cochlin [Canis lupus familiaris] 
gi|73997258 106132 0.04 PREDICTED: calsyntenin-3 isoform 1 [Canis lupus 
familiaris] 
gi|545551547 78081 0.06 PREDICTED: collagen alpha-2(VI) chain [Canis lupus 
familiaris] 
gi|545517725 149690 0.03 PREDICTED: collagen alpha-1(XV) chain isoform X1 
[Canis lupus familiaris] 
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gi|545529126 126396 0.03 PREDICTED: collagen alpha-1(I) chain [Canis lupus 
familiaris] 
gi|545499057 41024 0.23 PREDICTED: ankyrin repeat domain-containing protein 
65 isoform X2 [Canis lupus familiaris] 
gi|545519655 339256 0.03 PREDICTED: collagen alpha-1(XII) chain isoform X2 
[Canis lupus familiaris] 
gi|545550190 52694 0.08 PREDICTED: ankyrin repeat and death domain-
containing protein 1A isoform X2 [Canis lupus familiaris] 
gi|73966959 53672 0.08 PREDICTED: vitronectin isoform 2 [Canis lupus 
familiaris] 
gi|545521155 534043 0.04 PREDICTED: plectin isoform X9 [Canis lupus familiaris] 
gi|73961895 20485 0.23 PREDICTED: myosin regulatory light polypeptide 9-like 
isoformX1 [Canis lupus familiaris] 
gi|73986060 243902 0.02 PREDICTED: unconventional myosin-IXb isoform 1 
[Canis lupus familiaris] 
gi|345778515 114475 0.04 PREDICTED: collagen alpha-1(XIX) chain isoform X4 
[Canis lupus familiaris] 
gi|73953207 36599 0.12 PREDICTED: annexin A8 isoformX1 [Canis lupus 
familiaris] 
gi|545503404 174479 0.03 PREDICTED: collagen alpha-1(XXIV) chain isoform X2 
[Canis lupus familiaris] 
gi|73994333 117807 0.04 PREDICTED: FERM, RhoGEF and pleckstrin domain-
containing protein 2 isoform X3 [Canis lupus familiaris] 




gi|57095096 80886 0.05 PREDICTED: lebercilin isoform X11 [Canis lupus 
familiaris] 
gi|545519914 632508 0.01 PREDICTED: midasin isoform X1 [Canis lupus 
familiaris] 
gi|73981496 32964 0.14 PREDICTED: F-actin-capping protein subunit alpha-1 
isoform 2 [Canis lupus familiaris] 
gi|359322210 111999 0.08 PREDICTED: microtubule-associated protein 1S isoform 
X1 [Canis lupus familiaris] 
gi|545492158 195634 0.02 PREDICTED: LOW QUALITY PROTEIN: 
protocadherin gamma-A12 [Canis lupus familiaris] 
gi|359322609 151053 0.03 PREDICTED: nephrocystin-3 [Canis lupus familiaris] 
gi|345789814 142795 0.03 PREDICTED: collagen alpha-1(XX) chain [Canis lupus 
familiaris] 
gi|545501026 56949 0.08 PREDICTED: BAI1-associated protein 2-like 1 
isoformX1 [Canis lupus familiaris] 
gi|545533749 203686 0.02 PREDICTED: laminin subunit beta-2 isoform X1 [Canis 
lupus familiaris] 
gi|545539045 144440 0.03 PREDICTED: cohesin subunit SA-1 [Canis lupus 
familiaris] 
gi|545529816 113484 0.04 PREDICTED: ankyrin repeat and BTB/POZ domain-
containing protein 2 isoformX2 [Canis lupus familiaris] 
gi|545541617 77260 0.06 PREDICTED: cytoskeleton-associated protein 2 isoform 
X2 [Canis lupus familiaris] 
gi|73949468 130850 0.03 PREDICTED: protocadherin-12 [Canis lupus familiaris] 
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gi|545492234 473796 0.02 PREDICTED: LOW QUALITY PROTEIN: basement 
membrane-specific heparan sulfate proteoglycan core 
protein [Canis lupus familiaris] 
gi|73957734 84663 0.05 PREDICTED: procollagen-lysine,2-oxoglutarate 5-
dioxygenase 3 isoform 1 [Canis lupus familiaris] 
gi|545529571 85651 0.05 PREDICTED: CD44 antigen isoform X1 [Canis lupus 
familiaris] 
gi|545489377 58668 0.16 PREDICTED: collagen alpha-1(III) chain-like [Canis 
lupus familiaris] 
gi|545530382 45606 0.1 PREDICTED: lymphocyte-specific protein 1 isoform X1 
[Canis lupus familiaris] 
gi|73954163 480212 0.01 PREDICTED: protocadherin Fat 2 [Canis lupus 
familiaris] 
gi|545486940 78614 0.06 PREDICTED: extracellular matrix protein 2 isoform X1 
[Canis lupus familiaris] 
gi|545549404 39867 0.11 PREDICTED: ankyrin repeat domain-containing protein 
63 [Canis lupus familiaris] 
gi|165973990 222838 0.04 myosin-7 [Canis lupus familiaris] 
gi|545503105 61681 0.07 PREDICTED: palmdelphin [Canis lupus familiaris] 
gi|307938297 78906 0.06 nephrocystin-1 [Canis lupus familiaris] 
gi|95925865 87375 0.05 pinin 1 [Canis lupus familiaris] 
gi|545531227 579498 0.01 PREDICTED: LOW QUALITY PROTEIN: neuroblast 




gi|545551689 208083 0.02 PREDICTED: protein Shroom3 isoform X1 [Canis lupus 
familiaris] 
gi|545525131 310349 0.01 PREDICTED: LOW QUALITY PROTEIN: 
protocadherin-23-like [Canis lupus familiaris] 
gi|345796528 46416 0.1 PREDICTED: neuroserpin isoform X3 [Canis lupus 
familiaris] 
gi|4757952 21245 0.22 cell division control protein 42 homolog isoform 1 
precursor [Homo sapiens] 
gi|304376314 240303 0.02 tenascin precursor [Canis lupus familiaris] 
gi|345801801 172246 0.03 PREDICTED: leucine-rich repeat-containing protein 7 
isoform X2 [Canis lupus familiaris] 
gi|74000367 271428 0.02 PREDICTED: talin-2 isoformX1 [Canis lupus familiaris] 
 
ST 3-3: Transport Proteins Identified 
 
Accession Mass emPAI Description 
gi|545528359 11273
8 
0.64 PREDICTED: sodium/potassium-transporting ATPase 
subunit alpha-1 isoform X1 [Canis lupus familiaris] 
gi|345797872 11435
9 
0.08 PREDICTED: sodium/potassium-transporting ATPase 
subunit alpha-4 isoform X2 [Canis lupus familiaris] 
gi|73953093 31559 0.52 PREDICTED: voltage-dependent anion-selective channel 
protein 2 isoform 2 [Canis lupus familiaris] 
gi|345807347 13412
8 
0.03 PREDICTED: plasma membrane calcium-transporting 
ATPase 3 isoform X36 [Canis lupus familiaris] 
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gi|126723018 30722 2.38 voltage-dependent anion-selective channel protein 1 
[Oryctolagus cuniculus] 
gi|74008194 32996 1.47 PREDICTED: ADP/ATP translocase 2 isoform 2 [Canis 
lupus familiaris] 
gi|545559996 32512 1.5 PREDICTED: ADP/ATP translocase 3 [Canis lupus 
familiaris] 
gi|73965153 83507 0.05 PREDICTED: vesicle-fusing ATPase isoformX1 [Canis 
lupus familiaris] 
gi|325301273 18932 0.95 translocon-associated protein subunit delta precursor [Canis 
lupus familiaris] 
gi|545560056 17447 0.27 PREDICTED: proteolipid protein 2 [Canis lupus familiaris] 
gi|73963665 24765 0.19 PREDICTED: transmembrane emp24 domain-containing 
protein 10 isoform 1 [Canis lupus familiaris] 
gi|6002950 66639 0.07 triadin isoform 3 [Canis lupus familiaris] 
gi|545504506 27881
7 
0.02 PREDICTED: voltage-dependent R-type calcium channel 
subunit alpha-1E isoformX3 [Canis lupus familiaris] 
gi|73959904 61702 0.07 PREDICTED: potassium voltage-gated channel subfamily A 
member 10 [Canis lupus familiaris] 
gi|545489180 93799 0.05 PREDICTED: transmembrane channel-like 1 [Canis lupus 
familiaris] 
gi|30410788 39650 0.11 tumor suppressor candidate 3 isoform a precursor [Homo 
sapiens] 
gi|73967844 94035 0.05 PREDICTED: leucine-rich repeat-containing protein 8A 
isoformX1 [Canis lupus familiaris] 
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gi|545516959 73609 0.12 PREDICTED: polycystic kidney disease 2-like 2 protein 
isoform X2 [Canis lupus familiaris] 
gi|4557469 10448
6 
0.04 AP-2 complex subunit beta isoform b [Homo sapiens] 
gi|345781116 11139
2 
0.04 PREDICTED: anoctamin-4 isoformX1 [Canis lupus 
familiaris] 
gi|73998421 94181 0.05 PREDICTED: metal transporter CNNM2 isoformX4 [Canis 
lupus familiaris] 
gi|545547011 22720 0.2 PREDICTED: V-type proton ATPase subunit E 1 isoform 
X2 [Canis lupus familiaris] 
gi|22759019 14145
6 
0.03 multidrug resistance p-glycoprotein [Canis lupus familiaris] 
gi|73979747 43639 0.1 PREDICTED: V-type proton ATPase subunit C 2 isoformX1 
[Canis lupus familiaris] 
gi|545531548 12121
0 
0.04 PREDICTED: anoctamin-1 [Canis lupus familiaris] 
gi|345801671 26040 0.18 PREDICTED: transmembrane emp24 domain-containing 
protein 5 isoform 2 [Canis lupus familiaris] 
gi|359321467 13602
3 
0.03 PREDICTED: anion exchange protein 2 isoform 1 [Canis 
lupus familiaris] 
gi|345782667 11210 0.45 PREDICTED: protein S100-A10 isoform 1 [Canis lupus 
familiaris] 
gi|73997059 47923 0.09 PREDICTED: ATP-sensitive inward rectifier potassium 
channel 8 isoformX1 [Canis lupus familiaris] 
gi|545537221 52108 0.09 PREDICTED: synaptotagmin-9 [Canis lupus familiaris] 
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gi|6753074 49623 0.09 AP-2 complex subunit mu [Mus musculus] 
gi|345800844 45731 0.1 PREDICTED: vesicle amine transport protein 1 homolog (T. 
californica)-like [Canis lupus familiaris] 
gi|545491848 44646 0.1 PREDICTED: NIPA-like protein 3 isoform X1 [Canis lupus 
familiaris] 
gi|73983332 61656 0.07 PREDICTED: solute carrier family 22 member 9 isoformX1 
[Canis lupus familiaris] 
gi|73953291 36136 0.13 PREDICTED: graves disease carrier protein isoform X2 
[Canis lupus familiaris] 
gi|559098415 90911 0.05 sodium/hydrogen exchanger 1 [Canis lupus familiaris] 
gi|270288810 10778
6 
0.04 anoctamin-5 precursor [Canis lupus familiaris] 




0.03 PREDICTED: trafficking protein particle complex subunit 
10 isoform X2 [Canis lupus familiaris] 
gi|545494271 78141 0.06 PREDICTED: sodium-dependent phosphate transport 
protein 2B isoform X2 [Canis lupus familiaris] 
gi|55741729 22055
9 




0.03 PREDICTED: trafficking protein particle complex subunit 
11 [Canis lupus familiaris] 
gi|73979536 31206 0.15 PREDICTED: neuronal membrane glycoprotein M6-a 





0.02 PREDICTED: ATP-binding cassette sub-family A member 
6 [Canis lupus familiaris] 
 
 
ST 3-4: Immune Complex Proteins Identified 
Accession Mass emPAI  Description 
gi|122135 40437 0.11  RecName: Full=DLA class I histocompatibility antigen, 
A9/A9 alpha chain; Flags: Precursor 
gi|208342202 15306 0.32  immunoglobulin heavy chain variable region, partial 
[Canis lupus familiaris] 
gi|545493610 148085 0.03  PREDICTED: pro-interleukin-16 isoform X2 [Canis lupus 
familiaris] 
gi|350543372 10740 0.47  MHC class II antigen [Canis lupus familiaris] 
gi|345783307 72501 0.06  PREDICTED: T-cell differentiation antigen CD6 isoform 
X4 [Canis lupus familiaris] 
gi|545509559 20851 0.22  PREDICTED: CMRF35-like molecule 7-like [Canis lupus 
familiaris] 
gi|74007037 64149 0.07  PREDICTED: melanoma-associated antigen D2 
isoformX2 [Canis lupus familiaris] 
gi|6572519 32245 0.14  truncated B7-2 protein [Canis lupus familiaris] 
gi|57112869 28042 0.16  PREDICTED: B-cell receptor-associated protein 31 
isoform X3 [Canis lupus familiaris] 
gi|545514193 87364 0.05  PREDICTED: interleukin-1 receptor-associated kinase 3 
[Canis lupus familiaris] 
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gi|70794790 96206 0.05  interleukin-12 receptor subunit beta-2 precursor [Canis 
lupus familiaris] 
 
ST 3-5: GPCRs and G proteins identified 
 
Accession Mass emPAI Description 
gi|5174447 35055 1.08 guanine nucleotide-binding protein subunit beta-2-like 1 
[Homo sapiens] 
gi|50979222 40520 0.37 guanine nucleotide-binding protein G(i) subunit alpha-2 
[Canis lupus familiaris] 
gi|545506467 50860 0.18 PREDICTED: LOW QUALITY PROTEIN: guanine 
nucleotide-binding protein G(olf) subunit alpha [Canis 
lupus familiaris] 
gi|55742672 37120 0.12 guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit 
beta-3 [Canis lupus familiaris] 
gi|345777861 36294 0.12 PREDICTED: olfactory receptor 13F1-like [Canis lupus 
familiaris] 
gi|545510010 33160 0.14 PREDICTED: guanine nucleotide-binding protein subunit 
alpha-13 isoform X1 [Canis lupus familiaris] 
gi|74009012 32834
8 
0.01 PREDICTED: probable G-protein coupled receptor 112 
[Canis lupus familiaris] 
gi|545523201 34864 0.13 PREDICTED: olfactory receptor 2T27-like [Canis lupus 
familiaris] 




gi|72535184 20414 0.23 ADP-ribosylation factor-like protein 1 [Sus scrofa] 
gi|545509639 71038 0.06 PREDICTED: septin-9 [Canis lupus familiaris] 
gi|77736007 20515 0.23 ADP-ribosylation factor 4 [Bos taurus] 
gi|545545958 14400
9 




0.04 PREDICTED: SLIT-ROBO Rho GTPase-activating protein 
3 isoformX2 [Canis lupus familiaris] 
gi|73966150 25779
4 
0.02 PREDICTED: probable G-protein coupled receptor 179 
isoform X3 [Canis lupus familiaris] 
gi|511914243 26132 0.18 PREDICTED: GTPase KRas isoform X1 [Mustela putorius 
furo] 
gi|6981476 20467 0.23 GTP-binding protein Rheb precursor [Rattus norvegicus] 
gi|345793806 46359 0.1 PREDICTED: probable G-protein coupled receptor 151 
[Canis lupus familiaris] 
gi|545539728 21550
8 
0.02 PREDICTED: ral GTPase-activating protein subunit alpha-
2 isoform X1 [Canis lupus familiaris] 
gi|345807071 38241 0.12 PREDICTED: probable G-protein coupled receptor 82 
[Canis lupus familiaris] 
gi|359320566 51114 0.09 PREDICTED: rab-3A-interacting protein isoform X6 
[Canis lupus familiaris] 
gi|73983774 58829 0.08 PREDICTED: atlastin-3 isoform X4 [Canis lupus 
familiaris] 
gi|345788827 38635 0.12 PREDICTED: growth hormone-regulated TBC protein 1 





0.04 PREDICTED: rap guanine nucleotide exchange factor 5 
isoform X2 [Canis lupus familiaris] 
gi|545529658 59449 0.07 PREDICTED: synembryn-A [Canis lupus familiaris] 




0.03 PREDICTED: rho GTPase-activating protein 20 isoform 
X1 [Canis lupus familiaris] 
gi|545516132 13989
8 
0.03 PREDICTED: TBC1 domain family member 9B isoform 
X1 [Canis lupus familiaris] 
gi|545555224 10174
5 
0.04 PREDICTED: rap guanine nucleotide exchange factor 4 
isoform X1 [Canis lupus familiaris] 
gi|545548334 71664 0.06 PREDICTED: rho GTPase-activating protein 22 [Canis 
lupus familiaris] 
gi|194339213 9761 0.53 dynanmin 1 protein [Canis lupus familiaris] 
gi|345793422 13957
3 
0.03 PREDICTED: LOW QUALITY PROTEIN: probable G-
protein coupled receptor 158 [Canis lupus familiaris] 
gi|73971093 54255 0.08 PREDICTED: protein C9orf72 isoformX2 [Canis lupus 
familiaris] 
gi|545516757 51263 0.09 PREDICTED: septin-8 isoform X1 [Canis lupus familiaris] 
gi|545543197 53123 0.08 PREDICTED: septin-2 isoform X1 [Canis lupus familiaris] 
gi|8926588 48722 0.09 endothelin B receptor [Canis lupus familiaris] 
    
gi|131804 22555 0.76 RecName: Full=Ras-related protein Rab-10 [Canis lupus 
familiaris] 
gi|13569962 22157 0.77 ras-related protein Rab-1B [Homo sapiens] 
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gi|50979156 23505 0.2 ras-related protein Rab-7a [Canis lupus familiaris] 
gi|50979062 23441 0.2 ras-related protein Rab-5C [Canis lupus familiaris] 
gi|4506413 20974 0.22 ras-related protein Rap-1A precursor [Homo sapiens] 
gi|4758984 24378 0.19 ras-related protein Rab-11A isoform 1 [Homo sapiens] 
gi|345785574 10319
7 




0.03 PREDICTED: LOW QUALITY PROTEIN: protein very 
KIND [Canis lupus familiaris] 
gi|545525085 55435 0.08 PREDICTED: ras association domain-containing protein 9 
[Canis lupus familiaris] 
gi|9845511 21436 0.22 ras-related C3 botulinum toxin substrate 1 isoform Rac1 
[Homo sapiens] 
 
ST 3-6: Chaperone proteins identified 
Accession Mass emPAI Description 
gi|545508859 7288
1 
0.42 PREDICTED: heat shock protein HSP 90-alpha, partial 
[Canis lupus familiaris] 
gi|545500762 5823
0 




0.24 PREDICTED: LOW QUALITY PROTEIN: T-complex 
protein 1 subunit epsilon isoform 1 [Canis lupus familiaris] 
gi|159794954 7643
2 




0.06 PREDICTED: T-complex protein 1 subunit theta isoform 





0.07 PREDICTED: T-complex protein 1 subunit gamma isoform 
1 [Canis lupus familiaris] 
gi|73980527 5938
3 
0.07 PREDICTED: T-complex protein 1 subunit eta isoform 2 
[Canis lupus familiaris] 
gi|57032236 6021
6 
0.07 PREDICTED: T-complex protein 1 subunit alpha 
isoformX1 [Canis lupus familiaris] 
gi|73968673 5739
5 
0.16 PREDICTED: T-complex protein 1 subunit beta isoformX1 
[Canis lupus familiaris] 
 
ST- Receptors identified 
Accession Mass emPAI Description 
gi|3641357 11736 0.42 interferon gamma precursor [Canis lupus familiaris] 
gi|545534382 88794 0.05 PREDICTED: EGF-like module-containing mucin-like 




0.04 PREDICTED: semaphorin-6A isoformX2 [Canis lupus 
familiaris] 
gi|73998651 92273 0.05 PREDICTED: semaphorin-4G isoform X4 [Canis lupus 
familiaris] 
gi|545536637 36244 0.12 PREDICTED: LOW QUALITY PROTEIN: 
gastrin/cholecystokinin type B receptor, partial [Canis lupus 
familiaris] 
gi|73993667 53592 0.08 PREDICTED: scavenger receptor class A member 5 
isoformX1 [Canis lupus familiaris] 
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gi|545518755 96015 0.05 PREDICTED: metabotropic glutamate receptor 4 [Canis 
lupus familiaris] 








0.02 PREDICTED: thyroid receptor-interacting protein 11 
isoform X2 [Canis lupus familiaris] 
gi|359322039 31209
1 
0.01 PREDICTED: inositol 1,4,5-trisphosphate receptor type 1 
isoform X1 [Canis lupus familiaris] 
gi|73966275 63426 0.07 PREDICTED: insulin-like growth factor 2 mRNA binding 
protein 1 isoformX2 [Canis lupus familiaris] 
gi|545543633 51208 0.09 PREDICTED: LOW QUALITY PROTEIN: 
hydroxycarboxylic acid receptor 3 [Canis lupus familiaris] 
gi|545517466 22226
3 




0.04 PREDICTED: VPS10 domain-containing receptor SorCS1 
[Canis lupus familiaris] 
gi|545522902 50679 0.09 PREDICTED: corticotropin-releasing factor receptor 2 
isoform X3 [Canis lupus familiaris] 
gi|359318678 56421
8 




0.04 PREDICTED: glutamate receptor ionotropic, kainate 4 
[Canis lupus familiaris] 
gi|73959181 16517
7 
0.03 PREDICTED: glutamate receptor ionotropic, NMDA 2A 
isoform X3 [Canis lupus familiaris] 
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gi|545506274 81668 0.11 PREDICTED: collectin-12 [Canis lupus familiaris] 
gi|545555520 13075
3 
0.03 PREDICTED: sperm-specific antigen 2, partial [Canis lupus 
familiaris] 
gi|73987612 29284 0.16 PREDICTED: basigin [Canis lupus familiaris] 
gi|345796108 87112 0.1 PREDICTED: integrin beta-5 [Canis lupus familiaris] 
gi|545555528 11841
6 
0.04 PREDICTED: integrin alpha-V isoform 2 [Canis lupus 
familiaris] 
 
ST- 3-8 : Enzymes identified 
Accession Mass emPAI Description 
gi|73958481 39478 1.65 PREDICTED: fructose-bisphosphate aldolase A 
isoformX2 [Canis lupus familiaris] 
gi|73947982 62798 0.07 PREDICTED: glucose-6-phosphate isomerase isoformX1 
[Canis lupus familiaris] 
gi|308082020 26698 0.17 triosephosphate isomerase [Canis lupus familiaris] 
gi|345800677 48956 0.19 PREDICTED: LOW QUALITY PROTEIN: alpha-
enolase isoform 1 [Canis lupus familiaris] 
gi|359321459 72351 0.06 PREDICTED: protein disulfide-isomerase A4 isoform 3 
[Canis lupus familiaris] 
gi|73980965 92301 0.05 PREDICTED: mannosyl-oligosaccharide glucosidase 
[Canis lupus familiaris] 
gi|71043798 44292 0.21 cathepsin D precursor [Canis lupus familiaris] 
gi|73965482 56737 0.08 PREDICTED: glycylpeptide N-tetradecanoyltransferase 
1 isoformX1 [Canis lupus familiaris] 
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0.03 PREDICTED: membrane-associated guanylate kinase, 
WW and PDZ domain-containing protein 2 [Canis lupus 
familiaris] 
gi|359319350 34044 0.28 PREDICTED: cyclin-dependent kinase 1 isoformX1 
[Canis lupus familiaris] 
gi|11345462 20301 0.23 signal peptidase complex subunit 3 [Homo sapiens] 
gi|73973859 15003
4 
0.06 PREDICTED: inhibitor of Bruton tyrosine kinase isoform 
X5 [Canis lupus familiaris] 
gi|5002350 42651 0.11 alkaline phosphatase [Canis lupus familiaris] 
gi|73949883 12376
2 
0.07 PREDICTED: phosphorylase b kinase regulatory subunit 
beta isoformX2 [Canis lupus familiaris] 
gi|545552304 61205 0.07 PREDICTED: calcium/calmodulin-dependent protein 




0.02 PREDICTED: basic helix-loop-helix domain-containing 
protein KIAA2018 homolog isoform X1 [Canis lupus 
familiaris] 




0.03 PREDICTED: phosphorylase b kinase regulatory subunit 
alpha, skeletal muscle isoform isoformX5 [Canis lupus 
familiaris] 
gi|73975797 40015 0.11 PREDICTED: serum paraoxonase/arylesterase 1 isoform 





0.03 PREDICTED: PH domain leucine-rich repeat-containing 
protein phosphatase 1 [Canis lupus familiaris] 
gi|545507539 16994
8 
0.03 PREDICTED: leucine-rich repeat-containing protein 9-
like isoform X1 [Canis lupus familiaris] 
gi|345780013 10193
0 
0.04 PREDICTED: staphylococcal nuclease domain-
containing protein 1 [Canis lupus familiaris] 
gi|73950291 57308
1 
0.02 PREDICTED: E3 ubiquitin-protein ligase UBR4 
isoformX2 [Canis lupus familiaris] 
gi|545508966 50665 0.09 PREDICTED: casein kinase I isoform delta isoform X1 
[Canis lupus familiaris] 
gi|545559938 63644 0.07 PREDICTED: glucose-6-phosphate 1-dehydrogenase 
isoform X1 [Canis lupus familiaris] 
gi|74005468 10470
0 
0.04 PREDICTED: GPI inositol-deacylase isoform X2 [Canis 
lupus familiaris] 
gi|73979309 29068 0.16 PREDICTED: phosphatidate phosphatase PPAPDC1B 
isoform X2 [Canis lupus familiaris] 
gi|345777094 88480 0.05 PREDICTED: transmembrane protease serine 6 isoform 2 
[Canis lupus familiaris] 
gi|345782357 87215 0.05 PREDICTED: vitamin K-dependent gamma-carboxylase 
isoform X2 [Canis lupus familiaris] 
gi|545492172 21532
2 
0.02 PREDICTED: microtubule-associated serine/threonine-
protein kinase 4 [Canis lupus familiaris] 
gi|545486178 18138
4 
0.02 PREDICTED: mitogen-activated protein kinase kinase 
kinase 4 [Canis lupus familiaris] 
gi|345782971 16804 0.29 PREDICTED: oligosaccharyltransferase complex subunit 
OSTC-like [Canis lupus familiaris] 
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gi|312283574 45486 0.1 hydroxysteroid dehydrogenase-like protein 2 [Canis lupus 
familiaris] 
gi|73986266 36011 0.13 PREDICTED: very-long-chain enoyl-CoA reductase 
isoform 2 [Canis lupus familiaris] 
gi|359322989 10720
3 
0.04 PREDICTED: serine/threonine-protein kinase ULK1 
isoform X2 [Canis lupus familiaris] 
gi|545541538 29373 0.16 PREDICTED: cathepsin Z, partial [Canis lupus 
familiaris] 
gi|73976741 51421 0.09 PREDICTED: adenylyl cyclase-associated protein 1 
isoformX2 [Canis lupus familiaris] 
gi|545550634 60860 0.07 PREDICTED: carbohydrate sulfotransferase 14 [Canis 
lupus familiaris] 
gi|73969530 83522 0.05 PREDICTED: protein kinase C epsilon type isoformX1 
[Canis lupus familiaris] 
gi|545528333 52374
2 
0.01 PREDICTED: baculoviral IAP repeat-containing protein 
6 [Canis lupus familiaris] 
gi|545531571 84382 0.05 PREDICTED: N-acetylated alpha-linked acidic 
dipeptidase-like 1 [Canis lupus familiaris] 
gi|545535937 45964 0.1 PREDICTED: endonuclease domain-containing 1 
protein, partial [Canis lupus familiaris] 
gi|545511447 81119 0.05 PREDICTED: myeloperoxidase [Canis lupus familiaris] 
gi|74005739 13246
3 
0.03 PREDICTED: tubulin polyglutamylase TTLL4 isoform 
X3 [Canis lupus familiaris] 
gi|545532775 97866 0.04 PREDICTED: LOW QUALITY PROTEIN: tubulin 
monoglycylase TTLL3 [Canis lupus familiaris] 
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gi|73990288 42108 0.11 PREDICTED: caspase-14-like [Canis lupus familiaris] 
gi|399317 13024
0 
0.03 RecName: Full=Adenylate cyclase type 6; AltName: 
Full=ATP pyrophosphate-lyase 6; AltName: 
Full=Adenylate cyclase type VI; AltName: 
Full=Adenylyl cyclase 6; AltName: Full=Ca(2+)-
inhibitable adenylyl cyclase 
gi|545512439 16024
1 
0.03 PREDICTED: patatin-like phospholipase domain 
containing 7 isoformX1 [Canis lupus familiaris] 
gi|545554163 12750
9 
0.03 PREDICTED: phospholipase D1 [Canis lupus familiaris] 
gi|74006997 27138 0.37 PREDICTED: 3-hydroxyacyl-CoA dehydrogenase type-2 
isoform 1 [Canis lupus familiaris] 




0.03 PREDICTED: 1-phosphatidylinositol 4,5-bisphosphate 





phosphodiesterase epsilon-1 [Canis lupus familiaris] 
gi|545510617 49679 0.09 PREDICTED: 2',3'-cyclic-nucleotide 3'-
phosphodiesterase isoform X1 [Canis lupus familiaris] 
gi|545529305 88247 0.05 PREDICTED: calcium-independent phospholipase A2-
gamma isoform X2 [Canis lupus familiaris] 
gi|359320296 61456 0.07 PREDICTED: GPI transamidase component PIG-S 





ST- 3-9: Other Proteins Identified 
 
Accession Mass emPAI Description 
gi|345806081 72238 1.59 PREDICTED: 78 kDa glucose-regulated protein isoform 
5 [Canis lupus familiaris] 
gi|73971240 38546 0.74 PREDICTED: stomatin (EPB72)-like 2 isoform 1 [Canis 
lupus familiaris] 
gi|345800374 42267 0.22 PREDICTED: plasminogen activator inhibitor 1 RNA-
binding protein isoform 1 [Canis lupus familiaris] 
gi|335286672 22363 0.46 PREDICTED: transgelin-2 isoformX1 [Sus scrofa] 
gi|73968397 20542 0.23 PREDICTED: protein canopy homolog 2 isoformX1 
[Canis lupus familiaris] 
gi|545543609 46653 0.1 PREDICTED: LOW QUALITY PROTEIN: ADP-
ribosylation-like factor 6 interacting protein 4 [Canis 
lupus familiaris] 
gi|73994424 154240 0.03 PREDICTED: protein strawberry notch homolog 1 
isoformX2 [Canis lupus familiaris] 
gi|134031952 60903 0.07 suppressor of tumorigenicity 7 protein isoform 1 [Mus 
musculus] 
gi|50979076 31956 0.14 translocon-associated protein subunit alpha precursor 
[Canis lupus familiaris] 
gi|73945930 58023 0.25 PREDICTED: protein ERGIC-53 isoform X2 [Canis 
lupus familiaris] 
gi|73989504 44247 0.34 PREDICTED: lysosome-associated membrane 
glycoprotein 1 isoformX1 [Canis lupus familiaris] 
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gi|57096757 103880 0.04 PREDICTED: transmembrane and TPR repeat-containing 
protein 3 isoform X2 [Canis lupus familiaris] 
gi|345793179 35777 0.13 PREDICTED: regulator of microtubule dynamics protein 
1 isoform X3 [Canis lupus familiaris] 
gi|545511167 43137 0.1 PREDICTED: alpha-sarcoglycan isoform X1 [Canis 
lupus familiaris] 
gi|545536806 98933 0.04 PREDICTED: protein MRVI1 isoform X1 [Canis lupus 
familiaris] 
gi|545492524 75786 0.06 PREDICTED: erythrocyte membrane protein band 4.1 
like 4A isoform X1 [Canis lupus familiaris] 
gi|545526766 385163 0.01 PREDICTED: CUB and sushi domain-containing protein 
1 [Canis lupus familiaris] 
gi|73996813 73879 0.06 PREDICTED: dendrin isoform X4 [Canis lupus 
familiaris] 
gi|345791006 137207 0.03 PREDICTED: LOW QUALITY PROTEIN: probable 
tumor suppressor protein MN1 [Canis lupus familiaris] 
gi|359319183 44586 0.1 PREDICTED: arrestin domain-containing protein 4 
[Canis lupus familiaris] 
gi|345780090 451207 0.01 PREDICTED: A-kinase anchor protein 9 isoform X3 
[Canis lupus familiaris] 
gi|545549726 278230 0.02 PREDICTED: spatacsin isoform X1 [Canis lupus 
familiaris] 
gi|545489348 274118 0.03 PREDICTED: WD repeat-containing protein 87 [Canis 
lupus familiaris] 
gi|73982258 34069 0.13 PREDICTED: thioredoxin-related transmembrane protein 
2 isoform 1 [Canis lupus familiaris] 
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gi|73968452 55145 0.08 PREDICTED: transmembrane protein 194A [Canis lupus 
familiaris] 
gi|545503669 129290 0.07 PREDICTED: nodal modulator 1 [Canis lupus familiaris] 
gi|545520844 125995 0.03 PREDICTED: arf-GAP with SH3 domain, ANK repeat 
and PH domain-containing protein 1 isoform X1 [Canis 
lupus familiaris] 
gi|545537743 75354 0.12 PREDICTED: sciellin isoform X9 [Canis lupus 
familiaris] 
gi|545540568 101633 0.04 PREDICTED: disks large-associated protein 4 isoform 
X10 [Canis lupus familiaris] 
gi|545555959 122466 0.04 PREDICTED: partitioning defective 3 homolog B 
isoform X6 [Canis lupus familiaris] 
gi|545491435 63031 0.07 PREDICTED: alpha-taxilin [Canis lupus familiaris] 
gi|545486029 53932 0.08 PREDICTED: transmembrane protein 200A [Canis lupus 
familiaris] 
gi|57104550 55115 0.08 PREDICTED: growth/differentiation factor 5 [Canis 
lupus familiaris] 
gi|545511186 111858 0.04 PREDICTED: LOW QUALITY PROTEIN: MYCBP-
associated protein [Canis lupus familiaris] 
gi|73950747 27566 0.17 PREDICTED: transmembrane protein 51 isoform X6 
[Canis lupus familiaris] 
gi|545534941 120365 0.04 PREDICTED: A disintegrin and metalloproteinase with 
thrombospondin motifs 10 isoform X2 [Canis lupus 
familiaris] 
gi|73969963 74150 0.06 PREDICTED: DCC-interacting protein 13-beta 
isoformX2 [Canis lupus familiaris] 
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gi|545495448 29205 0.16 PREDICTED: surfactant protein A1 isoform 1 [Canis 
lupus familiaris] 
gi|545551868 400894 0.01 PREDICTED: WD repeat and FYVE domain-containing 
protein 3 isoformX1 [Canis lupus familiaris] 
 ST4: Proteomics data of plasma membrane protein from HMPOS 
 
 
ST4-1.  Overall proteomic profile 
 
emPAI Percentage 
Structural 41.72 56.01 









Chaperones  4.39 5.89 
Receptors 2.41 3.24 
Enzymes 7 9.40 
Others 3.9 5.24 
Total 74.49 100 
 
 
ST4-2: Structural Proteins Identified 
Accession Mass emPAI Description 
gi|50950177 38630 6.43 annexin A2 [Canis lupus familiaris] 
gi|61740600 57676 1.46 keratin, type I cytoskeletal 10 [Canis lupus familiaris] 
gi|545510666 54047 0.89 PREDICTED: keratin, type I cytoskeletal 42 [Canis lupus 
familiaris] 
gi|359279911 52279 0.94 keratin 14 [Canis lupus familiaris] 
gi|73965817 51649 0.95 PREDICTED: keratin, type I cytoskeletal 16 [Canis lupus 
familiaris] 
gi|359279916 43858 0.48 keratin, type I cytoskeletal 19 [Canis lupus familiaris] 
gi|545538333 96812 0.09 PREDICTED: programmed cell death 6-interacting 
protein isoform X2 [Canis lupus familiaris] 
gi|73974726 53257
9 
0.21 PREDICTED: plectin isoformX1 [Canis lupus familiaris] 
gi|4501885 41710 2.82 actin, cytoplasmic 1 [Homo sapiens] 
gi|4501883 41982 1.05 actin, aortic smooth muscle [Homo sapiens] 
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0.44 PREDICTED: collagen alpha-1(XII) chain isoformX1 
[Canis lupus familiaris] 
gi|7106439 49639 1.84 tubulin beta-5 chain [Mus musculus] 
gi|21361322 49554 1.39 tubulin beta-4A chain isoform 3 [Homo sapiens] 
gi|21746161 49921 1.18 tubulin beta-2B chain [Mus musculus] 
gi|50979272 63751 0.72 keratin, type II cytoskeletal 1 [Canis lupus familiaris] 
gi|345791904 62778 0.41 PREDICTED: keratin, type II cytoskeletal 5 isoform X1 
[Canis lupus familiaris] 
gi|359323093 54684 0.37 PREDICTED: keratin, type II cytoskeletal 8 [Canis lupus 
familiaris] 
gi|345791839 62832 0.41 PREDICTED: keratin, type II cytoskeletal 6A isoformX2 
[Canis lupus familiaris] 
gi|50979264 64527 0.31 keratin, type II cytoskeletal 2 epidermal [Canis lupus 
familiaris] 
gi|545545402 51588 0.18 PREDICTED: keratin, type II cytoskeletal 7 [Canis lupus 
familiaris] 
gi|545545370 63946 0.14 PREDICTED: keratin, type II cytoskeletal 73 isoform X1 
[Canis lupus familiaris] 
gi|34740335 50120 1.17 tubulin alpha-1B chain [Mus musculus] 
gi|160425231 22632
8 
0.21 myosin-9 [Canis lupus familiaris] 
gi|558695394 38602 0.75 annexin A1 [Canis lupus familiaris] 





0.21 PREDICTED: collagen alpha-1(III) chain isoform 2 
[Canis lupus familiaris] 
gi|359320831 26959
5 
0.07 PREDICTED: talin-1 isoform X1 [Canis lupus familiaris] 
gi|5031635 18491 0.58 cofilin-1 [Homo sapiens] 
gi|74005014 13181
0 
0.03 PREDICTED: unconventional myosin-Ib isoformX2 
[Canis lupus familiaris] 
gi|545558304 69724 0.06 PREDICTED: moesin isoform X3 [Canis lupus familiaris] 
gi|460417294 41977 0.11 actin-related protein 3 isoform 2 [Homo sapiens] 
gi|545497795 19402 0.24 PREDICTED: profilin-1 [Canis lupus familiaris] 




0.06 PREDICTED: filamin-A isoform 2 [Canis lupus 
familiaris] 
gi|545494454 47490 0.1 PREDICTED: lactadherin [Canis lupus familiaris] 
gi|345782840 19168
1 




0.02 PREDICTED: LOW QUALITY PROTEIN: PDZ domain-
containing protein 2 [Canis lupus familiaris] 
gi|545497238 45641 0.1 PREDICTED: LOW QUALITY PROTEIN: adhesion 




0.02 myosin-4 [Canis lupus familiaris] 
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gi|545510084 21109 0.22 PREDICTED: myosin heavy chain IB-like [Canis lupus 
familiaris] 
gi|17986258 16919 0.65 myosin light polypeptide 6 isoform 1 [Homo sapiens] 
gi|73969653 21283
7 
0.04 PREDICTED: girdin isoformX2 [Canis lupus familiaris] 




0.04 PREDICTED: contactin-2 [Canis lupus familiaris] 
gi|545531544 20861
1 
0.02 PREDICTED: LOW QUALITY PROTEIN: SH3 and 




0.04 PREDICTED: microtubule-associated protein 1S isoform 
X1 [Canis lupus familiaris] 
gi|73968528 44390 0.1 PREDICTED: dynactin subunit 2 isoformX3 [Canis lupus 
familiaris] 




0.01 PREDICTED: xin actin-binding repeat-containing protein 
2 isoform X1 [Canis lupus familiaris] 
gi|545544126 12043
3 
0.04 PREDICTED: unconventional myosin-Ih [Canis lupus 
familiaris] 
gi|5031571 44732 0.1 actin-related protein 2 isoform b [Homo sapiens] 
gi|73947726 10433
7 








0.02 PREDICTED: laminin subunit alpha-4 [Canis lupus 
familiaris] 
gi|545493680 57725 0.08 PREDICTED: ankyrin repeat domain-containing protein 
34C [Canis lupus familiaris] 
gi|545541615 77347 0.06 PREDICTED: cytoskeleton-associated protein 2 isoform 
X1 [Canis lupus familiaris] 
gi|545550658 21443
1 








0.04 PREDICTED: LOW QUALITY PROTEIN: nesprin-3 
[Canis lupus familiaris] 
gi|62122767 76308 0.06 keratin, type I cytoskeletal 9 [Canis lupus familiaris] 
gi|545485411 13481
6 
0.03 PREDICTED: jouberin isoform X1 [Canis lupus 
familiaris] 
gi|356640238 43975 0.1 CKLF-like MARVEL transmembrane domain-containing 
protein 1 [Canis lupus familiaris] 
gi|345788489 34542
3 
0.01 PREDICTED: LOW QUALITY PROTEIN: 
protocadherin-16 [Canis lupus familiaris] 




0.04 PREDICTED: SWI/SNF-related matrix-associated actin-
dependent regulator of chromatin subfamily A containing 
DEAD/H box 1 isoform X1 [Canis lupus familiaris] 
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gi|545489749 25797
4 
0.02 PREDICTED: supervillin isoform X3 [Canis lupus 
familiaris] 
gi|95925865 87375 0.05 pinin 1 [Canis lupus familiaris] 
gi|73953627 75842 0.33 PREDICTED: annexin A6 isoformX2 [Canis lupus 
familiaris] 
gi|545490274 16537 0.29 PREDICTED: endothelial cell surface expressed 
chemotaxis and apoptosis regulator isoform X2 [Canis 
lupus familiaris] 
gi|2499844 38043 0.12 RecName: Full=CD44 antigen; AltName: 
Full=Extracellular matrix receptor-III; Short=ECMR-III; 
AltName: Full=GP90 lymphocyte homing/adhesion 
receptor; AltName: Full=HUTCH-I; AltName: 
Full=Hermes antigen; AltName: Full=Hyaluronate 
receptor; AltName: Fu 
 
ST 4-3: Transport Proteins Identified 
 
Accession Mass emPAI Description 
gi|73953093 31559 1.26 PREDICTED: voltage-dependent anion-selective channel 
protein 2 isoform 2 [Canis lupus familiaris] 
gi|126723018 30722 0.32 voltage-dependent anion-selective channel protein 1 
[Oryctolagus cuniculus] 
gi|345805068 90259 0.05 PREDICTED: transient receptor potential cation channel 
subfamily V member 3 isoform X2 [Canis lupus familiaris] 
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gi|73997059 47923 0.09 PREDICTED: ATP-sensitive inward rectifier potassium 
channel 8 isoformX1 [Canis lupus familiaris] 
gi|545528359 112738 0.47 PREDICTED: sodium/potassium-transporting ATPase 
subunit alpha-1 isoform X1 [Canis lupus familiaris] 
gi|73963665 24765 0.68 PREDICTED: transmembrane emp24 domain-containing 
protein 10 isoform 1 [Canis lupus familiaris] 
gi|354459073 30749 0.15 voltage-dependent anion-selective channel protein 3 
isoform 1 [Canis lupus familiaris] 
gi|345787913 67489 0.07 PREDICTED: sodium-coupled monocarboxylate 
transporter 2 isoform 1 [Canis lupus familiaris] 
gi|545495952 43843 0.1 PREDICTED: magnesium transporter NIPA4 [Canis lupus 
familiaris] 
gi|73997059 47923 0.09 PREDICTED: ATP-sensitive inward rectifier potassium 
channel 8 isoformX1 [Canis lupus familiaris] 
gi|545495894 175252 0.05 PREDICTED: probable phospholipid-transporting 
ATPase VB isoform X1 [Canis lupus familiaris] 
gi|5031569 42587 0.11 alpha-centractin [Homo sapiens] 
gi|74008791 71836 0.06 PREDICTED: sodium- and chloride-dependent neutral 
and basic amino acid transporter B(0+) [Canis lupus 
familiaris] 
gi|73945930 58023 0.08 PREDICTED: protein ERGIC-53 isoform X2 [Canis lupus 
familiaris] 
gi|545560056 17447 0.28 PREDICTED: proteolipid protein 2 [Canis lupus 
familiaris] 
gi|545497820 149551 0.03 PREDICTED: LOW QUALITY PROTEIN: misshapen-
like kinase 1 [Canis lupus familiaris] 
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gi|345792321 15429 0.31 PREDICTED: vesicle transport protein GOT1B [Canis 
lupus familiaris] 
gi|345805068 90259 0.05 PREDICTED: transient receptor potential cation channel 
subfamily V member 3 isoform X2 [Canis lupus familiaris] 
gi|545531227 579498 0.02 PREDICTED: LOW QUALITY PROTEIN: neuroblast 
differentiation-associated protein AHNAK [Canis lupus 
familiaris] 
gi|73983713 85720 0.05 PREDICTED: vacuolar protein sorting-associated protein 
51 homolog [Canis lupus familiaris] 
gi|73979536 31206 0.15 PREDICTED: neuronal membrane glycoprotein M6-a 
isoform 1 [Canis lupus familiaris] 
gi|545522646 121825 0.04 PREDICTED: LOW QUALITY PROTEIN: multidrug 
resistance protein 1 [Canis lupus familiaris] 
gi|50978854 61427 0.07 excitatory amino acid transporter 4 [Canis lupus familiaris] 
gi|50979327 50151 0.09 equilibrative nucleoside transporter 1 [Canis lupus 
familiaris] 
gi|545539571 29641 0.16 PREDICTED: sodium/potassium-transporting ATPase 
subunit beta-3, partial [Canis lupus familiaris] 
gi|73956324 58186 0.08 PREDICTED: non-specific lipid-transfer protein 
isoformX3 [Canis lupus familiaris] 
ST 4-3: Immune Complexes identified 
 
Accession Mass emPAI Description 
gi|345807015 79859 0.06 PREDICTED: interleukin 1 receptor accessory protein-
like 1 [Canis lupus familiaris] 
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gi|3334903 47844 0.09 endothelin receptor B [Canis lupus familiaris] 
gi|545548378 118345 0.04 PREDICTED: VPS10 domain-containing receptor SorCS1 
[Canis lupus familiaris] 
gi|345787413 66034 0.07 PREDICTED: coiled-coil domain-containing protein 36 
isoform X1 [Canis lupus familiaris] 
gi|345797884 43717 0.1 PREDICTED: V-set and immunoglobulin domain-
containing protein 8 isoform X1 [Canis lupus familiaris] 
gi|545515158 45807 0.1 PREDICTED: LIM and senescent cell antigen-like 
domains 1 isoform X5 [Canis lupus familiaris] 
 
ST- 4-5: GPCRs and G proteins identified 
 
Accession Mass emPAI Description 
gi|74009012 328348 0.03 PREDICTED: probable G-protein coupled receptor 112 
[Canis lupus familiaris] 
gi|545546307 47526 0.1 PREDICTED: probable G-protein coupled receptor 19 
isoform X2 [Canis lupus familiaris] 
gi|345807071 38241 0.12 PREDICTED: probable G-protein coupled receptor 82 
[Canis lupus familiaris] 
gi|345783859 35013 0.13 PREDICTED: olfactory receptor 4C11-like [Canis lupus 
familiaris] 
gi|54607157 52344 0.09 5-hydroxytryptamine receptor 2A [Canis lupus familiaris] 
gi|305410870 21597 0.48 membrane-associated progesterone receptor component 1 
[Canis lupus familiaris] 
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gi|545531462 41785 0.11 PREDICTED: LOW QUALITY PROTEIN: olfactory 
receptor 5AK2 [Canis lupus familiaris] 
gi|345783868 35060 0.13 PREDICTED: olfactory receptor 4C16-like [Canis lupus 
familiaris] 
gi|545525474 51582 0.09 PREDICTED: muscarinic acetylcholine receptor M2 
isoform X1 [Canis lupus familiaris] 
gi|545506467 50860 0.09 PREDICTED: LOW QUALITY PROTEIN: guanine 
nucleotide-binding protein G(olf) subunit alpha [Canis 
lupus familiaris] 
gi|5174447 35055 0.44 guanine nucleotide-binding protein subunit beta-2-like 1 
[Homo sapiens] 
gi|6680045 37353 0.12 guanine nucleotide-binding protein G(I)/G(S)/G(T) 
subunit beta-1 [Mus musculus] 
gi|5174447 35055 0.44 guanine nucleotide-binding protein subunit beta-2-like 1 
[Homo sapiens] 
gi|73985077 21585 0.22 PREDICTED: PRA1 family protein 3 [Canis lupus 
familiaris] 
gi|4506365 23531 0.2 ras-related protein Rab-2A isoform a [Homo sapiens] 
gi|4502201 20684 0.51 ADP-ribosylation factor 1 [Homo sapiens] 
gi|6680045 37353 0.12 guanine nucleotide-binding protein G(I)/G(S)/G(T) 
subunit beta-1 [Mus musculus] 
gi|545532122 103408 0.04 PREDICTED: rab3 GTPase-activating protein catalytic 
subunit isoform X7 [Canis lupus familiaris] 
gi|359322679 79430 0.06 PREDICTED: LOW QUALITY PROTEIN: rho GTPase-
activating protein 40 [Canis lupus familiaris] 
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gi|345783868 35060 0.13 PREDICTED: olfactory receptor 4C16-like [Canis lupus 
familiaris] 
gi|4758796 40517 0.11 developmentally-regulated GTP-binding protein 1 [Homo 
sapiens] 
gi|73964747 23379 0.2 PREDICTED: rho GDP-dissociation inhibitor 1 isoform 2 
[Canis lupus familiaris] 
gi|545514178 82795 0.05 PREDICTED: arf-GAP with GTPase, ANK repeat and PH 
domain-containing protein 2 [Canis lupus familiaris] 
gi|345783859 35013 0.13 PREDICTED: olfactory receptor 4C11-like [Canis lupus 
familiaris] 
gi|545546307 47526 0.1 PREDICTED: probable G-protein coupled receptor 19 
isoform X2 [Canis lupus familiaris] 
gi|73991970 166752 0.03 PREDICTED: ral GTPase-activating protein subunit beta 
isoformX1 [Canis lupus familiaris] 
gi|345807071 38241 0.12 PREDICTED: probable G-protein coupled receptor 82 
[Canis lupus familiaris] 
gi|545531462 41785 0.11 PREDICTED: LOW QUALITY PROTEIN: olfactory 
receptor 5AK2 [Canis lupus familiaris] 
gi|545506467 50860 0.09 PREDICTED: LOW QUALITY PROTEIN: guanine 
nucleotide-binding protein G(olf) subunit alpha [Canis 
lupus familiaris] 
gi|73997540 127936 0.03 PREDICTED: ELKS/Rab6-interacting/CAST family 
member 1 isoformX1 [Canis lupus familiaris] 




gi|545546746 51893 0.09 PREDICTED: tubby-related protein 3 isoform X4 [Canis 
lupus familiaris] 
gi|545516757 51263 0.09 PREDICTED: septin-8 isoform X1 [Canis lupus 
familiaris] 
gi|545545931 101735 0.04 PREDICTED: FYVE, RhoGEF and PH domain-
containing protein 4 isoform X2 [Canis lupus familiaris] 
gi|73951551 189049 0.02 PREDICTED: IQ motif containing GTPase activating 
protein 1 [Canis lupus familiaris] 
gi|73965285 93254 0.05 PREDICTED: axin-2 isoformX1 [Canis lupus familiaris] 
gi|545509639 71038 0.06 PREDICTED: septin-9 [Canis lupus familiaris] 
gi|3334903 47844 0.09 endothelin receptor B [Canis lupus familiaris] 
    
gi|131804 22555 0.76 RecName: Full=Ras-related protein Rab-10 [Canis lupus 
familiaris] 
gi|4506413 20974 0.5 ras-related protein Rap-1A precursor [Homo sapiens] 
gi|50979062 23441 0.2 ras-related protein Rab-5C [Canis lupus familiaris] 
gi|50979156 23505 0.72 ras-related protein Rab-7a [Canis lupus familiaris] 
gi|345799503 52039 0.18 PREDICTED: ras GTPase-activating protein-binding 
protein 1 isoform 4 [Canis lupus familiaris] 
gi|50979150 23644 0.2 ras-related protein Rab-5A [Canis lupus familiaris] 







ST 3-6 Chaperone Proteins Identified 
 
Accession Mass emPAI Description 
gi|57032236 6021
6 
0.54 PREDICTED: T-complex protein 1 subunit alpha 
isoformX1 [Canis lupus familiaris] 
gi|359320591 5800
2 
0.45 PREDICTED: T-complex protein 1 subunit delta isoform 
X1 [Canis lupus familiaris] 
gi|545500762 5823
0 




0.38 PREDICTED: T-complex protein 1 subunit zeta-2 isoform 
X3 [Canis lupus familiaris] 
gi|345802573 6058
9 
0.33 PREDICTED: T-complex protein 1 subunit gamma isoform 
1 [Canis lupus familiaris] 
gi|545550950 7775
6 
0.18 PREDICTED: T-complex protein 1 subunit theta isoform 
X2 [Canis lupus familiaris] 
gi|73968673 5739
5 
0.35 PREDICTED: T-complex protein 1 subunit beta isoformX1 
[Canis lupus familiaris] 
gi|359323746 5955
9 
0.16 PREDICTED: LOW QUALITY PROTEIN: T-complex 
protein 1 subunit epsilon isoform 1 [Canis lupus familiaris] 
gi|545558786 4873
9 
0.09 PREDICTED: LOW QUALITY PROTEIN: t-complex 11 
family, X-linked 2 [Canis lupus familiaris] 
gi|126352614 8318
5 
0.6 heat shock protein HSP 90-beta [Equus caballus] 
gi|545508859 7288
1 
0.52 PREDICTED: heat shock protein HSP 90-alpha, partial 




ST 4-7 Receptors Identified 
 
Accession Mass emPAI Description 
gi|50978812 86594 0.11 transferrin receptor protein 1 [Canis lupus familiaris] 
gi|50979256 12294
4 
0.04 platelet-derived growth factor receptor beta precursor 
[Canis lupus familiaris] 
gi|345806764 11892
7 




0.04 platelet-derived growth factor receptor beta precursor 
[Canis lupus familiaris] 
gi|73987612 29284 0.34 PREDICTED: basigin [Canis lupus familiaris] 
gi|545509559 20851 0.23 PREDICTED: CMRF35-like molecule 7-like [Canis 
lupus familiaris] 
gi|73979339 56856 0.08 PREDICTED: TELO2-interacting protein 2 isoform X2 
[Canis lupus familiaris] 
gi|545548378 11834
5 
0.04 PREDICTED: VPS10 domain-containing receptor 
SorCS1 [Canis lupus familiaris] 
gi|305410870 21597 0.48 membrane-associated progesterone receptor component 1 
[Canis lupus familiaris] 
gi|545501026 56949 0.08 PREDICTED: BAI1-associated protein 2-like 1 
isoformX1 [Canis lupus familiaris] 
gi|54607157 52344 0.09 5-hydroxytryptamine receptor 2A [Canis lupus familiaris] 
gi|545546046 64112 0.07 PREDICTED: transmembrane 7 superfamily member 3 
isoform X1 [Canis lupus familiaris] 
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0.03 PREDICTED: LOW QUALITY PROTEIN: reticulon-4 
isoform 1 [Canis lupus familiaris] 
gi|545507543 16524
6 
0.03 PREDICTED: leucine-rich repeat-containing protein 9-
like isoform X3 [Canis lupus familiaris] 
gi|57089795 32521 0.14 PREDICTED: vesicle-associated membrane protein-
associated protein A isoform 1 [Canis lupus familiaris] 
gi|74008133 11741
0 
0.04 PREDICTED: angiomotin isoformX1 [Canis lupus 
familiaris] 
gi|545518973 88005 0.05 PREDICTED: leucine-rich repeat and fibronectin type-III 
domain-containing protein 2 [Canis lupus familiaris] 
gi|73966275 63426 0.07 PREDICTED: insulin-like growth factor 2 mRNA 
binding protein 1 isoformX2 [Canis lupus familiaris] 
gi|545514112 60102 0.07 PREDICTED: receptor-type tyrosine-protein phosphatase 
R isoform X1 [Canis lupus familiaris] 
gi|545548312 89310 0.05 PREDICTED: receptor-type tyrosine-protein phosphatase 
epsilon isoform X5 [Canis lupus familiaris] 
gi|359318678 56421
8 




0.03 PREDICTED: receptor-type tyrosine-protein phosphatase 
eta [Canis lupus familiaris] 
gi|545531508 14699
2 
0.03 PREDICTED: receptor-type tyrosine-protein phosphatase 
eta [Canis lupus familiaris] 




ST 4-8 Enzymes Identified 
Accession Mass emPAI Description 
gi|545535631 133147 0.03 PREDICTED: LOW QUALITY PROTEIN: non-
receptor tyrosine-protein kinase TYK2 [Canis lupus 
familiaris] 
gi|73980394 48268 0.87 PREDICTED: protein disulfide-isomerase A6 [Canis 
lupus familiaris] 
gi|73964749 57381 1.12 PREDICTED: protein disulfide-isomerase [Canis lupus 
familiaris] 
gi|345800677 48956 0.55 PREDICTED: LOW QUALITY PROTEIN: alpha-
enolase isoform 1 [Canis lupus familiaris] 
gi|545547462 87343 0.22 PREDICTED: delta-1-pyrroline-5-carboxylate synthase 
isoform X3 [Canis lupus familiaris] 
gi|74000476 23761 0.43 PREDICTED: peptidyl-prolyl cis-trans isomerase B 
isoform 2 [Canis lupus familiaris] 
gi|545539262 87576 0.22 PREDICTED: procollagen-lysine,2-oxoglutarate 5-
dioxygenase 2 isoform X2 [Canis lupus familiaris] 
gi|359321459 72351 0.13 PREDICTED: protein disulfide-isomerase A4 isoform 3 
[Canis lupus familiaris] 
gi|545512792 124956 0.04 PREDICTED: protein phosphatase 1 regulatory subunit 
26 isoform X1 [Canis lupus familiaris] 
gi|345802152 68262 0.07 PREDICTED: serine/threonine-protein kinase PLK1 
[Canis lupus familiaris] 




gi|73954910 52795 0.09 PREDICTED: serine/threonine-protein kinase Chk1 
[Canis lupus familiaris] 
gi|545548312 89310 0.05 PREDICTED: receptor-type tyrosine-protein 
phosphatase epsilon isoform X5 [Canis lupus familiaris] 
gi|545557037 116529 0.04 PREDICTED: serine/threonine-protein kinase MARK1 
[Canis lupus familiaris] 
gi|545555517 3901076 0 PREDICTED: LOW QUALITY PROTEIN: titin [Canis 
lupus familiaris] 
gi|73980965 92301 0.05 PREDICTED: mannosyl-oligosaccharide glucosidase 
[Canis lupus familiaris] 
gi|6755588 23300 0.2 synaptosomal-associated protein 25 isoform a [Mus 
musculus] 
gi|545521006 120316 0.04 PREDICTED: focal adhesion kinase 1 isoform X3 [Canis 
lupus familiaris] 
gi|308082020 26698 0.17 triosephosphate isomerase [Canis lupus familiaris] 
gi|345803586 35294 0.13 PREDICTED: retinol dehydrogenase 11 isoform X3 
[Canis lupus familiaris] 
gi|345804359 31495 0.15 PREDICTED: thioredoxin-related transmembrane 
protein 1 [Canis lupus familiaris] 
gi|345782889 204305 0.02 PREDICTED: LOW QUALITY PROTEIN: histone-
lysine N-methyltransferase 2E isoform 1 [Canis lupus 
familiaris] 
gi|545489174 204718 0.02 PREDICTED: proprotein convertase subtilisin/kexin 
type 5 [Canis lupus familiaris] 
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gi|545535534 158607 0.03 PREDICTED: membrane-associated guanylate kinase, 
WW and PDZ domain-containing protein 1 [Canis lupus 
familiaris] 
gi|57110216 43734 0.1 PREDICTED: p21-activated protein kinase-interacting 
protein 1 [Canis lupus familiaris] 
gi|74006997 27138 0.17 PREDICTED: 3-hydroxyacyl-CoA dehydrogenase type-
2 isoform 1 [Canis lupus familiaris] 
gi|545514789 72610 0.06 PREDICTED: TGF-beta-activated kinase 1 and 
MAP3K7-binding protein 1 isoformX1 [Canis lupus 
familiaris] 
gi|73966592 133435 0.03 PREDICTED: myotubularin-related protein 4 isoformX1 
[Canis lupus familiaris] 
gi|73958481 39478 0.12 PREDICTED: fructose-bisphosphate aldolase A 
isoformX2 [Canis lupus familiaris] 
gi|545544113 42798 0.11 PREDICTED: mevalonate kinase isoform X1 [Canis 
lupus familiaris] 
gi|532164718 54008 0.08 serine/threonine-protein phosphatase 2A 56 kDa 
regulatory subunit epsilon isoform isoform b [Homo 
sapiens] 
gi|73967304 152838 0.03 PREDICTED: carboxypeptidase D isoform 2 [Canis 
lupus familiaris] 
gi|347889344 97560 0.05 thyrotropin-releasing hormone-degrading ectoenzyme 
[Canis lupus familiaris] 
gi|545497443 77070 0.06 PREDICTED: serine/threonine-protein phosphatase 2A 
65 kDa regulatory subunit A beta isoform isoform X4 
[Canis lupus familiaris] 
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gi|545535631 133147 0.03 PREDICTED: LOW QUALITY PROTEIN: non-
receptor tyrosine-protein kinase TYK2 [Canis lupus 
familiaris] 
gi|74002818 57933 0.08 PREDICTED: serine/threonine-protein kinase PAK 2 
isoform 1 [Canis lupus familiaris] 
gi|73975797 40015 0.11 PREDICTED: serum paraoxonase/arylesterase 1 isoform 
2 [Canis lupus familiaris] 
gi|73978267 40232 0.11 PREDICTED: glycosyltransferase 8 domain-containing 
protein 2 isoform X4 [Canis lupus familiaris] 
gi|345790993 51995 0.09 PREDICTED: adenosine monophosphate-protein 
transferase FICD isoform X3 [Canis lupus familiaris] 
gi|545511519 105714 0.04 PREDICTED: E3 ubiquitin-protein ligase TRIM37 
isoform X3 [Canis lupus familiaris] 
gi|545508117 148451 0.03 PREDICTED: tubulin polyglutamylase TTLL5 isoform 
X1 [Canis lupus familiaris] 
gi|545516121 77140 0.06 PREDICTED: glutamine--fructose-6-phosphate 
aminotransferase [isomerizing] 2 [Canis lupus familiaris] 
gi|73970573 45905 0.1 PREDICTED: protein-lysine 6-oxidase isoformX1 
[Canis lupus familiaris] 
gi|73983265 138671 0.03 PREDICTED: 1-phosphatidylinositol 4,5-bisphosphate 
phosphodiesterase beta-3 isoformX2 [Canis lupus 
familiaris] 
gi|74008407 40859 0.11 PREDICTED: palmitoyltransferase ZDHHC9 isoform 2 
[Canis lupus familiaris] 




gi|545546189 73137 0.06 PREDICTED: 1-phosphatidylinositol 4,5-bisphosphate 
phosphodiesterase zeta-1 isoform X1 [Canis lupus 
familiaris] 
gi|359323381 134236 0.07 PREDICTED: 1-phosphatidylinositol 4,5-bisphosphate 
phosphodiesterase beta-2 isoform X1 [Canis lupus 
familiaris] 
gi|171184453 17118 0.28 prostaglandin E synthase [Canis lupus familiaris] 
gi|545558971 77661 0.06 PREDICTED: long-chain-fatty-acid--CoA ligase 4 
isoform X5 [Canis lupus familiaris] 
gi|545529305 88247 0.05 PREDICTED: calcium-independent phospholipase A2-
gamma isoform X2 [Canis lupus familiaris] 
gi|359323612 82513 0.05 PREDICTED: lanosterol synthase isoform 2 [Canis 
lupus familiaris] 
 
ST 4-9: Other Proteins Identified 
 
Accession Mass emPAI Description 
gi|73969959 65382 1.52 PREDICTED: cytoskeleton-associated protein 4 [Canis 
lupus familiaris] 
gi|345779293 27846 0.17 PREDICTED: transmembrane protein 51 [Canis lupus 
familiaris] 
gi|73971240 38546 0.25 PREDICTED: stomatin (EPB72)-like 2 isoform 1 [Canis 
lupus familiaris] 
gi|73983875 26187 0.18 PREDICTED: transmembrane protein 109 isoform X4 









0.04 PREDICTED: LOW QUALITY PROTEIN: kinesin 
family member 11 [Canis lupus familiaris] 
gi|71043798 44292 0.1 cathepsin D precursor [Canis lupus familiaris] 
gi|545497651 12042
5 
0.04 PREDICTED: myb-binding protein 1A [Canis lupus 
familiaris] 
gi|73984530 44862 0.21 PREDICTED: transmembrane protein 43 isoform 1 
[Canis lupus familiaris] 




0.02 PREDICTED: GRIP and coiled-coil domain-containing 
protein 2 [Canis lupus familiaris] 
gi|4502549 16827 0.29 calmodulin [Homo sapiens] 
gi|1353187 47337 0.1 RecName: Full=Zona pellucida sperm-binding protein 3; 
AltName: Full=Sperm receptor; AltName: Full=Zona 
pellucida glycoprotein 3; Short=Zp-3; AltName: 
Full=Zona pellucida protein C; Contains: RecName: 
Full=Processed zona pellucida sperm-binding prote 
gi|545492234 47379
6 
0.01 PREDICTED: LOW QUALITY PROTEIN: basement 
membrane-specific heparan sulfate proteoglycan core 
protein [Canis lupus familiaris] 
gi|345800374 42267 0.11 PREDICTED: plasminogen activator inhibitor 1 RNA-
binding protein isoform 1 [Canis lupus familiaris] 
gi|545511186 11185
8 
0.04 PREDICTED: LOW QUALITY PROTEIN: MYCBP-
associated protein [Canis lupus familiaris] 
246 
 
gi|545502406 43027 0.11 PREDICTED: clusterin-associated protein 1 isoform X2 
[Canis lupus familiaris] 




0.03 PREDICTED: LOW QUALITY PROTEIN: WD repeat-
containing protein 65 [Canis lupus familiaris] 
gi|73972924 37815 0.12 PREDICTED: protein YIPF3 isoform 1 [Canis lupus 
familiaris] 
gi|545488074 63561 0.07 PREDICTED: coiled-coil domain-containing protein 61 
isoform X1 [Canis lupus familiaris] 
gi|545489280 12755
9 
0.03 PREDICTED: LOW QUALITY PROTEIN: liprin-
alpha-3 [Canis lupus familiaris] 
gi|545520271 61863 0.07 PREDICTED: butyrophilin subfamily 1 member A1-like 
[Canis lupus familiaris] 
gi|345786928 15331
8 
0.03 PREDICTED: LOW QUALITY PROTEIN: calcium-




0.03 PREDICTED: PDZ domain-containing protein 8 isoform 








APPENDIX C: TABLES OF PROTEINS IDENTIFIED BY PEPTIDE 
FINGERPRINTING OF 143B MEMBRANE AND PROTEINS 
INCORPORATED IN NANODISC 1- 4 
ST1: Proteomics data of plasma membrane protein from 143B 
 
ST1-1.  Overall proteomic profile 
 
emPAI Percentage 
Structural 87.73 56.68 




G- proteins and 
GPCRs 
28.33 18.30 
Chaperones  2.27 1.47 














Enzymes 2.09 1.35 
Others 5.84 3.77 
 
ST1-2. Structural proteins detected 
Accession Mass emPAI Description 
 
gi|435476 62092 2.89 cytokeratin 9 [Homo sapiens] 
gi|12803709 51619 1.26 Keratin 14 [Homo sapiens] 
gi|12653819 48003 0.3 Keratin 18 [Homo sapiens] 
gi|11935049 66027 6.72 keratin 1 [Homo sapiens] 
gi|62414289 53619 9.57 vimentin [Homo sapiens] 
gi|47132620 65393 2.88 keratin, type II cytoskeletal 2 epidermal [Homo sapiens] 
gi|119617032 59874 0.76 keratin 6B, isoform CRA_a [Homo sapiens] 
gi|119395754 62340 0.84 keratin, type II cytoskeletal 5 [Homo sapiens] 
gi|119617057 57772 0.79 keratin 8, isoform CRA_a [Homo sapiens] 
gi|28173564 58887 0.15 keratin, type II cytoskeletal 73 [Homo sapiens] 
gi|73909156 40503 26.66 Annexin A2 [Homo sapiens] 
gi|62897671 41694 8.17 beta actin variant [Homo sapiens] 
gi|7106439 49639 1.77 tubulin beta-5 chain [Mus musculus] 
gi|119608775 48794 1.81 tubulin, beta 2C, isoform CRA_b [Homo sapiens] 
gi|157833780 35984 1.54 Chain A, Human Annexin V With Proline Substitution By 
Thioproline 
gi|34234 31774 0.7 laminin-binding protein, partial [Homo sapiens] 
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gi|16974825 8483 10.06 Chain A, Solution Structure Of Calcium-calmodulin N-
terminal Domain 
gi|5031635 18491 2.07 cofilin-1 [Homo sapiens] 
gi|4502101 38690 0.92 annexin A1 [Homo sapiens] 
gi|12667788 226392 0.18 myosin-9 [Homo sapiens] 
gi|24119203 29015 1.06 tropomyosin alpha-3 chain isoform 2 [Homo sapiens] 
gi|17986258 16919 1.67 myosin light polypeptide 6 isoform 1 [Homo sapiens] 
gi|179976 75857 0.48 calelectrin [Homo sapiens] 
gi|37492 50126 0.52 alpha-tubulin [Homo sapiens] 
gi|321400138 46537 0.31 CD44 antigen isoform 6 precursor [Homo sapiens] 
gi|119593154 263754 0.08 filamin A, alpha (actin binding protein 280), isoform 
CRA_e [Homo sapiens] 
gi|530393410 236464 0.07 PREDICTED: myoferlin isoform X1 [Homo sapiens] 
gi|7656991 53215 0.08 coronin-1C isoform b [Homo sapiens] 
gi|3282771 278018 0.06 actin-binding protein homolog ABP-278 [Homo sapiens] 
gi|4826898 15045 0.73 profilin-1 [Homo sapiens] 
gi|119584665 9744 0.52 ankyrin repeat domain 28, isoform CRA_d [Homo 
sapiens] 
gi|186837 197937 0.02 laminin B1 [Homo sapiens] 
gi|41322910 512292 0.03 plectin isoform 1d [Homo sapiens] 
gi|205831092 68253 0.06 RecName: Full=Putative IQ motif and ankyrin repeat 
domain-containing protein LOC642574 
gi|641958 228798 0.02 non-muscle myosin B [Homo sapiens] 
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gi|3287188 127296 0.03 ankyrin-like protein [Homo sapiens] 
gi|120660098 163133 0.03 CAMSAP1 protein [Homo sapiens] 
gi|444738793 5129 1.16 alternative protein CEP350 [Homo sapiens] 
gi|8885790 287292 0.03 filamin 2 [Homo sapiens] 
gi|762885 81583 0.05 Plakoglobin [Homo sapiens] 
gi|578821687 271519 0.02 PREDICTED: spectrin beta chain, non-erythrocytic 2 
isoform X3 [Homo sapiens] 
gi|438056 342550 0.01 laminin M chain (merosin) [Homo sapiens] 
gi|4507115 54496 0.08 fascin [Homo sapiens] 
gi|119576069 394840 0.01 myosin XVA, isoform CRA_c [Homo sapiens] 
gi|6563228 43212 0.1 rap2 interacting protein x [Homo sapiens] 
gi|4757944 25792 0.18 CD81 antigen [Homo sapiens] 
gi|1107687 505963 0.02 homologue of Drosophila Fat protein [Homo sapiens] 
gi|578837838 423562 0.01 PREDICTED: dystrophin isoform X5 [Homo sapiens] 
gi|578823153 93390 0.05 PREDICTED: tastin isoform X1 [Homo sapiens] 
gi|119574344 91877 0.05 ankyrin repeat domain 30B, partial [Homo sapiens] 
gi|2996006 70660 0.06 outer dense fiber protein 2/2 [Homo sapiens] 
gi|34226 288131 0.01 laminin A chain [Homo sapiens] 
gi|530370381 134263 0.03 PREDICTED: unconventional myosin-Ib isoform X2 
[Homo sapiens] 
gi|186964 177492 0.02 laminin B2 chain [Homo sapiens] 
gi|578819318 310817 0.01 PREDICTED: ankyrin-3 isoform X17 [Homo sapiens] 




ST 1-3: Transport Proteins detected 
Accession Mass emPAI Description 
gi|119574954 34459 0.84 voltage-dependent anion channel 2, isoform CRA_a 
[Homo sapiens] 
gi|198443050 31818 0.3 Chain A, Solution Structure Of Human Vdac-1 In Ldao 
Micelles 
gi|61744477 68059 0.28 4F2 cell-surface antigen heavy chain isoform b [Homo 
sapiens] 
gi|4505893 16680 0.28 proteolipid protein 2 [Homo sapiens] 
gi|51094709 10252
3 
0.04 tweety homolog 3 (Drosophila) [Homo sapiens] 
gi|48255951 13678
9 
0.03 plasma membrane calcium-transporting ATPase 2 isoform 
1 [Homo sapiens] 
gi|5733504 27630 0.16 voltage-dependent anion channel VDAC3 [Homo sapiens] 
gi|1478281 56585 0.16 neutral amino acid transporter B [Homo sapiens] 
gi|5730102 10625
8 
0.04 short transient receptor potential channel 6 [Homo sapiens] 
gi|4502281 31492 0.14 sodium/potassium-transporting ATPase subunit beta-3 
[Homo sapiens] 
gi|115583685 53909 0.17 monocarboxylate transporter 1 [Homo sapiens] 
gi|9957467 26978
6 
0.02 ATP-binding cassette sub-family A member 2 [Homo 
sapiens] 
gi|38516 20468 0.23 caveolin [Homo sapiens] 
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gi|347948492 8529 0.61 Chain A, Complex Of Cambr And Cam 
gi|62087606 50068 0.09 sorting nexin 1 isoform a variant [Homo sapiens] 
gi|2337920 29827 0.15 syntaxin 7 [Homo sapiens] 
gi|25777643 59949 0.07 small conductance calcium-activated potassium channel 
protein 1 [Homo sapiens] 
gi|51339295 12684
3 
0.07 cation channel sperm-associated protein subunit beta 
precursor [Homo sapiens] 
gi|4507297 68692 0.06 syntaxin-binding protein 1 isoform a [Homo sapiens] 
gi|169790839 59534 0.07 excitatory amino acid transporter 1 isoform 1 [Homo 
sapiens] 
 
ST 1-4 :  Immune Complex proteins detected 
Accession Mass emPAI Description 
gi|432139040 12890 0.38 immunoglobulin heavy chain variable region, partial [Homo 
sapiens] 
gi|290560013 11815 3.04 Chain B, Crystal Structure Of Mhc Class I Hla-A2.1 Bound 
To A Photocleavable Peptide 
gi|4324088 10594 0.47 immunoglobulin lambda light chain variable region [Homo 
sapiens] 
gi|307496 1390 9.07 T cell receptor beta chain [Homo sapiens] 
gi|333036593 21139 0.22 MHC class I antigen [Homo sapiens] 
gi|151188217 40719 0.11 killer-cell Ig-like receptor [Homo sapiens] 
gi|17986005 29943 0.15 major histocompatibility complex, class II, DR beta 3 
precursor [Homo sapiens] 
253 
 
gi|611962048 10753 0.46 immunoglobulin heavy chain variable region, partial [Homo 
sapiens] 
gi|247425243 13679 0.35 immunoglobulin heavy chain variable region [Homo 
sapiens] 
gi|15680023 27975 0.16 B-cell receptor-associated protein 31 [Homo sapiens] 
gi|4038122 4086 1.57 T-cell receptor beta chain [Homo sapiens] 
gi|226316189 21056 0.22 MHC class I antigen [Homo sapiens] 
gi|224962016 21226 0.48 MHC class II antigen [Homo sapiens] 
gi|119573139 39827 0.11 SLAM family member 9, isoform CRA_a [Homo sapiens] 
gi|26985944 13046 0.37 immunoglobulin IgG1 heavy chain [Homo sapiens] 
    
ST 1- 5: GPCRs and G- proteins detected 
Accession Mass emPAI Description 
gi|4506413 20974 0.81 ras-related protein Rap-1A precursor [Homo sapiens] 
gi|327195100 33961 0.45 UBE2L3/KRAS fusion protein [Homo sapiens] 
gi|119574084 39680 0.53 guanine nucleotide binding protein (G protein), beta 
polypeptide 2-like 1, isoform CRA_h [Homo sapiens] 
gi|508285 23553 0.43 Rab5c-like protein, similar to Canis familiaris Rab5c protein, 
PIR Accession Number S38625 [Homo sapiens] 
gi|13569962 22157 1.56 ras-related protein Rab-1B [Homo sapiens] 
gi|33946329 23552 0.43 ras-related protein Ral-A precursor [Homo sapiens] 
gi|1174149 23447 1.04 small GTP binding protein Rab7 [Homo sapiens] 
gi|14249144 24473 0.67 ras-related protein Rab-11B [Rattus norvegicus] 
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gi|5729850 40506 0.37 guanine nucleotide-binding protein G(k) subunit alpha [Homo 
sapiens] 
gi|21361884 24199 0.19 ras-related protein Rab-2B isoform 1 [Homo sapiens] 
gi|5031703 52132 0.18 ras GTPase-activating protein-binding protein 1 [Homo 
sapiens] 
gi|5031703 52132 0.18 ras GTPase-activating protein-binding protein 1 [Homo 
sapiens] 
gi|297660220 16459 0.29 Rho GTPase activating protein 26 variant 3 [Homo sapiens] 
gi|311697329 3564 1.93 KRAS protein [Homo sapiens] 
gi|4885287 7314 0.73 guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit 
gamma-5 precursor [Homo sapiens] 
gi|540344584 37576 0.12 guanine nucleotide-binding protein subunit alpha-12 isoform 
3 [Homo sapiens] 
gi|3292965 1071 15.8 m1 muscarinic acetylcholine receptor protein [Homo sapiens] 
gi|53828729 34724 0.13 olfactory receptor 7D2 [Homo sapiens] 
gi|334278900 35700 0.12 olfactory receptor 4N4 [Homo sapiens] 
gi|19338916 36399 0.12 G protein-coupled receptor SNSR5 [Homo sapiens] 
gi|2500069 21555 0.21 RecName: Full=Ras-related protein Rab-31; AltName: 
Full=Ras-related protein Rab-22B [Homo sapiens] 
gi|3327062 221821 0.02 KIAA0624 protein [Homo sapiens] 
gi|4139784 24393 0.19 Chain A, Canine Gdp-Ran Q69l Mutant 
gi|390635651 110782 0.04 ras-related protein Rab-44 [Homo sapiens] 
gi|21928341 34874 0.13 seven transmembrane helix receptor [Homo sapiens] 
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gi|530416765 113467 0.04 PREDICTED: ras-interacting protein 1 isoform X1 [Homo 
sapiens] 
gi|62088744 29577 0.15 regulator of G-protein signalling 11 isoform 1 variant [Homo 
sapiens] 
gi|359807059 20502 0.22 TBC1 domain family member 1 isoform 4 [Homo sapiens] 
gi|4836765 77704 0.06 G-protein-coupled receptor [Homo sapiens] 
gi|13122463 37605 0.12 G protein-coupled receptor [Homo sapiens] 
gi|9625037 21295 0.22 rho-related GTP-binding protein RhoG precursor [Mus 
musculus] 
gi|51036603 8001 0.66 guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit 
gamma-12 precursor [Homo sapiens] 
gi|15293749 23836 0.19 olfactory receptor [Homo sapiens] 
 
ST 1-6: Chaperone proteins detected 
Accession Mass emPAI Description 
gi|431822408 82269 0.95 heat shock protein HSP 90-beta isoform c [Homo sapiens] 
gi|153792590 98099 0.47 heat shock protein HSP 90-alpha isoform 1 [Homo sapiens] 
gi|62089036 57725 0.16 chaperonin containing TCP1, subunit 6A isoform a variant 
[Homo sapiens] 
gi|5453603 57452 0.16 T-complex protein 1 subunit beta isoform 1 [Homo sapiens] 
gi|1136741 58465 0.16 KIAA0002 [Homo sapiens] 
gi|5453607 59329 0.15 T-complex protein 1 subunit eta isoform a [Homo sapiens] 
gi|671527 60292 0.07 gamma subunit of CCT chaperonin [Homo sapiens] 




ST 1-7: Other Receptor proteins detected 
Accession Mass emPAI Description 
gi|1477388 132282 0.07 metabotropic glutamate receptor 1 alpha [Homo sapiens] 
gi|119581591 46372 0.2 basigin (Ok blood group), isoform CRA_g [Homo sapiens] 
gi|187609338 20107 0.51 Chain A, Crystal Structure Of The Extracellular Portion Of 
Hab18gCD147 
gi|19743813 88357 0.47 integrin beta-1 isoform 1A precursor [Homo sapiens] 
gi|124942 129214 0.14 RecName: Full=Integrin alpha-2; AltName: Full=CD49 
antigen-like family member B; AltName: Full=Collagen 
receptor; AltName: Full=Platelet membrane glycoprotein Ia; 
Short=GPIa; AltName: Full=VLA-2 subunit alpha; 
AltName: CD_antigen=CD49b; Flags: Precu 
gi|6424942 96019 0.05 ALG-2 interacting protein 1 [Homo sapiens] 
gi|5729875 21658 0.21 membrane-associated progesterone receptor component 1 
isoform 1 [Homo sapiens] 
gi|4530577 65546 0.07 LISCH protein [Homo sapiens] 
gi|21928311 35019 0.13 seven transmembrane helix receptor [Homo sapiens] 
gi|62089376 70414 0.06 complement component 1, q subcomponent, receptor 1 
variant [Homo sapiens] 
gi|119611708 110644 0.04 protein tyrosine phosphatase, receptor type, C, isoform 
CRA_c [Homo sapiens] 
gi|47077659 72805 0.06 FLJ00268 protein [Homo sapiens] 
gi|1374813 23368 0.43 SNAP-23 [Homo sapiens] 
257 
 
gi|20072835 59945 0.07 ACSL1 protein, partial [Homo sapiens] 
gi|5360115 89012 0.05 NY-REN-45 antigen [Homo sapiens] 
gi|257743046 43424 0.1 C-C chemokine receptor type 3 isoform 2 [Homo sapiens] 
gi|70913399 2021 4.89 T cell receptor alpha variable 7 [Homo sapiens] 
 
ST 1-8: Enzymes detected 
Accession Mass  emPAI Description 
gi|18909593
8 
11754  0.42 Chain A, Crystal Structure Of E60a Mutant Of Fkbp12 
gi|53037506
5 
51152  0.09 PREDICTED: neutral cholesterol ester hydrolase 1 
isoform X1 [Homo sapiens] 
gi|22209028 31786  0.3 Thioredoxin-related transmembrane protein 1 [Homo 
sapiens] 




56246  0.08 PREDICTED: death-associated protein kinase 2 isoform 
X1 [Homo sapiens] 
gi|4505783 12480
5 




 0.03 FMI protein [Homo sapiens] 
gi|1486363 41988  0.11 extracellular signal regulated kinase [Homo sapiens] 





 0.04 neuronal kinesin heavy chain [Homo sapiens] 
gi|181944 10818
5 
 0.04 protein-tyrosine kinase [Homo sapiens] 
gi|16306598 15353
3 














31726  0.14 Chain A, Crystal Structure Of Human Pyridoxal 5'-
Phosphate Phosphatase 
gi|837261 88581  0.05 ERK5 [Homo sapiens] 
gi|62897321 34328  0.13 steroid dehydrogenase homolog [Homo sapiens] 




73247  0.06 RecName: Full=Heparan-alpha-glucosaminide N-
acetyltransferase; AltName: Full=Transmembrane 
protein 76 [Homo sapiens] 
gi|13242866 31413  0.14 type 3 iodothyronine deiodinase [Homo sapiens] 
 
ST 1-9: Other membrane proteins detected 
Accession Mass emPAI Description 
gi|13129092 26194 0.38 transmembrane protein 109 precursor [Homo sapiens] 
gi|5821140 40308 0.37 ASY [Homo sapiens] 
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gi|345198270 23750 0.69 tumor protein D54 isoform j [Homo sapiens] 
gi|337930 27386 0.84 scar protein [Homo sapiens] 
gi|23712 45220 0.32 myoblast antigen 24.1D5 [Homo sapiens] 
gi|1160963 83616 0.29 transmembrane protein [Homo sapiens] 
gi|662994 72707 0.06 GPI-anchored protein p137 [Homo sapiens] 
gi|5729718 46003 0.1 trophoblast glycoprotein precursor [Homo sapiens] 
gi|578830259 58187 0.08 PREDICTED: brain-specific angiogenesis inhibitor 1-
associated protein 2 isoform X11 [Homo sapiens] 
gi|7767178 19180 0.24 Chain A, Apolipoprotein E3 (Apoe3) Truncation Mutant 165 
gi|6912582 30361 0.15 peflin [Homo sapiens] 
gi|6002678 45242 0.1 colon carcinoma related protein [Homo sapiens] 
gi|19923969 25820 0.18 coiled-coil domain-containing protein 124 [Homo sapiens] 
gi|39725636 27260 0.17 transmembrane emp24 domain-containing protein 9 
precursor [Homo sapiens] 
gi|19920317 65983 0.14 cytoskeleton-associated protein 4 [Homo sapiens] 
gi|1161384 384046 0.01 BRCA2 [Homo sapiens] 
gi|40789001 108477 0.04 KIAA0964 protein [Homo sapiens] 
gi|4240313 149996 0.03 KIAA0912 protein [Homo sapiens] 
gi|30089664 575806 0.01 ABC A13 [Homo sapiens] 
gi|27735113 50114 0.09 EF-hand calcium-binding domain-containing protein 3 
isoform b [Homo sapiens] 
gi|28680 21594 0.21 amphiglycan [Homo sapiens] 
gi|235397 24680 0.18 HMFG, partial [Homo sapiens] 
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gi|15012003 17359 0.27 Family with sequence similarity 162, member A [Homo 
sapiens] 
gi|1616918 46323 0.1 membrane protein with histidine rich charge clusters [Homo 
sapiens] 
gi|6331328 115103 0.04 KIAA1280 protein [Homo sapiens] 
gi|29648540 14892 0.32 MLL5 [Homo sapiens] 
gi|20521880 198894 0.02 KIAA1305 protein [Homo sapiens] 
gi|7706322 28051 0.16 UPF0568 protein C14orf166 [Homo sapiens] 
gi|471270576 23424 0.2 Chain L, Crystal Structure Of Tnf-alpha In Complex With 
Infliximab Fab Fragment 
gi|71891687 139575 0.03 KIAA0931 protein [Homo sapiens] 














ST2: Proteomics data of plasma membrane protein from POPC nanodiscs 





Structure 6.73 19.39 




GPCRs and G- 
proteins 
7.01 20.20 














Enzymes 1.34 3.86 
 
ST 2-2: Structural proteins detected 
Accession Mass emPAI Description 
gi|47132620 65393 0.69 keratin, type II cytoskeletal 2 epidermal [Homo sapiens] 
gi|11935049 66027 0.79 keratin 1 [Homo sapiens] 
gi|111600321 148955 0.06 Cingulin-like 1 [Homo sapiens] 
gi|119581148 57526 0.45 keratin 9 (epidermolytic palmoplantar keratoderma) [Homo 
sapiens] 
gi|124942 129214 0.18 RecName: Full=Integrin alpha-2; AltName: Full=CD49 
antigen-like family member B; AltName: Full=Collagen 
receptor; AltName: Full=Platelet membrane glycoprotein Ia; 
Short=GPIa; AltName: Full=VLA-2 subunit alpha; AltName: 
CD_antigen=CD49b; Flags: Precu 
gi|4757756 38580 0.93 annexin A2 isoform 2 [Homo sapiens] 
gi|35959 49599 0.09 tubulin 5-beta [Homo sapiens] 
gi|119606366 87389 0.05 integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen 
CD29 includes MDF2, MSK12), isoform CRA_f [Homo 
sapiens] 
gi|187609338 20107 0.23 Chain A, Crystal Structure Of The Extracellular Portion Of 
Hab18gCD147 
gi|63055057 41976 0.36 beta-actin-like protein 2 [Homo sapiens] 
gi|14250401 40978 0.51 actin, beta, partial [Homo sapiens] 
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gi|3043578 82629 0.05 KIAA0527 protein [Homo sapiens] 
gi|1335273 131387 0.03 pm5 protein [Homo sapiens] 
gi|29801 53563 0.08 CD44E (epithelial form) [Homo sapiens] 
gi|4757944 25792 0.18 CD81 antigen isoform 1 [Homo sapiens] 
gi|6755973 21820 0.21 protein lin-7 homolog C [Mus musculus] 
gi|11602890 242566 0.02 betaIV spectrin isoform sigma4 [Homo sapiens] 
gi|6331294 130203 0.03 KIAA1275 protein [Homo sapiens] 
gi|996057 25106 0.18 gp25l2 [Homo sapiens] 
gi|38194229 69830 0.06 kelch-like protein 17 [Homo sapiens] 
gi|4502101 38690 0.12 annexin A1 [Homo sapiens] 
gi|578832133 171296 0.03 PREDICTED: ankyrin repeat domain-containing protein 30B 
isoform X1 [Homo sapiens] 
gi|17223624 184249 0.02 ATP-binding cassette A9 [Homo sapiens] 
gi|47115317 53547 0.08 VIM [Homo sapiens] 
gi|119623210 109613 0.04 protocadherin 19, isoform CRA_b [Homo sapiens] 
gi|642945631 3992165 0 titin isoform IC [Homo sapiens] 
gi|588293041 5873 0.97 Chain A, Crystal Structure Of Human Striatin-3 Coiled Coil 
Domain 
gi|578828592 465974 0.01 PREDICTED: dynein heavy chain 3, axonemal isoform X1 
[Homo sapiens] 
gi|109627650 52955 0.08 coronin-6 [Homo sapiens] 
gi|15395290 520649 0.01 axonemal beta heavy chain dynein type 11 [Homo sapiens] 
gi|530355911 185529 0.02 PREDICTED: filaggrin-like isoform X1 [Homo sapiens] 
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gi|578800534 106620 0.04 PREDICTED: axonemal dynein light chain domain-
containing protein 1 isoform X4 [Homo sapiens] 
gi|35046 102386 0.04 NF-M [Homo sapiens] 
gi|530383617 82734 0.05 PREDICTED: discoidin, CUB and LCCL domain-containing 
protein 1 isoform X1 [Homo sapiens] 
gi|11128029 100981 0.04 protocadherin gamma-B6 isoform 1 precursor [Homo sapiens] 
 
 
ST 2-2: Transport proteins detected 
Accession Mass emPAI Description 
gi|21361181 112824 0.16 sodium/potassium-transporting ATPase subunit alpha-1 
isoform a [Homo sapiens] 
gi|340201 31575 0.5 voltage-dependent anion channel [Homo sapiens] 
gi|5803165 9968 1.28 protein transport protein Sec61 subunit beta [Homo sapiens] 
gi|4505893 16680 0.29 proteolipid protein 2 [Homo sapiens] 
gi|238427 30623 0.32 Porin 31HM [human, skeletal muscle membranes, Peptide, 282 
aa] 
gi|15216171 55958 0.08 putative 40-9-1 protein [Homo sapiens] 
gi|177207 57935 0.08 4F2 antigen heavy chain [Homo sapiens] 
gi|1478281 56585 0.08 neutral amino acid transporter B [Homo sapiens] 
gi|184039 227015 0.02 sodium channel alpha subunit [Homo sapiens] 
gi|2337920 29827 0.15 syntaxin 7 [Homo sapiens] 
gi|7243235 47877 0.09 KIAA1427 protein [Homo sapiens] 
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gi|18148873 62056 0.07 hUST3 [Homo sapiens] 
gi|62088660 13888 0.35 solute carrier family 19, member 2 variant [Homo sapiens] 
 
ST 2-3: Immune complex proteins identified 
Accession Mass emPAI Description 
gi|303398863 31635 0.31 MHC class I antigen [Homo sapiens] 
gi|695942218 11632 0.43 immunoglobulin G heavy chain variable region, partial 
[Homo sapiens] 
gi|307751150 21033 0.22 MHC class I antigen [Homo sapiens] 
gi|290560013 11815 0.42 Chain B, Crystal Structure Of Mhc Class I Hla-A2.1 
Bound To A Photocleavable Peptide 
gi|2654661 1795 6.07 T cell receptor beta chain, partial [Homo sapiens] 
gi|63003901 44057 0.1 lymphocyte transmembrane adapter 1 isoform a [Homo 
sapiens] 
gi|499592 12814 0.38 immunoglobulin heavy chain, partial [Homo sapiens] 
gi|1835715 8609 0.6 T cell receptor alpha chain [Homo sapiens] 
gi|304563130 13060 0.37 immunoglobulin gamma 1 heavy chain variable region 
[Homo sapiens] 
gi|432139159 12229 0.4 immunoglobulin heavy chain variable region, partial 
[Homo sapiens] 
gi|519672532 13596 0.36 immunoglobulin A heavy chain variable region, partial 
[Homo sapiens] 
gi|106638 24733 0.19 Ig lambda chain - human 
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gi|674841392 12150 0.41 immunoglobulin heavy chain variable region, partial 
[Homo sapiens] 
gi|7161029 10258 0.5 immunoglobulin heavy chain [Homo sapiens] 
gi|371446172 13557 0.36 immunoglobulin G heavy chain variable region, partial 
[Homo sapiens] 
gi|444738217 5338 1.1 alternative protein LY75 [Homo sapiens] 
gi|11137273 8448 0.62 immunoglobulin heavy chain variable region [Homo 
sapiens] 
gi|371447513 13673 0.36 immunoglobulin G heavy chain variable region, partial 
[Homo sapiens] 
ST 2-4: GPCRs and G-proteins detected 
Accession Mass emPAI Description 
gi|15718763 21642 2.21 GTPase KRas isoform a [Homo sapiens] 
gi|183182 40437 0.37 guanine nucleotide-binding regulatory protein alpha-
inhibitory subunit [Homo sapiens] 
gi|126031531 40084 0.53 Chain A, Crystal Structure Of The Heterodimeric Complex 
Of Human Rgs8 And Activated Gi Alpha 3 
gi|508285 23553 0.43 Rab5c-like protein, similar to Canis familiaris Rab5c protein, 
PIR Accession Number S38625 [Homo sapiens] 
gi|13569962 22157 0.46 ras-related protein Rab-1B [Homo sapiens] 
gi|1174149 23447 0.2 small GTP binding protein Rab7 [Homo sapiens] 
gi|20147713 23971 0.19 Ras family small GTP binding protein RALA [Homo 
sapiens] 
gi|4885287 7314 0.74 guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit 
gamma-5 precursor [Homo sapiens] 
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gi|93279476 22431 0.21 Chain A, 3d Structure Of Inactive Human Rab11b Gtpase 
gi|306785 37320 0.12 G protein beta subunit [Homo sapiens] 
gi|4758988 22663 0.2 ras-related protein Rab-1A isoform 1 [Homo sapiens] 
gi|119603524 83659 0.05 pleckstrin homology domain containing, family G (with 
RhoGef domain) member 4, isoform CRA_b [Homo sapiens] 
gi|7710086 22527 0.21 ras-related protein Rab-10 [Mus musculus] 
gi|38493105 7058 0.77 Chain B, Structure Of A Complex Of The Golgin-245 Grip 
Domain With Arl1 
gi|452085171 98705 0.04 NACHT, LRR and PYD domains-containing protein 6 
isoform 1 [Homo sapiens] 
gi|14276193 26949 0.17 rho GTPase activating protein 8 isoform 2 [Homo sapiens] 
gi|119590272 720673 0.01 obscurin, cytoskeletal calmodulin and titin-interacting 
RhoGEF, isoform CRA_a [Homo sapiens] 
gi|33341670 44729 0.1 FP2461 [Homo sapiens] 
 
ST 2-5: Chaperone proteins detected 
Accession Mass emPAI Description 
 
gi|5729877 70854 0.06 heat shock cognate 71 kDa protein isoform 1 [Homo 
sapiens] 
gi|74722493 47682 0.09 RecName: Full=Putative heat shock protein HSP 90-alpha 
A4; AltName: Full=Heat shock 90 kDa protein 1 alpha-like 
2; AltName: Full=Heat shock protein 90-alpha D; 
Short=Heat shock protein 90Ad [Homo sapiens] 
gi|635576870 15314 0.31 Chain A, Pih1d1/phospho-tel2 Complex 
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gi|165761148 20167 0.23 Chain A, Structure Of E163k Dj-1 
gi|119590562 6589 0.85 heat shock 10kDa protein 1 (chaperonin 10), isoform 
CRA_c [Homo sapiens] 
ST 2-6: Other receptors detected 
Accession Mass emPAI Description 
gi|7243270 102932 0.04 KIAA1436 protein [Homo sapiens] 
gi|4507685 87560 0.05 short transient receptor potential channel 1 isoform 2 
[Homo sapiens] 
gi|46107962 308295 0.01 inositol 1,4,5-trisphosphate receptor type 1 [Homo 
sapiens] 
gi|66267488 38155 0.12 Trace amine associated receptor 5 [Homo sapiens] 
gi|4504237 74776 0.06 semaphorin-7A isoform 1 preproprotein [Homo sapiens] 
gi|371502087 40860 0.11 protein Wnt-5a isoform 2 precursor [Homo sapiens] 
gi|182403 22199 0.21 TB2, partial [Homo sapiens] 
gi|545719854 7768 0.69 Chain A, Crystal Structure Of Bap31 Vded At Acidic Ph 
gi|1502343 160126 0.03 receptor phosphatase PCP-2 [Homo sapiens] 
gi|578804728 50295 0.09 PREDICTED: secretin receptor isoform X2 [Homo 
sapiens] 
ST 2-7: Enzymes detected 
Accession Mass emPAI Description 
gi|73909094 48513 0.09 AADACL1 protein, partial [Homo sapiens] 
gi|30348954 110066 0.04 E3 ubiquitin-protein ligase MIB1 [Homo sapiens] 
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gi|145579851 47479 0.09 Chain A, Structure Of The Mat Domain Of Human Fas With 
Malonyl-Coa 
gi|338827653 9574 0.54 elongation of very long chain fatty acids protein 5 isoform 4 
[Homo sapiens] 
gi|33150814 123549 0.04 adenylyl cyclase type II [Homo sapiens] 
gi|119601999 55892 0.08 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 13, partial [Homo sapiens] 
gi|1916935 34849 0.13 9-cis-retinol specific dehydrogenase [Homo sapiens] 
gi|62897163 53507 0.08 complement component 1, r subcomponent-like precursor 
variant [Homo sapiens] 
gi|30823 82619 0.05 diacylglycerol kinase [Homo sapiens] 
gi|530370531 115588 0.04 PREDICTED: inactive phospholipase C-like protein 1 
isoform X1 [Homo sapiens] 
gi|4504235 28864 0.16 granzyme K precursor [Homo sapiens] 
ST 2-8: Other membrane proteins detected 
Accession Mass emPAI Description 
gi|213512168 148003 0.03 protein FAM205A [Homo sapiens] 
gi|4929553 53130 0.08 CGI-41 protein [Homo sapiens] 
gi|298351848 542265 0.01 RecName: Full=Hemicentin-2; Flags: Precursor [Homo 
sapiens] 
gi|4929220 69777 0.06 colon cancer-associated protein Mic1 [Homo sapiens] 
gi|299578 1653 6.85 urinary gonadotrophin peptide, UGP {N-terminal, PEAK 
1} [human, urine, Peptide Partial, 15 aa] 
gi|116283709 20830 0.22 TCTN1 protein [Homo sapiens] 
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gi|28204822 45420 0.1 EMI domain containing 1 [Homo sapiens] 




ST 3: Proteomics data of plasma membrane protein from 20% POPS nanodiscs 
 
ST 3-1: Total Proteomic Composition 
 
emPAI Percentage 
Structure 44.16 63.65 












GPCRs and g- 
proteins 
7.51 10.82 
Chaperones  0.27 0.39 
Other Receptors 2.05 2.95 
Enzymes 1.54 2.22 
Others 0.58 0.84 
 
 
ST 3-2: Structural proteins detected 
Accession Mass emPAI Description 
gi|11935049 66027 5.55 keratin 1 [Homo sapiens] 
gi|119617035 59859 3.18 keratin 6E, isoform CRA_b [Homo sapiens] 
gi|908790 59962 2.88 keratin type II [Homo sapiens] 
gi|47132620 65393 1.19 keratin, type II cytoskeletal 2 epidermal [Homo sapiens] 
gi|119395754 62340 2.68 keratin, type II cytoskeletal 5 [Homo sapiens] 
gi|167887751 49623 1.17 vimentin variant 3 [Homo sapiens] 
gi|55956899 62027 2.97 keratin, type I cytoskeletal 9 [Homo sapiens] 
gi|1195531 51206 5.27 type I keratin 16 [Homo sapiens] 
gi|119581150 44694 5.12 keratin 14 (epidermolysis bullosa simplex, Dowling-
Meara, Koebner), isoform CRA_b [Homo sapiens] 
gi|118835468 49555 0.54 Keratin 13 [Homo sapiens] 
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gi|119581154 47947 1.23 keratin 17, isoform CRA_a [Homo sapiens] 
gi|4757756 38580 3.19 annexin A2 isoform 2 [Homo sapiens] 
gi|4502101 38690 0.93 annexin A1 [Homo sapiens] 
gi|28336 41786 1.78 mutant beta-actin (beta'-actin) [Homo sapiens] 
gi|63055057 41976 0.66 beta-actin-like protein 2 [Homo sapiens] 
gi|62420916 11548 1.05 actin-like protein [Homo sapiens] 
gi|7656991 53215 0.08 coronin-1C isoform b [Homo sapiens] 
gi|30506 113644 0.12 desmoglein type 1 [Homo sapiens] 
gi|4507729 49875 0.09 tubulin beta-2A chain [Homo sapiens] 
gi|119607750 48591 0.09 fascin homolog 1, actin-bundling protein 
(Strongylocentrotus purpuratus), isoform CRA_a [Homo 
sapiens] 
gi|18652859 216528 0.02 Shroom-related protein [Homo sapiens] 
gi|1020320 14066 0.81 CDM protein [Homo sapiens] 
gi|3891470 14935 0.32 Chain A, Crystal Structure Of Human Galectin-7 In 
Complex With Galactosamine 
gi|10047357 108677 0.04 KIAA1640 protein [Homo sapiens] 
gi|4757944 25792 0.18 CD81 antigen isoform 1 [Homo sapiens] 
gi|5031635 18491 0.25 cofilin-1 [Homo sapiens] 
gi|3560124 162768 0.03 LGMD2B protein [Homo sapiens] 
gi|29801 53563 0.08 CD44E (epithelial form) [Homo sapiens] 
gi|509806 176506 0.02 laminin A3 [Homo sapiens] 
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gi|19923497 108835 0.04 echinoderm microtubule-associated protein-like 4 isoform 
a [Homo sapiens] 
gi|3212355 11064 1.11 Chain A, P11 (s100a10), Ligand Of Annexin Ii 
gi|684936 34017 0.13 peptide with resemblance to the actin family; the actual 
start of the coding region has not been determined, partial 
[Homo sapiens] 
gi|5803106 55361 0.08 myotilin isoform a [Homo sapiens] 
gi|33870359 38753 0.12 RADIL protein [Homo sapiens] 
gi|8926617 86994 0.05 protocadherin beta 9 [Homo sapiens] 
gi|208435559 15686 0.31 Chain A, Structure Of C-Terminal Actin Depolymerizing 
Factor Homology (Adf-H) Domain Of Human Twinfilin-2 
gi|179106 284107 0.02 nonerythroid alpha-spectrin [Homo sapiens] 
gi|4507869 39805 0.11 vasodilator-stimulated phosphoprotein [Homo sapiens] 
gi|14009465 64812 0.07 protocadherin-psi1 [Homo sapiens] 
gi|530377585 446623 0.01 PREDICTED: ankyrin-2 isoform X5 [Homo sapiens] 
gi|20521772 228253 0.02 KIAA1132 protein [Homo sapiens] 
gi|530367826 153588 0.03 PREDICTED: girdin isoform X9 [Homo sapiens] 
gi|257467636 336007 0.01 TPR and ankyrin repeat-containing protein 1 [Homo 
sapiens] 
gi|18032008 174823 0.02 scribble [Homo sapiens] 
gi|190461797 21336 0.22 RecName: Full=Putative ankyrin repeat domain-containing 
protein ENSP00000383069 [Homo sapiens] 
gi|7243015 49905 0.09 KIAA1317 protein [Homo sapiens] 
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gi|38683807 274088 0.02 ankyrin repeat domain-containing protein 17 isoform a 
[Homo sapiens] 
gi|83404899 93103 0.05 KIF19 protein, partial [Homo sapiens] 
gi|19115954 528684 0.01 dynein heavy chain 5, axonemal [Homo sapiens] 
gi|20338988 285056 0.02 myosin heavy chain [Homo sapiens] 
gi|34526505 65730 0.07 FLJ00279 protein [Homo sapiens] 
gi|256222280 217331 0.02 ankyrin repeat domain-containing protein 36A [Homo 
sapiens] 
gi|119631904 739985 0.01 nebulin, isoform CRA_a [Homo sapiens] 
 
ST 3-3: Transport proteins detected 
Accession Mass emPAI Description 
gi|21361181 112824 0.26 sodium/potassium-transporting ATPase subunit alpha-1 
isoform a [Homo sapiens] 
gi|119573123 114151 0.12 ATPase, Na+/K+ transporting, alpha 4 polypeptide, 
isoform CRA_b [Homo sapiens] 
gi|23397696 59022 0.16 copine-1 isoform a [Homo sapiens] 
gi|62087554 56981 0.08 solute carrier family 2 (facilitated glucose transporter), 
member 1 variant [Homo sapiens] 
gi|4505893 16680 0.29 proteolipid protein 2 [Homo sapiens] 
gi|996057 25106 0.18 gp25l2 [Homo sapiens] 
gi|115583685 53909 0.08 monocarboxylate transporter 1 [Homo sapiens] 




gi|40789265 116441 0.04 N-acetyl-beta-glucosaminyl-glycoprotein 4-beta-N-
acetylgalactosaminyltransferase 1 [Homo sapiens] 
gi|61744477 68059 0.13 4F2 cell-surface antigen heavy chain isoform b [Homo 
sapiens] 
gi|578822063 221581 0.02 PREDICTED: exophilin-5 isoform X1 [Homo sapiens] 
gi|14133203 85249 0.05 KIAA0420 [Homo sapiens] 
gi|50083277 135782 0.03 probable phospholipid-transporting ATPase IM [Homo 
sapiens] 
gi|5870893 55736 0.08 sodium-coupled neutral amino acid transporter 3 [Homo 
sapiens] 
 
ST 3-4: Immune complex proteins detected 
Accession Mass emPAI Description 
 
gi|187609338 20107 0.52 Chain A, Crystal Structure Of The Extracellular Portion 
Of Hab18gCD147 
gi|4768677 25839 0.18 kappa 1 immunoglobulin light chain [Homo sapiens] 
gi|732549066 8537 0.61 immunoglobulin heavy chain variable region, partial 
[Homo sapiens] 
gi|969030 13557 0.36 HLA-drb5, partial [Homo sapiens] 
gi|630868148 7893 0.68 immunoglobulin heavy chain variable region, partial 
[Homo sapiens] 
gi|21956310 7087 0.77 immunoglobulin heavy chain variable region [Homo 
sapiens] 




gi|149673883 23520 0.2 immunoglobulin heavy chain [Homo sapiens] 
gi|1235763 13564 0.36 immunoglobulin heavy chain V-D-J region [Homo 
sapiens] 
gi|2895915 5313 1.11 T cell receptor beta chain [Homo sapiens] 
gi|47600789 9215 0.56 immunoglobulin kappa light chain [Homo sapiens] 
gi|46254169 12798 0.39 immunoglobulin heavy chain [Homo sapiens] 
gi|5080756 301609 0.01 Fc gamma BP, partial [Homo sapiens] 
gi|674841392 12150 0.41 immunoglobulin heavy chain variable region, partial 
[Homo sapiens] 
gi|118406063 12843 0.38 immunoglobulin heavy chain variable region [Homo 
sapiens] 
gi|293629988 20840 0.22 MHC class I antigen [Homo sapiens] 
gi|40255157 123355 0.04 leucine-rich repeats and immunoglobulin-like domains 
protein 3 isoform 2 precursor [Homo sapiens] 
gi|298465 2412 3.47 myelin basic protein specific T-cell receptor V beta-D 
beta-J beta, MBP reactive TCR VDJ beta {CDR3 region, 
clone JO(3)}v [human, normal peripheral blood 
lymphocytes, Peptide Partial, 23 aa] 
gi|270053250 12941 0.38 immunoglobulin heavy chain variable region [Homo 
sapiens] 
 
ST 3-5 GPCRs and G-proteins detected 
Accession Mass emPAI Description 
gi|51036603 8001 1.77 guanine nucleotide-binding protein G(I)/G(S)/G(O) 
subunit gamma-12 precursor [Homo sapiens] 
277 
 
gi|18204869 37194 0.12 TUBA1B protein [Homo sapiens] 
gi|183182 40437 0.23 guanine nucleotide-binding regulatory protein alpha-
inhibitory subunit [Homo sapiens] 
gi|327195100 33961 0.28 UBE2L3/KRAS fusion protein [Homo sapiens] 
gi|332205939 17648 0.27 ras-related protein Rab-11A isoform 2 [Homo sapiens] 
gi|550545552 21215 0.49 Chain A, Crystal Structure Of Gdp-bound Rab8:grab 
gi|119620329 28129 0.35 RAB1A, member RAS oncogene family, isoform CRA_f 
[Homo sapiens] 
gi|187281 77555 0.12 M4 protein [Homo sapiens] 
gi|311697329 3564 1.93 KRAS protein [Homo sapiens] 
gi|508285 23553 0.2 Rab5c-like protein, similar to Canis familiaris Rab5c 
protein, PIR Accession Number S38625 [Homo sapiens] 
gi|1174149 23447 0.43 small GTP binding protein Rab7 [Homo sapiens] 
gi|54114933 69033 0.06 DIS3 mitotic control homolog (S. cerevisiae)-like 2 
[Homo sapiens] 
gi|2921705 23947 0.19 olfactory receptor [Homo sapiens] 
gi|4506405 23394 0.2 ras-related protein Ral-B [Homo sapiens] 
gi|7363439 35230 0.13 olfactory receptor 10H1 [Homo sapiens] 
gi|1839517 25621 0.18 RhoE [Homo sapiens] 
gi|434765 74466 0.06 ORF [Homo sapiens] 
gi|5803145 76016 0.06 ralA-binding protein 1 [Homo sapiens] 




gi|46094081 125420 0.03 arf-GAP with SH3 domain, ANK repeat and PH domain-
containing protein 1 isoform 1 [Homo sapiens] 
gi|20147765 21767 0.21 regulator of G protein signalling 14 short variant [Homo 
sapiens] 
gi|14249174 49431 0.09 pleckstrin homology domain-containing family A 
member 8 isoform 3 [Homo sapiens] 
gi|5174617 107622 0.04 nucleotide-binding oligomerization domain-containing 
protein 1 [Homo sapiens] 
 
ST 3-6: Chaperone proteins detected 
Accession Mass emPAI Description 
gi|5729877 70854 0.2 heat shock cognate 71 kDa protein isoform 1 [Homo 
sapiens] 
gi|36796 60356 0.07 t-complex polypeptide 1 [Homo sapiens] 
 
ST 3-7: Other receptors detected 
Accession Mass emPAI Description 
gi|578815882 94485 0.05 PREDICTED: t-SNARE domain-containing protein 1 
isoform X2 [Homo sapiens] 
gi|19743813 88357 0.21 integrin beta-1 isoform 1A precursor [Homo sapiens] 
gi|119610286 18642 0.25 progesterone receptor membrane component 1, isoform 
CRA_b [Homo sapiens] 
gi|116295258 129215 0.1 integrin alpha-2 precursor [Homo sapiens] 
gi|4504533 43540 0.1 5-hydroxytryptamine receptor 1B [Homo sapiens] 
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gi|2655006 99504 0.04 thyroid hormone receptor coactivating protein [Homo 
sapiens] 
gi|440575811 11638 0.43 alternative protein CSF2RB [Homo sapiens] 
gi|1200235 207530 0.02 SEX protein [Homo sapiens] 
gi|182740 38376 0.12 N-formyl peptide receptor [Homo sapiens] 
gi|4894663 35921 0.13 estrogen receptor beta2 splice variant [Homo sapiens] 
gi|5032223 175630 0.02 plexin-C1 precursor [Homo sapiens] 
gi|119626971 10488 0.49 integrin beta 3 binding protein (beta3-endonexin), isoform 
CRA_c [Homo sapiens] 
gi|22651773 87487 0.05 vanilloid receptor like 3 protein splice variant b [Homo 
sapiens] 
gi|338502 123290 0.04 heat-stable enterotoxin receptor [Homo sapiens] 
 
ST 3-8: Enzymes detected 
Accession Mass emPAI Description 
gi|28614 39307 1.14 aldolase A [Homo sapiens] 
gi|181944 108185 0.04 protein-tyrosine kinase [Homo sapiens] 
gi|49457448 47850 0.09 STK24 [Homo sapiens] 
gi|5689457 100533 0.04 KIAA1060 protein [Homo sapiens] 
gi|7019561 116926 0.04 thyrotropin-releasing hormone-degrading ectoenzyme 
[Homo sapiens] 
gi|21361088 43916 0.1 sphingosine kinase 1 isoform 1 [Homo sapiens] 
gi|1730288 67879 0.07 acetolactate synthase homolog [Homo sapiens] 
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gi|2326227 231143 0.02 phosphatidylinositol 4-kinase 230 [Homo sapiens] 
 
ST 3-9: Other membrane proteins detected 
Accession Mass emPAI Description 
 
gi|119607125 183296 0.05 RB1-inducible coiled-coil 1, isoform CRA_a [Homo 
sapiens] 
gi|15055535 49142 0.09 BPI fold-containing family B member 2 precursor [Homo 
sapiens] 
gi|119585838 186945 0.02 ADAM metallopeptidase with thrombospondin type 1 
motif, 9, isoform CRA_a [Homo sapiens] 
gi|14250417 21874 0.21 TMEM223 protein, partial [Homo sapiens] 
gi|28204822 45420 0.1 EMI domain containing 1 [Homo sapiens] 
gi|257153467 75487 0.06 disrupted in schizophrenia 1 protein isoform e [Homo 
sapiens] 
gi|27368080 255664 0.02 retinitis pigmentosa 1-like 1 protein [Homo sapiens] 











ST4: Proteomics data of plasma membrane protein from 20% cholesterol nanodiscs 






Structure 0.78 31.45 




GPCRs and G 
proteins 
0.03 1.21 
Chaperones  0 0.00 












Enzymes 0.56 22.58 
Others 0.3 12.10 
 
ST 4-2: Structural proteins detected 
Accession Mass emPAI Description 
gi|530372454 247138 0.02 PREDICTED: microtubule-associated protein 4 isoform 
X1 [Homo sapiens] 
gi|226437606 58220 0.08 ankyrin repeat domain-containing protein 34C [Homo 
sapiens] 
gi|40788231 180085 0.02 KIAA0373 [Homo sapiens] 
gi|22477169 111219 0.04 CP110 protein [Homo sapiens] 
gi|119621503 18928 0.25 transmembrane protein 18, isoform CRA_b, partial 
[Homo sapiens] 
gi|1763665 21704 0.22 Snk interacting protein 2-28 [Homo sapiens] 
gi|18606111 86511 0.05 Ankyrin repeat domain 5 [Homo sapiens] 
gi|18650666 285075 0.02 myosin-like protein [Homo sapiens] 
gi|87578394 58919 0.08 microtubule-associated protein 2 isoform 5 [Homo 
sapiens] 
 
ST 4-3: Transport proteins detected 
Accession Mass emPAI Description 
gi|179212 81680 0.05 Na+ K+ ATPase alpha subunit, partial [Homo sapiens] 




gi|17511944 118239 0.04 SEC24 family, member C (S. cerevisiae) [Homo sapiens] 
gi|530393639 149887 0.03 PREDICTED: WASH complex subunit FAM21A isoform 
X2 [Homo sapiens] 
 
ST 4-4: Immune complexes detected 
Accession Mass emPAI Description 
gi|323433023 17228 0.28 immunoglobulin variable region [Homo 
sapiens] 
gi|323431585 15902 0.3 immunoglobulin variable region [Homo 
sapiens] 
 
ST 4-5: GPCRs and G proteins detected 
Accession Mass emPAI Description 
gi|27529961 151481 0.03 KIAA1938 protein [Homo 
sapiens] 
 
ST 4-6: Other receptor proteins detected 
Accession Mass emPAI Description 
gi|119588279 129185 0.03 protein tyrosine phosphatase, receptor type, J, isoform 
CRA_a [Homo sapiens] 
gi|2696015 550722 0.01 brain ryanodine receptor [Homo sapiens] 
 
ST 4-7: Enzymes detected 
Accession Mass emPAI Description 
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gi|4885349 67743 0.07 G protein-coupled receptor kinase 5 [Homo sapiens] 
gi|8101079 133254 0.03 FYVE domain-containing dual specificity protein 
phosphatase FYVE-DSP2 [Homo sapiens] 
gi|1109782 65799 0.07 protein-tyrosine phosphatase [Homo sapiens] 
gi|119617002 113726 0.04 ovochymase 1, isoform CRA_b, partial [Homo sapiens] 
gi|5453906 23523 0.2 CDP-diacylglycerol--inositol 3-phosphatidyltransferase 
isoform 1 [Homo sapiens] 
gi|119619352 57781 0.08 protein phosphatase, EF-hand calcium binding domain 1, 
isoform CRA_c [Homo sapiens] 
gi|33186804 63999 0.07 TPA: type II transmembrane serine protease 7 precursor 
[Homo sapiens] 
 
ST 4-8: Other membrane proteins detected 
Accession Mass emPAI Description 
gi|94721250 32593 0.14 vesicle-associated membrane protein-associated protein A 
isoform 1 [Homo sapiens] 
gi|10047317 148334 0.03 KIAA1620 protein [Homo sapiens] 
gi|28204822 45420 0.1 EMI domain containing 1 [Homo sapiens] 








ST5: Proteomics data of plasma membrane protein from 20% POPS+ 8% cholesterol 
nanodiscs 




Structure 21.79 25.98 




GPCRs and G- 
proteins 
36.81 43.89 
Chaperones  0.59 0.70 
Other receptors 2.32 2.77 








Others 0.9 1.07 
 
 
ST 5-2: Structural proteins identified 
Accession Mass emPAI Description 
gi|62414289 53619 6.71 vimentin [Homo sapiens] 
gi|11935049 66027 2.53 keratin 1 [Homo sapiens] 
gi|181402 65825 1.08 epidermal cytokeratin 2 [Homo sapiens] 
gi|119395754 62340 0.42 keratin, type II cytoskeletal 5 [Homo sapiens] 
gi|119617057 57772 0.46 keratin 8, isoform CRA_a [Homo sapiens] 
gi|435476 62092 2.57 cytokeratin 9 [Homo sapiens] 
gi|114431246 50536 0.41 keratin, type I cytoskeletal 28 [Homo sapiens] 
gi|119581150 44694 0.48 keratin 14 (epidermolysis bullosa simplex, Dowling-
Meara, Koebner), isoform CRA_b [Homo sapiens] 
gi|12653819 48003 0.2 Keratin 18 [Homo sapiens] 
gi|114794644 35277 2.44 Chain A, Human Annexin A2 With Heparin 
Tetrasaccharide Bound 
gi|28336 41786 0.69 mutant beta-actin (beta'-actin) [Homo sapiens] 
gi|530421753 67936 0.68 PREDICTED: moesin isoform X2 [Homo sapiens] 
gi|2773160 22941 0.76 neuronal tissue-enriched acidic protein [Homo sapiens] 
gi|5031635 18491 0.26 cofilin-1 [Homo sapiens] 
gi|338695 49727 0.3 beta-tubulin [Homo sapiens] 
gi|6755901 50104 0.09 tubulin alpha-1A chain [Mus musculus] 
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gi|34234 31774 0.15 laminin-binding protein, partial [Homo sapiens] 
gi|62088416 208278 0.02 ankyrin 1 isoform 4 variant [Homo sapiens] 
gi|21281675 96460 0.05 GAS2-like protein 2 [Homo sapiens] 
gi|29801 53563 0.09 CD44E (epithelial form) [Homo sapiens] 
gi|197100396 20444 0.24 myosin regulatory light chain 12A [Pongo abelii] 
gi|6731237 229553 0.02 myoferlin [Homo sapiens] 
gi|530372502 102492 0.04 PREDICTED: microtubule-associated protein 4 isoform 
X23 [Homo sapiens] 
gi|642945631 3992165 0 titin isoform IC [Homo sapiens] 
gi|45331339 29608 0.16 BCR [Homo sapiens] 
gi|4502719 78238 0.06 cadherin-13 isoform 1 preproprotein [Homo sapiens] 
gi|608025 480107 0.01 ankyrin G [Homo sapiens] 
gi|7239696 210642 0.02 myosin light chain kinase [Homo sapiens] 
gi|182258028 45280 0.1 RHD [Homo sapiens] 
gi|3323440 24479 0.19 myosin-IXb splice variant [Homo sapiens] 
gi|32526901 79696 0.06 intraflagellar transport protein 81 homolog isoform 1 
[Homo sapiens] 
gi|528082092 55788 0.08 Chain A, Crystal Structure Of Human Catenin-beta-like 
1 56 Kda Fragment 
gi|5419655 287177 0.02 filamin, muscle isoform [Homo sapiens] 
gi|1790878 306045 0.01 microtubule-associated protein 1a [Homo sapiens] 




gi|767918801 36581 0.13 PREDICTED: LIM and senescent cell antigen-like-
containing domain protein 2 isoform X2 [Homo sapiens] 
gi|188219549 120972 0.04 ankyrin repeat domain-containing protein 32 [Homo 
sapiens] 
gi|578825426 80723 0.06 PREDICTED: fermitin family homolog 2 isoform X1 
[Homo sapiens] 
gi|1000745 162108 0.03 Pro-a2(XI), partial [Homo sapiens] 
gi|119577699 76618 0.06 basal cell adhesion molecule (Lutheran blood group), 
isoform CRA_b [Homo sapiens] 
gi|767984060 150004 0.03 PREDICTED: kinesin-like protein KIF7 isoform X6 
[Homo sapiens] 
 
ST 5-3: Transport proteins identified 
Accession Mass emPAI Description 
gi|21361181 112824 0.12 sodium/potassium-transporting ATPase subunit alpha-1 
isoform a [Homo sapiens] 
gi|1478281 56585 0.26 neutral amino acid transporter B [Homo sapiens] 
gi|5803165 9968 1.32 protein transport protein Sec61 subunit beta [Homo 
sapiens] 
gi|4505893 16680 0.29 proteolipid protein 2 [Homo sapiens] 
gi|177207 57935 0.08 4F2 antigen heavy chain [Homo sapiens] 
gi|5803040 25190 0.19 transmembrane emp24 domain-containing protein 1 
precursor [Homo sapiens] 
gi|119573492 28411 0.17 metaxin 1, isoform CRA_c [Homo sapiens] 
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gi|457879 227770 0.02 voltage-gated sodium channel [Homo sapiens] 
gi|767944882 547785 0.01 PREDICTED: ATP-binding cassette sub-family A member 
13 isoform X6 [Homo sapiens] 
gi|119620095 109696 0.04 solute carrier family 4, sodium bicarbonate cotransporter, 
member 5, isoform CRA_b [Homo sapiens] 
gi|1923268 121146 0.04 AP-3 complex beta3A subunit [Homo sapiens] 
gi|9790143 50300 0.09 P3 protein isoform 1 precursor [Homo sapiens] 
gi|767915110 74789 0.06 PREDICTED: sodium/calcium exchanger 1 isoform X10 
[Homo sapiens] 
 
ST 5-4: Immune complex proteins identified 
Accession Mass emPAI Description 
gi|20146101 29134 0.35 EMMPRIN [Homo sapiens] 
gi|11526609 4177 1.54 Ig heavy chain, partial [Homo sapiens] 
gi|312273829 5398 1.1 TCR, partial [Homo sapiens] 
gi|58221613 12853 0.39 anti-tetanus toxoid immunoglobulin heavy chain variable 
region [Homo sapiens] 
gi|197115768 7786 0.7 immunoglobulin lambda chain variable region [Homo 
sapiens] 
gi|15777368 12168 0.42 immunoglobulin mu heavy chain variable region [Homo 
sapiens] 




gi|15722933 6474 0.89 immunoglobulin lambda chain variable region [Homo 
sapiens] 
gi|3212402 1673 6.85 Chain C, The Structure Of An Intermediate In Class Ii Mhc 
Maturation: Clip Bound To Hla-dr3 
gi|42760403 13053 0.38 immunoglobulin lambda-1 variable region [Homo sapiens] 
gi|281185535 11546 0.44 anti-HIV immunoglobulin light chain variable region 
[Homo sapiens] 
gi|219539 25902 0.18 nonspecific cross-reacting antigen [Homo sapiens] 
gi|897557 177528 0.03 TIAM1 protein [Homo sapiens] 
gi|371447513 13673 0.37 immunoglobulin G heavy chain variable region, partial 
[Homo sapiens] 
gi|323431585 15902 0.31 immunoglobulin variable region [Homo sapiens] 
gi|1633624 20982 0.23 HLA-G, partial [Homo sapiens] 
gi|270054249 12186 0.42 immunoglobulin heavy chain variable region [Homo 
sapiens] 
gi|323431159 15045 0.33 immunoglobulin variable region [Homo sapiens] 
gi|22255307 10042 0.52 pituitary gland specific factor 1b [Homo sapiens] 
gi|4323680 12747 0.39 immunoglobulin heavy chain variable region [Homo 
sapiens] 
gi|323432798 14869 0.33 immunoglobulin variable region [Homo sapiens] 






ST 5-5: GPCRs and G proteins identified 
Accession Mass emPAI Description 
gi|13569962 22157 0.79 ras-related protein Rab-1B [Homo sapiens] 
gi|119620329 28129 0.36 RAB1A, member RAS oncogene family, isoform CRA_f 
[Homo sapiens] 
gi|19923231 23534 2.01 ras-related protein Rab-6A isoform a [Homo sapiens] 
gi|16933567 23653 0.73 ras-related protein Rab-8A [Homo sapiens] 
gi|16758368 23912 0.72 ras-related protein Rab-14 [Rattus norvegicus] 
gi|110591381 19753 1.97 Chain A, The Crystal Structure Of Human Neuronal Rab6b 
In Its Inactive Gdp-bound Form 
gi|1174149 23447 1.09 small GTP binding protein Rab7 [Homo sapiens] 
gi|508285 23553 1.51 Rab5c-like protein, similar to Canis familiaris Rab5c protein, 
PIR Accession Number S38625 [Homo sapiens] 
gi|19923262 23644 0.73 ras-related protein Rab-5A isoform 1 [Homo sapiens] 
gi|3126878 73512 0.35 M4 protein deletion mutant [Homo sapiens] 
gi|4506413 20974 0.85 ras-related protein Rap-1A precursor [Homo sapiens] 
gi|763130 24559 0.7 YPT3 [Homo sapiens] 
gi|51036603 8001 1.82 guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit 
gamma-12 precursor [Homo sapiens] 
gi|183182 40437 0.24 guanine nucleotide-binding regulatory protein alpha-
inhibitory subunit [Homo sapiens] 
gi|190875 21323 0.5 ras-like protein [Homo sapiens] 
gi|6808528 19737 0.24 Rab6-like protein [Homo sapiens] 
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gi|83753568 21521 0.49 Chain A, Crystal Structure Of Human Rab18 In Complex 
With Gppnhp 
gi|4506405 23394 0.74 ras-related protein Ral-B [Homo sapiens] 
gi|20147713 23971 0.72 Ras family small GTP binding protein RALA [Homo 
sapiens] 
gi|306785 37320 0.12 G protein beta subunit [Homo sapiens] 
gi|311697329 3564 1.93 KRAS protein [Homo sapiens] 
gi|186764 21457 0.22 K-ras oncogene protein [Homo sapiens] 
gi|4139784 24393 0.19 Chain A, Canine Gdp-Ran Q69l Mutant 
gi|10190714 21841 0.22 ras-related protein Rab-22A [Homo sapiens] 
gi|21703367 22471 0.21 GTP-binding protein Di-Ras2 [Homo sapiens] 
gi|30749373 20607 0.23 Chain A, Crystal Structure Of A Constitutively Activated 
Rhoa Mutant (Q63l) 
gi|21928356 37181 0.12 seven transmembrane helix receptor [Homo sapiens] 
gi|219867 44452 0.1 HM74 [Homo sapiens] 
gi|62088744 29577 0.16 regulator of G-protein signalling 11 isoform 1 variant [Homo 
sapiens] 
gi|433720 145291 0.03 CDC25 [Homo sapiens] 
gi|3292965 1071 15.8 m1 muscarinic acetylcholine receptor protein [Homo 
sapiens] 
gi|119581051 52736 0.09 Rap guanine nucleotide exchange factor (GEF)-like 1, 
isoform CRA_c [Homo sapiens] 
gi|122920033 54912 0.08 Chain A, Crystal Structure Of Rhogef Protein Asef 
gi|6005794 19246 0.25 PRA1 family protein 2 [Homo sapiens] 
293 
 
gi|3327166 141499 0.03 KIAA0676 protein [Homo sapiens] 
gi|4505187 14010 0.36 C-X-C motif chemokine 9 precursor [Homo sapiens] 
gi|19702127 186116 0.02 P-Rex1 protein [Homo sapiens] 
gi|768024595 49427 0.09 PREDICTED: ral-GDS-related protein isoform X1 [Homo 
sapiens] 
 
ST 5-6: Chaperone proteins detected 
Accession Mass emPAI Description 
gi|119602173 57697 0.35 heat shock protein 90kDa alpha (cytosolic), class A member 
1, isoform CRA_b [Homo sapiens] 
gi|1136741 58465 0.08 KIAA0002 [Homo sapiens] 
gi|671527 60292 0.08 gamma subunit of CCT chaperonin [Homo sapiens] 
gi|5453607 59329 0.08 T-complex protein 1 subunit eta isoform a [Homo sapiens] 
 
ST 5-7: Other receptors identified 
Accession Mass emPAI Description 
gi|19743813 88357 0.28 integrin beta-1 isoform 1A precursor [Homo sapiens] 
gi|124942 129214 0.11 RecName: Full=Integrin alpha-2; AltName: Full=CD49 
antigen-like family member B; AltName: Full=Collagen 
receptor; AltName: Full=Platelet membrane glycoprotein Ia; 
Short=GPIa; AltName: Full=VLA-2 subunit alpha; 
AltName: CD_antigen=CD49b; Flags: Precu 




gi|767927470 56504 0.17 PREDICTED: transferrin receptor protein 1 isoform X1 
[Homo sapiens] 
gi|62087318 166422 0.03 protein tyrosine phosphatase, receptor type, D isoform 4 
precursor variant [Homo sapiens] 
gi|119612685 544418 0.01 ryanodine receptor 3, isoform CRA_d, partial [Homo 
sapiens] 
gi|41406086 89594 0.05 semaphorin-3D precursor [Homo sapiens] 
gi|1632816 17317 0.64 C-Type lectin [Homo sapiens] 
gi|30410880 125355 0.04 CD163 molecule [Homo sapiens] 
gi|2337920 29827 0.16 syntaxin 7 [Homo sapiens] 
gi|339570 64498 0.07 TGF-beta type II receptor [Homo sapiens] 
    
 
ST 5-8: Enzymes detected 
Accession Mass emPAI Description 
gi|22209028 31786 0.32 Thioredoxin-related transmembrane protein 1 [Homo 
sapiens] 
gi|7243107 48042 0.1 KIAA1363 protein [Homo sapiens] 
gi|1617312 72592 0.13 UDP-GalNAc:polypeptide N-
acetylgalactosaminyltransferase (GalNAc-T3) [Homo 
sapiens] 
gi|152149137 11017 0.47 Chain A, Crystal Structure Of Pdz Domain Of Synaptojanin-
2 Binding Protein 
gi|4826932 40738 0.11 peptidyl-prolyl cis-trans isomerase D [Homo sapiens] 
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gi|4506529 63485 0.07 rhodopsin kinase [Homo sapiens] 
gi|641389703 64465 0.07 Chain A, Phosphatidylinositol 4-kinase Iii Beta-pik93 In A 
Complex With Rab11a-gtp Gammas 
gi|58082081 84205 0.05 phosphoinositide 3-kinase regulatory subunit 6 isoform 1 
[Homo sapiens] 
gi|118573093 124985 0.04 RecName: Full=Ovochymase-1; Flags: Precursor [Homo 
sapiens] 
gi|4885583 158076 0.03 rho-associated protein kinase 1 [Homo sapiens] 
gi|1572645 9693 0.54 protein tyrosine phosphatase PEP, partial [Homo sapiens] 
 
ST 5-9: Other membrane proteins identified 
Accession Mass emPAI Description 
gi|119594185 36338 0.27 thioredoxin domain containing 14, isoform CRA_c [Homo 
sapiens] 
gi|2465729 24642 0.19 TFAR15 [Homo sapiens] 
gi|20521764 207178 0.02 KIAA1096 protein [Homo sapiens] 
gi|33340133 79767 0.06 La binding protein 1 [Homo sapiens] 
gi|46094081 125420 0.04 arf-GAP with SH3 domain, ANK repeat and PH domain-
containing protein 1 isoform 1 [Homo sapiens] 
gi|119600030 44772 0.1 GRAM domain containing 1C, isoform CRA_d [Homo 
sapiens] 
gi|349587565 40057 0.12 Chain A, The Dodecameric Human Ruvbl1:ruvbl2 Complex 
With Truncated Domains Ii 
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gi|530411601 84186 0.05 PREDICTED: AP-4 complex accessory subunit tepsin 
isoform X2 [Homo sapiens] 





















APPENDIX D: TABLES OF LIPIDS IDENTIFIED BY HIGH 
THROUGHPUT LIPIDOMICS OF FOB, HOS AND 143B CELL LINES 









Cer(d18:1/10:0)+H  0.002  ±  0.000  0.001  ±  0.000  0.001  ±  0.000 
Cer(d18:0/12:0)+H  0.002  ±  0.000  0.002  ±  0.000  0.001  ±  0.000 
 
0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
Cer(d18:1/13:0)+H  0.001  ±  0.000  0.001  ±  0.000  0.001  ±  0.001 
Cer(d18:0/14:0)+H  0.002  ±  0.000  0.001  ±  0.000  0.003  ±  0.001 
Cer(d18:1/14:0)+H  0.027  ±  0.006  0.006  ±  0.000  0.003  ±  0.001 
Cer(d17:1/16:0)+H  0.006  ±  0.001  0.001  ±  0.000  0.002  ±  0.001 
Cer(d18:0/16:0)+H  0.003  ±  0.001  0.001  ±  0.000  0.017  ±  0.015 
Cer(d18:1/16:0)+H  0.162  ±  0.047  0.027  ±  0.001  0.022  ±  0.012 
Cer(d34:1)+H  0.002  ±  0.000  0.001  ±  0.000  0.001  ±  0.001 
Cer(d18:2/16:0)+H  0.016  ±  0.005  0.003  ±  0.000  0.001  ±  0.001 
Cer(d18:0/17:0)+H  0.001  ±  0.000  0.001  ±  0.000  0.000  ±  0.000 
Cer(d18:1/17:0)+H  0.009  ±  0.002  0.002  ±  0.000  0.001  ±  0.001 
Cer(d18:0/18:0)+H  0.003  ±  0.000  0.004  ±  0.000  0.002  ±  0.001 
Cer(d18:1/18:0)+H  0.021  ±  0.004  0.008  ±  0.000  0.002  ±  0.001 
Cer(d36:1)+H  0.002  ±  0.000  0.001  ±  0.000  0.000  ±  0.000 
Cer(d18:2/18:0)+H  0.002  ±  0.001  0.000  ±  0.000  0.001  ±  0.001 
Cer(d18:0/20:0)+H  0.002  ±  0.000  0.002  ±  0.000  0.001  ±  0.000 
Cer(d18:1/20:0)+H  0.007  ±  0.001  0.003  ±  0.000  0.001  ±  0.000 
Cer(d38:1)+H  0.001  ±  0.000  0.001  ±  0.000  0.000  ±  0.000 
Cer(d17:1/22:0)+H  0.003  ±  0.000  0.001  ±  0.000  0.000  ±  0.000 
Cer(d40:0)+H  0.001  ±  0.001  0.000  ±  0.000  0.007  ±  0.006 
Cer(d18:0/22:0)+H  0.005  ±  0.001  0.010  ±  0.001  0.007  ±  0.003 
Cer(d18:0/22:1)+H  0.001  ±  0.000  0.001  ±  0.000  0.005  ±  0.004 
Cer(d18:1/22:0)+H  0.055  ±  0.014  0.016  ±  0.001  0.006  ±  0.003 
Cer(d18:2/22:0)+H  0.014  ±  0.005  0.003  ±  0.000  0.001  ±  0.000 
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Cer(d18:0/23:0)+H  0.001  ±  0.000  0.001  ±  0.000  0.001  ±  0.000 
Cer(d18:0/23:1)+H  0.001  ±  0.000  0.001  ±  0.000  0.002  ±  0.001 
Cer(d18:1/23:0)+H  0.013  ±  0.003  0.003  ±  0.000  0.002  ±  0.000 
Cer(d18:2/23:0)+H  0.012  ±  0.003  0.002  ±  0.000  0.034  ±  0.033 
Cer(d18:0/24:0)+H  0.006  ±  0.001  0.022  ±  0.002  0.037  ±  0.020 
Cer(d18:1/24:0)+H  0.001  ±  0.000  0.000  ±  0.000  0.012  ±  0.012 
Cer(d18:0/24:1)+H  0.008  ±  0.002  0.011  ±  0.001  0.040  ±  0.020 
Cer(d18:1/24:0)+H  0.101  ±  0.028  0.051  ±  0.004  0.047  ±  0.008 
Cer(d18:1/24:1)+H  0.145  ±  0.049  0.038  ±  0.006  0.020  ±  0.010 
Cer(d18:2/24:0)+H  0.007  ±  0.002  0.001  ±  0.000  0.002  ±  0.001 
Cer(d18:2/24:1)+H  0.038  ±  0.011  0.008  ±  0.001  0.002  ±  0.001 
Cer(d18:1/24:2)+H  0.002  ±  0.000  0.003  ±  0.000  0.002  ±  0.000 
Cer(d18:1/24:3)+H  0.010  ±  0.001  0.007  ±  0.000  0.002  ±  0.000 
Cer(d18:0/25:0)+H  0.001  ±  0.000  0.001  ±  0.000  0.001  ±  0.000 
Cer(d18:0/25:1)+H  0.000  ±  0.000  0.000  ±  0.000  0.002  ±  0.001 
Cer(d18:1/25:0)+H  0.004  ±  0.001  0.002  ±  0.000  0.002  ±  0.000 
Cer(d18:1/25:1)+H  0.006  ±  0.002  0.002  ±  0.000  0.001  ±  0.000 
Cer(d18:2/25:1)+H  0.004  ±  0.001  0.001  ±  0.000  0.009  ±  0.009 
Cer(d18:0/26:0)+H  0.001  ±  0.000  0.005  ±  0.001  0.014  ±  0.002 
Cer(d18:0/26:1)+H  0.001  ±  0.000  0.001  ±  0.000  0.013  ±  0.007 
Cer(d18:1/26:0)+H  0.007  ±  0.002  0.006  ±  0.001  0.010  ±  0.005 
Cer(d18:2/26:0)+H  0.001  ±  0.000  0.001  ±  0.000  0.006  ±  0.005 
Cer(d18:1/26:1)+H  0.017  ±  0.006  0.005  ±  0.000  0.008  ±  0.003 
Cer(d18:2/26:1)+H  0.009  ±  0.003  0.002  ±  0.000  0.001  ±  0.000 
Cer(d18:1/26:3)+H  0.002  ±  0.001  0.000  ±  0.000  0.000  ±  0.000 
Cer(d20:0/25:0)+H  0.001  ±  0.000  0.002  ±  0.001  0.001  ±  0.000 
Cer(d18:1/27:0)+H  0.000  ±  0.000  0.001  ±  0.001  0.001  ±  0.000 
Cer(d20:0/26:0)+H  0.001  ±  0.000  0.003  ±  0.002  0.001  ±  0.000 
Cer(d18:0/28:1)+H  0.000  ±  0.000  0.000  ±  0.000  0.001  ±  0.000 
Cer(d18:1/28:0)+H  0.001  ±  0.000  0.002  ±  0.001  0.001  ±  0.000 
Cer(d18:1/28:1)+H  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
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Cer(d22:1/24:1)+H  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
Cer(d22:0/25:0)+H  0.001  ±  0.000  0.003  ±  0.002  0.000  ±  0.000 
Cer(d20:1/27:0)+H  0.000  ±  0.000  0.001  ±  0.001  0.000  ±  0.000 
Cer(d22:1/25:1)+H  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
Cer(d24:0/24:0)+H  0.001  ±  0.000  0.005  ±  0.004  0.001  ±  0.000 
Cer(d20:1/28:0)+H  0.000  ±  0.000  0.002  ±  0.002  0.000  ±  0.000 
Cer(d20:2/28:0)+H  0.000  ±  0.000  0.001  ±  0.001  0.000  ±  0.000 
Cer(d25:0/24:0)+H  0.000  ±  0.000  0.003  ±  0.002  0.000  ±  0.000 
Cer(d22:1/27:0)+H  0.000  ±  0.000  0.001  ±  0.001  0.000  ±  0.000 
Cer(d24:0/26:0)+H  0.001  ±  0.000  0.003  ±  0.003  0.000  ±  0.000 
Cer(d22:1/28:0)+H  0.000  ±  0.000  0.002  ±  0.001  0.000  ±  0.000 
Cer(d25:0/26:0)+H  0.000  ±  0.000  0.001  ±  0.001  0.000  ±  0.000 
Cer(d22:1/29:0)+H  0.000  ±  0.000  0.001  ±  0.001  0.000  ±  0.000 
Cer(d22:1/30:0)+H  0.000  ±  0.000  0.001  ±  0.001  0.000  ±  0.000 
Cer(d25:0/28:0)+H  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
CerG1(d18:0/14:0)+H  0.001  ±  0.000  0.000  ±  0.000  0.002  ±  0.001 
CerG1(d18:1/14:0)+H  0.021  ±  0.007  0.001  ±  0.000  0.002  ±  0.000 
CerG1(d17:1/16:0)+H  0.008  ±  0.002  0.001  ±  0.000  0.013  ±  0.012 
CerG1(d18:0/16:0)+H  0.027  ±  0.007  0.013  ±  0.001  0.048  ±  0.027 
CerG1(d18:1/16:0)+H  0.446  ±  0.116  0.047  ±  0.007  0.043  ±  0.020 
CerG1(d18:2/16:0)+H  0.007  ±  0.002  0.002  ±  0.000  0.002  ±  0.000 
CerG1(d18:1/17:0)+H  0.018  ±  0.004  0.002  ±  0.000  0.002  ±  0.001 
CerG1(d18:1/18:0)+H  0.029  ±  0.004  0.011  ±  0.000  0.002  ±  0.001 
CerG1(d18:0/20:0)+H  0.001  ±  0.000  0.002  ±  0.000  0.001  ±  0.001 
CerG1(d18:1/20:0)+H  0.009  ±  0.001  0.005  ±  0.000  0.005  ±  0.004 
CerG1(d18:0/22:0)+H  0.006  ±  0.002  0.008  ±  0.000  0.012  ±  0.005 
CerG1(d18:1/22:0)+H  0.083  ±  0.018  0.020  ±  0.001  0.007  ±  0.003 
CerG1(d18:1/22:1)+H  0.012  ±  0.002  0.003  ±  0.000  0.001  ±  0.000 
CerG1(d18:0/23:0)+H  0.001  ±  0.000  0.000  ±  0.000  0.003  ±  0.003 
CerG1(d18:1/23:0)+H  0.024  ±  0.007  0.003  ±  0.000  0.003  ±  0.001 
CerG1(d18:1/23:1)+H  0.010  ±  0.003  0.002  ±  0.000  0.014  ±  0.014 
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CerG1(d18:0/24:0)+H  0.007  ±  0.002  0.005  ±  0.000  0.018  ±  0.001 
CerG1(d18:0/24:1)+H  0.005  ±  0.001  0.005  ±  0.000  0.060  ±  0.051 
CerG1(d18:1/24:0)+H  0.286  ±  0.110  0.031  ±  0.002  0.065  ±  0.005 
CerG1(d18:1/24:1)+H  0.140  ±  0.048  0.024  ±  0.003  0.021  ±  0.008 
CerG1(d18:2/24:1)+H  0.021  ±  0.006  0.005  ±  0.001  0.002  ±  0.001 
CerG1(d18:0/25:0)+H  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
CerG1(d18:1/25:0)+H  0.002  ±  0.001  0.000  ±  0.000  0.001  ±  0.000 
CerG1(d18:1/25:1)+H  0.007  ±  0.002  0.001  ±  0.000  0.002  ±  0.001 
CerG1(d18:0/26:0)+H  0.000  ±  0.000  0.000  ±  0.000  0.002  ±  0.000 
CerG1(d18:0/26:1)+H  0.001  ±  0.000  0.000  ±  0.000  0.008  ±  0.006 
CerG1(d18:1/26:0)+H  0.012  ±  0.005  0.002  ±  0.000  0.012  ±  0.002 
CerG1(d18:1/26:1)+H  0.023  ±  0.010  0.002  ±  0.000  0.005  ±  0.003 
CerG1(d44:4)+H  0.002  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
CerG1(d46:1)+H  0.000  ±  0.000  0.000  ±  0.000  0.006  ±  0.006 
CerG2(d18:1/16:0)+H  0.028  ±  0.010  0.008  ±  0.004  0.006  ±  0.003 
CerG2(d34:2)+H  0.002  ±  0.001  0.002  ±  0.000  0.002  ±  0.002 
CerG2(d18:1/22:0)+H  0.010  ±  0.002  0.007  ±  0.000  0.002  ±  0.001 
CerG2(d18:1/22:1)+H  0.002  ±  0.000  0.002  ±  0.000  0.000  ±  0.000 
CerG2(d18:1/23:0)+H  0.002  ±  0.001  0.001  ±  0.000  0.000  ±  0.000 
CerG2(d18:1/23:1)+H  0.002  ±  0.001  0.001  ±  0.000  0.001  ±  0.001 
CerG2(d18:0/24:1)+H  0.001  ±  0.000  0.001  ±  0.000  0.009  ±  0.007 
CerG2(d18:1/24:0)+H  0.018  ±  0.007  0.004  ±  0.000  0.012  ±  0.002 
CerG2(d18:1/24:1)+H  0.018  ±  0.005  0.009  ±  0.001  0.006  ±  0.003 
CerG2(d18:2/24:1)+H  0.004  ±  0.001  0.002  ±  0.000  0.001  ±  0.000 
CerG2(d18:1/25:0)+H  0.001  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
CerG2(d43:2)+H  0.001  ±  0.000  0.000  ±  0.000  0.001  ±  0.001 
CerG2(d18:1/26:0)+H  0.001  ±  0.000  0.000  ±  0.000  0.002  ±  0.000 
CerG2(d18:1/26:1)+H  0.002  ±  0.001  0.001  ±  0.000  0.001  ±  0.000 
CerG3(d18:1/14:0)+H  0.001  ±  0.000  0.000  ±  0.000  0.001  ±  0.001 
CerG3(d18:1/16:0)+H  0.015  ±  0.004  0.002  ±  0.000  0.001  ±  0.000 
CerG3(d18:1/22:0)+H  0.005  ±  0.001  0.001  ±  0.000  0.000  ±  0.000 
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CerG3(d18:1/23:0)+H  0.001  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
CerG3(d18:1/24:0)+H  0.008  ±  0.003  0.001  ±  0.000  0.001  ±  0.000 
CerG3(d18:1/24:1)+H  0.010  ±  0.003  0.002  ±  0.000  0.000  ±  0.000 
CerG3(d18:2/24:1)+H  0.002  ±  0.001  0.000  ±  0.000  0.000  ±  0.000 
CerG3(d18:1/26:0)+H  0.001  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
CerG3(d18:1/26:1)+H  0.001  ±  0.000  0.000  ±  0.000  0.373  ±  0.373 
 
 









ChE(18:1)+NH4  0.047  ±  0.012  0.013  ±  0.001  0.007  ±  0.002 
ChE(18:2)+NH4  0.030  ±  0.006  0.006  ±  0.001  0.005  ±  0.001 
ChE(20:1)+NH4  0.005  ±  0.002  0.003  ±  0.000  0.001  ±  0.000 
ChE(20:2)+NH4  0.014  ±  0.006  0.010  ±  0.001  0.001  ±  0.000 
ChE(20:3)+NH4  0.043  ±  0.011  0.031  ±  0.003  0.002  ±  0.000 
ChE(20:4)+NH4  0.075  ±  0.012  0.052  ±  0.005  0.007  ±  0.001 
ChE(20:5)+NH4  0.030  ±  0.007  0.022  ±  0.002  0.003  ±  0.001 
ChE(22:1)+NH4  0.002  ±  0.001  0.002  ±  0.000  0.000  ±  0.000 
ChE(22:2)+NH4  0.005  ±  0.002  0.004  ±  0.001  0.000  ±  0.000 
ChE(22:3)+NH4  0.015  ±  0.005  0.024  ±  0.004  0.001  ±  0.000 
ChE(22:4)+NH4  0.031  ±  0.005  0.174  ±  0.018  0.001  ±  0.000 
ChE(22:5)+NH4  0.079  ±  0.019  0.125  ±  0.009  0.005  ±  0.001 
ChE(22:6)+NH4  0.325  ±  0.121  0.430  ±  0.067  0.032  ±  0.009 
ChE(24:1)+NH4  0.005  ±  0.002  0.002  ±  0.000  0.002  ±  0.001 
ChE(24:3)+NH4  0.014  ±  0.006  0.016  ±  0.003  0.001  ±  0.000 
ChE(24:4)+NH4  0.025  ±  0.008  0.073  ±  0.013  0.001  ±  0.000 
ChE(24:5)+NH4  0.042  ±  0.015  0.135  ±  0.020  0.002  ±  0.001 
ChE(24:6)+NH4  0.074  ±  0.032  0.127  ±  0.021  0.003  ±  0.001 
ChE(26:0)+NH4  0.001  ±  0.000  0.000  ±  0.000  0.004  ±  0.001 
ChE(26:1)+NH4  0.010  ±  0.005  0.001  ±  0.000  0.008  ±  0.002 
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ChE(26:2)+NH4  0.009  ±  0.005  0.004  ±  0.001  0.006  ±  0.001 
ChE(26:3)+NH4  0.020  ±  0.009  0.011  ±  0.001  0.002  ±  0.000 
ChE(26:4)+NH4  0.036  ±  0.016  0.028  ±  0.004  0.002  ±  0.000 
ChE(26:5)+NH4  0.119  ±  0.050  0.100  ±  0.019  0.004  ±  0.001 
ChE(26:6)+NH4  0.193  ±  0.088  0.076  ±  0.012  0.005  ±  0.001 
ChE(28:1)+NH4  0.001  ±  0.001  0.000  ±  0.000  0.003  ±  0.001 
ChE(28:2)+NH4  0.002  ±  0.001  0.000  ±  0.000  0.001  ±  0.000 
ChE(28:3)+NH4  0.003  ±  0.002  0.001  ±  0.000  0.001  ±  0.000 
ChE(28:4)+NH4  0.006  ±  0.003  0.003  ±  0.000  0.000  ±  0.000 
ChE(28:5)+NH4  0.031  ±  0.014  0.028  ±  0.004  0.001  ±  0.000 
ChE(28:6)+NH4  0.059  ±  0.028  0.017  ±  0.002  0.002  ±  0.000 
ChE(30:1)+NH4  0.000  ±  0.000  0.000  ±  0.000  0.001  ±  0.000 
ChE(30:3)+NH4  0.001  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
ChE(30:4)+NH4  0.001  ±  0.001  0.001  ±  0.000  0.000  ±  0.000 
ChE(30:5)+NH4  0.007  ±  0.003  0.010  ±  0.001  0.001  ±  0.000 
ChE(30:6)+NH4  0.025  ±  0.012  0.010  ±  0.001  0.002  ±  0.000 
ChE(32:5)+NH4  0.002  ±  0.001  0.001  ±  0.000  0.001  ±  0.000 
ChE(32:6)+NH4  0.007  ±  0.003  0.003  ±  0.000  0.002  ±  0.000 
 









CL(14:0/16:0/16:0/16:0)‐H  0.000  ±  0.000  0.001  ±  0.000  0.000  ±  0.000 
CL(14:0/16:0/16:1/16:0)‐H  0.000  ±  0.000  0.003  ±  0.000  0.001  ±  0.000 
CL(14:0/14:0/18:1/16:1)‐H  0.000  ±  0.000  0.001  ±  0.000  0.002  ±  0.000 
CL(14:0/16:1/16:1/16:1)‐H  0.001  ±  0.000  0.000  ±  0.000  0.002  ±  0.000 
CL(16:0/16:0/16:0/16:0)‐H  0.000  ±  0.000  0.003  ±  0.000  0.000  ±  0.000 
CL(14:0/16:0/16:0/18:1)‐H  0.000  ±  0.000  0.013  ±  0.003  0.002  ±  0.001 
CL(14:0/18:1/16:0/16:1)‐H  0.001  ±  0.000  0.006  ±  0.001  0.006  ±  0.001 
CL(14:0/16:1/16:1/18:1)‐H  0.003  ±  0.001  0.001  ±  0.000  0.008  ±  0.002 
CL(16:1/16:1/16:1/16:1)‐H  0.003  ±  0.002  0.000  ±  0.000  0.004  ±  0.001 
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CL(15:0/16:0/16:0/18:1)‐H  0.000  ±  0.000  0.004  ±  0.001  0.000  ±  0.000 
CL(14:0/15:0/18:1/18:1)‐H  0.000  ±  0.000  0.003  ±  0.001  0.001  ±  0.000 
CL(17:1/14:0/18:1/16:1)‐H  0.001  ±  0.000  0.001  ±  0.000  0.001  ±  0.000 
CL(17:1/16:1/16:1/16:1)‐H  0.001  ±  0.001  0.000  ±  0.000  0.001  ±  0.000 
CL(16:0/16:0/16:0/18:0)‐H  0.000  ±  0.000  0.002  ±  0.000  0.000  ±  0.000 
CL(18:1/16:0/16:0/16:0)‐H  0.000  ±  0.000  0.050  ±  0.007  0.002  ±  0.001 
CL(14:0/18:1/16:0/18:1)‐H  0.003  ±  0.001  0.050  ±  0.010  0.013  ±  0.003 
CL(18:1/16:1/16:0/16:1)‐H  0.006  ±  0.003  0.009  ±  0.002  0.021  ±  0.006 
CL(16:1/16:1/16:1/18:1)‐H  0.013  ±  0.006  0.004  ±  0.001  0.023  ±  0.006 
CL(18:3/14:0/16:0/18:1)‐H  0.000  ±  0.000  0.003  ±  0.000  0.001  ±  0.000 
CL(18:2/16:1/16:1/16:1)‐H  0.004  ±  0.002  0.002  ±  0.000  0.005  ±  0.001 
CL(12:2/18:1/18:1/18:1)‐H  0.000  ±  0.000  0.001  ±  0.000  0.001  ±  0.000 
CL(22:5/14:0/16:1/14:0)‐H  0.001  ±  0.000  0.000  ±  0.000  0.002  ±  0.000 
CL(18:4/16:1/16:1/16:1)‐H  0.001  ±  0.000  0.000  ±  0.000  0.001  ±  0.000 
CL(17:0/16:0/16:0/18:1)‐H  0.000  ±  0.000  0.006  ±  0.001  0.000  ±  0.000 
CL(18:1/16:0/18:1/15:0)‐H  0.001  ±  0.000  0.021  ±  0.004  0.001  ±  0.000 
CL(17:1/16:0/16:1/18:1)‐H  0.002  ±  0.000  0.005  ±  0.001  0.003  ±  0.001 
CL(17:1/16:1/16:1/18:1)‐H  0.004  ±  0.002  0.003  ±  0.000  0.004  ±  0.001 
CL(17:1/16:1/18:2/16:1)‐H  0.001  ±  0.001  0.001  ±  0.000  0.001  ±  0.000 
CL(16:0/16:0/16:0/20:0)‐H  0.000  ±  0.000  0.002  ±  0.000  0.000  ±  0.000 
CL(18:1/16:0/18:0/16:0)‐H  0.000  ±  0.000  0.029  ±  0.005  0.001  ±  0.000 
CL(18:1/16:0/16:0/18:1)‐H  0.005  ±  0.001  0.297  ±  0.046  0.026  ±  0.006 
CL(18:1/16:0/16:1/18:1)‐H  0.011  ±  0.003  0.069  ±  0.014  0.036  ±  0.008 
CL(18:1/16:1/18:2/16:0)‐H  0.029  ±  0.011  0.019  ±  0.003  0.063  ±  0.018 
CL(18:3/16:0/16:0/18:1)‐H  0.001  ±  0.000  0.004  ±  0.001  0.001  ±  0.000 
CL(18:3/18:1/16:0/16:0)‐H  0.000  ±  0.000  0.008  ±  0.001  0.001  ±  0.000 
CL(18:2/16:1/18:1/16:1)‐H  0.019  ±  0.008  0.013  ±  0.003  0.027  ±  0.007 
CL(20:4/16:0/14:0/18:1)‐H  0.001  ±  0.000  0.010  ±  0.002  0.002  ±  0.000 
CL(18:2/16:1/18:2/16:1)‐H  0.004  ±  0.002  0.003  ±  0.001  0.003  ±  0.001 
CL(18:4/16:0/16:1/18:1)‐H  0.002  ±  0.001  0.002  ±  0.001  0.004  ±  0.001 
CL(20:4/16:1/16:1/16:1)‐H  0.001  ±  0.001  0.000  ±  0.000  0.001  ±  0.000 
304 
 
CL(18:4/16:1/16:1/18:1)‐H  0.003  ±  0.002  0.001  ±  0.000  0.005  ±  0.001 
CL(18:4/16:1/18:2/16:1)‐H  0.001  ±  0.001  0.000  ±  0.000  0.001  ±  0.000 
CL(17:0/18:1/18:1/16:0)‐H  0.001  ±  0.000  0.023  ±  0.004  0.001  ±  0.000 
CL(17:1/18:1/16:0/18:1)‐H  0.002  ±  0.000  0.018  ±  0.004  0.004  ±  0.001 
CL(17:1/18:1/16:1/18:1)‐H  0.006  ±  0.002  0.008  ±  0.002  0.009  ±  0.002 
CL(18:1/15:1/18:1/18:1)‐H  0.000  ±  0.000  0.001  ±  0.000  0.000  ±  0.000 
CL(17:1/16:1/18:2/18:1)‐H  0.005  ±  0.002  0.006  ±  0.001  0.004  ±  0.001 
CL(18:3/18:1/15:0/18:1)‐H  0.000  ±  0.000  0.005  ±  0.001  0.000  ±  0.000 
CL(17:1/16:1/18:2/18:2)‐H  0.001  ±  0.000  0.002  ±  0.000  0.000  ±  0.000 
CL(17:1/16:1/16:1/20:4)‐H  0.001  ±  0.000  0.001  ±  0.000  0.001  ±  0.000 
CL(18:1/16:0/18:0/18:0)‐H  0.001  ±  0.001  0.001  ±  0.000  0.005  ±  0.001 
CL(18:1/16:0/18:0/18:1)‐H  0.002  ±  0.000  0.095  ±  0.017  0.004  ±  0.001 
CL(18:1/16:0/18:1/18:1)‐H  0.009  ±  0.002  0.238  ±  0.036  0.022  ±  0.005 
CL(18:1/16:1/18:1/18:1)‐H  0.029  ±  0.009  0.055  ±  0.011  0.056  ±  0.013 
CL(18:3/18:1/16:0/18:0)‐H  0.000  ±  0.000  0.007  ±  0.001  0.000  ±  0.000 
CL(18:2/18:1/16:1/18:1)‐H  0.032  ±  0.009  0.041  ±  0.007  0.056  ±  0.015 
CL(18:3/18:1/16:0/18:1)‐H  0.001  ±  0.000  0.039  ±  0.005  0.006  ±  0.001 
CL(18:2/16:1/18:1/18:2)‐H  0.016  ±  0.005  0.025  ±  0.005  0.014  ±  0.004 
CL(18:2/18:2/16:1/18:1)‐H  0.003  ±  0.001  0.017  ±  0.003  0.007  ±  0.001 
CL(18:2/18:2/18:2/16:1)‐H  0.003  ±  0.001  0.005  ±  0.001  0.002  ±  0.001 
CL(20:4/16:1/16:1/18:1)‐H  0.004  ±  0.001  0.003  ±  0.000  0.003  ±  0.001 
CL(20:4/16:1/18:1/16:1)‐H  0.008  ±  0.003  0.005  ±  0.001  0.011  ±  0.002 
CL(22:5/16:1/16:1/16:1)‐H  0.001  ±  0.000  0.001  ±  0.000  0.001  ±  0.000 
CL(18:2/20:4/16:1/16:1)‐H  0.005  ±  0.002  0.003  ±  0.001  0.006  ±  0.001 
CL(20:5/16:1/16:1/18:2)‐H  0.001  ±  0.000  0.001  ±  0.000  0.001  ±  0.000 
CL(17:0/18:1/18:0/18:1)‐H  0.000  ±  0.000  0.005  ±  0.001  0.000  ±  0.000 
CL(17:0/18:1/18:1/18:1)‐H  0.001  ±  0.000  0.011  ±  0.002  0.001  ±  0.000 
CL(17:1/18:1/18:1/18:1)‐H  0.005  ±  0.001  0.008  ±  0.001  0.005  ±  0.001 
CL(17:1/18:1/18:2/18:1)‐H  0.005  ±  0.001  0.010  ±  0.002  0.005  ±  0.001 
CL(17:0/20:4/16:0/18:1)‐H  0.000  ±  0.000  0.005  ±  0.001  0.000  ±  0.000 
CL(17:1/18:1/18:2/18:2)‐H  0.003  ±  0.001  0.006  ±  0.001  0.001  ±  0.000 
305 
 
CL(17:0/18:2/18:2/18:2)‐H  0.001  ±  0.000  0.001  ±  0.000  0.001  ±  0.000 
CL(17:1/20:4/16:0/18:1)‐H  0.001  ±  0.000  0.004  ±  0.001  0.001  ±  0.000 
CL(17:1/18:2/18:2/18:2)‐H  0.001  ±  0.000  0.001  ±  0.000  0.001  ±  0.000 
CL(17:1/20:4/16:1/18:1)‐H  0.002  ±  0.001  0.002  ±  0.000  0.002  ±  0.000 
CL(17:1/16:1/20:4/18:2)‐H  0.001  ±  0.000  0.001  ±  0.000  0.001  ±  0.000 
CL(16:0/18:0/18:0/20:0)‐H  0.000  ±  0.000  0.002  ±  0.000  0.001  ±  0.000 
CL(18:4/18:2/18:2/18:2)‐H  0.001  ±  0.000  0.001  ±  0.000  0.000  ±  0.000 
CL(18:1/18:0/18:0/18:1)‐H  0.005  ±  0.002  0.002  ±  0.000  0.013  ±  0.003 
CL(18:1/18:0/18:1/18:1)‐H  0.002  ±  0.000  0.037  ±  0.007  0.002  ±  0.001 
CL(18:1/18:1/18:1/18:1)‐H  0.012  ±  0.002  0.058  ±  0.009  0.016  ±  0.004 
CL(18:2/18:1/18:1/18:1)‐H  0.021  ±  0.002  0.038  ±  0.008  0.027  ±  0.006 
CL(20:4/16:0/18:0/18:1)‐H  0.001  ±  0.000  0.021  ±  0.003  0.001  ±  0.000 
CL(18:2/18:1/18:1/18:2)‐H  0.020  ±  0.001  0.042  ±  0.007  0.017  ±  0.004 
CL(20:4/16:0/18:1/18:1)‐H  0.002  ±  0.001  0.031  ±  0.004  0.005  ±  0.001 
CL(18:2/18:2/18:2/18:1)‐H  0.009  ±  0.001  0.021  ±  0.004  0.005  ±  0.001 
CL(18:2/18:1/18:2/18:2)‐H  0.008  ±  0.002  0.015  ±  0.003  0.012  ±  0.002 
CL(18:2/18:1/20:4/16:1)‐H  0.002  ±  0.000  0.004  ±  0.001  0.001  ±  0.000 
CL(18:2/20:4/16:1/18:1)‐H  0.009  ±  0.002  0.010  ±  0.001  0.009  ±  0.002 
CL(18:2/16:1/16:1/22:5)‐H  0.002  ±  0.000  0.002  ±  0.000  0.001  ±  0.000 
CL(18:2/16:1/20:4/18:2)‐H  0.004  ±  0.001  0.006  ±  0.001  0.003  ±  0.001 
CL(19:1/18:1/18:1/18:1)‐H  0.000  ±  0.000  0.001  ±  0.000  0.001  ±  0.000 
CL(19:1/18:1/18:2/18:1)‐H  0.001  ±  0.000  0.002  ±  0.000  0.001  ±  0.000 
CL(19:1/18:1/18:2/18:2)‐H  0.001  ±  0.000  0.003  ±  0.001  0.001  ±  0.000 
CL(17:0/18:1/20:4/18:1)‐H  0.000  ±  0.000  0.002  ±  0.000  0.000  ±  0.000 
CL(17:1/18:1/18:1/20:4)‐H  0.000  ±  0.000  0.002  ±  0.000  0.001  ±  0.000 
CL(17:1/18:1/20:4/18:1)‐H  0.001  ±  0.000  0.002  ±  0.000  0.001  ±  0.000 
CL(17:1/18:1/18:2/20:4)‐H  0.001  ±  0.000  0.002  ±  0.001  0.001  ±  0.000 
CL(17:1/18:2/18:2/20:4)‐H  0.001  ±  0.000  0.001  ±  0.000  0.000  ±  0.000 
CL(18:1/18:0/18:0/20:0)‐H  0.029  ±  0.008  0.009  ±  0.002  0.021  ±  0.004 
CL(18:2/18:2/18:2/20:4)‐H  0.002  ±  0.000  0.001  ±  0.000  0.000  ±  0.000 
CL(20:5/18:2/18:2/18:2)‐H  0.001  ±  0.000  0.001  ±  0.000  0.000  ±  0.000 
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CL(18:1/16:0/16:0/24:1)‐H  0.001  ±  0.001  0.001  ±  0.000  0.003  ±  0.001 
CL(22:2/16:0/18:0/18:1)‐H  0.009  ±  0.003  0.005  ±  0.001  0.010  ±  0.002 
CL(20:4/18:0/18:0/18:0)‐H  0.009  ±  0.002  0.008  ±  0.001  0.007  ±  0.001 
CL(18:1/18:1/18:1/20:1)‐H  0.001  ±  0.000  0.003  ±  0.001  0.001  ±  0.000 
CL(18:1/16:0/20:1/20:3)‐H  0.000  ±  0.000  0.005  ±  0.001  0.000  ±  0.000 
CL(18:1/18:0/18:0/20:4)‐H  0.000  ±  0.000  0.003  ±  0.000  0.000  ±  0.000 
CL(20:4/18:1/18:0/18:1)‐H  0.001  ±  0.000  0.009  ±  0.001  0.001  ±  0.000 
CL(18:2/18:1/20:3/18:1)‐H  0.005  ±  0.000  0.014  ±  0.003  0.003  ±  0.001 
CL(20:4/18:1/18:1/18:1)‐H  0.004  ±  0.001  0.011  ±  0.001  0.004  ±  0.001 
CL(18:2/18:1/20:4/18:1)‐H  0.002  ±  0.000  0.004  ±  0.001  0.001  ±  0.000 
CL(18:2/20:4/18:1/18:1)‐H  0.006  ±  0.000  0.011  ±  0.002  0.005  ±  0.001 
CL(18:2/18:1/18:2/20:4)‐H  0.006  ±  0.001  0.009  ±  0.002  0.003  ±  0.001 
CL(18:2/18:1/20:4/18:2)‐H  0.006  ±  0.000  0.011  ±  0.002  0.004  ±  0.001 
CL(23:0/16:0/18:1/18:1)‐H  0.002  ±  0.001  0.002  ±  0.001  0.003  ±  0.001 
CL(21:0/20:4/16:0/18:0)‐H  0.005  ±  0.000  0.006  ±  0.001  0.003  ±  0.001 
CL(20:5/18:1/20:4/18:1)‐H  0.000  ±  0.000  0.001  ±  0.000  0.000  ±  0.000 
CL(18:2/18:2/18:2/22:6)‐H  0.001  ±  0.000  0.001  ±  0.000  0.000  ±  0.000 
CL(18:4/22:6/20:4/16:1)‐H  0.001  ±  0.001  0.001  ±  0.000  0.002  ±  0.000 
CL(18:1/18:0/20:1/20:1)‐H  0.005  ±  0.001  0.002  ±  0.000  0.002  ±  0.000 
CL(18:1/16:0/18:1/24:1)‐H  0.000  ±  0.000  0.001  ±  0.000  0.000  ±  0.000 
CL(22:3/18:0/18:0/18:1)‐H  0.011  ±  0.002  0.004  ±  0.001  0.005  ±  0.000 
CL(22:1/18:1/18:1/18:1)‐H  0.000  ±  0.000  0.001  ±  0.000  0.000  ±  0.000 
CL(20:4/18:0/18:1/20:0)‐H  0.015  ±  0.003  0.010  ±  0.002  0.010  ±  0.002 
CL(22:3/18:1/18:1/18:1)‐H  0.000  ±  0.000  0.001  ±  0.000  0.000  ±  0.000 
CL(20:2/18:0/18:1/20:4)‐H  0.004  ±  0.001  0.002  ±  0.001  0.003  ±  0.000 
CL(22:5/18:0/18:1/18:1)‐H  0.000  ±  0.000  0.003  ±  0.001  0.000  ±  0.000 
CL(22:5/18:1/18:1/18:1)‐H  0.001  ±  0.000  0.004  ±  0.001  0.000  ±  0.000 
CL(23:0/18:0/18:0/18:1)‐H  0.001  ±  0.000  0.000  ±  0.000  0.001  ±  0.000 
CL(20:5/20:4/20:4/18:1)‐H  0.000  ±  0.000  0.005  ±  0.001  0.001  ±  0.000 
CL(22:2/18:0/18:1/20:4)‐H  0.024  ±  0.006  0.034  ±  0.005  0.005  ±  0.001 
CL(22:3/18:0/18:1/20:4)‐H  0.006  ±  0.002  0.004  ±  0.001  0.004  ±  0.001 
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CL(23:0/18:0/18:0/20:3)‐H  0.002  ±  0.001  0.002  ±  0.001  0.001  ±  0.000 
CL(23:1/18:0/18:0/20:4)‐H  0.002  ±  0.000  0.002  ±  0.000  0.001  ±  0.000 
CL(21:0/18:0/18:0/22:6)‐H  0.005  ±  0.001  0.006  ±  0.001  0.005  ±  0.001 
CL(22:2/18:0/20:4/20:4)‐H  0.007  ±  0.001  0.007  ±  0.001  0.001  ±  0.000 
CL(22:6/18:1/22:6/18:1)‐H  0.000  ±  0.000  0.002  ±  0.000  0.000  ±  0.000 
CL(22:6/20:4/20:4/18:1)‐H  0.001  ±  0.000  0.001  ±  0.000  0.001  ±  0.000 
CL(20:4/18:0/20:4/22:0)‐H  0.003  ±  0.001  0.004  ±  0.001  0.002  ±  0.000 
CL(23:0/18:0/18:0/22:4)‐H  0.002  ±  0.000  0.001  ±  0.000  0.001  ±  0.000 
CL(23:1/18:0/18:0/22:6)‐H  0.003  ±  0.001  0.002  ±  0.001  0.002  ±  0.000 
 









DG(16:0/14:0)+NH4  0.004  ±  0.001  0.006  ±  0.000  0.027  ±  0.004 
DG(16:1/14:0)+NH4  0.001  ±  0.001  0.000  ±  0.000  0.006  ±  0.001 
DG(16:0/16:0)+NH4  0.017  ±  0.004  0.038  ±  0.003  0.143  ±  0.028 
DG(18:1/14:0)+NH4  0.043  ±  0.014  0.025  ±  0.002  0.171  ±  0.025 
DG(17:1/16:0)+NH4  0.010  ±  0.002  0.008  ±  0.001  0.009  ±  0.002 
DG(18:0/16:0)+NH4  0.013  ±  0.004  0.046  ±  0.003  0.102  ±  0.021 
DG(16:0/18:1)+NH4  0.222  ±  0.061  0.214  ±  0.016  0.756  ±  0.152 
DG(16:1/18:1)+NH4  0.108  ±  0.042  0.023  ±  0.001  0.156  ±  0.024 
DG(16:0/18:2)+NH4  0.041  ±  0.019  0.031  ±  0.002  0.045  ±  0.010 
DG(19:1/16:0)+NH4  0.008  ±  0.001  0.007  ±  0.000  0.008  ±  0.002 
DG(17:1/18:1)+NH4  0.018  ±  0.005  0.007  ±  0.001  0.014  ±  0.004 
DG(18:0/18:0)+NH4  0.013  ±  0.009  0.005  ±  0.001  0.029  ±  0.017 
DG(18:0/18:1)+NH4  0.072  ±  0.017  0.068  ±  0.003  0.239  ±  0.057 
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DG(18:1/18:1)+NH4  0.270  ±  0.082  0.130  ±  0.018  0.639  ±  0.128 
DG(18:1/18:2)+NH4  0.055  ±  0.014  0.025  ±  0.002  0.043  ±  0.013 
DG(18:2/18:2)+NH4  0.015  ±  0.005  0.007  ±  0.003  0.001  ±  0.001 
DG(16:0/20:4)+NH4  0.032  ±  0.003  0.026  ±  0.002  0.007  ±  0.001 
DG(19:1/18:1)+NH4  0.006  ±  0.002  0.003  ±  0.000  0.006  ±  0.001 
DG(16:0/22:0)+NH4  0.001  ±  0.000  0.001  ±  0.000  0.004  ±  0.001 
DG(20:0/18:1)+NH4  0.002  ±  0.001  0.002  ±  0.000  0.020  ±  0.006 
DG(20:1/18:1)+NH4  0.012  ±  0.004  0.007  ±  0.001  0.066  ±  0.017 
DG(18:1/20:2)+NH4  0.032  ±  0.007  0.015  ±  0.001  0.017  ±  0.003 
DG(18:0/20:3)+NH4  0.033  ±  0.007  0.014  ±  0.001  0.009  ±  0.002 
DG(18:1/20:3)+NH4  0.019  ±  0.004  0.010  ±  0.001  0.005  ±  0.001 
DG(18:0/20:4)+NH4  0.131  ±  0.002  0.127  ±  0.003  0.041  ±  0.009 
DG(18:1/20:4)+NH4  0.074  ±  0.007  0.035  ±  0.004  0.022  ±  0.003 
DG(18:0/20:5)+NH4  0.012  ±  0.003  0.008  ±  0.001  0.004  ±  0.001 
DG(16:0/22:6)+NH4  0.027  ±  0.004  0.021  ±  0.003  0.011  ±  0.002 
DG(16:1/22:6)+NH4  0.010  ±  0.003  0.001  ±  0.000  0.002  ±  0.000 
DG(26:0/14:0)+NH4  0.001  ±  0.000  0.001  ±  0.000  0.013  ±  0.003 
DG(16:0/24:1)+NH4  0.000  ±  0.000  0.001  ±  0.000  0.014  ±  0.005 
DG(18:1/22:1)+NH4  0.002  ±  0.001  0.002  ±  0.000  0.017  ±  0.005 
DG(18:1/22:2)+NH4  0.005  ±  0.000  0.001  ±  0.000  0.005  ±  0.001 
DG(18:0/22:4)+NH4  0.006  ±  0.001  0.006  ±  0.000  0.004  ±  0.001 
DG(18:0/22:5)+NH4  0.014  ±  0.001  0.012  ±  0.000  0.020  ±  0.005 
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DG(18:1/22:5)+NH4  0.014  ±  0.002  0.007  ±  0.001  0.009  ±  0.002 
DG(18:0/22:6)+NH4  0.021  ±  0.005  0.018  ±  0.002  0.022  ±  0.005 
DG(18:1/22:6)+NH4  0.040  ±  0.007  0.013  ±  0.002  0.012  ±  0.002 
DG(25:0/16:0)+NH4  0.000  ±  0.000  0.000  ±  0.000  0.001  ±  0.000 
DG(26:0/16:0)+NH4  0.001  ±  0.000  0.002  ±  0.000  0.037  ±  0.009 
DG(26:1/16:0)+NH4  0.001  ±  0.000  0.001  ±  0.000  0.041  ±  0.012 
DG(26:1/16:1)+NH4  0.002  ±  0.001  0.001  ±  0.000  0.034  ±  0.010 
DG(27:1/16:0)+NH4  0.000  ±  0.000  0.000  ±  0.000  0.002  ±  0.000 
DG(28:0/16:0)+NH4  0.000  ±  0.000  0.001  ±  0.000  0.011  ±  0.002 
DG(28:1/16:0)+NH4  0.001  ±  0.000  0.000  ±  0.000  0.016  ±  0.005 
DG(26:1/18:1)+NH4  0.002  ±  0.001  0.001  ±  0.000  0.075  ±  0.022 
DG(30:0/16:0)+NH4  0.000  ±  0.000  0.001  ±  0.000  0.003  ±  0.001 
DG(30:1/16:0)+NH4  0.000  ±  0.000  0.001  ±  0.001  0.027  ±  0.014 
DG(28:1/18:1)+NH4  0.000  ±  0.000  0.001  ±  0.000  0.026  ±  0.008 
DG(29:1/18:1)+NH4  0.000  ±  0.000  0.000  ±  0.000  0.003  ±  0.001 
DG(32:1/16:0)+NH4  0.004  ±  0.000  0.007  ±  0.001  0.014  ±  0.004 
DG(30:1/18:1)+NH4  0.001  ±  0.000  0.001  ±  0.001  0.013  ±  0.003 
DG(31:1/18:1)+NH4  0.000  ±  0.000  0.000  ±  0.000  0.001  ±  0.000 
DG(32:1/18:1)+NH4  0.001  ±  0.000  0.001  ±  0.000  0.008  ±  0.002 
 









LPC(16:0)+H  0.004  ±  0.001  0.004  ±  0.001  0.005  ±  0.002 
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LPC(16:0e)+H  0.001  ±  0.000  0.001  ±  0.000  0.001  ±  0.000 
LPC(16:0p)+H  0.001  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
LPC(16:1)+H  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
LPC(18:0)+H  0.007  ±  0.000  0.005  ±  0.001  0.003  ±  0.001 
LPC(18:0e)+H  0.001  ±  0.000  0.001  ±  0.000  0.001  ±  0.000 
LPC(18:0p)+H  0.001  ±  0.000  0.001  ±  0.000  0.001  ±  0.000 
LPC(18:1)+H  0.005  ±  0.001  0.004  ±  0.001  0.005  ±  0.001 
LPC(18:1p)+H  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
LPC(20:0)+H  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
LPC(20:0p)+H  0.001  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
LPC(20:1)+H  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
LPC(20:3)+H  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
LPC(22:0)+H  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
LPC(24:0)+H  0.001  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
LPC(24:1)+H  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
LPC(26:0)+H  0.006  ±  0.000  0.007  ±  0.000  0.003  ±  0.001 
LPC(26:1)+H  0.001  ±  0.000  0.000  ±  0.000  0.002  ±  0.000 
LPC(28:0)+H  0.337  ±  0.093  0.160  ±  0.011  0.046  ±  0.011 
LPC(28:1)+H  0.022  ±  0.002  0.013  ±  0.001  0.007  ±  0.002 
LPC(30:0)+H  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
 









PC(11:0/16:0)+H  0.001  ±  0.000  0.001  ±  0.000  0.002  ±  0.000 
PC(28:0)+H  0.038  ±  0.017  0.027  ±  0.004  0.090  ±  0.022 
PC(14:0e/14:0)+H  0.350  ±  0.095  0.166  ±  0.011  0.048  ±  0.011 
PC(14:0p/14:0)+H  0.009  ±  0.001  0.003  ±  0.000  0.001  ±  0.000 
PC(29:0)+H  0.017  ±  0.005  0.019  ±  0.003  0.009  ±  0.002 
PC(16:0/13:0)+H  0.004  ±  0.001  0.002  ±  0.000  0.002  ±  0.001 
PC(11:0/18:1)+H  0.024  ±  0.007  0.010  ±  0.004  0.027  ±  0.005 
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PC(30:0)+H  0.367  ±  0.117  0.390  ±  0.037  0.531  ±  0.075 
PC(30:0e)+H  0.101  ±  0.012  0.074  ±  0.005  0.139  ±  0.029 
PC(16:0p/14:0)+H  0.063  ±  0.005  0.042  ±  0.003  0.039  ±  0.009 
PC(14:0p/16:0)+H  0.024  ±  0.006  0.026  ±  0.001  0.024  ±  0.005 
PC(30:1)+H  0.196  ±  0.085  0.080  ±  0.009  0.237  ±  0.058 
PC(16:0/14:1)+H  0.005  ±  0.001  0.003  ±  0.000  0.003  ±  0.001 
PC(30:1e)+H  0.079  ±  0.005  0.048  ±  0.004  0.046  ±  0.012 
PC(14:0p/16:1)+H  0.005  ±  0.001  0.003  ±  0.000  0.002  ±  0.000 
PC(30:2)+H  0.008  ±  0.004  0.002  ±  0.000  0.005  ±  0.001 
PC(16:1/14:1)+H  0.001  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
PC(30:2e)+H  0.008  ±  0.002  0.007  ±  0.001  0.002  ±  0.000 
PC(18:1/12:2)+H  0.003  ±  0.001  0.002  ±  0.000  0.006  ±  0.001 
PC(31:0)+H  0.073  ±  0.003  0.100  ±  0.010  0.037  ±  0.008 
PC(18:0/13:0)+H  0.002  ±  0.001  0.007  ±  0.001  0.003  ±  0.000 
PC(17:1/14:0)+H  0.044  ±  0.013  0.027  ±  0.004  0.018  ±  0.005 
PC(32:0)+H  0.232  ±  0.116  0.476  ±  0.014  0.379  ±  0.030 
PC(32:0e)+H  0.219  ±  0.071  0.173  ±  0.017  0.347  ±  0.050 
PC(16:0p/16:0)+H  0.064  ±  0.013  0.097  ±  0.007  0.059  ±  0.009 
PC(16:0/16:1)+H  1.930  ±  0.546  1.129  ±  0.314  1.390  ±  0.158 
PC(16:1p/16:0)+H  0.011  ±  0.003  0.006  ±  0.001  0.007  ±  0.003 
PC(32:1p)+H  0.047  ±  0.015  0.056  ±  0.005  0.044  ±  0.009 
PC(32:2)+H  0.484  ±  0.229  0.083  ±  0.014  0.165  ±  0.030 
PC(18:1/14:1)+H  0.016  ±  0.004  0.004  ±  0.001  0.005  ±  0.001 
PC(14:0p/18:3)+H  0.004  ±  0.000  0.003  ±  0.000  0.003  ±  0.001 
PC(18:4/14:0)+H  0.007  ±  0.004  0.004  ±  0.000  0.009  ±  0.004 
PC(32:4e)+H  0.077  ±  0.042  0.020  ±  0.001  0.000  ±  0.000 
PC(12:0p/20:5)+H  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
PC(33:0)+H  0.024  ±  0.001  0.054  ±  0.004  0.011  ±  0.002 
PC(33:1)+H  0.432  ±  0.086  0.318  ±  0.031  0.145  ±  0.029 
PC(17:1/16:1)+H  0.046  ±  0.017  0.012  ±  0.002  0.016  ±  0.004 
PC(34:0)+H  0.132  ±  0.018  0.497  ±  0.010  0.188  ±  0.034 
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PC(34:0e)+H  0.099  ±  0.029  0.111  ±  0.009  0.157  ±  0.031 
PC(16:0p/18:0)+H  0.630  ±  0.142  0.403  ±  0.052  0.745  ±  0.106 
PC(34:1)+H  2.954  ±  0.501  1.987  ±  0.116  1.631  ±  0.200 
PC(16:0p/18:1)+H  0.104  ±  0.026  0.069  ±  0.005  0.097  ±  0.017 
PC(34:2)+H  2.005  ±  0.678  0.930  ±  0.093  1.072  ±  0.151 
PC(16:1p/18:1)+H  0.009  ±  0.002  0.007  ±  0.000  0.005  ±  0.000 
PC(34:3)+H  0.174  ±  0.064  0.042  ±  0.007  0.045  ±  0.012 
PC(16:0/18:3)+H  0.004  ±  0.000  0.004  ±  0.000  0.001  ±  0.000 
PC(34:4)+H  0.036  ±  0.012  0.009  ±  0.001  0.004  ±  0.001 
PC(18:4/16:0)+H  0.043  ±  0.011  0.018  ±  0.004  0.009  ±  0.001 
PC(14:0/20:5)+H  0.004  ±  0.001  0.001  ±  0.000  0.000  ±  0.000 
PC(34:6e)+H  0.023  ±  0.005  0.009  ±  0.001  0.000  ±  0.000 
PC(35:0)+H  0.002  ±  0.000  0.012  ±  0.001  0.001  ±  0.000 
PC(17:0/18:1)+H  0.085  ±  0.019  0.051  ±  0.006  0.044  ±  0.008 
PC(35:1)+H  0.191  ±  0.027  0.132  ±  0.013  0.070  ±  0.014 
PC(17:1/18:1)+H  0.235  ±  0.065  0.116  ±  0.014  0.130  ±  0.028 
PC(36:0)+H  0.007  ±  0.000  0.029  ±  0.002  0.013  ±  0.003 
PC(36:0e)+H  0.012  ±  0.004  0.016  ±  0.001  0.015  ±  0.004 
PC(16:0/20:1)+H  1.061  ±  0.171  0.546  ±  0.048  0.622  ±  0.098 
PC(36:1e)+H  0.048  ±  0.017  0.043  ±  0.004  0.215  ±  0.047 
PC(18:0p/18:1)+H  0.110  ±  0.035  0.051  ±  0.009  0.114  ±  0.023 
PC(20:1p/16:0)+H  0.017  ±  0.006  0.015  ±  0.002  0.027  ±  0.006 
PC(18:1p/18:0)+H  0.010  ±  0.004  0.011  ±  0.001  0.030  ±  0.008 
PC(18:1/18:1)+H  1.718  ±  0.417  0.677  ±  0.054  1.091  ±  0.156 
PC(16:1p/20:1)+H  0.018  ±  0.005  0.018  ±  0.002  0.014  ±  0.003 
PC(18:2p/18:0)+H  0.026  ±  0.008  0.013  ±  0.002  0.011  ±  0.002 
PC(36:2p)+H  0.033  ±  0.010  0.022  ±  0.002  0.028  ±  0.005 
PC(36:3)+H  0.528  ±  0.113  0.273  ±  0.028  0.171  ±  0.024 
PC(36:4)+H  0.394  ±  0.056  0.239  ±  0.012  0.024  ±  0.003 
PC(18:1/18:3)+H  0.036  ±  0.005  0.022  ±  0.001  0.008  ±  0.001 
PC(36:4e)+H  0.147  ±  0.005  0.127  ±  0.010  0.022  ±  0.004 
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PC(16:0p/20:4)+H  0.075  ±  0.002  0.050  ±  0.003  0.006  ±  0.002 
PC(36:5)+H  0.094  ±  0.025  0.032  ±  0.007  0.007  ±  0.002 
PC(18:4/18:1)+H  0.034  ±  0.006  0.011  ±  0.002  0.007  ±  0.001 
PC(14:0/22:5)+H  0.003  ±  0.000  0.003  ±  0.000  0.001  ±  0.001 
PC(36:6)+H  0.013  ±  0.002  0.004  ±  0.001  0.003  ±  0.001 
PC(22:2/14:4)+H  0.005  ±  0.001  0.002  ±  0.000  0.001  ±  0.000 
PC(16:1/21:0)+H  0.006  ±  0.002  0.001  ±  0.000  0.003  ±  0.001 
PC(19:1/18:1)+H  0.073  ±  0.019  0.049  ±  0.008  0.056  ±  0.012 
PC(15:0/22:4)+H  0.011  ±  0.001  0.013  ±  0.001  0.008  ±  0.002 
PC(37:5)+H  0.020  ±  0.004  0.008  ±  0.002  0.001  ±  0.000 
PC(17:0/20:5)+H  0.003  ±  0.001  0.004  ±  0.001  0.001  ±  0.000 
PC(38:0e)+H  0.007  ±  0.002  0.005  ±  0.000  0.006  ±  0.002 
PC(20:0/18:1)+H  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
PC(38:1e)+H  0.009  ±  0.003  0.008  ±  0.001  0.036  ±  0.009 
PC(20:1p/18:0)+H  0.006  ±  0.002  0.003  ±  0.000  0.011  ±  0.002 
PC(20:1/18:1)+H  0.142  ±  0.049  0.077  ±  0.017  0.184  ±  0.027 
PC(38:2e)+H  0.004  ±  0.002  0.001  ±  0.000  0.007  ±  0.002 
PC(38:3)+H  0.196  ±  0.038  0.070  ±  0.009  0.056  ±  0.012 
PC(38:3e)+H  0.006  ±  0.002  0.004  ±  0.000  0.005  ±  0.001 
PC(38:4)+H  0.186  ±  0.042  0.062  ±  0.007  0.026  ±  0.006 
PC(38:4e)+H  0.075  ±  0.011  0.068  ±  0.006  0.009  ±  0.002 
PC(18:0/20:5)+H  0.040  ±  0.006  0.015  ±  0.002  0.006  ±  0.002 
PC(38:5)+H  0.428  ±  0.041  0.238  ±  0.017  0.034  ±  0.005 
PC(16:0/22:6)+H  0.141  ±  0.029  0.085  ±  0.012  0.034  ±  0.009 
PC(38:6e)+H  0.147  ±  0.026  0.086  ±  0.008  0.024  ±  0.005 
PC(38:7)+H  0.039  ±  0.013  0.008  ±  0.002  0.006  ±  0.002 
PC(39:2)+H  0.005  ±  0.002  0.004  ±  0.000  0.007  ±  0.001 
PC(40:0)+H  0.001  ±  0.000  0.001  ±  0.000  0.008  ±  0.002 
PC(40:1)+H  0.004  ±  0.002  0.004  ±  0.001  0.026  ±  0.007 
PC(40:2)+H  0.016  ±  0.006  0.012  ±  0.002  0.046  ±  0.011 
PC(40:3)+H  0.014  ±  0.004  0.010  ±  0.001  0.014  ±  0.003 
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PC(40:4)+H  0.026  ±  0.005  0.018  ±  0.002  0.009  ±  0.002 
PC(18:0/22:5)+H  0.048  ±  0.002  0.042  ±  0.004  0.012  ±  0.003 
PC(40:5e)+H  0.040  ±  0.003  0.019  ±  0.002  0.006  ±  0.001 
PC(18:0/22:6)+H  0.083  ±  0.011  0.055  ±  0.005  0.010  ±  0.002 
PC(40:6e)+H  0.045  ±  0.009  0.029  ±  0.003  0.009  ±  0.002 
PC(18:1/22:6)+H  0.127  ±  0.030  0.067  ±  0.010  0.039  ±  0.011 
PC(18:1/23:0)+H  0.001  ±  0.001  0.000  ±  0.000  0.003  ±  0.001 
PC(31:0/10:2)+H  0.001  ±  0.001  0.001  ±  0.000  0.002  ±  0.001 
PC(18:1/23:1)+H  0.002  ±  0.001  0.000  ±  0.000  0.003  ±  0.001 
PC(26:0/16:0)+H  0.001  ±  0.000  0.001  ±  0.000  0.019  ±  0.006 
PC(42:1)+H  0.006  ±  0.002  0.003  ±  0.000  0.036  ±  0.003 
PC(42:2)+H  0.011  ±  0.005  0.005  ±  0.001  0.055  ±  0.015 
PC(42:3)+H  0.007  ±  0.003  0.006  ±  0.001  0.016  ±  0.004 
PC(18:2p/24:1)+H  0.005  ±  0.001  0.002  ±  0.000  0.001  ±  0.000 
PC(27:1/16:0)+H  0.001  ±  0.000  0.000  ±  0.000  0.003  ±  0.001 
PC(25:1/18:1)+H  0.001  ±  0.001  0.000  ±  0.000  0.005  ±  0.001 
PC(44:0)+H  0.000  ±  0.000  0.001  ±  0.000  0.011  ±  0.003 
PC(44:1)+H  0.003  ±  0.001  0.002  ±  0.000  0.055  ±  0.014 
PC(44:2)+H  0.006  ±  0.003  0.003  ±  0.000  0.065  ±  0.018 
PC(44:3)+H  0.006  ±  0.003  0.003  ±  0.001  0.020  ±  0.003 
PC(29:0/16:0)+H  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
PC(27:0/18:1)+H  0.000  ±  0.000  0.000  ±  0.000  0.003  ±  0.001 
PC(45:2)+H  0.000  ±  0.000  0.000  ±  0.000  0.003  ±  0.001 
PC(46:1)+H  0.000  ±  0.000  0.000  ±  0.000  0.023  ±  0.009 
PC(46:2)+H  0.001  ±  0.000  0.001  ±  0.000  0.028  ±  0.007 
PC(31:1/16:0)+H  0.000  ±  0.000  0.000  ±  0.000  0.001  ±  0.000 
PC(47:2)+H  0.000  ±  0.000  0.000  ±  0.000  0.003  ±  0.001 
PC(48:1)+H  0.000  ±  0.000  0.000  ±  0.000  0.007  ±  0.002 
PC(48:2)+H  0.000  ±  0.000  0.000  ±  0.000  0.015  ±  0.004 













PE(26:0)+H  0.004  ±  0.001  0.002  ±  0.000  0.001  ±  0.000 
PE(12:0p/16:0)+H  0.028  ±  0.001  0.015  ±  0.001  0.002  ±  0.001 
PE(16:0/14:0)+H  0.009  ±  0.005  0.011  ±  0.001  0.029  ±  0.005 
PE(16:0p/14:0)+H  0.007  ±  0.002  0.012  ±  0.000  0.002  ±  0.000 
PE(16:1/14:0)+H  0.012  ±  0.005  0.003  ±  0.000  0.015  ±  0.005 
PE(12:0p/18:1)+H  0.034  ±  0.003  0.019  ±  0.001  0.011  ±  0.002 
PE(12:0p/18:2)+H  0.003  ±  0.002  0.003  ±  0.000  0.001  ±  0.000 
PE(16:0/16:0)+H  0.035  ±  0.007  0.057  ±  0.004  0.054  ±  0.011 
PE(16:0p/16:0)+H  0.034  ±  0.013  0.115  ±  0.007  0.011  ±  0.002 
PE(16:0/16:1)+H  0.362  ±  0.097  0.133  ±  0.055  0.385  ±  0.064 
PE(16:0p/16:1)+H  0.077  ±  0.020  0.048  ±  0.010  0.137  ±  0.025 
PE(16:1/16:1)+H  0.039  ±  0.017  0.006  ±  0.002  0.039  ±  0.010 
PE(12:0p/20:4)+H  0.126  ±  0.057  0.063  ±  0.000  0.005  ±  0.001 
PE(12:0p/20:5)+H  0.009  ±  0.001  0.003  ±  0.000  0.001  ±  0.000 
PE(18:0p/15:0)+H  0.003  ±  0.001  0.012  ±  0.001  0.000  ±  0.000 
PE(17:1/16:0)+H  0.086  ±  0.028  0.045  ±  0.002  0.043  ±  0.008 
PE(16:0p/17:1)+H  0.030  ±  0.009  0.019  ±  0.001  0.019  ±  0.003 
PE(18:0/16:0)+H  0.029  ±  0.009  0.109  ±  0.005  0.036  ±  0.007 
PE(18:0p/16:0)+H  0.029  ±  0.010  0.090  ±  0.005  0.010  ±  0.002 
PE(16:0/18:1)+H  1.620  ±  0.426  0.980  ±  0.041  1.720  ±  0.294 
PE(16:0p/18:1)+H  0.698  ±  0.238  0.318  ±  0.017  0.706  ±  0.136 
PE(16:1/18:1)+H  1.018  ±  0.258  0.165  ±  0.023  0.550  ±  0.076 
PE(18:1p/16:1)+H  0.054  ±  0.018  0.029  ±  0.001  0.045  ±  0.008 
PE(16:0p/18:2)+H  0.046  ±  0.013  0.047  ±  0.002  0.035  ±  0.002 
PE(12:0p/22:4)+H  0.018  ±  0.011  0.005  ±  0.000  0.001  ±  0.000 
PE(14:0p/20:4)+H  0.085  ±  0.023  0.041  ±  0.002  0.005  ±  0.001 
PE(12:0p/22:5)+H  0.013  ±  0.007  0.004  ±  0.000  0.002  ±  0.001 
PE(14:0p/20:5)+H  0.011  ±  0.002  0.004  ±  0.001  0.001  ±  0.000 
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PE(12:0p/22:6)+H  0.044  ±  0.004  0.021  ±  0.000  0.004  ±  0.001 
PE(17:0/18:1)+H  0.249  ±  0.065  0.138  ±  0.014  0.151  ±  0.037 
PE(16:0p/19:1)+H  0.033  ±  0.012  0.021  ±  0.001  0.030  ±  0.006 
PE(17:1/18:1)+H  0.237  ±  0.055  0.068  ±  0.006  0.079  ±  0.011 
PE(18:1p/17:1)+H  0.017  ±  0.006  0.013  ±  0.000  0.007  ±  0.000 
PE(16:0p/20:0)+H  0.004  ±  0.002  0.020  ±  0.001  0.004  ±  0.001 
PE(18:0/18:1)+H  3.323  ±  0.877  1.100  ±  0.067  2.016  ±  0.418 
PE(18:0p/18:1)+H  0.162  ±  0.057  0.122  ±  0.008  0.438  ±  0.087 
PE(18:1/18:1)+H  2.676  ±  0.873  0.958  ±  0.063  1.975  ±  0.262 
PE(18:1p/18:1)+H  0.285  ±  0.087  0.135  ±  0.010  0.211  ±  0.041 
PE(18:0p/18:2)+H  0.062  ±  0.024  0.045  ±  0.002  0.086  ±  0.015 
PE(18:1/18:2)+H  0.406  ±  0.114  0.268  ±  0.006  0.244  ±  0.064 
PE(18:1p/18:2)+H  0.120  ±  0.020  0.136  ±  0.003  0.055  ±  0.010 
PE(16:0p/20:3)+H  0.082  ±  0.025  0.048  ±  0.004  0.099  ±  0.019 
PE(16:0/20:4)+H  0.486  ±  0.022  0.598  ±  0.013  0.228  ±  0.032 
PE(16:0p/20:4)+H  1.985  ±  0.307  2.331  ±  0.071  0.878  ±  0.187 
PE(16:1/20:4)+H  0.078  ±  0.027  0.017  ±  0.003  0.019  ±  0.005 
PE(16:0/20:5)+H  0.043  ±  0.010  0.024  ±  0.002  0.027  ±  0.007 
PE(14:0p/22:5)+H  0.053  ±  0.023  0.029  ±  0.011  0.004  ±  0.001 
PE(16:0p/20:5)+H  0.271  ±  0.080  0.137  ±  0.013  0.130  ±  0.023 
PE(16:1/20:5)+H  0.007  ±  0.003  0.001  ±  0.000  0.002  ±  0.000 
PE(14:0p/22:6)+H  0.060  ±  0.005  0.013  ±  0.001  0.003  ±  0.001 
PE(18:0p/19:1)+H  1.613  ±  0.376  1.280  ±  0.038  1.459  ±  0.282 
PE(17:0/20:4)+H  0.109  ±  0.004  0.151  ±  0.009  0.031  ±  0.006 
PE(17:1/20:4)+H  0.039  ±  0.010  0.036  ±  0.002  0.006  ±  0.001 
PE(17:1/20:5)+H  0.009  ±  0.003  0.004  ±  0.000  0.000  ±  0.000 
PE(20:0/18:1)+H  0.052  ±  0.017  0.024  ±  0.004  0.039  ±  0.013 
PE(16:0p/22:1)+H  0.021  ±  0.009  0.017  ±  0.002  0.088  ±  0.022 
PE(20:1/18:1)+H  0.115  ±  0.041  0.060  ±  0.007  0.120  ±  0.047 
PE(16:0p/22:2)+H  0.020  ±  0.008  0.008  ±  0.001  0.025  ±  0.005 
PE(18:0/20:3)+H  0.570  ±  0.149  0.173  ±  0.007  0.114  ±  0.025 
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PE(18:0p/20:3)+H  0.021  ±  0.009  0.012  ±  0.001  0.042  ±  0.011 
PE(18:0/20:4)+H  5.322  ±  0.402  4.656  ±  0.069  1.319  ±  0.275 
PE(38:4e)+H  0.052  ±  0.009  0.080  ±  0.004  0.027  ±  0.006 
PE(16:0p/22:4)+H  0.351  ±  0.017  0.483  ±  0.029  0.143  ±  0.029 
PE(18:0p/20:4)+H  0.923  ±  0.172  1.398  ±  0.062  0.506  ±  0.100 
PE(18:1/20:4)+H  1.579  ±  0.187  0.930  ±  0.040  0.537  ±  0.099 
PE(18:0/20:5)+H  0.540  ±  0.132  0.274  ±  0.010  0.233  ±  0.041 
PE(18:1p/20:4)+H  2.288  ±  0.208  1.734  ±  0.064  0.852  ±  0.149 
PE(18:0p/20:5)+H  0.172  ±  0.054  0.168  ±  0.011  0.088  ±  0.012 
PE(16:1/22:5)+H  0.001  ±  0.000  0.000  ±  0.000  0.003  ±  0.001 
PE(38:6)+H  0.158  ±  0.051  0.054  ±  0.005  0.071  ±  0.019 
PE(16:0/22:6)+H  0.271  ±  0.032  0.195  ±  0.004  0.086  ±  0.015 
PE(18:1p/20:5)+H  0.166  ±  0.038  0.079  ±  0.002  0.031  ±  0.004 
PE(16:0p/22:6)+H  2.735  ±  0.870  1.121  ±  0.080  0.699  ±  0.135 
PE(16:1/22:6)+H  0.051  ±  0.022  0.009  ±  0.000  0.019  ±  0.004 
PE(16:1p/22:6)+H  0.038  ±  0.011  0.006  ±  0.002  0.002  ±  0.001 
PE(17:0/22:6)+H  0.021  ±  0.004  0.034  ±  0.003  0.020  ±  0.006 
PE(18:1/22:0)+H  0.083  ±  0.031  0.013  ±  0.001  0.038  ±  0.011 
PE(18:0p/22:1)+H  0.007  ±  0.002  0.003  ±  0.000  0.024  ±  0.004 
PE(18:1/22:1)+H  0.082  ±  0.026  0.031  ±  0.003  0.052  ±  0.013 
PE(18:1p/22:1)+H  0.008  ±  0.004  0.003  ±  0.000  0.013  ±  0.003 
PE(18:0p/22:3)+H  0.018  ±  0.006  0.014  ±  0.001  0.018  ±  0.005 
PE(18:0/22:4)+H  0.179  ±  0.022  0.217  ±  0.000  0.109  ±  0.022 
PE(20:0/20:4)+H  0.024  ±  0.002  0.021  ±  0.001  0.014  ±  0.004 
PE(18:0p/22:4)+H  0.118  ±  0.011  0.214  ±  0.017  0.072  ±  0.018 
PE(20:0p/20:4)+H  0.063  ±  0.004  0.031  ±  0.002  0.016  ±  0.004 
PE(18:0/22:5)+H  0.326  ±  0.020  0.270  ±  0.016  0.339  ±  0.081 
PE(40:5e)+H  0.027  ±  0.003  0.027  ±  0.001  0.010  ±  0.002 
PE(40:5p)+H  0.201  ±  0.011  0.216  ±  0.008  0.095  ±  0.020 
PE(18:0p/22:5)+H  0.451  ±  0.032  0.371  ±  0.032  0.325  ±  0.064 
PE(18:0/22:6)+H  0.758  ±  0.168  0.698  ±  0.050  0.483  ±  0.077 
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PE(18:1p/22:5)+H  0.375  ±  0.039  0.179  ±  0.012  0.123  ±  0.027 
PE(18:0p/22:6)+H  1.018  ±  0.292  0.733  ±  0.060  0.347  ±  0.071 
PE(18:1/22:6)+H  0.570  ±  0.151  0.357  ±  0.021  0.208  ±  0.038 
PE(18:1p/22:6)+H  1.223  ±  0.369  0.532  ±  0.045  0.184  ±  0.042 
PE(18:2/22:6)+H  0.016  ±  0.005  0.008  ±  0.001  0.004  ±  0.001 
PE(18:2p/22:6)+H  0.014  ±  0.006  0.002  ±  0.001  0.000  ±  0.000 
PE(18:1/24:0)+H  0.097  ±  0.040  0.009  ±  0.001  0.063  ±  0.013 
PE(20:4/22:6)+H  0.007  ±  0.002  0.004  ±  0.001  0.004  ±  0.001 
PE(18:0p/24:1)+H  0.002  ±  0.000  0.000  ±  0.000  0.002  ±  0.001 
PE(18:1/24:1)+H  0.079  ±  0.032  0.008  ±  0.001  0.051  ±  0.010 
PE(22:0/20:4)+H  0.012  ±  0.003  0.004  ±  0.000  0.008  ±  0.002 
PE(20:0p/22:5)+H  0.021  ±  0.003  0.021  ±  0.002  0.013  ±  0.003 
PE(20:1p/22:5)+H  0.021  ±  0.004  0.017  ±  0.002  0.006  ±  0.002 
PE(20:0p/22:6)+H  0.037  ±  0.010  0.010  ±  0.001  0.007  ±  0.002 
PE(25:0/18:1)+H  0.005  ±  0.002  0.000  ±  0.000  0.004  ±  0.001 
PE(43:2)+H  0.008  ±  0.003  0.001  ±  0.000  0.003  ±  0.001 
PE(26:0/18:1)+H  0.022  ±  0.010  0.002  ±  0.000  0.050  ±  0.015 
PE(26:1/18:1)+H  0.037  ±  0.015  0.002  ±  0.000  0.043  ±  0.014 
PE(44:2)+H  0.002  ±  0.001  0.000  ±  0.000  0.003  ±  0.001 
PE(44:3)+H  0.003  ±  0.001  0.000  ±  0.000  0.001  ±  0.000 
PE(24:0/20:4)+H  0.016  ±  0.006  0.003  ±  0.000  0.017  ±  0.005 
PE(24:1/20:4)+H  0.011  ±  0.005  0.003  ±  0.000  0.020  ±  0.005 
PE(28:1/18:1)+H  0.001  ±  0.000  0.000  ±  0.000  0.011  ±  0.003 
PE(26:0/20:4)+H  0.002  ±  0.001  0.000  ±  0.000  0.007  ±  0.001 
PE(24:0/22:6)+H  0.007  ±  0.003  0.005  ±  0.001  0.020  ±  0.005 
PE(24:1/22:6)+H  0.003  ±  0.001  0.001  ±  0.000  0.003  ±  0.001 















LPE(20:4)‐H  0.005  ±  0.001  0.005  ±  0.001  0.001  ±  0.000 
LPE(22:5)‐H  0.002  ±  0.000  0.001  ±  0.000  0.000  ±  0.000 
LPE(22:6)‐H  0.004  ±  0.001  0.002  ±  0.000  0.001  ±  0.000 
LPE(24:1)‐H  0.000  ±  0.000  0.000  ±  0.000  0.001  ±  0.000 
 









PI(16:0/14:1)‐H  0.000  ±  0.000  0.000  ±  0.000  0.003  ±  0.001 
PI(16:0/16:0)‐H  0.004  ±  0.002  0.008  ±  0.002  0.013  ±  0.005 
PI(18:1/14:1)‐H  0.006  ±  0.003  0.001  ±  0.000  0.014  ±  0.003 
PI(17:1/16:0)‐H  0.008  ±  0.002  0.005  ±  0.001  0.005  ±  0.001 
PI(18:0/16:0)‐H  0.004  ±  0.001  0.011  ±  0.001  0.015  ±  0.003 
PI(16:0/18:1)‐H  0.552  ±  0.207  0.432  ±  0.108  0.885  ±  0.156 
PI(16:0e/18:1)‐
H  0.003  ±  0.001  0.005  ±  0.002  0.006  ±  0.001 
PI(18:0/17:0)‐H  0.001  ±  0.001  0.001  ±  0.000  0.001  ±  0.000 
PI(17:0/18:1)‐H  0.007  ±  0.002  0.005  ±  0.000  0.008  ±  0.002 
PI(18:0/18:0)‐H  0.003  ±  0.001  0.002  ±  0.000  0.006  ±  0.001 
PI(18:0/18:1)‐H  0.317  ±  0.112  0.214  ±  0.045  0.802  ±  0.179 
PI(18:0e/18:1)‐
H  0.000  ±  0.000  0.000  ±  0.000  0.003  ±  0.001 
PI(18:0p/18:1)‐
H  0.001  ±  0.000  0.001  ±  0.000  0.002  ±  0.001 
PI(18:1/18:1)‐H  1.107  ±  0.432  0.595  ±  0.178  2.352  ±  0.411 
PI(18:1/18:3)‐H  0.006  ±  0.001  0.007  ±  0.001  0.000  ±  0.000 
PI(16:0e/20:4)‐
H  0.000  ±  0.000  0.004  ±  0.001  0.001  ±  0.000 
PI(16:1/20:4)‐H  0.005  ±  0.000  0.002  ±  0.000  0.001  ±  0.000 
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PI(16:0/20:5)‐H  0.002  ±  0.001  0.001  ±  0.000  0.001  ±  0.000 
PI(19:1/18:0)‐H  0.005  ±  0.002  0.005  ±  0.001  0.012  ±  0.005 
PI(17:0/20:2)‐H  0.004  ±  0.001  0.002  ±  0.000  0.008  ±  0.002 
PI(19:1/18:2)‐H  0.014  ±  0.004  0.002  ±  0.001  0.005  ±  0.001 
PI(17:0/20:3)‐H  0.025  ±  0.010  0.015  ±  0.005  0.010  ±  0.002 
PI(17:1/20:4)‐H  0.006  ±  0.002  0.007  ±  0.001  0.000  ±  0.000 
PI(18:0/20:0)‐H  0.002  ±  0.001  0.001  ±  0.000  0.002  ±  0.000 
PI(18:0/20:1)‐H  0.001  ±  0.001  0.003  ±  0.001  0.009  ±  0.002 
PI(18:0p/20:1)‐
H  0.000  ±  0.000  0.000  ±  0.000  0.001  ±  0.000 
PI(18:0/20:4)‐H  2.434  ±  0.120  4.080  ±  1.119  0.612  ±  0.117 
PI(18:0/20:5)‐H  0.027  ±  0.004  0.022  ±  0.003  0.006  ±  0.001 
PI(19:1/20:1)‐H  0.000  ±  0.000  0.000  ±  0.000  0.002  ±  0.001 
PI(19:1/20:2)‐H  0.001  ±  0.000  0.002  ±  0.000  0.004  ±  0.001 
PI(19:1/20:3)‐H  0.010  ±  0.003  0.007  ±  0.002  0.004  ±  0.001 
PI(19:0/20:4)‐H  0.007  ±  0.001  0.009  ±  0.002  0.001  ±  0.000 
PI(18:0/22:1)‐H  0.002  ±  0.001  0.002  ±  0.001  0.005  ±  0.001 
PI(18:0/22:3)‐H  0.036  ±  0.019  0.019  ±  0.006  0.019  ±  0.005 
PI(20:0/20:4)‐H  0.003  ±  0.001  0.004  ±  0.002  0.002  ±  0.000 
PI(18:0/24:1)‐H  0.000  ±  0.000  0.002  ±  0.000  0.002  ±  0.001 
PI(18:1/24:2)‐H  0.001  ±  0.000  0.001  ±  0.000  0.003  ±  0.001 
PI(22:4/20:4)‐H  0.001  ±  0.000  0.006  ±  0.001  0.001  ±  0.000 
PI(26:0/18:1)‐H  0.000  ±  0.000  0.001  ±  0.000  0.002  ±  0.001 
PI(26:1/18:1)‐H  0.000  ±  0.000  0.000  ±  0.000  0.001  ±  0.000 
 









PG(12:0/14:0)‐H  0.003  ±  0.000  0.003  ±  0.000  0.001  ±  0.000 
PG(15:0/14:0)‐H  0.000  ±  0.000  0.001  ±  0.000  0.000  ±  0.000 
PG(16:0/14:0)‐H  0.001  ±  0.000  0.025  ±  0.002  0.003  ±  0.001 
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PG(16:1/14:0)‐H  0.010  ±  0.001  0.006  ±  0.000  0.002  ±  0.000 
PG(15:0/16:0)‐H  0.000  ±  0.000  0.006  ±  0.001  0.000  ±  0.000 
PG(16:0/16:0)‐H  0.104  ±  0.042  0.081  ±  0.009  0.014  ±  0.002 
PG(16:0/16:1)‐H  0.005  ±  0.005  0.000  ±  0.000  0.007  ±  0.002 
PG(18:1/14:0)‐H  0.020  ±  0.001  0.021  ±  0.002  0.009  ±  0.002 
PG(16:0/17:0)‐H  0.000  ±  0.000  0.004  ±  0.000  0.000  ±  0.000 
PG(17:1/16:0)‐H  0.019  ±  0.004  0.003  ±  0.001  0.004  ±  0.001 
PG(18:0/16:0)‐H  0.032  ±  0.010  0.035  ±  0.003  0.012  ±  0.002 
PG(16:0/18:1)‐H  0.053  ±  0.010  0.405  ±  0.051  0.141  ±  0.031 
PG(16:1/18:1)‐H  0.021  ±  0.012  0.000  ±  0.000  0.021  ±  0.007 
PG(16:1/18:2)‐H  0.004  ±  0.002  0.001  ±  0.000  0.001  ±  0.000 
PG(19:1/16:0)‐H  0.016  ±  0.002  0.014  ±  0.001  0.004  ±  0.001 
PG(17:1/18:0)‐H  0.028  ±  0.007  0.018  ±  0.002  0.006  ±  0.001 
PG(17:1/18:1)‐H  0.010  ±  0.003  0.008  ±  0.001  0.002  ±  0.001 
PG(18:0/18:1)‐H  0.155  ±  0.043  0.115  ±  0.012  0.060  ±  0.011 
PG(18:1/18:1)‐H  0.078  ±  0.041  0.020  ±  0.002  0.098  ±  0.023 
PG(18:1/18:2)‐H  0.004  ±  0.002  0.004  ±  0.001  0.002  ±  0.001 
PG(16:0/20:3)‐H  0.002  ±  0.001  0.001  ±  0.000  0.000  ±  0.000 
PG(16:0/20:4)‐H  0.002  ±  0.000  0.002  ±  0.000  0.001  ±  0.000 
PG(14:0/22:6)‐H  0.001  ±  0.001  0.000  ±  0.000  0.001  ±  0.000 
PG(20:1/18:1)‐H  0.002  ±  0.001  0.001  ±  0.000  0.003  ±  0.001 
PG(18:1/20:2)‐H  0.015  ±  0.008  0.003  ±  0.001  0.006  ±  0.001 
PG(16:0/22:4)‐H  0.003  ±  0.001  0.003  ±  0.001  0.000  ±  0.000 
PG(18:0/20:4)‐H  0.003  ±  0.001  0.004  ±  0.000  0.001  ±  0.000 
PG(18:1/20:4)‐H  0.001  ±  0.000  0.002  ±  0.000  0.000  ±  0.000 
PG(18:1/20:5)‐H  0.007  ±  0.001  0.002  ±  0.000  0.000  ±  0.000 
PG(16:0/22:6)‐H  0.022  ±  0.010  0.007  ±  0.002  0.011  ±  0.004 
PG(16:1/22:6)‐H  0.019  ±  0.008  0.003  ±  0.000  0.004  ±  0.002 
PG(20:2/20:2)‐H  0.006  ±  0.003  0.002  ±  0.000  0.000  ±  0.000 
PG(18:1/22:4)‐H  0.007  ±  0.003  0.005  ±  0.001  0.000  ±  0.000 
PG(18:0/22:6)‐H  0.002  ±  0.001  0.004  ±  0.001  0.001  ±  0.000 
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PG(18:1/22:6)‐H  0.247  ±  0.108  0.072  ±  0.011  0.076  ±  0.024 
PG(18:2/22:6)‐H  0.032  ±  0.008  0.012  ±  0.002  0.002  ±  0.000 
PG(20:4/22:6)‐H  0.019  ±  0.006  0.009  ±  0.002  0.001  ±  0.000 
PG(20:5/22:6)‐H  0.004  ±  0.001  0.001  ±  0.000  0.000  ±  0.000 
PG(20:2/22:6)‐H  0.013  ±  0.003  0.005  ±  0.000  0.001  ±  0.000 
PG(20:3/22:6)‐H  0.023  ±  0.004  0.006  ±  0.001  0.000  ±  0.000 
PG(22:4/22:6)‐H  0.014  ±  0.003  0.009  ±  0.001  0.000  ±  0.000 
PG(22:5/22:6)‐H  0.026  ±  0.007  0.012  ±  0.002  0.002  ±  0.000 
PG(22:6/22:6)‐H  0.109  ±  0.031  0.068  ±  0.008  0.011  ±  0.003 
 









PS(12:0/14:0)‐H  0.007  ±  0.004  0.002  ±  0.000  0.001  ±  0.000 
PS(16:0/14:0)‐H  0.005  ±  0.004  0.003  ±  0.001  0.002  ±  0.001 
PS(16:0/14:1)‐H  0.033  ±  0.033  0.000  ±  0.000  0.002  ±  0.001 
PS(16:0/16:0)‐H  0.012  ±  0.006  0.012  ±  0.002  0.004  ±  0.002 
PS(16:1/16:1)‐H  0.006  ±  0.005  0.000  ±  0.000  0.001  ±  0.001 
PS(16:1/17:0)‐H  0.029  ±  0.017  0.035  ±  0.015  0.001  ±  0.000 
PS(18:0/16:0)‐H  0.023  ±  0.005  0.033  ±  0.008  0.004  ±  0.001 
PS(16:0e/18:1)‐H  0.005  ±  0.003  0.003  ±  0.001  0.009  ±  0.002 
PS(16:1/18:2)‐H  0.002  ±  0.000  0.000  ±  0.000  0.002  ±  0.000 
PS(18:0/18:0)‐H  0.005  ±  0.002  0.003  ±  0.001  0.000  ±  0.000 
PS(18:0e/18:1)‐H  0.072  ±  0.067  0.008  ±  0.001  0.017  ±  0.003 
PS(18:1/18:1)‐H  0.105  ±  0.059  0.142  ±  0.030  0.217  ±  0.040 
PS(18:0/18:3)‐H  0.044  ±  0.029  0.006  ±  0.001  0.001  ±  0.001 
PS(16:0/20:3)‐H  0.013  ±  0.002  0.009  ±  0.001  0.013  ±  0.002 
PS(16:0/20:4)‐H  0.006  ±  0.003  0.006  ±  0.000  0.003  ±  0.001 
PS(16:1/20:3)‐H  0.011  ±  0.006  0.013  ±  0.004  0.012  ±  0.001 
PS(16:0/22:0)‐H  0.003  ±  0.001  0.002  ±  0.001  0.000  ±  0.000 
PS(18:1/20:2)‐H  0.037  ±  0.016  0.020  ±  0.003  0.010  ±  0.002 
323 
 
PS(18:0/20:3)‐H  0.013  ±  0.005  0.004  ±  0.001  0.002  ±  0.001 
PS(18:1/20:3)‐H  0.010  ±  0.005  0.012  ±  0.002  0.008  ±  0.001 
PS(18:0/20:4)‐H  0.050  ±  0.025  0.049  ±  0.006  0.032  ±  0.004 
PS(18:1/20:4)‐H  0.011  ±  0.006  0.013  ±  0.002  0.011  ±  0.002 
PS(20:3/18:2)‐H  0.009  ±  0.003  0.012  ±  0.002  0.006  ±  0.001 
PS(19:0/20:3)‐H  0.005  ±  0.003  0.007  ±  0.002  0.003  ±  0.001 
PS(17:0/22:4)‐H  0.017  ±  0.008  0.033  ±  0.008  0.008  ±  0.002 
PS(17:0/22:5)‐H  0.006  ±  0.004  0.009  ±  0.002  0.004  ±  0.001 
PS(16:0/24:0)‐H  0.001  ±  0.001  0.002  ±  0.000  0.000  ±  0.000 
PS(20:2/20:2)‐H  0.004  ±  0.003  0.007  ±  0.001  0.005  ±  0.001 
PS(18:1/22:4)‐H  0.122  ±  0.092  0.151  ±  0.036  0.352  ±  0.104 
PS(18:0/22:5)‐H  0.009  ±  0.006  0.028  ±  0.004  0.003  ±  0.000 
PS(18:1/22:5)‐H  0.022  ±  0.015  0.027  ±  0.001  0.110  ±  0.024 
PS(20:3/20:3)‐H  0.009  ±  0.005  0.005  ±  0.001  0.002  ±  0.000 
PS(20:0/22:5)‐H  0.006  ±  0.004  0.010  ±  0.002  0.016  ±  0.002 
PS(25:0/18:1)‐H  0.001  ±  0.001  0.001  ±  0.000  0.002  ±  0.000 
PS(25:1/18:1)‐H  0.002  ±  0.002  0.001  ±  0.000  0.002  ±  0.000 
PS(26:0/18:1)‐H  0.003  ±  0.003  0.002  ±  0.000  0.015  ±  0.003 
PS(24:0/20:4)‐H  0.006  ±  0.005  0.003  ±  0.001  0.005  ±  0.001 
PS(24:1/20:4)‐H  0.002  ±  0.002  0.002  ±  0.000  0.002  ±  0.000 
PS(27:1/18:1)‐H  0.000  ±  0.000  0.000  ±  0.000  0.001  ±  0.000 
PS(28:0/18:1)‐H  0.000  ±  0.000  0.000  ±  0.000  0.001  ±  0.000 
PS(28:1/18:1)‐H  0.002  ±  0.002  0.003  ±  0.000  0.010  ±  0.002 
PS(24:0/22:5)‐H  0.000  ±  0.000  0.001  ±  0.000  0.001  ±  0.000 
PS(30:1/18:1)‐H  0.000  ±  0.000  0.000  ±  0.000  0.002  ±  0.000 
 









SM(d30:0)+H  0.000  ±  0.000  0.001  ±  0.000  0.001  ±  0.000 
SM(d30:1)+H  0.003  ±  0.001  0.001  ±  0.000  0.001  ±  0.000 
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SM(d31:1)+H  0.005  ±  0.002  0.001  ±  0.000  0.001  ±  0.000 
SM(d32:0)+H  0.047  ±  0.014  0.053  ±  0.004  0.069  ±  0.018 
SM(d32:1)+H  0.367  ±  0.130  0.119  ±  0.015  0.102  ±  0.028 
SM(d32:2)+H  0.008  ±  0.003  0.002  ±  0.000  0.001  ±  0.000 
SM(d33:1)+H  0.196  ±  0.055  0.103  ±  0.011  0.089  ±  0.024 
SM(d33:2)+H  0.002  ±  0.000  0.001  ±  0.000  0.000  ±  0.000 
SM(d33:5)+H  0.007  ±  0.001  0.004  ±  0.000  0.002  ±  0.000 
SM(d34:0)+H  0.570  ±  0.070  1.439  ±  0.056  1.423  ±  0.227 
SM(d18:1/16:0)+H  4.483  ±  0.850  3.217  ±  0.235  2.031  ±  0.334 
SM(d18:1/16:1)+H  0.383  ±  0.114  0.161  ±  0.008  0.126  ±  0.029 
SM(d18:2/16:1)+H  0.003  ±  0.001  0.005  ±  0.000  0.003  ±  0.000 
SM(d34:4)+H  0.050  ±  0.016  0.017  ±  0.003  0.015  ±  0.004 
SM(d35:1)+H  0.193  ±  0.015  0.163  ±  0.006  0.028  ±  0.006 
SM(d35:2)+H  0.014  ±  0.002  0.008  ±  0.001  0.002  ±  0.000 
SM(d35:4)+H  0.017  ±  0.003  0.011  ±  0.001  0.007  ±  0.001 
SM(d36:0)+H  0.023  ±  0.002  0.190  ±  0.006  0.029  ±  0.006 
SM(d36:1)+H  0.157  ±  0.010  0.366  ±  0.016  0.020  ±  0.002 
SM(d36:2)+H  0.061  ±  0.003  0.105  ±  0.011  0.008  ±  0.002 
SM(d18:2/18:1)+H  0.012  ±  0.002  0.025  ±  0.002  0.016  ±  0.001 
SM(d18:1/18:3)+H  0.157  ±  0.015  0.111  ±  0.004  0.043  ±  0.005 
SM(d36:5)+H  0.038  ±  0.011  0.018  ±  0.001  0.011  ±  0.002 
SM(d18:1/19:0)+H  0.003  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
SM(d37:4)+H  0.005  ±  0.002  0.005  ±  0.000  0.000  ±  0.000 
SM(d37:5)+H  0.001  ±  0.000  0.001  ±  0.000  0.000  ±  0.000 
SM(d37:6)+H  0.018  ±  0.005  0.007  ±  0.000  0.002  ±  0.000 
SM(d38:0)+H  0.005  ±  0.000  0.035  ±  0.002  0.005  ±  0.002 
SM(d38:1)+H  0.058  ±  0.002  0.149  ±  0.005  0.016  ±  0.003 
SM(d38:2)+H  0.009  ±  0.001  0.020  ±  0.001  0.001  ±  0.000 
SM(d38:3)+H  0.001  ±  0.000  0.008  ±  0.001  0.001  ±  0.000 
SM(d18:1/21:0)+H  0.003  ±  0.001  0.000  ±  0.000  0.000  ±  0.000 
SM(d39:1)+H  0.015  ±  0.001  0.020  ±  0.002  0.003  ±  0.001 
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SM(d39:4)+H  0.000  ±  0.000  0.001  ±  0.000  0.003  ±  0.001 
SM(d40:0)+H  0.013  ±  0.002  0.080  ±  0.005  0.046  ±  0.012 
SM(d40:1)+H  0.011  ±  0.002  0.047  ±  0.003  0.014  ±  0.004 
SM(d18:1/22:0)+H  0.301  ±  0.062  0.507  ±  0.044  0.171  ±  0.040 
SM(d40:2)+H  0.098  ±  0.020  0.179  ±  0.017  0.030  ±  0.006 
SM(d40:4)+H  0.002  ±  0.001  0.006  ±  0.000  0.000  ±  0.000 
SM(d40:6)+H  0.004  ±  0.002  0.003  ±  0.000  0.013  ±  0.003 
SM(d18:0/23:0)+H  0.002  ±  0.000  0.001  ±  0.000  0.002  ±  0.000 
SM(d41:0)+H  0.001  ±  0.000  0.005  ±  0.000  0.005  ±  0.001 
SM(d18:1/23:0)+H  0.031  ±  0.006  0.004  ±  0.000  0.004  ±  0.000 
SM(d41:1)+H  0.004  ±  0.001  0.025  ±  0.002  0.006  ±  0.001 
SM(d41:1)+H  0.046  ±  0.010  0.042  ±  0.003  0.028  ±  0.006 
SM(d41:2)+H  0.110  ±  0.028  0.119  ±  0.013  0.040  ±  0.011 
SM(d41:3)+H  0.013  ±  0.003  0.016  ±  0.002  0.001  ±  0.000 
SM(d42:0)+H  0.010  ±  0.002  0.031  ±  0.002  0.108  ±  0.031 
SM(d42:1)+H  0.040  ±  0.012  0.190  ±  0.021  0.312  ±  0.082 
SM(d18:1/24:0)+H  0.472  ±  0.155  0.371  ±  0.032  0.707  ±  0.177 
SM(d18:1/24:1)+H  0.936  ±  0.245  1.457  ±  0.139  0.888  ±  0.196 
SM(d18:0/24:2)+H  0.049  ±  0.020  0.005  ±  0.001  0.016  ±  0.005 
SM(d18:1/24:2)+H  0.216  ±  0.044  0.256  ±  0.014  0.057  ±  0.010 
SM(d18:0/24:3)+H  0.002  ±  0.001  0.010  ±  0.001  0.005  ±  0.001 
SM(d18:1/24:3)+H  0.043  ±  0.007  0.071  ±  0.003  0.016  ±  0.003 
SM(d42:5)+H  0.003  ±  0.001  0.076  ±  0.005  0.000  ±  0.000 
SM(d42:5)+H  0.010  ±  0.001  0.014  ±  0.000  0.001  ±  0.000 
SM(d42:6)+H  0.000  ±  0.000  0.013  ±  0.001  0.000  ±  0.000 
SM(d42:6)+H  0.000  ±  0.000  0.020  ±  0.001  0.000  ±  0.000 
SM(d42:7)+H  0.000  ±  0.000  0.003  ±  0.000  0.000  ±  0.000 
SM(d18:1/25:0)+H  0.003  ±  0.000  0.001  ±  0.000  0.000  ±  0.000 
SM(d43:1)+H  0.007  ±  0.002  0.004  ±  0.000  0.012  ±  0.003 
SM(d43:2)+H  0.025  ±  0.008  0.022  ±  0.003  0.018  ±  0.005 
SM(d18:1/25:3)+H  0.000  ±  0.000  0.002  ±  0.000  0.000  ±  0.000 
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SM(d43:4)+H  0.005  ±  0.001  0.004  ±  0.001  0.003  ±  0.001 
SM(d43:5)+H  0.012  ±  0.002  0.015  ±  0.001  0.003  ±  0.000 
SM(d44:0)+H  0.000  ±  0.000  0.001  ±  0.000  0.005  ±  0.002 
SM(d44:1)+H  0.010  ±  0.004  0.006  ±  0.000  0.039  ±  0.009 
SM(d44:2)+H  0.000  ±  0.000  0.004  ±  0.000  0.003  ±  0.001 
SM(d18:1/26:1)+H  0.047  ±  0.017  0.030  ±  0.005  0.097  ±  0.030 
SM(d44:3)+H  0.038  ±  0.014  0.035  ±  0.003  0.016  ±  0.004 
SM(d18:2/26:1)+H  0.001  ±  0.000  0.003  ±  0.000  0.011  ±  0.003 
SM(d44:4)+H  0.000  ±  0.000  0.006  ±  0.000  0.000  ±  0.000 
SM(d18:1/26:3)+H  0.053  ±  0.019  0.048  ±  0.005  0.062  ±  0.011 
SM(d44:5)+H  0.003  ±  0.000  0.042  ±  0.009  0.000  ±  0.000 
SM(d18:1/26:4)+H  0.113  ±  0.021  0.121  ±  0.004  0.050  ±  0.006 
SM(d44:6)+H  0.021  ±  0.004  0.014  ±  0.000  0.003  ±  0.000 
SM(d44:7)+H  0.002  ±  0.000  0.013  ±  0.001  0.000  ±  0.000 
SM(d44:8)+H  0.000  ±  0.000  0.005  ±  0.000  0.000  ±  0.000 
SM(d18:1/27:0)+H  0.003  ±  0.001  0.000  ±  0.000  0.001  ±  0.000 
SM(d18:1/27:1)+H  0.002  ±  0.001  0.000  ±  0.000  0.000  ±  0.000 
SM(d45:6)+H  0.013  ±  0.002  0.003  ±  0.000  0.003  ±  0.000 
SM(d18:1/28:0)+H  0.005  ±  0.001  0.001  ±  0.000  0.001  ±  0.000 
SM(d46:3)+H  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
SM(d46:4)+H  0.001  ±  0.000  0.000  ±  0.000  0.003  ±  0.001 
SM(d46:5)+H  0.004  ±  0.001  0.003  ±  0.000  0.008  ±  0.002 
SM(d46:6)+H  0.004  ±  0.001  0.005  ±  0.000  0.001  ±  0.000 
SM(d46:7)+H  0.001  ±  0.000  0.001  ±  0.000  0.000  ±  0.000 
SM(d18:1/30:0)+H  0.013  ±  0.005  0.002  ±  0.000  0.005  ±  0.001 
SM(d48:1)+H  0.007  ±  0.002  0.008  ±  0.001  0.003  ±  0.001 
SM(d48:2)+H  0.002  ±  0.001  0.000  ±  0.000  0.000  ±  0.000 
SM(d18:1/30:1)+H  0.008  ±  0.003  0.002  ±  0.000  0.002  ±  0.000 
SM(d17:0/32:1)+H  0.038  ±  0.013  0.006  ±  0.000  0.015  ±  0.004 
SM(d17:0/32:2)+H  0.003  ±  0.001  0.001  ±  0.000  0.001  ±  0.000 
SM(d18:1/32:0)+H  0.002  ±  0.001  0.000  ±  0.000  0.001  ±  0.000 
327 
 
SM(d50:1)+H  0.009  ±  0.002  0.004  ±  0.000  0.001  ±  0.000 
SM(d50:2)+H  0.001  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
SM(d18:1/32:1)+H  0.001  ±  0.000  0.000  ±  0.000  0.001  ±  0.000 
SM(d56:2)+H  0.014  ±  0.001  0.003  ±  0.000  0.004  ±  0.001 
SM(d56:3)+H  0.011  ±  0.002  0.002  ±  0.000  0.004  ±  0.001 
SM(d56:4)+H  0.007  ±  0.001  0.001  ±  0.000  0.002  ±  0.000 
 
 









TG(8:0/8:0/8:0)+NH4  0.004  ±  0.002  0.002  ±  0.000  0.001  ±  0.000 
TG(8:0/8:0/10:0)+NH4  0.009  ±  0.005  0.003  ±  0.001  0.002  ±  0.000 
TG(8:0/10:0/10:0)+NH4  0.009  ±  0.004  0.003  ±  0.001  0.001  ±  0.001 
TG(8:0/12:0/14:0)+NH4  0.004  ±  0.002  0.002  ±  0.000  0.001  ±  0.000 
TG(10:0/12:0/14:0)+NH4  0.006  ±  0.003  0.002  ±  0.000  0.001  ±  0.000 
TG(4:0/16:0/16:0)+NH4  0.002  ±  0.000  0.001  ±  0.000  0.001  ±  0.000 
TG(12:0/12:0/14:0)+NH4  0.004  ±  0.001  0.002  ±  0.000  0.001  ±  0.000 
TG(12:0/14:0/14:0)+NH4  0.005  ±  0.001  0.002  ±  0.000  0.001  ±  0.000 
TG(16:1/12:0/12:0)+NH4  0.001  ±  0.001  0.003  ±  0.001  0.001  ±  0.001 
TG(16:0/12:0/14:0)+NH4  0.007  ±  0.001  0.004  ±  0.000  0.002  ±  0.000 
TG(14:0e/14:0/14:0)+NH4  0.001  ±  0.000  0.004  ±  0.000  0.002  ±  0.000 
TG(16:0/10:3/16:0)+NH4  0.026  ±  0.005  0.012  ±  0.001  0.006  ±  0.001 
TG(16:0/13:0/14:0)+NH4  0.007  ±  0.002  0.007  ±  0.001  0.003  ±  0.001 
TG(15:0/13:0/16:0)+NH4  0.002  ±  0.000  0.002  ±  0.000  0.001  ±  0.000 
TG(16:0/14:0/14:0)+NH4  0.021  ±  0.005  0.020  ±  0.003  0.010  ±  0.003 
TG(12:0e/16:0/16:0)+NH4  0.015  ±  0.001  0.024  ±  0.001  0.012  ±  0.001 
TG(16:1/14:0/14:0)+NH4  0.019  ±  0.009  0.022  ±  0.009  0.011  ±  0.005 
TG(15:0/14:0/16:0)+NH4  0.015  ±  0.004  0.018  ±  0.005  0.009  ±  0.003 
TG(15:0/14:0/16:1)+NH4  0.020  ±  0.016  0.037  ±  0.018  0.018  ±  0.009 
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TG(12:0e/16:0/17:1)+NH4  0.002  ±  0.000  0.006  ±  0.000  0.003  ±  0.000 
TG(16:0/14:0/16:0)+NH4  0.081  ±  0.015  0.038  ±  0.010  0.019  ±  0.006 
TG(16:0e/14:0/16:0)+NH4  0.012  ±  0.001  0.018  ±  0.001  0.009  ±  0.001 
TG(14:0p/16:0/16:0)+NH4  0.029  ±  0.002  0.062  ±  0.002  0.031  ±  0.002 
TG(16:0/14:0/16:1)+NH4  0.055  ±  0.018  0.051  ±  0.009  0.027  ±  0.007 
TG(16:1/14:0/16:1)+NH4  0.017  ±  0.005  0.009  ±  0.005  0.005  ±  0.003 
TG(12:0p/16:1/18:1)+NH4  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
TG(15:0/16:0/16:0)+NH4  0.035  ±  0.008  0.068  ±  0.011  0.035  ±  0.009 
TG(15:0/16:0/16:1)+NH4  0.047  ±  0.011  0.065  ±  0.012  0.033  ±  0.009 
TG(16:1/14:0/17:1)+NH4  0.015  ±  0.003  0.016  ±  0.006  0.008  ±  0.004 
TG(16:0/16:0/16:0)+NH4  0.186  ±  0.025  0.102  ±  0.018  0.053  ±  0.014 
TG(16:0e/16:0/16:0)+NH4  0.008  ±  0.003  0.015  ±  0.001  0.008  ±  0.001 
TG(16:0p/16:0/16:0)+NH4  0.018  ±  0.006  0.024  ±  0.003  0.012  ±  0.001 
TG(16:0/16:0/16:1)+NH4  0.184  ±  0.051  0.124  ±  0.018  0.063  ±  0.015 
TG(20:1p/14:0/14:0)+NH4  0.008  ±  0.001  0.016  ±  0.001  0.008  ±  0.001 
TG(16:1/14:0/18:1)+NH4  0.082  ±  0.024  0.059  ±  0.008  0.030  ±  0.007 
TG(12:0p/18:1/18:1)+NH4  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
TG(16:1/16:1/16:1)+NH4  0.017  ±  0.005  0.010  ±  0.002  0.005  ±  0.002 
TG(16:0/16:0/17:0)+NH4  0.050  ±  0.009  0.036  ±  0.003  0.018  ±  0.004 
TG(15:0/16:0/18:1)+NH4  0.072  ±  0.015  0.064  ±  0.011  0.033  ±  0.009 
TG(15:0/16:1/18:1)+NH4  0.040  ±  0.010  0.039  ±  0.011  0.020  ±  0.007 
TG(16:1/16:1/17:1)+NH4  0.009  ±  0.002  0.008  ±  0.002  0.004  ±  0.001 
TG(18:0/16:0/16:0)+NH4  0.150  ±  0.027  0.091  ±  0.043  0.045  ±  0.021 
TG(18:0e/16:0/16:0)+NH4  0.011  ±  0.004  0.026  ±  0.002  0.013  ±  0.001 
TG(16:0/16:0/18:1)+NH4  0.455  ±  0.123  0.267  ±  0.022  0.135  ±  0.022 
TG(16:0e/16:0/18:1)+NH4  0.032  ±  0.012  0.062  ±  0.008  0.031  ±  0.002 
TG(18:0p/16:0/16:1)+NH4  0.019  ±  0.006  0.029  ±  0.003  0.014  ±  0.001 
TG(16:0/16:1/18:1)+NH4  0.366  ±  0.113  0.188  ±  0.015  0.094  ±  0.013 
TG(16:1/16:1/18:1)+NH4  0.095  ±  0.032  0.043  ±  0.004  0.022  ±  0.004 
TG(18:0/16:0/17:0)+NH4  0.024  ±  0.004  0.018  ±  0.001  0.009  ±  0.001 
TG(16:0/17:0/18:1)+NH4  0.070  ±  0.016  0.049  ±  0.005  0.025  ±  0.005 
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TG(20:1p/15:0/16:0)+NH4  0.006  ±  0.002  0.011  ±  0.001  0.005  ±  0.000 
TG(16:0/17:1/18:1)+NH4  0.088  ±  0.025  0.054  ±  0.005  0.027  ±  0.005 
TG(16:1/17:1/18:1)+NH4  0.032  ±  0.009  0.019  ±  0.003  0.010  ±  0.002 
TG(20:0/16:0/16:0)+NH4  0.097  ±  0.010  0.048  ±  0.005  0.025  ±  0.005 
TG(18:0/16:0/18:0)+NH4  0.068  ±  0.017  0.101  ±  0.009  0.050  ±  0.002 
TG(18:0e/16:0/18:0)+NH4  0.006  ±  0.002  0.017  ±  0.001  0.009  ±  0.001 
TG(18:0/16:0/18:1)+NH4  0.340  ±  0.089  0.264  ±  0.025  0.130  ±  0.006 
TG(18:0e/16:0/18:1)+NH4  0.029  ±  0.010  0.073  ±  0.008  0.036  ±  0.003 
TG(16:0/18:1/18:1)+NH4  0.655  ±  0.193  0.406  ±  0.030  0.205  ±  0.032 
TG(16:0e/18:1/18:1)+NH4  0.041  ±  0.014  0.074  ±  0.012  0.036  ±  0.004 
TG(20:0p/16:1/16:1)+NH4  0.010  ±  0.003  0.017  ±  0.002  0.008  ±  0.000 
TG(16:1/18:1/18:1)+NH4  0.325  ±  0.112  0.159  ±  0.021  0.080  ±  0.014 
TG(16:1/18:1/18:2)+NH4  0.090  ±  0.023  0.055  ±  0.003  0.028  ±  0.004 
TG(16:0/16:0/20:4)+NH4  0.019  ±  0.002  0.016  ±  0.001  0.008  ±  0.000 
TG(16:1/16:1/20:3)+NH4  0.015  ±  0.004  0.006  ±  0.000  0.003  ±  0.000 
TG(16:0/14:0/22:6)+NH4  0.004  ±  0.001  0.001  ±  0.000  0.001  ±  0.000 
TG(19:1/16:0/18:0)+NH4  0.030  ±  0.007  0.027  ±  0.004  0.013  ±  0.002 
TG(19:1/16:0/18:1)+NH4  0.066  ±  0.017  0.042  ±  0.003  0.021  ±  0.002 
TG(18:1/17:1/18:1)+NH4  0.054  ±  0.016  0.030  ±  0.002  0.015  ±  0.002 
TG(18:1/17:1/18:2)+NH4  0.022  ±  0.006  0.011  ±  0.001  0.006  ±  0.000 
TG(15:0/18:1/20:5)+NH4  0.030  ±  0.006  0.012  ±  0.001  0.006  ±  0.001 
TG(18:0/18:0/18:0)+NH4  0.032  ±  0.008  0.032  ±  0.003  0.016  ±  0.002 
TG(20:0e/16:0/18:0)+NH4  0.003  ±  0.001  0.003  ±  0.000  0.001  ±  0.000 
TG(20:0/16:0/18:1)+NH4  0.241  ±  0.048  0.105  ±  0.011  0.054  ±  0.011 
TG(18:0/18:0/18:1)+NH4  0.064  ±  0.020  0.075  ±  0.003  0.038  ±  0.003 
TG(20:0e/16:0/18:1)+NH4  0.007  ±  0.003  0.014  ±  0.001  0.007  ±  0.001 
TG(18:0/18:1/18:1)+NH4  0.321  ±  0.091  0.194  ±  0.014  0.097  ±  0.008 
TG(16:0e/18:1/20:1)+NH4  0.011  ±  0.004  0.023  ±  0.003  0.011  ±  0.001 
TG(18:1/18:1/18:1)+NH4  0.425  ±  0.115  0.293  ±  0.028  0.149  ±  0.028 
TG(16:0e/18:1/20:2)+NH4  0.012  ±  0.004  0.017  ±  0.003  0.009  ±  0.001 
TG(18:1/18:1/18:2)+NH4  0.151  ±  0.036  0.108  ±  0.004  0.054  ±  0.007 
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TG(18:1/18:2/18:2)+NH4  0.036  ±  0.008  0.045  ±  0.003  0.022  ±  0.003 
TG(18:1/18:1/18:3)+NH4  0.067  ±  0.008  0.043  ±  0.004  0.021  ±  0.001 
TG(18:2/18:2/18:2)+NH4  0.035  ±  0.010  0.029  ±  0.004  0.015  ±  0.002 
TG(16:0/16:0/22:6)+NH4  0.026  ±  0.007  0.009  ±  0.001  0.004  ±  0.000 
TG(16:0/16:1/22:6)+NH4  0.022  ±  0.006  0.006  ±  0.001  0.003  ±  0.000 
TG(15:0/16:0/24:0)+NH4  0.009  ±  0.002  0.008  ±  0.002  0.004  ±  0.001 
TG(16:0/16:0/23:1)+NH4  0.013  ±  0.002  0.013  ±  0.002  0.007  ±  0.002 
TG(19:1/18:0/18:1)+NH4  0.027  ±  0.004  0.016  ±  0.001  0.008  ±  0.001 
TG(19:1/18:1/18:1)+NH4  0.024  ±  0.008  0.013  ±  0.001  0.006  ±  0.000 
TG(19:1/18:1/18:2)+NH4  0.027  ±  0.007  0.012  ±  0.001  0.006  ±  0.001 
TG(18:1/17:1/20:3)+NH4  0.019  ±  0.004  0.009  ±  0.001  0.005  ±  0.000 
TG(16:0/16:0/24:0)+NH4  0.018  ±  0.005  0.014  ±  0.004  0.007  ±  0.003 
TG(16:0e/16:0/24:0)+NH4  0.002  ±  0.001  0.001  ±  0.000  0.000  ±  0.000 
TG(16:0/16:0/24:1)+NH4  0.013  ±  0.004  0.015  ±  0.002  0.007  ±  0.002 
TG(18:0e/16:0/22:1)+NH4  0.006  ±  0.003  0.005  ±  0.001  0.003  ±  0.000 
TG(18:0/18:1/20:1)+NH4  0.033  ±  0.010  0.028  ±  0.002  0.014  ±  0.002 
TG(20:0e/18:1/18:1)+NH4  0.006  ±  0.002  0.008  ±  0.001  0.004  ±  0.000 
TG(20:1/18:1/18:1)+NH4  0.082  ±  0.025  0.044  ±  0.004  0.022  ±  0.002 
TG(16:0e/18:1/22:2)+NH4  0.006  ±  0.002  0.006  ±  0.001  0.003  ±  0.000 
TG(18:1/18:1/20:2)+NH4  0.082  ±  0.023  0.036  ±  0.003  0.018  ±  0.001 
TG(18:1/18:1/20:3)+NH4  0.065  ±  0.011  0.032  ±  0.001  0.016  ±  0.001 
TG(16:0e/18:1/22:4)+NH4  0.008  ±  0.001  0.005  ±  0.000  0.003  ±  0.000 
TG(18:1/18:1/20:4)+NH4  0.050  ±  0.010  0.036  ±  0.007  0.018  ±  0.002 
TG(18:0/16:0/22:6)+NH4  0.012  ±  0.004  0.007  ±  0.001  0.003  ±  0.000 
TG(16:0/18:1/22:6)+NH4  0.066  ±  0.014  0.022  ±  0.003  0.011  ±  0.001 
TG(16:1/18:1/22:6)+NH4  0.038  ±  0.007  0.010  ±  0.002  0.005  ±  0.000 
TG(25:0/16:0/16:0)+NH4  0.008  ±  0.001  0.006  ±  0.001  0.003  ±  0.001 
TG(25:0/16:0/16:1)+NH4  0.007  ±  0.001  0.008  ±  0.002  0.004  ±  0.001 
TG(25:1/16:0/16:1)+NH4  0.010  ±  0.002  0.008  ±  0.001  0.004  ±  0.001 
TG(18:1/18:1/21:1)+NH4  0.090  ±  0.018  0.050  ±  0.005  0.025  ±  0.005 
TG(18:1/18:2/21:1)+NH4  0.048  ±  0.009  0.023  ±  0.001  0.012  ±  0.001 
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TG(26:0/16:0/16:0)+NH4  0.008  ±  0.001  0.006  ±  0.002  0.003  ±  0.001 
TG(26:1/16:0/16:0)+NH4  0.011  ±  0.003  0.009  ±  0.001  0.005  ±  0.001 
TG(18:0e/16:0/24:1)+NH4  0.004  ±  0.002  0.002  ±  0.000  0.001  ±  0.000 
TG(18:0p/16:0/24:1)+NH4  0.006  ±  0.003  0.004  ±  0.000  0.002  ±  0.000 
TG(16:0/18:1/24:1)+NH4  0.026  ±  0.005  0.020  ±  0.001  0.010  ±  0.001 
TG(18:0p/18:1/22:1)+NH4  0.003  ±  0.001  0.003  ±  0.000  0.001  ±  0.000 
TG(16:1/18:1/24:1)+NH4  0.018  ±  0.007  0.012  ±  0.001  0.006  ±  0.001 
TG(18:1/18:1/22:2)+NH4  0.024  ±  0.006  0.011  ±  0.001  0.006  ±  0.000 
TG(18:1/18:1/22:3)+NH4  0.073  ±  0.014  0.023  ±  0.001  0.012  ±  0.001 
TG(18:1/18:1/22:4)+NH4  0.059  ±  0.008  0.035  ±  0.003  0.017  ±  0.001 
TG(18:1/18:1/22:5)+NH4  0.028  ±  0.005  0.013  ±  0.002  0.006  ±  0.001 
TG(18:1/18:1/22:6)+NH4  0.048  ±  0.006  0.017  ±  0.002  0.008  ±  0.001 
TG(18:1/20:4/20:4)+NH4  0.019  ±  0.002  0.006  ±  0.001  0.003  ±  0.000 
TG(27:0/16:0/16:0)+NH4  0.004  ±  0.001  0.002  ±  0.000  0.001  ±  0.000 
TG(27:1/16:0/16:0)+NH4  0.003  ±  0.001  0.003  ±  0.001  0.002  ±  0.001 
TG(25:1/16:0/18:1)+NH4  0.006  ±  0.001  0.004  ±  0.001  0.002  ±  0.001 
TG(25:1/16:1/18:1)+NH4  0.006  ±  0.001  0.003  ±  0.001  0.001  ±  0.000 
TG(26:1/16:0/18:0)+NH4  0.007  ±  0.003  0.004  ±  0.001  0.002  ±  0.001 
TG(26:1/16:0/18:1)+NH4  0.017  ±  0.005  0.009  ±  0.002  0.005  ±  0.001 
TG(18:1/18:1/24:1)+NH4  0.423  ±  0.043  0.225  ±  0.025  0.114  ±  0.020 
TG(26:1/16:1/18:1)+NH4  0.027  ±  0.006  0.019  ±  0.001  0.010  ±  0.001 
TG(18:1/18:1/24:2)+NH4  0.015  ±  0.004  0.008  ±  0.002  0.004  ±  0.000 
TG(20:0/18:1/22:6)+NH4  0.021  ±  0.004  0.011  ±  0.001  0.005  ±  0.001 
TG(27:1/16:0/18:1)+NH4  0.003  ±  0.001  0.002  ±  0.001  0.001  ±  0.000 
TG(25:1/18:1/18:1)+NH4  0.002  ±  0.001  0.001  ±  0.000  0.001  ±  0.000 
TG(28:0/16:0/18:0)+NH4  0.000  ±  0.000  0.001  ±  0.000  0.000  ±  0.000 
TG(28:0/16:0/18:1)+NH4  0.002  ±  0.001  0.001  ±  0.000  0.001  ±  0.000 
TG(28:1/16:0/18:1)+NH4  0.006  ±  0.002  0.003  ±  0.000  0.002  ±  0.000 
TG(26:1/18:1/18:1)+NH4  0.008  ±  0.004  0.003  ±  0.000  0.002  ±  0.000 
TG(26:1/18:1/18:2)+NH4  0.005  ±  0.002  0.002  ±  0.000  0.001  ±  0.000 
TG(18:1/20:4/24:0)+NH4  0.002  ±  0.001  0.001  ±  0.000  0.000  ±  0.000 
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TG(29:0/16:0/18:1)+NH4  0.002  ±  0.001  0.001  ±  0.000  0.001  ±  0.000 
TG(29:1/16:0/18:1)+NH4  0.001  ±  0.000  0.001  ±  0.001  0.001  ±  0.000 
TG(27:1/18:1/18:1)+NH4  0.001  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
TG(30:0/16:0/18:1)+NH4  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
TG(30:1/16:0/18:1)+NH4  0.001  ±  0.000  0.001  ±  0.000  0.000  ±  0.000 
TG(28:1/18:1/18:1)+NH4  0.002  ±  0.001  0.001  ±  0.000  0.000  ±  0.000 
TG(26:1/18:1/20:2)+NH4  0.001  ±  0.000  0.001  ±  0.000  0.000  ±  0.000 
TG(29:1/18:0/18:1)+NH4  0.002  ±  0.001  0.001  ±  0.000  0.000  ±  0.000 
TG(29:1/18:1/18:1)+NH4  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
TG(30:0/18:0/18:1)+NH4  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
TG(30:0/18:1/18:1)+NH4  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
TG(30:1/18:1/18:1)+NH4  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
TG(28:1/18:1/20:2)+NH4  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
TG(26:0/18:1/24:0)+NH4  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
TG(26:1/18:1/24:0)+NH4  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
TG(26:1/18:1/24:1)+NH4  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
TG(26:1/18:1/24:2)+NH4  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
TG(28:0/18:1/24:1)+NH4  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
TG(28:1/18:1/24:1)+NH4  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
TG(28:1/22:1/22:1)+NH4  0.000  ±  0.000  0.000  ±  0.000  0.000  ±  0.000 
 









PA(16:1/18:1)‐H  0.004  ±  0.002  0.000  ±  0.000  0.001  ±  0.001 
PA(18:0/18:1)‐H  0.011  ±  0.003  0.005  ±  0.001  0.006  ±  0.003 
PA(26:0/18:1)‐H  0.000  ±  0.000  0.000  ±  0.000  0.001  ±  0.000 
PA(24:0/23:0)‐H  0.009  ±  0.003  0.006  ±  0.001  0.013  ±  0.003 
PA(24:1/23:0)‐H  0.025  ±  0.008  0.005  ±  0.001  0.006  ±  0.001 













MG(30:0)+H  0.000  ±  0.000  0.000  ±  0.000  0.003  ±  0.000 
MG(32:0)+H  0.003  ±  0.001  0.005  ±  0.000  0.032  ±  0.006 
MG(32:1)+H  0.001  ±  0.001  0.001  ±  0.000  0.007  ±  0.002 
MG(34:0)+H  0.002  ±  0.001  0.009  ±  0.000  0.029  ±  0.006 
MG(36:0)+H  0.000  ±  0.000  0.001  ±  0.000  0.006  ±  0.002 
MG(36:1)+H  0.002  ±  0.001  0.002  ±  0.000  0.026  ±  0.007 
MG(38:1)+H  0.001  ±  0.000  0.001  ±  0.000  0.012  ±  0.004 
 
 















Cer(d18:1/10:0)+H  0.05  0.05  0.05  0.20  0.32  ‐0.52 
Cer(d18:0/12:0)+H  0.10  0.05  0.05  0.13  0.31  ‐0.45 
Cer(d18:1/13:0)+H  0.05  0.05  0.05  0.22  0.19  ‐0.41 
Cer(d18:0/14:0)+H  0.05  0.05  0.35  0.38  ‐0.49  0.11 
Cer(d18:1/14:0)+H  0.05  0.05  0.05  0.64  0.16  ‐0.80 
Cer(d17:1/16:0)+H  0.05  0.20  0.05  0.74  0.12  ‐0.85 
Cer(d18:0/16:0)+H  0.05  0.05  0.65  0.44  ‐0.42  ‐0.02 
Cer(d18:1/16:0)+H  0.05  0.35  0.05  0.78  ‐0.15  ‐0.64 
Cer(d34:1)+H  0.05  0.05  0.05  0.24  0.14  ‐0.38 
Cer(d18:2/16:0)+H  0.05  0.05  0.05  0.67  0.21  ‐0.89 
Cer(d18:0/17:0)+H  0.05  0.05  0.05  0.24  0.47  ‐0.71 
Cer(d18:1/17:0)+H  0.05  0.05  0.05  0.75  0.70  ‐1.45 
Cer(d18:0/18:0)+H  0.05  0.05  0.10  ‐0.16  0.36  ‐0.20 
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Cer(d18:1/18:0)+H  0.05  0.05  0.05  0.40  0.48  ‐0.88 
Cer(d36:1)+H  0.05  0.10  0.05  0.19  0.23  ‐0.42 
Cer(d18:2/18:0)+H  0.20  0.10  0.10  0.73  0.63  ‐1.36 
Cer(d18:0/20:0)+H  0.20  0.10  0.10  ‐0.08  0.24  ‐0.16 
Cer(d18:1/20:0)+H  0.05  0.05  0.05  0.36  0.44  ‐0.80 
Cer(d38:1)+H  0.05  0.05  0.05  0.19  0.21  ‐0.40 
Cer(d17:1/22:0)+H  0.05  0.05  0.05  0.55  0.34  ‐0.89 
Cer(d40:0)+H  0.50  0.80  0.80  0.53  ‐0.65  0.13 
Cer(d18:0/22:0)+H  0.05  0.35  0.05  ‐0.35  ‐0.10  0.45 
Cer(d18:0/22:1)+H  0.05  0.65  0.20  0.11  ‐0.02  ‐0.09 
Cer(d18:1/22:0)+H  0.05  0.05  0.05  0.53  0.22  ‐0.75 
Cer(d18:2/22:0)+H  0.05  0.05  0.05  0.71  0.38  ‐1.09 
Cer(d18:0/23:0)+H  0.50  0.50  0.50  ‐0.04  ‐0.02  0.06 
Cer(d18:0/23:1)+H  0.05  0.50  0.20  0.14  0.03  ‐0.18 
Cer(d18:1/23:0)+H  0.05  0.50  0.05  0.59  0.08  ‐0.68 
Cer(d18:2/23:0)+H  0.05  0.05  0.05  0.68  0.34  ‐1.02 
Cer(d18:0/24:0)+H  0.05  0.05  0.05  ‐0.59  ‐0.50  1.09 
Cer(d18:1/24:0)+H  0.10  0.50  0.10  0.69  0.08  ‐0.78 
Cer(d18:0/24:1)+H  0.10  0.05  0.05  ‐0.17  ‐0.37  0.53 
Cer(d18:1/24:0)+H  0.20  0.35  0.20  0.29  ‐0.05  ‐0.25 
Cer(d18:1/24:1)+H  0.10  0.50  0.10  0.58  0.02  ‐0.60 
Cer(d18:2/24:0)+H  0.05  0.10  0.05  0.70  0.20  ‐0.90 
Cer(d18:2/24:1)+H  0.05  0.05  0.05  0.66  0.40  ‐1.07 
Cer(d18:1/24:2)+H  0.05  0.05  0.20  ‐0.34  0.20  0.14 
Cer(d18:1/24:3)+H  0.05  0.05  0.05  0.20  0.62  ‐0.82 
Cer(d18:0/25:0)+H  0.20  0.20  0.05  ‐0.30  ‐0.12  0.42 
Cer(d18:0/25:1)+H  0.65  0.05  0.05  ‐0.06  ‐0.32  0.37 
Cer(d18:1/25:0)+H  0.10  0.20  0.20  0.37  ‐0.15  ‐0.22 
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Cer(d18:1/25:1)+H  0.05  0.20  0.05  0.62  0.13  ‐0.75 
Cer(d18:2/25:1)+H  0.05  0.05  0.05  0.47  0.40  ‐0.87 
Cer(d18:0/26:0)+H  0.05  0.05  0.05  ‐0.55  ‐0.55  1.10 
Cer(d18:0/26:1)+H  0.05  0.05  0.05  ‐0.40  ‐0.75  1.15 
Cer(d18:1/26:0)+H  0.35  0.05  0.05  0.04  ‐0.48  0.43 
Cer(d18:2/26:0)+H  0.50  0.80  0.50  ‐0.14  0.05  0.08 
Cer(d18:1/26:1)+H  0.10  0.05  0.35  0.56  ‐0.42  ‐0.14 
Cer(d18:2/26:1)+H  0.05  0.20  0.05  0.69  0.14  ‐0.83 
Cer(d18:1/26:3)+H  0.05  0.05  0.05  0.87  1.16  ‐2.03 
Cer(d20:0/25:0)+H  0.65  0.65  0.50  ‐0.43  0.41  0.02 
Cer(d18:1/27:0)+H  0.50  0.50  0.20  ‐0.44  0.34  0.09 
Cer(d20:0/26:0)+H  0.35  0.35  0.50  ‐0.54  0.51  0.04 
Cer(d18:0/28:1)+H  0.05  0.05  0.05  #NAME?  ‐0.67  Inf 
Cer(d18:1/28:0)+H  0.10  0.65  0.10  ‐0.59  0.21  0.38 
Cer(d18:1/28:1)+H  0.35  0.05  0.05  0.22  ‐0.58  0.36 
Cer(d22:1/24:1)+H  0.10  0.35  0.50  ‐0.66  0.42  0.24 
Cer(d22:0/25:0)+H  0.65  0.50  0.35  ‐0.71  0.80  ‐0.09 
Cer(d20:1/27:0)+H  0.65  0.35  0.80  ‐0.64  0.61  0.03 
Cer(d22:1/25:1)+H  0.35  0.50  0.40  ‐0.95  0.78  0.17 
Cer(d24:0/24:0)+H  0.20  0.20  0.65  ‐0.79  0.87  ‐0.07 
Cer(d20:1/28:0)+H  0.20  0.20  0.50  ‐0.70  0.69  0.02 
Cer(d20:2/28:0)+H  0.65  0.20  0.35  ‐0.31  0.31  ‐0.01 
Cer(d25:0/24:0)+H  0.20  0.20  0.35  ‐0.85  0.95  ‐0.10 
Cer(d22:1/27:0)+H  0.80  0.50  0.50  ‐0.90  1.00  ‐0.11 
Cer(d24:0/26:0)+H  0.35  0.05  0.10  ‐0.74  1.00  ‐0.26 
Cer(d22:1/28:0)+H  0.20  0.20  0.35  ‐0.74  0.93  ‐0.18 
Cer(d25:0/26:0)+H  0.35  0.20  0.35  ‐0.91  1.20  ‐0.29 
Cer(d22:1/29:0)+H  0.05  0.05  0.20  ‐1.20  1.44  ‐0.24 
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Cer(d22:1/30:0)+H  0.20  0.20  0.35  ‐0.81  0.84  ‐0.03 
Cer(d25:0/28:0)+H  0.60  0.20  0.20  ‐0.93  Inf  #NAME? 
CerG1(d18:0/14:0)+H  0.10  0.20  0.35  0.60  ‐0.30  ‐0.30 
CerG1(d18:1/14:0)+H  0.05  0.05  0.05  1.17  ‐0.31  ‐0.86 
CerG1(d17:1/16:0)+H  0.05  0.80  0.05  0.90  ‐0.09  ‐0.81 
CerG1(d18:0/16:0)+H  0.10  0.05  0.50  0.32  ‐0.32  0.00 
CerG1(d18:1/16:0)+H  0.05  0.10  0.05  0.98  ‐0.21  ‐0.77 
CerG1(d18:2/16:0)+H  0.05  0.05  0.20  0.66  ‐0.28  ‐0.38 
CerG1(d18:1/17:0)+H  0.05  0.05  0.05  0.97  0.45  ‐1.42 
CerG1(d18:1/18:0)+H  0.05  0.05  0.05  0.42  0.60  ‐1.02 
CerG1(d18:0/20:0)+H  0.05  0.05  0.20  ‐0.32  0.44  ‐0.12 
CerG1(d18:1/20:0)+H  0.05  0.05  0.05  0.28  0.52  ‐0.80 
CerG1(d18:0/22:0)+H  0.50  0.80  0.50  ‐0.07  ‐0.05  0.12 
CerG1(d18:1/22:0)+H  0.05  0.20  0.05  0.61  0.16  ‐0.77 
CerG1(d18:1/22:1)+H  0.05  0.05  0.05  0.58  0.60  ‐1.18 
CerG1(d18:0/23:0)+H  0.05  0.10  0.35  0.35  ‐0.22  ‐0.14 
CerG1(d18:1/23:0)+H  0.05  0.20  0.05  0.88  ‐0.24  ‐0.64 
CerG1(d18:1/23:1)+H  0.05  0.05  0.05  0.80  0.50  ‐1.30 
CerG1(d18:0/24:0)+H  0.35  0.05  0.05  0.15  ‐0.74  0.59 
CerG1(d18:0/24:1)+H  0.35  0.05  0.05  ‐0.01  ‐0.38  0.39 
CerG1(d18:1/24:0)+H  0.05  0.05  0.20  0.96  ‐0.50  ‐0.46 
CerG1(d18:1/24:1)+H  0.05  0.10  0.10  0.77  ‐0.21  ‐0.56 
CerG1(d18:2/24:1)+H  0.05  0.20  0.05  0.60  0.15  ‐0.75 
CerG1(d18:0/25:0)+H  0.35  0.05  0.20  0.17  ‐0.34  0.16 
CerG1(d18:1/25:0)+H  0.05  0.05  0.10  0.87  ‐0.36  ‐0.51 
CerG1(d18:1/25:1)+H  0.05  0.20  0.05  0.94  ‐0.17  ‐0.77 
CerG1(d18:0/26:0)+H  0.35  0.05  0.05  0.12  ‐0.96  0.83 
CerG1(d18:0/26:1)+H  0.05  0.05  0.20  0.48  ‐0.68  0.20 
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CerG1(d18:1/26:0)+H  0.05  0.05  0.50  0.83  ‐0.85  0.02 
CerG1(d18:1/26:1)+H  0.05  0.05  0.35  0.99  ‐0.64  ‐0.35 
CerG1(d44:4)+H  0.05  0.05  0.05  0.54  1.14  ‐1.68 
CerG1(d46:1)+H  0.20  0.05  0.50  0.29  ‐0.46  0.16 
CerG2(d18:1/16:0)+H  0.20  0.35  0.20  0.54  ‐0.17  ‐0.37 
CerG2(d34:2)+H  0.80  0.05  0.05  0.04  1.72  ‐1.75 
CerG2(d18:1/22:0)+H  0.35  0.05  0.10  0.13  0.27  ‐0.40 
CerG2(d18:1/22:1)+H  0.10  0.05  0.05  ‐0.05  1.21  ‐1.16 
CerG2(d18:1/23:0)+H  0.05  0.65  0.10  0.49  ‐0.03  ‐0.46 
CerG2(d18:1/23:1)+H  0.05  0.05  0.05  0.47  0.41  ‐0.88 
CerG2(d18:0/24:1)+H  0.50  0.05  0.10  0.08  ‐0.42  0.35 
CerG2(d18:1/24:0)+H  0.05  0.05  0.50  0.63  ‐0.58  ‐0.05 
CerG2(d18:1/24:1)+H  0.35  0.35  0.20  0.31  ‐0.06  ‐0.25 
CerG2(d18:2/24:1)+H  0.35  0.05  0.05  0.22  0.62  ‐0.83 
CerG2(d18:1/25:0)+H  0.05  0.05  0.35  0.82  ‐0.59  ‐0.23 
CerG2(d43:2)+H  0.35  0.50  0.20  0.44  0.03  ‐0.46 
CerG2(d18:1/26:0)+H  0.20  0.05  0.10  0.68  ‐1.02  0.34 
CerG2(d18:1/26:1)+H  0.10  0.05  0.35  0.58  ‐0.45  ‐0.13 
CerG3(d18:1/14:0)+H  0.05  0.05  0.05  1.71  Inf  #NAME? 
CerG3(d18:1/16:0)+H  0.05  0.35  0.05  0.99  0.08  ‐1.07 
CerG3(d18:1/22:0)+H  0.05  0.05  0.05  0.68  0.80  ‐1.48 
CerG3(d18:1/23:0)+H  0.05  0.60  0.05  1.84  0.05  ‐1.88 
CerG3(d18:1/24:0)+H  0.05  0.50  0.05  1.13  ‐0.06  ‐1.07 
CerG3(d18:1/24:1)+H  0.05  0.05  0.05  0.81  0.32  ‐1.13 
CerG3(d18:2/24:1)+H  0.05  0.20  0.05  1.39  Inf  #NAME? 
CerG3(d18:1/26:0)+H  0.05  0.05  0.10  Inf  #NAME?  ‐0.90 
CerG3(d18:1/26:1)+H  0.05  0.05  0.05  1.74  ‐0.62  ‐1.12 
ChE(18:1)+NH4  0.05  0.10  0.05  0.57  0.23  ‐0.79 
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ChE(18:2)+NH4  0.05  0.65  0.05  0.71  0.04  ‐0.75 
ChE(20:1)+NH4  0.35  0.05  0.10  0.22  0.57  ‐0.79 
ChE(20:2)+NH4  0.35  0.05  0.05  0.14  1.24  ‐1.38 
ChE(20:3)+NH4  0.35  0.05  0.05  0.14  1.23  ‐1.37 
ChE(20:4)+NH4  0.10  0.05  0.05  0.16  0.87  ‐1.02 
ChE(20:5)+NH4  0.35  0.05  0.05  0.12  0.92  ‐1.04 
ChE(22:1)+NH4  0.50  0.05  0.35  ‐0.13  0.68  ‐0.55 
ChE(22:2)+NH4  0.35  0.05  0.05  0.06  1.06  ‐1.12 
ChE(22:3)+NH4  0.10  0.05  0.05  ‐0.20  1.53  ‐1.33 
ChE(22:4)+NH4  0.05  0.05  0.05  ‐0.75  2.20  ‐1.45 
ChE(22:5)+NH4  0.05  0.05  0.05  ‐0.20  1.43  ‐1.23 
ChE(22:6)+NH4  0.50  0.05  0.05  ‐0.12  1.13  ‐1.01 
ChE(24:1)+NH4  0.35  0.50  0.35  0.43  ‐0.07  ‐0.36 
ChE(24:3)+NH4  0.65  0.05  0.05  ‐0.03  1.20  ‐1.17 
ChE(24:4)+NH4  0.05  0.05  0.05  ‐0.47  1.78  ‐1.32 
ChE(24:5)+NH4  0.05  0.05  0.05  ‐0.50  1.79  ‐1.28 
ChE(24:6)+NH4  0.20  0.05  0.05  ‐0.23  1.62  ‐1.39 
ChE(26:0)+NH4  0.35  0.05  0.05  0.91  ‐1.64  0.73 
ChE(26:1)+NH4  0.35  0.05  0.35  0.83  ‐0.73  ‐0.10 
ChE(26:2)+NH4  0.35  0.20  0.35  0.33  ‐0.16  ‐0.17 
ChE(26:3)+NH4  0.35  0.05  0.20  0.27  0.68  ‐0.94 
ChE(26:4)+NH4  0.35  0.05  0.05  0.12  1.15  ‐1.27 
ChE(26:5)+NH4  0.35  0.05  0.05  0.08  1.44  ‐1.52 
ChE(26:6)+NH4  0.35  0.05  0.05  0.41  1.16  ‐1.57 
ChE(28:1)+NH4  0.35  0.05  0.20  1.06  ‐1.41  0.35 
ChE(28:2)+NH4  0.35  0.05  0.35  0.85  ‐0.68  ‐0.18 
ChE(28:3)+NH4  0.35  0.20  0.35  0.65  0.12  ‐0.77 
ChE(28:4)+NH4  0.35  0.05  0.10  0.30  0.84  ‐1.14 
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ChE(28:5)+NH4  0.35  0.05  0.05  0.04  1.50  ‐1.54 
ChE(28:6)+NH4  0.35  0.05  0.05  0.55  1.05  ‐1.59 
ChE(30:1)+NH4  0.50  0.05  0.05  Inf  #NAME?  1.07 
ChE(30:3)+NH4  0.20  0.05  0.50  Inf  #NAME?  ‐0.15 
ChE(30:4)+NH4  0.35  0.05  0.35  0.26  0.34  ‐0.60 
ChE(30:5)+NH4  0.35  0.05  0.20  ‐0.18  1.10  ‐0.92 
ChE(30:6)+NH4  0.35  0.05  0.20  0.42  0.68  ‐1.09 
ChE(32:5)+NH4  0.50  0.05  0.35  0.13  0.35  ‐0.48 
ChE(32:6)+NH4  0.35  0.10  0.35  0.35  0.18  ‐0.53 
CL(14:0/16:0/16:0/16:0)‐H  0.05  0.05  0.20  #NAME?  1.15  Inf 
CL(14:0/16:0/16:1/16:0)‐H  0.05  0.05  0.05  #NAME?  0.48  Inf 
CL(14:0/14:0/18:1/16:1)‐H  0.05  0.05  0.05  ‐0.49  ‐0.31  0.80 
CL(14:0/16:1/16:1/16:1)‐H  0.20  0.05  0.05  Inf  #NAME?  0.48 
CL(16:0/16:0/16:0/16:0)‐H  0.05  0.05  0.20  #NAME?  1.56  Inf 
CL(14:0/16:0/16:0/18:1)‐H  0.05  0.05  0.05  ‐1.72  0.74  0.97 
CL(14:0/18:1/16:0/16:1)‐H  0.05  0.35  0.05  ‐0.72  0.03  0.70 
CL(14:0/16:1/16:1/18:1)‐H  0.35  0.05  0.05  0.35  ‐0.80  0.45 
CL(16:1/16:1/16:1/16:1)‐H  0.35  0.05  0.20  0.82  ‐0.98  0.15 
CL(15:0/16:0/16:0/18:1)‐H  0.05  0.05  0.10  ‐2.00  1.44  0.55 
CL(14:0/15:0/18:1/18:1)‐H  0.05  0.05  0.20  ‐1.08  0.69  0.39 
CL(17:1/14:0/18:1/16:1)‐H  0.35  0.10  0.35  0.10  ‐0.27  0.17 
CL(17:1/16:1/16:1/16:1)‐H  0.35  0.05  0.50  0.50  ‐0.45  ‐0.05 
CL(16:0/16:0/16:0/18:0)‐H  0.05  0.05  1.00  #NAME?  Inf  NaN 
CL(18:1/16:0/16:0/16:0)‐H  0.05  0.05  0.05  ‐2.02  1.30  0.72 
CL(14:0/18:1/16:0/18:1)‐H  0.05  0.05  0.05  ‐1.21  0.58  0.63 
CL(18:1/16:1/16:0/16:1)‐H  0.35  0.05  0.05  ‐0.14  ‐0.36  0.50 
CL(16:1/16:1/16:1/18:1)‐H  0.35  0.05  0.20  0.46  ‐0.72  0.26 
CL(18:3/14:0/16:0/18:1)‐H  0.05  0.05  0.05  #NAME?  0.73  Inf 
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CL(18:2/16:1/16:1/16:1)‐H  0.35  0.05  0.65  0.41  ‐0.47  0.05 
CL(12:2/18:1/18:1/18:1)‐H  0.05  0.20  0.05  ‐1.20  0.13  1.07 
CL(22:5/14:0/16:1/14:0)‐H  0.25  0.05  0.10  0.76  ‐1.12  0.36 
CL(18:4/16:1/16:1/16:1)‐H  0.20  0.05  0.35  Inf  #NAME?  0.13 
CL(17:0/16:0/16:0/18:1)‐H  0.05  0.05  0.05  #NAME?  1.68  Inf 
CL(18:1/16:0/18:1/15:0)‐H  0.05  0.05  0.35  ‐1.43  1.26  0.16 
CL(17:1/16:0/16:1/18:1)‐H  0.05  0.10  0.20  ‐0.40  0.22  0.18 
CL(17:1/16:1/16:1/18:1)‐H  0.35  0.10  0.65  0.19  ‐0.23  0.04 
CL(17:1/16:1/18:2/16:1)‐H  0.35  0.65  0.50  0.17  0.00  ‐0.17 
CL(16:0/16:0/16:0/20:0)‐H  0.05  0.05  0.05  #NAME?  0.69  Inf 
CL(18:1/16:0/18:0/16:0)‐H  0.05  0.05  0.05  ‐2.05  1.53  0.51 
CL(18:1/16:0/16:0/18:1)‐H  0.05  0.05  0.05  ‐1.79  1.06  0.73 
CL(18:1/16:0/16:1/18:1)‐H  0.05  0.10  0.05  ‐0.82  0.29  0.53 
CL(18:1/16:1/18:2/16:0)‐H  0.35  0.05  0.10  0.18  ‐0.53  0.34 
CL(18:3/16:0/16:0/18:1)‐H  0.05  0.05  0.35  ‐0.55  0.62  ‐0.07 
CL(18:3/18:1/16:0/16:0)‐H  0.05  0.05  0.05  #NAME?  1.03  Inf 
CL(18:2/16:1/18:1/16:1)‐H  0.35  0.10  0.35  0.15  ‐0.30  0.15 
CL(20:4/16:0/14:0/18:1)‐H  0.05  0.05  0.05  ‐1.20  0.60  0.60 
CL(18:2/16:1/18:2/16:1)‐H  0.50  0.65  0.50  0.08  0.01  ‐0.08 
CL(18:4/16:0/16:1/18:1)‐H  0.35  0.10  0.05  ‐0.09  ‐0.29  0.38 
CL(20:4/16:1/16:1/16:1)‐H  0.35  0.05  0.35  0.53  ‐0.34  ‐0.18 
CL(18:4/16:1/16:1/18:1)‐H  0.35  0.05  0.35  0.52  ‐0.71  0.19 
CL(18:4/16:1/18:2/16:1)‐H  0.35  0.05  0.65  0.46  ‐0.46  0.00 
CL(17:0/18:1/18:1/16:0)‐H  0.05  0.05  0.20  ‐1.41  1.23  0.18 
CL(17:1/18:1/16:0/18:1)‐H  0.05  0.05  0.20  ‐0.94  0.68  0.26 
CL(17:1/18:1/16:1/18:1)‐H  0.35  0.35  0.35  ‐0.08  ‐0.07  0.16 
CL(18:1/15:1/18:1/18:1)‐H  0.05  0.05  1.00  #NAME?  Inf  NaN 
CL(17:1/16:1/18:2/18:1)‐H  0.50  0.20  0.50  ‐0.07  0.15  ‐0.08 
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CL(18:3/18:1/15:0/18:1)‐H  0.05  0.05  0.05  #NAME?  1.22  Inf 
CL(17:1/16:1/18:2/18:2)‐H  0.35  0.05  0.20  ‐0.17  0.59  ‐0.41 
CL(17:1/16:1/16:1/20:4)‐H  0.35  0.20  0.65  0.15  ‐0.17  0.02 
CL(18:1/16:0/18:0/18:0)‐H  0.35  0.05  0.05  0.11  ‐0.67  0.57 
CL(18:1/16:0/18:0/18:1)‐H  0.05  0.05  0.05  ‐1.74  1.38  0.36 
CL(18:1/16:0/18:1/18:1)‐H  0.05  0.05  0.05  ‐1.43  1.03  0.40 
CL(18:1/16:1/18:1/18:1)‐H  0.10  0.65  0.10  ‐0.28  ‐0.01  0.29 
CL(18:3/18:1/16:0/18:0)‐H  0.05  0.05  0.05  ‐1.59  1.14  0.46 
CL(18:2/18:1/16:1/18:1)‐H  0.35  0.35  0.10  ‐0.10  ‐0.13  0.24 
CL(18:3/18:1/16:0/18:1)‐H  0.05  0.05  0.05  ‐1.50  0.80  0.69 
CL(18:2/16:1/18:1/18:2)‐H  0.10  0.10  0.50  ‐0.20  0.26  ‐0.05 
CL(18:2/18:2/16:1/18:1)‐H  0.05  0.05  0.05  ‐0.75  0.38  0.36 
CL(18:2/18:2/18:2/16:1)‐H  0.35  0.05  0.20  ‐0.20  0.41  ‐0.21 
CL(20:4/16:1/16:1/18:1)‐H  0.35  0.35  0.50  0.20  ‐0.10  ‐0.10 
CL(20:4/16:1/18:1/16:1)‐H  0.35  0.05  0.35  0.18  ‐0.33  0.15 
CL(22:5/16:1/16:1/16:1)‐H  0.20  0.35  0.20  0.25  ‐0.07  ‐0.18 
CL(18:2/20:4/16:1/16:1)‐H  0.35  0.10  0.50  0.15  ‐0.24  0.09 
CL(20:5/16:1/16:1/18:2)‐H  0.50  0.50  0.50  0.08  0.02  ‐0.10 
CL(17:0/18:1/18:0/18:1)‐H  0.05  0.05  0.50  ‐1.39  1.39  0.00 
CL(17:0/18:1/18:1/18:1)‐H  0.05  0.05  0.35  ‐0.89  0.95  ‐0.07 
CL(17:1/18:1/18:1/18:1)‐H  0.10  0.20  0.35  ‐0.22  0.17  0.06 
CL(17:1/18:1/18:2/18:1)‐H  0.05  0.10  0.50  ‐0.29  0.26  0.03 
CL(17:0/20:4/16:0/18:1)‐H  0.05  0.05  0.20  ‐1.46  1.14  0.32 
CL(17:1/18:1/18:2/18:2)‐H  0.05  0.05  0.10  ‐0.31  0.64  ‐0.32 
CL(17:0/18:2/18:2/18:2)‐H  0.35  0.20  0.50  ‐0.11  0.15  ‐0.04 
CL(17:1/20:4/16:0/18:1)‐H  0.05  0.05  0.20  ‐0.81  0.65  0.17 
CL(17:1/18:2/18:2/18:2)‐H  0.50  0.10  0.10  0.06  0.29  ‐0.35 
CL(17:1/20:4/16:1/18:1)‐H  0.50  0.50  0.35  ‐0.05  ‐0.04  0.09 
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CL(17:1/16:1/20:4/18:2)‐H  0.50  0.20  0.50  ‐0.05  0.16  ‐0.11 
CL(16:0/18:0/18:0/20:0)‐H  0.05  0.05  0.10  ‐0.69  0.43  0.25 
CL(18:4/18:2/18:2/18:2)‐H  0.20  0.05  0.20  ‐0.24  0.48  ‐0.24 
CL(18:1/18:0/18:0/18:1)‐H  0.35  0.05  0.05  0.49  ‐0.86  0.37 
CL(18:1/18:0/18:1/18:1)‐H  0.05  0.05  0.50  ‐1.19  1.20  ‐0.01 
CL(18:1/18:1/18:1/18:1)‐H  0.05  0.05  0.20  ‐0.68  0.57  0.11 
CL(18:2/18:1/18:1/18:1)‐H  0.05  0.35  0.35  ‐0.25  0.15  0.10 
CL(20:4/16:0/18:0/18:1)‐H  0.05  0.05  0.05  ‐1.62  1.23  0.39 
CL(18:2/18:1/18:1/18:2)‐H  0.05  0.05  0.35  ‐0.32  0.39  ‐0.07 
CL(20:4/16:0/18:1/18:1)‐H  0.05  0.05  0.05  ‐1.11  0.76  0.34 
CL(18:2/18:2/18:2/18:1)‐H  0.05  0.05  0.05  ‐0.35  0.62  ‐0.28 
CL(18:2/18:1/18:2/18:2)‐H  0.10  0.35  0.35  ‐0.27  0.11  0.16 
CL(18:2/18:1/20:4/16:1)‐H  0.10  0.05  0.05  ‐0.27  0.68  ‐0.40 
CL(18:2/20:4/16:1/18:1)‐H  0.50  0.35  0.50  ‐0.07  0.03  0.04 
CL(18:2/16:1/16:1/22:5)‐H  0.50  0.05  0.10  0.06  0.34  ‐0.40 
CL(18:2/16:1/20:4/18:2)‐H  0.20  0.05  0.35  ‐0.22  0.33  ‐0.12 
CL(19:1/18:1/18:1/18:1)‐H  0.05  0.05  0.50  ‐0.44  0.36  0.08 
CL(19:1/18:1/18:2/18:1)‐H  0.05  0.10  0.35  ‐0.41  0.30  0.11 
CL(19:1/18:1/18:2/18:2)‐H  0.05  0.05  0.05  ‐0.48  0.69  ‐0.21 
CL(17:0/18:1/20:4/18:1)‐H  0.05  0.05  0.50  ‐1.04  1.07  ‐0.03 
CL(17:1/18:1/18:1/20:4)‐H  0.10  0.05  0.35  ‐0.54  0.42  0.11 
CL(17:1/18:1/20:4/18:1)‐H  0.10  0.20  0.35  ‐0.28  0.19  0.09 
CL(17:1/18:1/18:2/20:4)‐H  0.10  0.10  0.50  ‐0.26  0.26  0.00 
CL(17:1/18:2/18:2/20:4)‐H  0.05  0.05  0.10  ‐0.36  0.68  ‐0.33 
CL(18:1/18:0/18:0/20:0)‐H  0.05  0.05  0.35  0.51  ‐0.38  ‐0.13 
CL(18:2/18:2/18:2/20:4)‐H  0.35  0.05  0.05  0.11  0.53  ‐0.64 
CL(20:5/18:2/18:2/18:2)‐H  0.20  0.05  0.05  ‐0.24  0.69  ‐0.45 
CL(18:1/16:0/16:0/24:1)‐H  0.35  0.05  0.20  0.39  ‐0.74  0.35 
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CL(22:2/16:0/18:0/18:1)‐H  0.35  0.05  0.50  0.29  ‐0.32  0.03 
CL(20:4/18:0/18:0/18:0)‐H  0.50  0.35  0.20  0.04  0.06  ‐0.11 
CL(18:1/18:1/18:1/20:1)‐H  0.05  0.05  0.35  ‐0.72  0.78  ‐0.06 
CL(18:1/16:0/20:1/20:3)‐H  0.05  0.05  0.20  ‐1.01  1.15  ‐0.14 
CL(18:1/18:0/18:0/20:4)‐H  0.05  0.05  0.05  #NAME?  1.45  Inf 
CL(20:4/18:1/18:0/18:1)‐H  0.05  0.05  0.35  ‐1.18  1.12  0.06 
CL(18:2/18:1/20:3/18:1)‐H  0.05  0.05  0.05  ‐0.48  0.74  ‐0.27 
CL(20:4/18:1/18:1/18:1)‐H  0.05  0.05  0.50  ‐0.50  0.45  0.05 
CL(18:2/18:1/20:4/18:1)‐H  0.05  0.05  0.05  ‐0.21  0.64  ‐0.43 
CL(18:2/20:4/18:1/18:1)‐H  0.05  0.05  0.50  ‐0.23  0.30  ‐0.07 
CL(18:2/18:1/18:2/20:4)‐H  0.10  0.05  0.05  ‐0.19  0.52  ‐0.33 
CL(18:2/18:1/20:4/18:2)‐H  0.05  0.05  0.05  ‐0.31  0.48  ‐0.18 
CL(23:0/16:0/18:1/18:1)‐H  0.65  0.20  0.35  0.10  ‐0.20  0.10 
CL(21:0/20:4/16:0/18:0)‐H  0.35  0.10  0.05  ‐0.07  0.38  ‐0.30 
CL(20:5/18:1/20:4/18:1)‐H  0.05  0.05  1.00  #NAME?  Inf  NaN 
CL(18:2/18:2/18:2/22:6)‐H  0.10  0.05  0.05  ‐0.17  0.57  ‐0.40 
CL(18:4/22:6/20:4/16:1)‐H  0.20  0.05  0.35  0.38  ‐0.48  0.10 
CL(18:1/18:0/20:1/20:1)‐H  0.05  0.20  0.05  0.44  ‐0.11  ‐0.34 
CL(18:1/16:0/18:1/24:1)‐H  0.05  0.05  1.00  #NAME?  Inf  NaN 
CL(22:3/18:0/18:0/18:1)‐H  0.05  0.10  0.05  0.42  ‐0.10  ‐0.32 
CL(22:1/18:1/18:1/18:1)‐H  0.05  0.05  1.00  #NAME?  Inf  NaN 
CL(20:4/18:0/18:1/20:0)‐H  0.20  0.65  0.20  0.17  ‐0.01  ‐0.16 
CL(22:3/18:1/18:1/18:1)‐H  0.05  0.05  0.10  ‐1.87  1.30  0.58 
CL(20:2/18:0/18:1/20:4)‐H  0.10  0.35  0.35  0.25  ‐0.14  ‐0.11 
CL(22:5/18:0/18:1/18:1)‐H  0.05  0.05  0.35  ‐1.37  1.68  ‐0.32 
CL(22:5/18:1/18:1/18:1)‐H  0.05  0.05  0.05  ‐0.73  1.33  ‐0.60 
CL(23:0/18:0/18:0/18:1)‐H  0.10  0.20  0.10  0.51  ‐0.23  ‐0.27 
CL(20:5/20:4/20:4/18:1)‐H  0.05  0.05  0.10  ‐1.00  0.67  0.33 
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CL(22:2/18:0/18:1/20:4)‐H  0.20  0.05  0.05  ‐0.14  0.85  ‐0.71 
CL(22:3/18:0/18:1/20:4)‐H  0.35  0.50  0.35  0.16  0.04  ‐0.20 
CL(23:0/18:0/18:0/20:3)‐H  0.50  0.10  0.35  0.00  0.32  ‐0.32 
CL(23:1/18:0/18:0/20:4)‐H  0.20  0.05  0.05  ‐0.07  0.39  ‐0.32 
CL(21:0/18:0/18:0/22:6)‐H  0.20  0.35  0.50  ‐0.14  0.11  0.02 
CL(22:2/18:0/20:4/20:4)‐H  0.50  0.05  0.05  0.00  0.96  ‐0.95 
CL(22:6/18:1/22:6/18:1)‐H  0.05  0.05  0.05  #NAME?  1.16  Inf 
CL(22:6/20:4/20:4/18:1)‐H  0.20  0.20  0.35  ‐0.10  0.17  ‐0.07 
CL(20:4/18:0/20:4/22:0)‐H  0.35  0.05  0.05  ‐0.07  0.32  ‐0.25 
CL(23:0/18:0/18:0/22:4)‐H  0.20  0.20  0.20  0.04  0.25  ‐0.29 
CL(23:1/18:0/18:0/22:6)‐H  0.35  0.50  0.35  0.12  ‐0.04  ‐0.08 
DG(16:0/14:0)+NH4  0.05  0.05  0.05  ‐0.21  ‐0.66  0.87 
DG(16:1/14:0)+NH4  0.05  0.05  0.05  Inf  #NAME?  0.72 
DG(16:0/16:0)+NH4  0.05  0.05  0.05  ‐0.34  ‐0.57  0.92 
DG(18:1/14:0)+NH4  0.35  0.05  0.05  0.23  ‐0.84  0.60 
DG(17:1/16:0)+NH4  0.35  0.50  0.50  0.11  ‐0.08  ‐0.03 
DG(18:0/16:0)+NH4  0.05  0.05  0.05  ‐0.54  ‐0.35  0.88 
DG(16:0/18:1)+NH4  0.35  0.05  0.05  0.02  ‐0.55  0.53 
DG(16:1/18:1)+NH4  0.05  0.05  0.35  0.66  ‐0.82  0.16 
DG(16:0/18:2)+NH4  0.80  0.35  0.35  0.12  ‐0.16  0.03 
DG(19:1/16:0)+NH4  0.35  0.50  0.65  0.04  ‐0.05  0.00 
DG(17:1/18:1)+NH4  0.10  0.20  0.20  0.42  ‐0.31  ‐0.11 
DG(18:0/18:0)+NH4  0.50  0.05  0.20  0.37  ‐0.73  0.36 
DG(18:0/18:1)+NH4  0.35  0.05  0.05  0.02  ‐0.55  0.52 
DG(18:1/18:1)+NH4  0.20  0.05  0.05  0.32  ‐0.69  0.37 
DG(18:1/18:2)+NH4  0.05  0.05  0.50  0.34  ‐0.23  ‐0.11 
DG(18:2/18:2)+NH4  0.10  0.10  0.05  0.37  0.70  ‐1.07 
DG(16:0/20:4)+NH4  0.10  0.05  0.05  0.09  0.58  ‐0.67 
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DG(19:1/18:1)+NH4  0.35  0.05  0.35  0.32  ‐0.38  0.05 
DG(16:0/22:0)+NH4  0.20  0.05  0.05  ‐0.05  ‐0.75  0.80 
DG(20:0/18:1)+NH4  0.50  0.05  0.05  ‐0.10  ‐0.90  1.01 
DG(20:1/18:1)+NH4  0.35  0.05  0.05  0.25  ‐0.98  0.73 
DG(18:1/20:2)+NH4  0.05  0.35  0.10  0.34  ‐0.06  ‐0.28 
DG(18:0/20:3)+NH4  0.05  0.10  0.05  0.38  0.18  ‐0.56 
DG(18:1/20:3)+NH4  0.05  0.05  0.05  0.30  0.25  ‐0.56 
DG(18:0/20:4)+NH4  0.20  0.05  0.05  0.01  0.49  ‐0.51 
DG(18:1/20:4)+NH4  0.05  0.05  0.05  0.32  0.20  ‐0.52 
DG(18:0/20:5)+NH4  0.35  0.05  0.05  0.17  0.29  ‐0.46 
DG(16:0/22:6)+NH4  0.20  0.05  0.05  0.11  0.29  ‐0.40 
DG(16:1/22:6)+NH4  0.05  0.10  0.05  0.97  ‐0.27  ‐0.69 
DG(26:0/14:0)+NH4  0.65  0.05  0.05  0.00  ‐1.09  1.09 
DG(16:0/24:1)+NH4  0.05  0.05  0.05  ‐0.65  ‐0.99  1.64 
DG(18:1/22:1)+NH4  0.35  0.05  0.05  0.17  ‐1.01  0.84 
DG(18:1/22:2)+NH4  0.05  0.05  0.65  0.61  ‐0.66  0.06 
DG(18:0/22:4)+NH4  0.50  0.10  0.20  ‐0.02  0.18  ‐0.16 
DG(18:0/22:5)+NH4  0.05  0.10  0.35  0.06  ‐0.23  0.17 
DG(18:1/22:5)+NH4  0.05  0.35  0.10  0.28  ‐0.06  ‐0.22 
DG(18:0/22:6)+NH4  0.35  0.35  0.50  0.06  ‐0.08  0.02 
DG(18:1/22:6)+NH4  0.05  0.50  0.05  0.49  0.04  ‐0.53 
DG(25:0/16:0)+NH4  0.50  0.05  0.10  0.06  ‐0.41  0.35 
DG(26:0/16:0)+NH4  0.10  0.05  0.05  ‐0.31  ‐1.24  1.55 
DG(26:1/16:0)+NH4  0.20  0.05  0.05  ‐0.22  ‐1.46  1.68 
DG(26:1/16:1)+NH4  0.35  0.05  0.05  0.26  ‐1.55  1.29 
DG(27:1/16:0)+NH4  0.80  0.05  0.05  0.01  ‐1.09  1.08 
DG(28:0/16:0)+NH4  0.05  0.05  0.05  ‐0.55  ‐1.26  1.81 
DG(28:1/16:0)+NH4  0.65  0.05  0.05  0.40  ‐1.75  1.35 
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DG(26:1/18:1)+NH4  0.35  0.05  0.05  0.33  ‐1.86  1.54 
DG(30:0/16:0)+NH4  0.05  0.05  0.05  ‐0.54  ‐0.70  1.24 
DG(30:1/16:0)+NH4  0.80  0.05  0.05  ‐0.53  ‐1.42  1.94 
DG(28:1/18:1)+NH4  0.10  0.05  0.05  ‐0.41  ‐1.48  1.89 
DG(29:1/18:1)+NH4  0.35  0.05  0.05  0.19  ‐1.40  1.21 
DG(32:1/16:0)+NH4  0.05  0.05  0.05  ‐0.26  ‐0.29  0.55 
DG(30:1/18:1)+NH4  0.50  0.05  0.05  ‐0.12  ‐1.01  1.13 
DG(31:1/18:1)+NH4  0.20  0.05  0.05  Inf  #NAME?  1.07 
DG(32:1/18:1)+NH4  0.05  0.05  0.05  ‐0.35  ‐0.74  1.09 
LPC(16:0)+H  0.65  0.50  0.65  0.03  ‐0.10  0.08 
LPC(16:0e)+H  0.35  0.20  0.50  0.11  ‐0.14  0.03 
LPC(16:0p)+H  0.20  0.50  0.35  0.17  ‐0.04  ‐0.12 
LPC(16:1)+H  0.50  0.20  0.65  0.59  ‐0.50  ‐0.10 
LPC(18:0)+H  0.05  0.20  0.05  0.20  0.21  ‐0.41 
LPC(18:0e)+H  0.35  0.20  0.50  ‐0.05  0.11  ‐0.06 
LPC(18:0p)+H  0.35  0.65  0.20  0.12  0.00  ‐0.13 
LPC(18:1)+H  0.20  0.20  0.50  0.14  ‐0.16  0.02 
LPC(18:1p)+H  0.35  0.35  0.20  0.14  0.06  ‐0.20 
LPC(20:0)+H  0.05  0.50  0.05  0.31  0.04  ‐0.35 
LPC(20:0p)+H  0.10  0.10  0.50  0.50  ‐0.45  ‐0.05 
LPC(20:1)+H  0.35  0.20  0.50  0.02  ‐0.15  0.13 
LPC(20:3)+H  0.20  0.35  0.20  0.25  0.08  ‐0.34 
LPC(22:0)+H  0.05  0.05  0.05  0.87  ‐0.38  ‐0.48 
LPC(24:0)+H  0.05  0.05  0.50  1.02  ‐0.92  ‐0.09 
LPC(24:1)+H  0.10  0.05  0.65  0.88  ‐0.92  0.04 
LPC(26:0)+H  0.50  0.05  0.05  ‐0.01  0.39  ‐0.38 
LPC(26:1)+H  0.10  0.05  0.20  0.88  ‐1.17  0.29 
LPC(28:0)+H  0.05  0.05  0.05  0.32  0.54  ‐0.86 
347 
 
LPC(28:1)+H  0.05  0.05  0.05  0.22  0.27  ‐0.49 
LPC(30:0)+H  0.05  0.05  0.05  0.39  ‐1.25  0.86 
PC(11:0/16:0)+H  0.35  0.05  0.05  ‐0.01  ‐0.47  0.48 
PC(28:0)+H  0.35  0.05  0.10  0.15  ‐0.52  0.37 
PC(14:0e/14:0)+H  0.05  0.05  0.05  0.32  0.54  ‐0.87 
PC(14:0p/14:0)+H  0.05  0.10  0.05  0.55  0.26  ‐0.81 
PC(29:0)+H  0.50  0.05  0.20  ‐0.04  0.31  ‐0.27 
PC(16:0/13:0)+H  0.35  0.35  0.20  0.23  0.03  ‐0.27 
PC(11:0/18:1)+H  0.10  0.05  0.50  0.39  ‐0.45  0.06 
PC(30:0)+H  0.80  0.10  0.20  ‐0.03  ‐0.13  0.16 
PC(30:0e)+H  0.10  0.05  0.20  0.13  ‐0.27  0.14 
PC(16:0p/14:0)+H  0.05  0.50  0.05  0.18  0.02  ‐0.20 
PC(14:0p/16:0)+H  0.80  0.35  0.65  ‐0.02  0.02  0.00 
PC(30:1)+H  0.35  0.05  0.50  0.39  ‐0.47  0.08 
PC(16:0/14:1)+H  0.35  0.50  0.35  0.23  ‐0.03  ‐0.20 
PC(30:1e)+H  0.05  0.35  0.05  0.21  0.02  ‐0.23 
PC(14:0p/16:1)+H  0.10  0.05  0.05  0.22  0.21  ‐0.43 
PC(30:2)+H  0.35  0.05  0.35  0.72  ‐0.50  ‐0.22 
PC(16:1/14:1)+H  0.10  0.05  0.35  0.93  ‐0.59  ‐0.34 
PC(30:2e)+H  0.65  0.05  0.05  0.04  0.63  ‐0.67 
PC(18:1/12:2)+H  0.35  0.05  0.10  0.10  ‐0.45  0.35 
PC(31:0)+H  0.05  0.05  0.05  ‐0.13  0.43  ‐0.30 
PC(18:0/13:0)+H  0.05  0.05  0.50  ‐0.51  0.42  0.09 
PC(17:1/14:0)+H  0.35  0.20  0.10  0.21  0.17  ‐0.38 
PC(32:0)+H  0.05  0.05  0.20  ‐0.31  0.10  0.21 
PC(32:0e)+H  0.35  0.05  0.10  0.10  ‐0.30  0.20 
PC(16:0p/16:0)+H  0.05  0.05  0.50  ‐0.18  0.22  ‐0.04 
PC(16:0/16:1)+H  0.20  0.35  0.35  0.23  ‐0.09  ‐0.14 
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PC(16:1p/16:0)+H  0.10  0.50  0.20  0.30  ‐0.06  ‐0.24 
PC(32:1p)+H  0.35  0.20  0.50  ‐0.07  0.10  ‐0.03 
PC(32:2)+H  0.20  0.10  0.35  0.77  ‐0.30  ‐0.47 
PC(18:1/14:1)+H  0.05  0.20  0.05  0.57  ‐0.12  ‐0.45 
PC(14:0p/18:3)+H  0.05  0.50  0.05  0.17  0.03  ‐0.20 
PC(18:4/14:0)+H  0.35  0.35  0.35  0.20  ‐0.34  0.14 
PC(32:4e)+H  0.05  0.05  0.05  0.58  1.69  ‐2.27 
PC(12:0p/20:5)+H  0.05  0.05  0.05  0.51  0.45  ‐0.96 
PC(33:0)+H  0.05  0.05  0.05  ‐0.34  0.71  ‐0.37 
PC(33:1)+H  0.35  0.05  0.05  0.13  0.34  ‐0.47 
PC(17:1/16:1)+H  0.10  0.20  0.20  0.60  ‐0.14  ‐0.46 
PC(34:0)+H  0.05  0.05  0.05  ‐0.58  0.42  0.15 
PC(34:0e)+H  0.65  0.10  0.20  ‐0.05  ‐0.15  0.20 
PC(16:0p/18:0)+H  0.20  0.05  0.50  0.19  ‐0.27  0.07 
PC(34:1)+H  0.10  0.20  0.05  0.17  0.09  ‐0.26 
PC(16:0p/18:1)+H  0.35  0.10  0.50  0.18  ‐0.15  ‐0.03 
PC(34:2)+H  0.35  0.35  0.35  0.33  ‐0.06  ‐0.27 
PC(16:1p/18:1)+H  0.35  0.05  0.10  0.11  0.10  ‐0.20 
PC(34:3)+H  0.10  0.50  0.10  0.62  ‐0.03  ‐0.59 
PC(16:0/18:3)+H  0.35  0.05  0.05  ‐0.01  0.53  ‐0.52 
PC(34:4)+H  0.05  0.05  0.05  0.59  0.42  ‐1.01 
PC(18:4/16:0)+H  0.05  0.05  0.05  0.38  0.32  ‐0.69 
PC(14:0/20:5)+H  0.05  0.05  0.05  0.81  0.32  ‐1.13 
PC(34:6e)+H  0.05  0.05  0.05  0.43  1.58  ‐2.00 
PC(35:0)+H  0.05  0.05  0.05  ‐0.86  1.19  ‐0.34 
PC(17:0/18:1)+H  0.20  0.35  0.10  0.23  0.06  ‐0.29 
PC(35:1)+H  0.10  0.05  0.05  0.16  0.27  ‐0.44 
PC(17:1/18:1)+H  0.20  0.50  0.20  0.31  ‐0.05  ‐0.26 
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PC(36:0)+H  0.05  0.05  0.05  ‐0.64  0.36  0.28 
PC(36:0e)+H  0.20  0.35  0.50  ‐0.12  0.04  0.08 
PC(16:0/20:1)+H  0.05  0.50  0.10  0.29  ‐0.06  ‐0.23 
PC(36:1e)+H  0.35  0.05  0.05  0.05  ‐0.70  0.65 
PC(18:0p/18:1)+H  0.35  0.05  0.50  0.33  ‐0.35  0.02 
PC(20:1p/16:0)+H  0.35  0.05  0.35  0.07  ‐0.27  0.20 
PC(18:1p/18:0)+H  0.65  0.05  0.05  ‐0.03  ‐0.43  0.46 
PC(18:1/18:1)+H  0.05  0.05  0.20  0.40  ‐0.21  ‐0.20 
PC(16:1p/20:1)+H  0.50  0.20  0.35  0.00  0.12  ‐0.12 
PC(18:2p/18:0)+H  0.35  0.35  0.20  0.28  0.09  ‐0.37 
PC(36:2p)+H  0.35  0.20  0.35  0.18  ‐0.11  ‐0.07 
PC(36:3)+H  0.10  0.05  0.05  0.29  0.20  ‐0.49 
PC(36:4)+H  0.05  0.05  0.05  0.22  1.00  ‐1.22 
PC(18:1/18:3)+H  0.05  0.05  0.05  0.22  0.44  ‐0.66 
PC(36:4e)+H  0.10  0.05  0.05  0.06  0.76  ‐0.82 
PC(16:0p/20:4)+H  0.05  0.05  0.05  0.18  0.90  ‐1.08 
PC(36:5)+H  0.10  0.05  0.05  0.47  0.65  ‐1.12 
PC(18:4/18:1)+H  0.05  0.05  0.05  0.47  0.19  ‐0.66 
PC(14:0/22:5)+H  0.35  0.05  0.05  0.04  0.42  ‐0.45 
PC(36:6)+H  0.05  0.20  0.05  0.46  0.18  ‐0.64 
PC(22:2/14:4)+H  0.10  0.05  0.05  0.41  0.43  ‐0.83 
PC(16:1/21:0)+H  0.05  0.05  0.35  0.85  ‐0.54  ‐0.31 
PC(19:1/18:1)+H  0.35  0.50  0.35  0.17  ‐0.05  ‐0.12 
PC(15:0/22:4)+H  0.05  0.05  0.05  ‐0.07  0.24  ‐0.17 
PC(37:5)+H  0.05  0.05  0.05  0.40  0.99  ‐1.39 
PC(17:0/20:5)+H  0.50  0.05  0.10  ‐0.07  0.44  ‐0.37 
PC(38:0e)+H  0.35  0.35  0.65  0.11  ‐0.10  ‐0.01 
PC(20:0/18:1)+H  0.05  0.05  0.05  ‐0.47  ‐0.65  1.12 
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PC(38:1e)+H  0.35  0.05  0.05  0.04  ‐0.64  0.60 
PC(20:1p/18:0)+H  0.35  0.05  0.20  0.24  ‐0.49  0.24 
PC(20:1/18:1)+H  0.35  0.05  0.50  0.26  ‐0.38  0.11 
PC(38:2e)+H  0.35  0.05  0.20  0.44  ‐0.71  0.27 
PC(38:3)+H  0.05  0.20  0.05  0.45  0.09  ‐0.54 
PC(38:3e)+H  0.35  0.35  0.50  0.20  ‐0.14  ‐0.06 
PC(38:4)+H  0.05  0.05  0.05  0.48  0.38  ‐0.86 
PC(38:4e)+H  0.35  0.05  0.05  0.04  0.90  ‐0.94 
PC(18:0/20:5)+H  0.05  0.05  0.05  0.43  0.37  ‐0.81 
PC(38:5)+H  0.05  0.05  0.05  0.25  0.85  ‐1.10 
PC(16:0/22:6)+H  0.10  0.05  0.05  0.22  0.40  ‐0.62 
PC(38:6e)+H  0.10  0.05  0.05  0.23  0.55  ‐0.78 
PC(38:7)+H  0.05  0.20  0.05  0.66  0.15  ‐0.81 
PC(39:2)+H  0.35  0.05  0.35  0.13  ‐0.29  0.16 
PC(40:0)+H  0.35  0.05  0.05  0.03  ‐1.03  0.99 
PC(40:1)+H  0.35  0.05  0.05  ‐0.02  ‐0.77  0.79 
PC(40:2)+H  0.35  0.05  0.05  0.11  ‐0.57  0.46 
PC(40:3)+H  0.35  0.10  0.50  0.15  ‐0.17  0.02 
PC(40:4)+H  0.20  0.05  0.05  0.16  0.30  ‐0.46 
PC(18:0/22:5)+H  0.20  0.05  0.05  0.06  0.53  ‐0.59 
PC(40:5e)+H  0.05  0.05  0.05  0.33  0.52  ‐0.85 
PC(18:0/22:6)+H  0.10  0.05  0.05  0.18  0.72  ‐0.90 
PC(40:6e)+H  0.20  0.05  0.05  0.18  0.53  ‐0.72 
PC(18:1/22:6)+H  0.10  0.20  0.05  0.28  0.24  ‐0.52 
PC(18:1/23:0)+H  0.05  0.05  0.10  1.14  ‐1.51  0.37 
PC(31:0/10:2)+H  0.35  0.05  0.20  0.24  ‐0.53  0.29 
PC(18:1/23:1)+H  0.05  0.05  0.50  1.24  ‐1.34  0.10 
PC(26:0/16:0)+H  0.35  0.05  0.05  0.08  ‐1.33  1.25 
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PC(42:1)+H  0.35  0.05  0.05  0.35  ‐1.14  0.79 
PC(42:2)+H  0.35  0.05  0.05  0.31  ‐1.02  0.71 
PC(42:3)+H  0.35  0.05  0.10  0.11  ‐0.45  0.34 
PC(18:2p/24:1)+H  0.05  0.10  0.05  0.52  0.25  ‐0.77 
PC(27:1/16:0)+H  0.35  0.05  0.05  0.37  ‐1.13  0.75 
PC(25:1/18:1)+H  0.35  0.05  0.05  0.48  ‐1.05  0.57 
PC(44:0)+H  0.20  0.05  0.05  ‐0.17  ‐1.31  1.48 
PC(44:1)+H  0.35  0.05  0.05  0.28  ‐1.52  1.24 
PC(44:2)+H  0.35  0.05  0.05  0.39  ‐1.41  1.02 
PC(44:3)+H  0.35  0.05  0.05  0.33  ‐0.88  0.55 
PC(29:0/16:0)+H  0.50  0.05  0.05  Inf  #NAME?  2.25 
PC(27:0/18:1)+H  0.35  0.05  0.05  0.27  ‐1.57  1.30 
PC(45:2)+H  0.35  0.05  0.05  0.41  ‐1.25  0.84 
PC(46:1)+H  0.35  0.05  0.05  0.07  ‐1.77  1.70 
PC(46:2)+H  0.35  0.05  0.05  0.25  ‐1.68  1.43 
PC(31:1/16:0)+H  1.00  0.05  0.05  NaN  #NAME?  Inf 
PC(47:2)+H  0.35  0.05  0.05  0.27  ‐1.78  1.50 
PC(48:1)+H  0.80  0.05  0.05  0.10  ‐2.08  1.98 
PC(48:2)+H  0.35  0.05  0.05  0.12  ‐2.24  2.11 
PC(50:2)+H  0.05  0.05  0.05  #NAME?  ‐2.74  Inf 
PE(26:0)+H  0.05  0.05  0.05  0.24  0.41  ‐0.65 
PE(12:0p/16:0)+H  0.05  0.05  0.05  0.26  0.97  ‐1.23 
PE(16:0/14:0)+H  0.35  0.05  0.05  ‐0.11  ‐0.42  0.53 
PE(16:0p/14:0)+H  0.05  0.05  0.05  ‐0.23  0.85  ‐0.62 
PE(16:1/14:0)+H  0.35  0.05  0.50  0.60  ‐0.68  0.08 
PE(12:0p/18:1)+H  0.05  0.05  0.05  0.27  0.24  ‐0.50 
PE(12:0p/18:2)+H  0.35  0.05  0.05  ‐0.04  0.76  ‐0.72 
PE(16:0/16:0)+H  0.05  0.50  0.10  ‐0.21  0.02  0.19 
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PE(16:0p/16:0)+H  0.05  0.05  0.35  ‐0.53  1.02  ‐0.49 
PE(16:0/16:1)+H  0.10  0.05  0.50  0.43  ‐0.46  0.03 
PE(16:0p/16:1)+H  0.35  0.05  0.05  0.21  ‐0.46  0.25 
PE(16:1/16:1)+H  0.10  0.05  0.50  0.83  ‐0.84  0.01 
PE(12:0p/20:4)+H  0.05  0.05  0.05  0.30  1.07  ‐1.37 
PE(12:0p/20:5)+H  0.05  0.05  0.05  0.41  0.62  ‐1.03 
PE(18:0p/15:0)+H  0.05  0.05  0.05  ‐0.59  1.80  ‐1.21 
PE(17:1/16:0)+H  0.35  0.35  0.20  0.28  0.02  ‐0.30 
PE(16:0p/17:1)+H  0.35  0.35  0.35  0.20  0.00  ‐0.20 
PE(18:0/16:0)+H  0.05  0.05  0.50  ‐0.58  0.48  0.09 
PE(18:0p/16:0)+H  0.05  0.05  0.10  ‐0.49  0.93  ‐0.45 
PE(16:0/18:1)+H  0.35  0.05  0.50  0.22  ‐0.24  0.03 
PE(16:0p/18:1)+H  0.35  0.05  0.50  0.34  ‐0.35  0.00 
PE(16:1/18:1)+H  0.05  0.05  0.10  0.79  ‐0.52  ‐0.27 
PE(18:1p/16:1)+H  0.35  0.05  0.35  0.27  ‐0.19  ‐0.08 
PE(16:0p/18:2)+H  0.80  0.05  0.35  ‐0.02  0.13  ‐0.11 
PE(12:0p/22:4)+H  0.05  0.05  0.05  0.54  0.68  ‐1.22 
PE(14:0p/20:4)+H  0.05  0.05  0.05  0.32  0.88  ‐1.20 
PE(12:0p/22:5)+H  0.05  0.05  0.05  0.52  0.22  ‐0.74 
PE(14:0p/20:5)+H  0.05  0.05  0.05  0.42  0.81  ‐1.22 
PE(12:0p/22:6)+H  0.05  0.05  0.05  0.33  0.76  ‐1.09 
PE(17:0/18:1)+H  0.20  0.65  0.20  0.26  ‐0.04  ‐0.22 
PE(16:0p/19:1)+H  0.35  0.10  0.35  0.21  ‐0.16  ‐0.05 
PE(17:1/18:1)+H  0.05  0.20  0.05  0.54  ‐0.07  ‐0.48 
PE(18:1p/17:1)+H  0.35  0.05  0.20  0.10  0.25  ‐0.35 
PE(16:0p/20:0)+H  0.05  0.05  0.50  ‐0.69  0.71  ‐0.02 
PE(18:0/18:1)+H  0.05  0.05  0.20  0.48  ‐0.26  ‐0.22 
PE(18:0p/18:1)+H  0.35  0.05  0.05  0.12  ‐0.55  0.43 
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PE(18:1/18:1)+H  0.10  0.05  0.35  0.45  ‐0.31  ‐0.13 
PE(18:1p/18:1)+H  0.35  0.05  0.35  0.32  ‐0.19  ‐0.13 
PE(18:0p/18:2)+H  0.35  0.05  0.50  0.14  ‐0.28  0.14 
PE(18:1/18:2)+H  0.35  0.35  0.20  0.18  0.04  ‐0.22 
PE(18:1p/18:2)+H  0.35  0.05  0.05  ‐0.06  0.40  ‐0.34 
PE(16:0p/20:3)+H  0.35  0.05  0.35  0.23  ‐0.31  0.08 
PE(16:0/20:4)+H  0.05  0.05  0.05  ‐0.09  0.42  ‐0.33 
PE(16:0p/20:4)+H  0.20  0.05  0.05  ‐0.07  0.42  ‐0.35 
PE(16:1/20:4)+H  0.05  0.50  0.10  0.66  ‐0.04  ‐0.62 
PE(16:0/20:5)+H  0.20  0.65  0.20  0.25  ‐0.04  ‐0.21 
PE(14:0p/22:5)+H  0.20  0.05  0.05  0.26  0.84  ‐1.09 
PE(16:0p/20:5)+H  0.20  0.50  0.20  0.30  0.02  ‐0.32 
PE(16:1/20:5)+H  0.10  0.05  0.35  1.03  ‐0.53  ‐0.49 
PE(14:0p/22:6)+H  0.05  0.05  0.05  0.67  0.65  ‐1.32 
PE(18:0p/19:1)+H  0.35  0.35  0.50  0.10  ‐0.06  ‐0.04 
PE(17:0/20:4)+H  0.05  0.05  0.05  ‐0.14  0.69  ‐0.54 
PE(17:1/20:4)+H  0.35  0.05  0.05  0.03  0.79  ‐0.82 
PE(17:1/20:5)+H  0.35  0.05  0.05  0.38  0.94  ‐1.32 
PE(20:0/18:1)+H  0.35  0.20  0.35  0.34  ‐0.22  ‐0.12 
PE(16:0p/22:1)+H  0.50  0.05  0.05  0.09  ‐0.71  0.62 
PE(20:1/18:1)+H  0.35  0.10  0.50  0.29  ‐0.30  0.02 
PE(16:0p/22:2)+H  0.35  0.05  0.50  0.37  ‐0.47  0.10 
PE(18:0/20:3)+H  0.05  0.10  0.05  0.52  0.18  ‐0.70 
PE(18:0p/20:3)+H  0.35  0.05  0.20  0.25  ‐0.55  0.30 
PE(18:0/20:4)+H  0.20  0.05  0.05  0.06  0.55  ‐0.61 
PE(38:4e)+H  0.05  0.05  0.10  ‐0.19  0.47  ‐0.29 
PE(16:0p/22:4)+H  0.05  0.05  0.05  ‐0.14  0.53  ‐0.39 
PE(18:0p/20:4)+H  0.05  0.05  0.10  ‐0.18  0.44  ‐0.26 
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PE(18:1/20:4)+H  0.05  0.05  0.05  0.23  0.24  ‐0.47 
PE(18:0/20:5)+H  0.10  0.20  0.10  0.29  0.07  ‐0.37 
PE(18:1p/20:4)+H  0.05  0.05  0.05  0.12  0.31  ‐0.43 
PE(18:0p/20:5)+H  0.35  0.05  0.35  0.01  0.28  ‐0.29 
PE(16:1/22:5)+H  0.35  0.05  0.05  0.32  ‐1.02  0.70 
PE(38:6)+H  0.10  0.35  0.20  0.47  ‐0.12  ‐0.35 
PE(16:0/22:6)+H  0.05  0.05  0.05  0.14  0.36  ‐0.50 
PE(18:1p/20:5)+H  0.05  0.05  0.05  0.32  0.40  ‐0.72 
PE(16:0p/22:6)+H  0.35  0.05  0.05  0.39  0.21  ‐0.59 
PE(16:1/22:6)+H  0.35  0.05  0.35  0.77  ‐0.33  ‐0.44 
PE(16:1p/22:6)+H  0.05  0.10  0.05  0.80  0.48  ‐1.28 
PE(17:0/22:6)+H  0.05  0.05  0.50  ‐0.20  0.23  ‐0.03 
PE(18:1/22:0)+H  0.05  0.05  0.35  0.81  ‐0.47  ‐0.34 
PE(18:0p/22:1)+H  0.35  0.05  0.05  0.33  ‐0.89  0.56 
PE(18:1/22:1)+H  0.10  0.10  0.35  0.42  ‐0.22  ‐0.20 
PE(18:1p/22:1)+H  0.35  0.05  0.35  0.48  ‐0.68  0.20 
PE(18:0p/22:3)+H  0.35  0.35  0.50  0.11  ‐0.09  ‐0.02 
PE(18:0/22:4)+H  0.35  0.05  0.05  ‐0.08  0.30  ‐0.22 
PE(20:0/20:4)+H  0.35  0.20  0.10  0.05  0.19  ‐0.24 
PE(18:0p/22:4)+H  0.05  0.05  0.05  ‐0.26  0.47  ‐0.22 
PE(20:0p/20:4)+H  0.05  0.05  0.05  0.31  0.29  ‐0.61 
PE(18:0/22:5)+H  0.10  0.35  0.50  0.08  ‐0.10  0.02 
PE(40:5e)+H  0.80  0.05  0.05  0.01  0.41  ‐0.42 
PE(40:5p)+H  0.20  0.05  0.05  ‐0.03  0.36  ‐0.33 
PE(18:0p/22:5)+H  0.10  0.50  0.10  0.08  0.06  ‐0.14 
PE(18:0/22:6)+H  0.50  0.05  0.20  0.04  0.16  ‐0.20 
PE(18:1p/22:5)+H  0.05  0.10  0.05  0.32  0.16  ‐0.48 
PE(18:0p/22:6)+H  0.35  0.05  0.10  0.14  0.32  ‐0.47 
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PE(18:1/22:6)+H  0.35  0.05  0.05  0.20  0.23  ‐0.44 
PE(18:1p/22:6)+H  0.10  0.05  0.05  0.36  0.46  ‐0.82 
PE(18:2/22:6)+H  0.20  0.05  0.05  0.31  0.29  ‐0.60 
PE(18:2p/22:6)+H  0.10  0.20  0.05  0.92  0.89  ‐1.82 
PE(18:1/24:0)+H  0.05  0.05  0.35  1.02  ‐0.83  ‐0.19 
PE(20:4/22:6)+H  0.10  0.50  0.20  0.26  ‐0.04  ‐0.23 
PE(18:0p/24:1)+H  0.05  0.05  0.50  0.87  ‐0.87  ‐0.01 
PE(18:1/24:1)+H  0.05  0.05  0.35  1.00  ‐0.80  ‐0.19 
PE(22:0/20:4)+H  0.05  0.10  0.20  0.45  ‐0.28  ‐0.17 
PE(20:0p/22:5)+H  0.35  0.05  0.10  0.01  0.21  ‐0.23 
PE(20:1p/22:5)+H  0.20  0.05  0.05  0.10  0.42  ‐0.52 
PE(20:0p/22:6)+H  0.05  0.20  0.05  0.55  0.16  ‐0.71 
PE(25:0/18:1)+H  0.05  0.05  0.35  1.16  ‐1.06  ‐0.10 
PE(43:2)+H  0.05  0.05  0.35  1.07  ‐0.70  ‐0.36 
PE(26:0/18:1)+H  0.05  0.05  0.20  1.07  ‐1.43  0.36 
PE(26:1/18:1)+H  0.05  0.05  0.50  1.23  ‐1.30  0.07 
PE(44:2)+H  0.35  0.05  0.50  0.92  ‐1.03  0.11 
PE(44:3)+H  0.05  0.05  0.20  1.06  ‐0.43  ‐0.63 
PE(24:0/20:4)+H  0.05  0.05  0.50  0.81  ‐0.82  0.01 
PE(24:1/20:4)+H  0.10  0.05  0.20  0.65  ‐0.90  0.25 
PE(28:1/18:1)+H  0.35  0.05  0.05  1.19  ‐2.26  1.06 
PE(26:0/20:4)+H  0.05  0.05  0.05  1.01  ‐1.51  0.51 
PE(24:0/22:6)+H  0.35  0.05  0.10  0.21  ‐0.65  0.44 
PE(24:1/22:6)+H  0.35  0.05  0.50  0.46  ‐0.52  0.06 
PE(48:5)+H  0.05  0.05  0.05  0.48  ‐1.23  0.76 
LPE(20:4)‐H  0.50  0.05  0.05  0.04  0.94  ‐0.97 
LPE(22:5)‐H  0.10  0.05  0.05  0.23  0.39  ‐0.62 
LPE(22:6)‐H  0.05  0.05  0.05  0.33  0.48  ‐0.81 
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LPE(24:1)‐H  0.05  0.05  0.65  1.68  ‐1.72  0.05 
PEt(14:0/14:0)‐H  0.05  0.10  0.05  ‐0.37  ‐0.30  0.68 
PEt(16:0/14:0)‐H  0.05  0.20  0.05  ‐0.18  ‐0.11  0.30 
PEt(16:1/14:0)‐H  0.35  0.05  0.35  0.63  ‐0.50  ‐0.14 
PEt(16:0/16:0)‐H  0.05  0.35  0.05  ‐0.58  0.11  0.47 
PEt(16:0/16:1)‐H  0.35  0.10  0.10  0.07  0.20  ‐0.27 
PEt(16:0/18:1)‐H  0.05  0.05  0.05  ‐1.46  0.79  0.68 
PEt(16:1/18:1)‐H  0.05  0.80  0.35  0.27  ‐0.19  ‐0.07 
PI(16:0/14:1)‐H  1.00  0.05  0.05  NaN  #NAME?  Inf 
PI(16:0/16:0)‐H  0.10  0.20  0.10  ‐0.29  ‐0.24  0.53 
PI(18:1/14:1)‐H  0.35  0.05  0.05  0.94  ‐1.29  0.34 
PI(17:1/16:0)‐H  0.35  0.50  0.35  0.16  0.02  ‐0.19 
PI(18:0/16:0)‐H  0.05  0.20  0.05  ‐0.47  ‐0.13  0.60 
PI(16:0/18:1)‐H  0.50  0.05  0.20  0.11  ‐0.31  0.20 
PI(16:0e/18:1)‐H  0.50  0.20  0.20  ‐0.12  ‐0.09  0.21 
PI(18:0/17:0)‐H  0.65  0.35  0.50  0.11  ‐0.13  0.02 
PI(17:0/18:1)‐H  0.35  0.10  0.50  0.17  ‐0.26  0.10 
PI(18:0/18:0)‐H  0.35  0.05  0.05  0.11  ‐0.45  0.33 
PI(18:0/18:1)‐H  0.35  0.05  0.05  0.17  ‐0.57  0.40 
PI(18:0e/18:1)‐H  0.05  0.05  0.05  #NAME?  ‐0.79  Inf 
PI(18:0p/18:1)‐H  0.20  0.35  0.05  ‐0.24  ‐0.24  0.48 
PI(18:1/18:1)‐H  0.35  0.05  0.05  0.27  ‐0.60  0.33 
PI(18:1/18:3)‐H  0.20  0.05  0.05  ‐0.08  1.12  ‐1.04 
PI(16:0e/20:4)‐H  0.05  0.05  0.05  ‐1.12  0.48  0.64 
PI(16:1/20:4)‐H  0.05  0.10  0.05  0.29  0.21  ‐0.50 
PI(16:0/20:5)‐H  0.35  0.20  0.35  0.24  ‐0.11  ‐0.13 
PI(19:1/18:0)‐H  0.50  0.10  0.10  0.03  ‐0.41  0.38 
PI(17:0/20:2)‐H  0.10  0.05  0.20  0.35  ‐0.60  0.25 
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PI(19:1/18:2)‐H  0.05  0.05  0.05  0.86  ‐0.44  ‐0.42 
PI(17:0/20:3)‐H  0.35  0.35  0.35  0.23  0.16  ‐0.40 
PI(17:1/20:4)‐H  0.35  0.05  0.05  ‐0.06  1.46  ‐1.40 
PI(18:0/20:0)‐H  0.35  0.05  0.35  0.39  ‐0.34  ‐0.05 
PI(18:0/20:1)‐H  0.20  0.05  0.05  ‐0.41  ‐0.47  0.89 
PI(18:0p/20:1)‐H  1.00  0.05  0.05  NaN  #NAME?  Inf 
PI(18:0/20:4)‐H  0.05  0.05  0.05  ‐0.22  0.82  ‐0.60 
PI(18:0/20:5)‐H  0.20  0.05  0.05  0.09  0.58  ‐0.66 
PI(19:1/20:1)‐H  0.05  0.05  0.05  #NAME?  ‐0.92  Inf 
PI(19:1/20:2)‐H  0.35  0.05  0.05  ‐0.13  ‐0.31  0.44 
PI(19:1/20:3)‐H  0.35  0.20  0.20  0.14  0.21  ‐0.35 
PI(19:0/20:4)‐H  0.20  0.05  0.05  ‐0.11  0.86  ‐0.75 
PI(18:0/22:1)‐H  0.50  0.05  0.05  ‐0.06  ‐0.41  0.47 
PI(18:0/22:3)‐H  0.35  0.65  0.35  0.28  ‐0.01  ‐0.28 
PI(20:0/20:4)‐H  0.65  0.20  0.10  ‐0.07  0.40  ‐0.33 
PI(18:0/24:1)‐H  0.05  0.35  0.05  ‐1.20  ‐0.12  1.32 
PI(18:1/24:2)‐H  0.05  0.05  0.05  ‐0.30  ‐0.36  0.66 
PI(22:4/20:4)‐H  0.05  0.05  0.65  ‐0.77  0.75  0.02 
PI(26:0/18:1)‐H  0.05  0.05  0.05  ‐0.84  ‐0.37  1.22 
PI(26:1/18:1)‐H  0.05  0.05  0.05  ‐0.66  ‐0.77  1.43 
PG(12:0/14:0)‐H  0.20  0.05  0.05  0.07  0.35  ‐0.41 
PG(15:0/14:0)‐H  0.05  0.05  1.00  #NAME?  Inf  NaN 
PG(16:0/14:0)‐H  0.05  0.05  0.05  ‐1.41  0.89  0.51 
PG(16:1/14:0)‐H  0.05  0.05  0.05  0.20  0.61  ‐0.80 
PG(15:0/16:0)‐H  0.05  0.05  1.00  #NAME?  Inf  NaN 
PG(16:0/16:0)‐H  0.35  0.05  0.05  0.10  0.77  ‐0.87 
PG(16:0/16:1)‐H  0.35  0.05  0.35  2.28  ‐2.44  0.16 
PG(18:1/14:0)‐H  0.35  0.05  0.05  ‐0.03  0.38  ‐0.36 
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PG(16:0/17:0)‐H  0.05  0.05  1.00  #NAME?  Inf  NaN 
PG(17:1/16:0)‐H  0.05  0.35  0.05  0.76  ‐0.07  ‐0.69 
PG(18:0/16:0)‐H  0.65  0.05  0.10  ‐0.04  0.46  ‐0.43 
PG(16:0/18:1)‐H  0.05  0.05  0.05  ‐0.88  0.46  0.42 
PG(16:1/18:1)‐H  0.20  0.05  0.50  1.96  ‐1.95  0.00 
PG(16:1/18:2)‐H  0.20  0.50  0.35  0.53  ‐0.15  ‐0.39 
PG(19:1/16:0)‐H  0.35  0.05  0.05  0.06  0.52  ‐0.59 
PG(17:1/18:0)‐H  0.35  0.05  0.05  0.18  0.50  ‐0.68 
PG(17:1/18:1)‐H  0.35  0.05  0.05  0.11  0.69  ‐0.80 
PG(18:0/18:1)‐H  0.35  0.05  0.10  0.13  0.28  ‐0.41 
PG(18:1/18:1)‐H  0.35  0.05  0.50  0.59  ‐0.69  0.10 
PG(18:1/18:2)‐H  0.35  0.10  0.35  0.07  0.19  ‐0.26 
PG(16:0/20:3)‐H  0.50  0.05  0.05  0.12  Inf  #NAME? 
PG(16:0/20:4)‐H  0.35  0.05  0.05  ‐0.04  0.52  ‐0.48 
PG(14:0/22:6)‐H  0.25  0.05  0.50  0.83  ‐0.77  ‐0.07 
PG(20:1/18:1)‐H  0.35  0.05  0.35  0.43  ‐0.64  0.22 
PG(18:1/20:2)‐H  0.35  0.10  0.35  0.64  ‐0.26  ‐0.37 
PG(16:0/22:4)‐H  0.65  0.05  0.05  ‐0.05  Inf  #NAME? 
PG(18:0/20:4)‐H  0.10  0.05  0.05  ‐0.13  0.69  ‐0.56 
PG(18:1/20:4)‐H  0.10  0.05  0.05  ‐0.18  0.82  ‐0.63 
PG(18:1/20:5)‐H  0.05  0.05  0.05  0.50  1.00  ‐1.51 
PG(16:0/22:6)‐H  0.20  0.35  0.50  0.48  ‐0.20  ‐0.28 
PG(16:1/22:6)‐H  0.20  0.80  0.10  0.76  ‐0.07  ‐0.69 
PG(20:2/20:2)‐H  0.35  0.05  0.05  0.50  0.66  ‐1.16 
PG(18:1/22:4)‐H  0.35  0.05  0.05  0.10  1.50  ‐1.60 
PG(18:0/22:6)‐H  0.20  0.05  0.20  ‐0.27  0.88  ‐0.61 
PG(18:1/22:6)‐H  0.35  0.65  0.20  0.54  ‐0.03  ‐0.51 
PG(18:2/22:6)‐H  0.05  0.05  0.05  0.41  0.84  ‐1.25 
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PG(20:4/22:6)‐H  0.05  0.05  0.05  0.34  1.21  ‐1.55 
PG(20:5/22:6)‐H  0.05  0.05  0.05  0.62  1.39  ‐2.01 
PG(20:2/22:6)‐H  0.05  0.05  0.05  0.43  0.68  ‐1.11 
PG(20:3/22:6)‐H  0.05  0.05  0.05  0.61  1.08  ‐1.68 
PG(22:4/22:6)‐H  0.20  0.05  0.05  0.18  1.28  ‐1.46 
PG(22:5/22:6)‐H  0.05  0.05  0.05  0.33  0.77  ‐1.10 
PG(22:6/22:6)‐H  0.35  0.05  0.05  0.20  0.77  ‐0.98 
PS(12:0/14:0)‐H  0.35  0.05  0.05  0.47  0.42  ‐0.89 
PS(16:0/14:0)‐H  0.50  0.20  0.35  0.28  0.21  ‐0.49 
PS(16:0/14:1)‐H  0.50  0.05  0.75  Inf  #NAME?  ‐1.31 
PS(16:0/16:0)‐H  0.35  0.05  0.35  0.02  0.42  ‐0.43 
PS(16:1/16:1)‐H  0.20  0.05  0.35  Inf  #NAME?  ‐0.87 
PS(16:1/17:0)‐H  0.65  0.05  0.05  ‐0.09  1.39  ‐1.30 
PS(18:0/16:0)‐H  0.35  0.05  0.05  ‐0.15  0.96  ‐0.81 
PS(16:0e/18:1)‐H  0.50  0.05  0.20  0.19  ‐0.40  0.21 
PS(16:1/18:2)‐H  0.05  0.05  0.50  0.75  ‐0.70  ‐0.05 
PS(18:0/18:0)‐H  0.35  0.05  0.05  0.22  0.84  ‐1.06 
PS(18:0e/18:1)‐H  0.50  0.05  0.80  0.96  ‐0.33  ‐0.63 
PS(18:1/18:1)‐H  0.35  0.10  0.10  ‐0.13  ‐0.18  0.31 
PS(18:0/18:3)‐H  0.35  0.05  0.05  0.85  0.72  ‐1.57 
PS(16:0/20:3)‐H  0.20  0.05  0.50  0.14  ‐0.16  0.01 
PS(16:0/20:4)‐H  0.80  0.05  0.50  0.03  0.23  ‐0.26 
PS(16:1/20:3)‐H  0.50  0.65  0.35  ‐0.07  0.03  0.04 
PS(16:0/22:0)‐H  0.50  0.05  0.05  0.13  0.89  ‐1.02 
PS(18:1/20:2)‐H  0.35  0.05  0.35  0.26  0.33  ‐0.59 
PS(18:0/20:3)‐H  0.10  0.10  0.05  0.54  0.27  ‐0.82 
PS(18:1/20:3)‐H  0.35  0.20  0.80  ‐0.05  0.17  ‐0.12 
PS(18:0/20:4)‐H  0.35  0.05  0.35  0.01  0.19  ‐0.20 
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PS(18:1/20:4)‐H  0.50  0.50  0.65  ‐0.08  0.08  0.00 
PS(20:3/18:2)‐H  0.20  0.05  0.10  ‐0.10  0.33  ‐0.23 
PS(19:0/20:3)‐H  0.35  0.05  0.50  ‐0.15  0.35  ‐0.20 
PS(17:0/22:4)‐H  0.35  0.05  0.35  ‐0.29  0.63  ‐0.34 
PS(17:0/22:5)‐H  0.35  0.05  0.35  ‐0.18  0.39  ‐0.21 
PS(16:0/24:0)‐H  0.20  0.05  0.50  ‐0.23  0.74  ‐0.51 
PS(20:2/20:2)‐H  0.35  0.20  0.35  ‐0.18  0.13  0.05 
PS(18:1/22:4)‐H  0.35  0.05  0.20  ‐0.09  ‐0.37  0.46 
PS(18:0/22:5)‐H  0.05  0.05  0.35  ‐0.48  1.01  ‐0.53 
PS(18:1/22:5)‐H  0.35  0.05  0.05  ‐0.07  ‐0.62  0.69 
PS(20:3/20:3)‐H  0.35  0.05  0.35  0.23  0.44  ‐0.66 
PS(20:0/22:5)‐H  0.35  0.10  0.10  ‐0.21  ‐0.18  0.40 
PS(25:0/18:1)‐H  0.65  0.05  0.35  0.21  ‐0.48  0.27 
PS(25:1/18:1)‐H  0.80  0.20  0.80  0.23  ‐0.11  ‐0.12 
PS(26:0/18:1)‐H  0.80  0.05  0.05  0.10  ‐0.79  0.69 
PS(24:0/20:4)‐H  0.50  0.20  0.80  0.25  ‐0.22  ‐0.03 
PS(24:1/20:4)‐H  0.65  0.35  0.80  0.18  ‐0.17  ‐0.01 
PS(27:1/18:1)‐H  0.35  0.10  0.20  ‐0.12  ‐0.25  0.37 
PS(28:0/18:1)‐H  1.00  0.05  0.05  NaN  #NAME?  Inf 
PS(28:1/18:1)‐H  0.35  0.05  0.05  ‐0.15  ‐0.48  0.63 
PS(24:0/22:5)‐H  0.05  0.20  0.05  ‐0.60  ‐0.21  0.81 
PS(30:1/18:1)‐H  0.60  0.05  0.05  0.12  ‐1.25  1.13 
SM(d30:0)+H  0.05  0.20  0.10  ‐0.21  0.09  0.12 
SM(d30:1)+H  0.10  0.50  0.10  0.48  ‐0.09  ‐0.39 
SM(d31:1)+H  0.05  0.35  0.20  0.75  ‐0.22  ‐0.53 
SM(d32:0)+H  0.65  0.50  0.50  ‐0.05  ‐0.11  0.16 
SM(d32:1)+H  0.10  0.35  0.10  0.49  0.06  ‐0.55 
SM(d32:2)+H  0.05  0.20  0.05  0.61  0.15  ‐0.76 
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SM(d33:1)+H  0.20  0.35  0.10  0.28  0.07  ‐0.34 
SM(d33:2)+H  0.10  0.05  0.05  0.19  0.42  ‐0.61 
SM(d33:5)+H  0.05  0.05  0.05  0.19  0.33  ‐0.52 
SM(d34:0)+H  0.05  0.35  0.05  ‐0.40  0.00  0.40 
SM(d18:1/16:0)+H  0.35  0.05  0.05  0.14  0.20  ‐0.34 
SM(d18:1/16:1)+H  0.05  0.35  0.10  0.38  0.11  ‐0.48 
SM(d18:2/16:1)+H  0.05  0.05  0.35  ‐0.21  0.23  ‐0.02 
SM(d34:4)+H  0.10  0.20  0.10  0.47  0.07  ‐0.53 
SM(d35:1)+H  0.20  0.05  0.05  0.07  0.76  ‐0.83 
SM(d35:2)+H  0.05  0.05  0.05  0.24  0.70  ‐0.94 
SM(d35:4)+H  0.10  0.05  0.05  0.18  0.20  ‐0.38 
SM(d36:0)+H  0.05  0.05  0.35  ‐0.92  0.81  0.11 
SM(d36:1)+H  0.05  0.05  0.05  ‐0.37  1.27  ‐0.90 
SM(d36:2)+H  0.05  0.05  0.05  ‐0.24  1.14  ‐0.90 
SM(d18:2/18:1)+H  0.05  0.05  0.10  ‐0.33  0.18  0.14 
SM(d18:1/18:3)+H  0.05  0.05  0.05  0.15  0.41  ‐0.56 
SM(d36:5)+H  0.10  0.05  0.05  0.32  0.21  ‐0.53 
SM(d18:1/19:0)+H  0.05  1.00  0.05  Inf  NaN  #NAME? 
SM(d37:4)+H  0.35  0.05  0.05  0.06  1.02  ‐1.08 
SM(d37:5)+H  0.20  0.05  0.05  0.15  0.93  ‐1.08 
SM(d37:6)+H  0.05  0.05  0.05  0.39  0.66  ‐1.05 
SM(d38:0)+H  0.05  0.05  0.80  ‐0.83  0.81  0.02 
SM(d38:1)+H  0.05  0.05  0.05  ‐0.41  0.96  ‐0.55 
SM(d38:2)+H  0.05  0.05  0.05  ‐0.36  1.13  ‐0.77 
SM(d38:3)+H  0.05  0.05  0.35  ‐0.93  1.02  ‐0.08 
SM(d18:1/21:0)+H  0.05  0.05  0.10  1.54  ‐0.72  ‐0.83 
SM(d39:1)+H  0.10  0.05  0.05  ‐0.15  0.85  ‐0.70 
SM(d39:4)+H  0.05  0.05  0.05  #NAME?  ‐0.70  Inf 
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SM(d40:0)+H  0.05  0.05  0.05  ‐0.78  0.24  0.54 
SM(d40:1)+H  0.05  0.05  0.50  ‐0.61  0.54  0.07 
SM(d18:1/22:0)+H  0.05  0.05  0.10  ‐0.23  0.47  ‐0.24 
SM(d40:2)+H  0.05  0.05  0.05  ‐0.26  0.78  ‐0.52 
SM(d40:4)+H  0.05  0.05  0.05  ‐0.49  1.74  ‐1.25 
SM(d40:6)+H  0.35  0.05  0.05  0.10  ‐0.57  0.47 
SM(d18:0/23:0)+H  0.05  0.05  0.35  0.35  ‐0.30  ‐0.05 
SM(d41:0)+H  0.05  0.35  0.05  ‐0.60  0.04  0.56 
SM(d18:1/23:0)+H  0.05  0.35  0.05  0.93  ‐0.01  ‐0.92 
SM(d41:1)+H  0.05  0.05  0.05  ‐0.82  0.61  0.21 
SM(d41:1)+H  0.35  0.10  0.10  0.05  0.18  ‐0.22 
SM(d41:2)+H  0.65  0.05  0.10  ‐0.04  0.48  ‐0.44 
SM(d41:3)+H  0.35  0.05  0.05  ‐0.09  1.08  ‐0.99 
SM(d42:0)+H  0.05  0.05  0.05  ‐0.50  ‐0.54  1.04 
SM(d42:1)+H  0.05  0.10  0.05  ‐0.68  ‐0.21  0.90 
SM(d18:1/24:0)+H  0.35  0.05  0.50  0.11  ‐0.28  0.17 
SM(d18:1/24:1)+H  0.10  0.10  0.50  ‐0.19  0.22  ‐0.02 
SM(d18:0/24:2)+H  0.05  0.05  0.20  0.99  ‐0.51  ‐0.49 
SM(d18:1/24:2)+H  0.35  0.05  0.05  ‐0.07  0.65  ‐0.58 
SM(d18:0/24:3)+H  0.05  0.05  0.10  ‐0.60  0.31  0.28 
SM(d18:1/24:3)+H  0.05  0.05  0.05  ‐0.22  0.65  ‐0.43 
SM(d42:5)+H  0.05  0.05  0.05  ‐1.46  3.41  ‐1.95 
SM(d42:5)+H  0.05  0.05  0.05  ‐0.14  1.17  ‐1.03 
SM(d42:6)+H  0.05  0.05  0.05  #NAME?  2.13  Inf 
SM(d42:6)+H  0.05  0.05  0.20  ‐1.66  3.26  ‐1.60 
SM(d42:7)+H  0.05  0.05  0.35  ‐1.39  1.64  ‐0.26 
SM(d18:1/25:0)+H  0.05  0.05  0.05  0.55  0.79  ‐1.34 
SM(d43:1)+H  0.20  0.05  0.35  0.30  ‐0.51  0.20 
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SM(d43:2)+H  0.35  0.20  0.35  0.04  0.10  ‐0.14 
SM(d18:1/25:3)+H  0.05  0.05  0.20  ‐0.85  1.10  ‐0.26 
SM(d43:4)+H  0.50  0.20  0.20  0.05  0.15  ‐0.20 
SM(d43:5)+H  0.10  0.05  0.05  ‐0.09  0.76  ‐0.68 
SM(d44:0)+H  0.05  0.05  0.05  ‐0.53  ‐0.80  1.33 
SM(d44:1)+H  0.35  0.05  0.05  0.26  ‐0.84  0.59 
SM(d44:2)+H  0.05  0.35  0.05  ‐1.08  0.11  0.97 
SM(d18:1/26:1)+H  0.35  0.05  0.10  0.20  ‐0.52  0.31 
SM(d44:3)+H  0.35  0.05  0.35  0.03  0.35  ‐0.38 
SM(d18:2/26:1)+H  0.05  0.05  0.05  ‐0.74  ‐0.56  1.30 
SM(d44:4)+H  0.05  0.05  0.20  ‐1.41  Inf  #NAME? 
SM(d18:1/26:3)+H  0.35  0.50  0.50  0.05  ‐0.11  0.07 
SM(d44:5)+H  0.05  0.05  0.05  ‐1.16  2.42  ‐1.26 
SM(d18:1/26:4)+H  0.50  0.05  0.05  ‐0.03  0.38  ‐0.35 
SM(d44:6)+H  0.20  0.05  0.05  0.16  0.74  ‐0.91 
SM(d44:7)+H  0.05  0.05  0.05  ‐0.87  Inf  #NAME? 
SM(d44:8)+H  0.05  0.05  1.00  #NAME?  Inf  NaN 
SM(d18:1/27:0)+H  0.05  0.05  0.10  1.12  ‐0.43  ‐0.69 
SM(d18:1/27:1)+H  0.05  0.65  0.05  0.70  0.03  ‐0.72 
SM(d45:6)+H  0.05  0.35  0.05  0.70  ‐0.03  ‐0.67 
SM(d18:1/28:0)+H  0.05  0.10  0.05  0.65  0.21  ‐0.85 
SM(d46:3)+H  1.00  0.05  0.05  NaN  #NAME?  Inf 
SM(d46:4)+H  0.35  0.05  0.05  0.42  ‐0.81  0.39 
SM(d46:5)+H  0.35  0.05  0.10  0.15  ‐0.48  0.33 
SM(d46:6)+H  0.80  0.05  0.10  ‐0.06  0.57  ‐0.52 
SM(d46:7)+H  0.05  0.05  0.05  ‐0.35  Inf  #NAME? 
SM(d18:1/30:0)+H  0.05  0.05  0.20  0.82  ‐0.37  ‐0.45 
SM(d48:1)+H  0.35  0.05  0.10  ‐0.08  0.46  ‐0.38 
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SM(d48:2)+H  0.05  0.05  0.05  0.88  0.74  ‐1.62 
SM(d18:1/30:1)+H  0.05  0.35  0.05  0.66  ‐0.06  ‐0.60 
SM(d17:0/32:1)+H  0.05  0.05  0.20  0.80  ‐0.40  ‐0.39 
SM(d17:0/32:2)+H  0.05  0.35  0.10  0.67  ‐0.12  ‐0.55 
SM(d18:1/32:0)+H  0.05  0.05  0.35  1.08  ‐0.64  ‐0.45 
SM(d50:1)+H  0.05  0.05  0.05  0.32  0.48  ‐0.79 
SM(d50:2)+H  0.05  0.50  0.05  0.74  ‐0.04  ‐0.70 
SM(d18:1/32:1)+H  0.05  0.05  0.35  0.84  ‐0.46  ‐0.38 
SM(d56:2)+H  0.05  0.50  0.05  0.63  ‐0.03  ‐0.60 
SM(d56:3)+H  0.05  0.20  0.05  0.66  ‐0.19  ‐0.46 
SM(d56:4)+H  0.05  0.20  0.05  0.74  ‐0.12  ‐0.62 
TG(8:0/8:0/8:0)+NH4  0.05  0.05  0.05  0.43  0.29  ‐0.72 
TG(8:0/8:0/10:0)+NH4  0.10  0.10  0.05  0.44  0.29  ‐0.73 
TG(8:0/10:0/10:0)+NH4  0.20  0.20  0.05  0.52  0.27  ‐0.79 
TG(8:0/12:0/14:0)+NH4  0.05  0.05  0.05  0.44  0.31  ‐0.75 
TG(10:0/12:0/14:0)+NH4  0.05  0.05  0.05  0.41  0.30  ‐0.71 
TG(4:0/16:0/16:0)+NH4  0.05  0.05  0.05  0.30  0.30  ‐0.60 
TG(12:0/12:0/14:0)+NH4  0.05  0.05  0.05  0.38  0.29  ‐0.67 
TG(12:0/14:0/14:0)+NH4  0.05  0.05  0.05  0.28  0.30  ‐0.59 
TG(16:1/12:0/12:0)+NH4  0.20  0.20  0.50  ‐0.45  0.33  0.12 
TG(16:0/12:0/14:0)+NH4  0.05  0.05  0.05  0.24  0.30  ‐0.54 
TG(14:0e/14:0/14:0)+NH4  0.05  0.05  0.10  ‐0.45  0.30  0.15 
TG(16:0/10:3/16:0)+NH4  0.05  0.05  0.05  0.33  0.30  ‐0.63 
TG(16:0/13:0/14:0)+NH4  0.50  0.20  0.10  0.01  0.28  ‐0.29 
TG(15:0/13:0/16:0)+NH4  0.20  0.05  0.05  0.12  0.29  ‐0.42 
TG(16:0/14:0/14:0)+NH4  0.50  0.05  0.10  0.00  0.29  ‐0.29 
TG(12:0e/16:0/16:0)+NH4  0.05  0.05  0.05  ‐0.19  0.30  ‐0.11 
TG(16:1/14:0/14:0)+NH4  0.50  0.20  0.35  ‐0.06  0.32  ‐0.26 
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TG(15:0/14:0/16:0)+NH4  0.35  0.20  0.20  ‐0.07  0.28  ‐0.21 
TG(15:0/14:0/16:1)+NH4  0.35  0.20  0.65  ‐0.26  0.32  ‐0.06 
TG(12:0e/16:0/17:1)+NH4  0.05  0.05  0.05  ‐0.48  0.30  0.18 
TG(16:0/14:0/16:0)+NH4  0.05  0.20  0.05  0.33  0.29  ‐0.62 
TG(16:0e/14:0/16:0)+NH4  0.05  0.05  0.10  ‐0.18  0.30  ‐0.12 
TG(14:0p/16:0/16:0)+NH4  0.05  0.05  0.35  ‐0.32  0.30  0.02 
TG(16:0/14:0/16:1)+NH4  0.50  0.10  0.10  0.03  0.29  ‐0.32 
TG(16:1/14:0/16:1)+NH4  0.20  0.35  0.10  0.26  0.26  ‐0.52 
TG(12:0p/16:1/18:1)+NH4  0.20  1.00  0.20  Inf  NaN  #NAME? 
TG(15:0/16:0/16:0)+NH4  0.05  0.05  0.50  ‐0.29  0.29  0.01 
TG(15:0/16:0/16:1)+NH4  0.20  0.10  0.20  ‐0.14  0.29  ‐0.15 
TG(16:1/14:0/17:1)+NH4  0.50  0.20  0.10  ‐0.02  0.27  ‐0.26 
TG(16:0/16:0/16:0)+NH4  0.10  0.10  0.05  0.26  0.29  ‐0.55 
TG(16:0e/16:0/16:0)+NH4  0.05  0.05  0.35  ‐0.25  0.30  ‐0.05 
TG(16:0p/16:0/16:0)+NH4  0.50  0.05  0.35  ‐0.14  0.31  ‐0.17 
TG(16:0/16:0/16:1)+NH4  0.35  0.05  0.10  0.17  0.29  ‐0.46 
TG(20:1p/14:0/14:0)+NH4  0.05  0.05  0.35  ‐0.30  0.30  ‐0.01 
TG(16:1/14:0/18:1)+NH4  0.35  0.05  0.10  0.14  0.29  ‐0.43 
TG(12:0p/18:1/18:1)+NH4  0.35  0.25  0.50  ‐0.31  0.31  0.00 
TG(16:1/16:1/16:1)+NH4  0.20  0.10  0.10  0.23  0.29  ‐0.51 
TG(16:0/16:0/17:0)+NH4  0.10  0.05  0.05  0.15  0.29  ‐0.44 
TG(15:0/16:0/18:1)+NH4  0.50  0.05  0.10  0.05  0.29  ‐0.34 
TG(15:0/16:1/18:1)+NH4  0.50  0.10  0.10  0.01  0.29  ‐0.29 
TG(16:1/16:1/17:1)+NH4  0.50  0.10  0.10  0.07  0.29  ‐0.35 
TG(18:0/16:0/16:0)+NH4  0.20  0.20  0.05  0.22  0.30  ‐0.52 
TG(18:0e/16:0/16:0)+NH4  0.05  0.05  0.65  ‐0.39  0.30  0.08 
TG(16:0/16:0/18:1)+NH4  0.35  0.05  0.05  0.23  0.30  ‐0.53 
TG(16:0e/16:0/18:1)+NH4  0.05  0.05  0.35  ‐0.28  0.31  ‐0.02 
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TG(18:0p/16:0/16:1)+NH4  0.10  0.05  0.35  ‐0.18  0.30  ‐0.12 
TG(16:0/16:1/18:1)+NH4  0.35  0.05  0.05  0.29  0.30  ‐0.59 
TG(16:1/16:1/18:1)+NH4  0.35  0.05  0.05  0.34  0.30  ‐0.64 
TG(18:0/16:0/17:0)+NH4  0.20  0.05  0.05  0.13  0.30  ‐0.43 
TG(16:0/17:0/18:1)+NH4  0.35  0.05  0.05  0.16  0.29  ‐0.45 
TG(20:1p/15:0/16:0)+NH4  0.05  0.05  0.35  ‐0.25  0.30  ‐0.05 
TG(16:0/17:1/18:1)+NH4  0.35  0.05  0.05  0.21  0.30  ‐0.51 
TG(16:1/17:1/18:1)+NH4  0.35  0.05  0.10  0.21  0.29  ‐0.50 
TG(20:0/16:0/16:0)+NH4  0.05  0.05  0.05  0.30  0.29  ‐0.59 
TG(18:0/16:0/18:0)+NH4  0.20  0.05  0.35  ‐0.18  0.31  ‐0.13 
TG(18:0e/16:0/18:0)+NH4  0.05  0.05  0.20  ‐0.48  0.30  0.18 
TG(18:0/16:0/18:1)+NH4  0.35  0.05  0.05  0.11  0.31  ‐0.42 
TG(18:0e/16:0/18:1)+NH4  0.05  0.05  0.50  ‐0.40  0.31  0.10 
TG(16:0/18:1/18:1)+NH4  0.35  0.05  0.05  0.21  0.30  ‐0.50 
TG(16:0e/18:1/18:1)+NH4  0.10  0.05  0.35  ‐0.26  0.31  ‐0.05 
TG(20:0p/16:1/16:1)+NH4  0.05  0.05  0.35  ‐0.22  0.31  ‐0.09 
TG(16:1/18:1/18:1)+NH4  0.35  0.05  0.10  0.31  0.30  ‐0.61 
TG(16:1/18:1/18:2)+NH4  0.35  0.05  0.05  0.22  0.30  ‐0.52 
TG(16:0/16:0/20:4)+NH4  0.20  0.05  0.05  0.08  0.30  ‐0.38 
TG(16:1/16:1/20:3)+NH4  0.05  0.05  0.05  0.39  0.30  ‐0.69 
TG(16:0/14:0/22:6)+NH4  0.10  0.05  0.05  0.53  0.31  ‐0.84 
TG(19:1/16:0/18:0)+NH4  0.35  0.05  0.10  0.05  0.30  ‐0.35 
TG(19:1/16:0/18:1)+NH4  0.35  0.05  0.05  0.20  0.30  ‐0.50 
TG(18:1/17:1/18:1)+NH4  0.35  0.05  0.05  0.26  0.30  ‐0.56 
TG(18:1/17:1/18:2)+NH4  0.20  0.05  0.05  0.29  0.30  ‐0.59 
TG(15:0/18:1/20:5)+NH4  0.05  0.05  0.05  0.41  0.29  ‐0.70 
TG(18:0/18:0/18:0)+NH4  0.50  0.05  0.10  0.00  0.30  ‐0.30 
TG(20:0e/16:0/18:0)+NH4  0.65  0.05  0.35  ‐0.06  0.30  ‐0.25 
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TG(20:0/16:0/18:1)+NH4  0.05  0.05  0.05  0.36  0.29  ‐0.65 
TG(18:0/18:0/18:1)+NH4  0.65  0.05  0.35  ‐0.07  0.30  ‐0.23 
TG(20:0e/16:0/18:1)+NH4  0.05  0.05  0.35  ‐0.30  0.30  ‐0.01 
TG(18:0/18:1/18:1)+NH4  0.35  0.05  0.05  0.22  0.30  ‐0.52 
TG(16:0e/18:1/20:1)+NH4  0.05  0.05  0.80  ‐0.32  0.31  0.01 
TG(18:1/18:1/18:1)+NH4  0.35  0.05  0.10  0.16  0.29  ‐0.45 
TG(16:0e/18:1/20:2)+NH4  0.35  0.05  0.35  ‐0.17  0.31  ‐0.14 
TG(18:1/18:1/18:2)+NH4  0.35  0.05  0.05  0.15  0.30  ‐0.44 
TG(18:1/18:2/18:2)+NH4  0.35  0.05  0.20  ‐0.10  0.30  ‐0.20 
TG(18:1/18:1/18:3)+NH4  0.10  0.05  0.05  0.19  0.31  ‐0.50 
TG(18:2/18:2/18:2)+NH4  0.50  0.05  0.05  0.08  0.30  ‐0.39 
TG(16:0/16:0/22:6)+NH4  0.05  0.05  0.05  0.46  0.31  ‐0.77 
TG(16:0/16:1/22:6)+NH4  0.05  0.05  0.05  0.56  0.31  ‐0.87 
TG(15:0/16:0/24:0)+NH4  0.35  0.10  0.05  0.07  0.28  ‐0.35 
TG(16:0/16:0/23:1)+NH4  0.50  0.10  0.10  0.00  0.29  ‐0.29 
TG(19:1/18:0/18:1)+NH4  0.05  0.05  0.05  0.22  0.30  ‐0.52 
TG(19:1/18:1/18:1)+NH4  0.35  0.05  0.05  0.27  0.31  ‐0.58 
TG(19:1/18:1/18:2)+NH4  0.10  0.05  0.05  0.33  0.30  ‐0.63 
TG(18:1/17:1/20:3)+NH4  0.05  0.05  0.05  0.31  0.30  ‐0.62 
TG(16:0/16:0/24:0)+NH4  0.50  0.20  0.05  0.11  0.28  ‐0.39 
TG(16:0e/16:0/24:0)+NH4  0.35  0.05  0.35  0.26  0.30  ‐0.56 
TG(16:0/16:0/24:1)+NH4  0.65  0.05  0.35  ‐0.04  0.29  ‐0.25 
TG(18:0e/16:0/22:1)+NH4  0.35  0.05  0.35  0.07  0.31  ‐0.38 
TG(18:0/18:1/20:1)+NH4  0.35  0.05  0.20  0.07  0.30  ‐0.37 
TG(20:0e/18:1/18:1)+NH4  0.50  0.05  0.35  ‐0.12  0.30  ‐0.18 
TG(20:1/18:1/18:1)+NH4  0.35  0.05  0.05  0.27  0.30  ‐0.57 
TG(16:0e/18:1/22:2)+NH4  0.50  0.05  0.35  ‐0.05  0.31  ‐0.26 
TG(18:1/18:1/20:2)+NH4  0.10  0.05  0.05  0.36  0.30  ‐0.66 
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TG(18:1/18:1/20:3)+NH4  0.05  0.05  0.05  0.30  0.30  ‐0.61 
TG(16:0e/18:1/22:4)+NH4  0.05  0.05  0.05  0.17  0.30  ‐0.48 
TG(18:1/18:1/20:4)+NH4  0.20  0.05  0.05  0.14  0.31  ‐0.45 
TG(18:0/16:0/22:6)+NH4  0.35  0.05  0.05  0.25  0.31  ‐0.56 
TG(16:0/18:1/22:6)+NH4  0.05  0.05  0.05  0.47  0.31  ‐0.78 
TG(16:1/18:1/22:6)+NH4  0.05  0.05  0.05  0.59  0.31  ‐0.90 
TG(25:0/16:0/16:0)+NH4  0.20  0.10  0.05  0.14  0.28  ‐0.43 
TG(25:0/16:0/16:1)+NH4  0.50  0.20  0.10  ‐0.01  0.28  ‐0.27 
TG(25:1/16:0/16:1)+NH4  0.10  0.05  0.05  0.12  0.29  ‐0.41 
TG(18:1/18:1/21:1)+NH4  0.05  0.05  0.05  0.26  0.29  ‐0.55 
TG(18:1/18:2/21:1)+NH4  0.05  0.05  0.05  0.32  0.30  ‐0.62 
TG(26:0/16:0/16:0)+NH4  0.35  0.20  0.05  0.11  0.28  ‐0.39 
TG(26:1/16:0/16:0)+NH4  0.35  0.05  0.10  0.09  0.29  ‐0.38 
TG(18:0e/16:0/24:1)+NH4  0.35  0.05  0.35  0.28  0.30  ‐0.58 
TG(18:0p/16:0/24:1)+NH4  0.35  0.05  0.35  0.21  0.31  ‐0.51 
TG(16:0/18:1/24:1)+NH4  0.20  0.05  0.05  0.13  0.30  ‐0.42 
TG(18:0p/18:1/22:1)+NH4  0.65  0.05  0.35  ‐0.01  0.31  ‐0.29 
TG(16:1/18:1/24:1)+NH4  0.35  0.05  0.10  0.20  0.30  ‐0.50 
TG(18:1/18:1/22:2)+NH4  0.10  0.05  0.05  0.33  0.31  ‐0.64 
TG(18:1/18:1/22:3)+NH4  0.05  0.05  0.05  0.49  0.30  ‐0.80 
TG(18:1/18:1/22:4)+NH4  0.05  0.05  0.05  0.22  0.30  ‐0.53 
TG(18:1/18:1/22:5)+NH4  0.05  0.05  0.05  0.33  0.31  ‐0.64 
TG(18:1/18:1/22:6)+NH4  0.05  0.05  0.05  0.46  0.30  ‐0.76 
TG(18:1/20:4/20:4)+NH4  0.05  0.05  0.05  0.51  0.31  ‐0.82 
TG(27:0/16:0/16:0)+NH4  0.10  0.05  0.05  0.20  0.29  ‐0.49 
TG(27:1/16:0/16:0)+NH4  0.65  0.20  0.20  ‐0.04  0.27  ‐0.23 
TG(25:1/16:0/18:1)+NH4  0.10  0.20  0.05  0.17  0.28  ‐0.45 
TG(25:1/16:1/18:1)+NH4  0.05  0.10  0.05  0.37  0.29  ‐0.66 
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TG(26:1/16:0/18:0)+NH4  0.35  0.05  0.10  0.19  0.29  ‐0.48 
TG(26:1/16:0/18:1)+NH4  0.35  0.10  0.10  0.27  0.28  ‐0.55 
TG(18:1/18:1/24:1)+NH4  0.05  0.05  0.05  0.27  0.29  ‐0.57 
TG(26:1/16:1/18:1)+NH4  0.20  0.05  0.05  0.16  0.30  ‐0.45 
TG(18:1/18:1/24:2)+NH4  0.10  0.05  0.05  0.28  0.31  ‐0.59 
TG(20:0/18:1/22:6)+NH4  0.05  0.05  0.05  0.30  0.30  ‐0.60 
TG(27:1/16:0/18:1)+NH4  0.10  0.20  0.10  0.22  0.27  ‐0.50 
TG(25:1/18:1/18:1)+NH4  0.35  0.05  0.20  0.30  0.29  ‐0.59 
TG(28:0/16:0/18:0)+NH4  0.50  0.35  0.50  ‐0.20  0.27  ‐0.07 
TG(28:0/16:0/18:1)+NH4  0.35  0.05  0.35  0.13  0.29  ‐0.42 
TG(28:1/16:0/18:1)+NH4  0.35  0.05  0.10  0.30  0.30  ‐0.60 
TG(26:1/18:1/18:1)+NH4  0.35  0.05  0.10  0.42  0.30  ‐0.71 
TG(26:1/18:1/18:2)+NH4  0.35  0.05  0.05  0.48  0.30  ‐0.78 
TG(18:1/20:4/24:0)+NH4  0.20  0.05  0.05  0.40  0.30  ‐0.70 
TG(29:0/16:0/18:1)+NH4  0.35  0.05  0.35  0.23  0.31  ‐0.54 
TG(29:1/16:0/18:1)+NH4  0.35  0.20  0.35  ‐0.24  0.32  ‐0.08 
TG(27:1/18:1/18:1)+NH4  0.35  0.05  0.05  0.49  0.30  ‐0.79 
TG(30:0/16:0/18:1)+NH4  0.20  0.20  0.35  ‐0.22  0.27  ‐0.06 
TG(30:1/16:0/18:1)+NH4  0.50  0.20  0.10  0.13  0.28  ‐0.41 
TG(28:1/18:1/18:1)+NH4  0.35  0.10  0.10  0.28  0.29  ‐0.57 
TG(26:1/18:1/20:2)+NH4  0.35  0.05  0.35  0.23  0.31  ‐0.54 
TG(29:1/18:0/18:1)+NH4  0.35  0.10  0.35  0.32  0.32  ‐0.64 
TG(29:1/18:1/18:1)+NH4  0.05  0.20  0.05  #NAME?  0.26  Inf 
TG(30:0/18:0/18:1)+NH4  0.05  0.20  0.05  #NAME?  0.29  Inf 
TG(30:0/18:1/18:1)+NH4  0.35  0.10  0.10  0.03  0.28  ‐0.31 
TG(30:1/18:1/18:1)+NH4  0.50  0.20  0.10  0.04  0.28  ‐0.31 
TG(28:1/18:1/20:2)+NH4  0.05  0.20  0.05  #NAME?  0.28  Inf 
TG(26:0/18:1/24:0)+NH4  0.05  0.05  0.05  #NAME?  0.30  Inf 
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TG(26:1/18:1/24:0)+NH4  0.05  0.10  0.05  #NAME?  0.28  Inf 
TG(26:1/18:1/24:1)+NH4  1.00  1.00  1.00  NaN  NaN  NaN 
TG(26:1/18:1/24:2)+NH4  1.00  1.00  1.00  NaN  NaN  NaN 
TG(28:0/18:1/24:1)+NH4  1.00  1.00  1.00  NaN  NaN  NaN 
TG(28:1/18:1/24:1)+NH4  1.00  1.00  1.00  NaN  NaN  NaN 
TG(28:1/22:1/22:1)+NH4  1.00  1.00  1.00  NaN  NaN  NaN 
PA(16:1/18:1)‐H  0.05  0.05  0.35  Inf  #NAME?  ‐0.44 
PA(18:0/18:1)‐H  0.20  0.50  0.20  0.32  ‐0.09  ‐0.23 
PA(26:0/18:1)‐H  1.00  0.05  0.05  NaN  #NAME?  Inf 
PA(24:0/23:0)‐H  0.35  0.05  0.20  0.14  ‐0.32  0.17 
PA(24:1/23:0)‐H  0.05  0.50  0.05  0.67  ‐0.03  ‐0.64 
PA(24:1/23:1)‐H  0.05  0.05  0.05  0.52  0.48  ‐1.00 
MG(30:0)+H  0.05  0.05  0.05  #NAME?  ‐0.91  Inf 
MG(32:0)+H  0.10  0.05  0.05  ‐0.23  ‐0.81  1.04 
MG(32:1)+H  0.35  0.05  0.05  0.38  ‐1.09  0.71 
MG(34:0)+H  0.05  0.05  0.05  ‐0.62  ‐0.53  1.15 
MG(36:0)+H  0.05  0.05  0.05  ‐0.46  ‐0.75  1.20 
MG(36:1)+H  0.50  0.05  0.05  0.00  ‐1.08  1.07 
MG(38:1)+H  0.35  0.05  0.05  ‐0.02  ‐1.05  1.07 
 
 
Table of 143B lipidome after U73122 (PLC inhibitor) treatment 




Cer(d18:1/10:0)+H  0.000  ±  0.000 
Cer(d18:0/12:0)+H  0.001  ±  0.000 
Cer(d18:0/14:0)+H  0.004  ±  0.001 
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Cer(d18:1/14:0)+H  0.007  ±  0.000 
Cer(d17:1/16:0)+H  0.002  ±  0.000 
Cer(d18:0/16:0)+H  0.004  ±  0.001 
Cer(d18:1/16:0)+H  0.073  ±  0.006 
Cer(d18:2/16:0)+H  0.005  ±  0.000 
Cer(d18:0/17:0)+H  0.001  ±  0.000 
Cer(d18:0/18:0)+H  0.006  ±  0.002 
Cer(d18:1/18:0)+H  0.007  ±  0.001 
Cer(d18:0/20:0)+H  0.004  ±  0.001 
Cer(d18:1/20:0)+H  0.002  ±  0.000 
Cer(d18:0/21:0)+H  0.000  ±  0.000 
Cer(d18:0/22:0)+H  0.035  ±  0.011 
Cer(d18:0/22:1)+H  0.003  ±  0.001 
Cer(d18:1/22:0)+H  0.024  ±  0.003 
Cer(d18:2/22:0)+H  0.003  ±  0.000 
Cer(d18:0/23:0)+H  0.005  ±  0.001 
Cer(d18:1/23:0)+H  0.007  ±  0.001 
Cer(d18:2/23:0)+H  0.003  ±  0.000 
Cer(d18:0/24:0)+H  0.093  ±  0.033 
Cer(d18:0/24:1)+H  0.071  ±  0.022 
Cer(d18:1/24:0)+H  0.096  ±  0.012 
Cer(d18:1/24:1)+H  0.088  ±  0.011 
Cer(d18:1/24:2)+H  0.012  ±  0.001 
Cer(d18:0/25:0)+H  0.003  ±  0.001 
Cer(d18:0/25:1)+H  0.003  ±  0.001 
Cer(d18:1/25:0)+H  0.005  ±  0.001 
Cer(d18:1/25:1)+H  0.003  ±  0.001 
Cer(d18:2/25:1)+H  0.001  ±  0.000 
Cer(d18:1/25:2)+H  0.001  ±  0.000 
Cer(d18:0/26:0)+H  0.027  ±  0.011 
Cer(d18:0/26:1)+H  0.020  ±  0.007 
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Cer(d18:1/26:0)+H  0.028  ±  0.006 
Cer(d18:1/26:1)+H  0.025  ±  0.004 
Cer(d18:2/26:1)+H  0.004  ±  0.001 
Cer(d18:0/27:1)+H  0.000  ±  0.000 
Cer(d18:0/28:0)+H  0.001  ±  0.000 
Cer(d18:0/28:1)+H  0.001  ±  0.000 
Cer(d18:1/28:0)+H  0.001  ±  0.000 
Cer(d18:1/28:1)+H  0.001  ±  0.000 
CerG1(d18:0/14:0)+H  0.001  ±  0.000 
CerG1(d18:1/14:0)+H  0.007  ±  0.001 
CerG1(d17:1/16:0)+H  0.002  ±  0.000 
CerG1(d18:0/16:0)+H  0.029  ±  0.005 
CerG1(d18:1/16:0)+H  0.184  ±  0.017 
CerG1(d18:2/16:0)+H  0.005  ±  0.001 
CerG1(d34:2)+H  0.001  ±  0.000 
CerG1(d18:1/17:0)+H  0.001  ±  0.000 
CerG1(d18:1/18:0)+H  0.007  ±  0.001 
CerG1(d18:0/22:0)+H  0.012  ±  0.004 
CerG1(d18:1/22:0)+H  0.025  ±  0.004 
CerG1(d18:0/23:0)+H  0.001  ±  0.000 
CerG1(d18:1/23:0)+H  0.009  ±  0.002 
CerG1(d18:0/24:0)+H  0.017  ±  0.004 
CerG1(d18:0/24:1)+H  0.014  ±  0.003 
CerG1(d18:1/24:0)+H  0.161  ±  0.029 
CerG1(d18:1/24:1)+H  0.087  ±  0.016 
CerG1(d18:2/24:1)+H  0.007  ±  0.002 
CerG1(d18:0/25:0)+H  0.000  ±  0.000 
CerG1(d18:1/25:0)+H  0.001  ±  0.000 
CerG1(d43:2)+H  0.002  ±  0.000 
CerG1(d18:0/26:0)+H  0.002  ±  0.001 
CerG1(d18:0/26:1)+H  0.002  ±  0.001 
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CerG1(d18:1/26:0)+H  0.016  ±  0.003 
CerG1(d18:1/26:1)+H  0.014  ±  0.003 
CerG2(d18:1/14:0)+H  0.001  ±  0.000 
CerG2(d18:1/16:0)+H  0.011  ±  0.001 
CerG2(d34:2)+H  0.003  ±  0.000 
CerG2(d18:1/22:0)+H  0.003  ±  0.001 
CerG2(d18:0/24:1)+H  0.001  ±  0.000 
CerG2(d18:1/24:0)+H  0.011  ±  0.002 
CerG2(d18:1/24:1)+H  0.009  ±  0.002 
CerG2(d18:2/24:0)+H  0.002  ±  0.000 
CerG2(d18:1/26:0)+H  0.001  ±  0.000 
CerG2(d18:1/26:1)+H  0.001  ±  0.000 
CerG3(d18:1/16:0)+H  0.001  ±  0.000 
CerG3(d18:1/24:0)+H  0.001  ±  0.000 
Cer(d18:1/12:0)+H  1.332  ±  0.235 
 




ChE(18:1)+NH4  0.024502  ±  0.001227 
ChE(18:2)+NH4  0.010048  ±  0.000607 
ChE(20:2)+NH4  0.003115  ±  0.000556 
ChE(20:3)+NH4  0.004809  ±  0.000382 
ChE(20:4)+NH4  0.03015  ±  0.002917 
ChE(20:5)+NH4  0.005493  ±  0.000414 
ChE(22:3)+NH4  0.004706  ±  0.000582 
ChE(22:4)+NH4  0.015999  ±  0.001584 
ChE(22:5)+NH4  0.057184  ±  0.011906 
ChE(22:6)+NH4  0.124234  ±  0.016162 
ChE(24:0)+NH4  0.001126  ±  8.53E‐05 
ChE(24:1)+NH4  0.009209  ±  0.000684 
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ChE(24:2)+NH4  0.004459  ±  0.000549 
ChE(24:3)+NH4  0.006157  ±  0.000763 
ChE(24:4)+NH4  0.015306  ±  0.002121 
ChE(24:5)+NH4  0.021138  ±  0.004692 
ChE(24:6)+NH4  0.017383  ±  0.003211 
ChE(26:0)+NH4  0.010886  ±  0.000898 
ChE(26:1)+NH4  0.03936  ±  0.002653 
ChE(26:2)+NH4  0.022062  ±  0.001273 
ChE(26:3)+NH4  0.008532  ±  0.000586 
ChE(26:4)+NH4  0.01503  ±  0.001988 
ChE(26:5)+NH4  0.020798  ±  0.002724 
ChE(26:6)+NH4  0.020606  ±  0.003958 
ChE(28:0)+NH4  0.001121  ±  0.000182 
ChE(28:1)+NH4  0.014791  ±  0.001597 
ChE(28:2)+NH4  0.007167  ±  0.000704 
ChE(28:3)+NH4  0.002882  ±  0.000223 
ChE(28:5)+NH4  0.00634  ±  0.000857 
ChE(28:6)+NH4  0.00549  ±  0.000346 
ChE(30:1)+NH4  0.005637  ±  0.000733 
ChE(30:2)+NH4  0.003917  ±  0.000442 
ChE(30:3)+NH4  0.002172  ±  0.000103 
ChE(30:4)+NH4  0.002169  ±  0.00023 
ChE(30:5)+NH4  0.004719  ±  0.00051 
ChE(30:6)+NH4  0.007527  ±  0.000775 
ChE(32:1)+NH4  0.001241  ±  0.000292 
ChE(32:2)+NH4  0.001804  ±  0.00027 
ChE(32:3)+NH4  0.000978  ±  0.000163 
ChE(32:4)+NH4  0.001769  ±  6.66E‐05 
ChE(32:5)+NH4  0.005715  ±  0.000449 
ChE(32:6)+NH4  0.008476  ±  0.000995 
ChE(34:6)+NH4  0.003752  ±  0.000597 
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CL(14:0/14:0/14:0/20:1)‐H  0.001  ±  0.000 
CL(14:0/14:0/18:1/16:1)‐H  0.002  ±  0.000 
CL(16:1/16:1/16:1/14:0)‐H  0.002  ±  0.000 
CL(15:0/16:1/16:1/16:1)‐H  0.000  ±  0.000 
CL(14:0/16:0/18:1/16:0)‐H  0.001  ±  0.000 
CL(14:0/16:0/16:1/18:1)‐H  0.004  ±  0.001 
CL(14:0/16:1/16:1/18:1)‐H  0.010  ±  0.002 
CL(16:1/16:1/16:1/16:1)‐H  0.008  ±  0.002 
CL(20:2/14:0/15:0/16:0)‐H  0.000  ±  0.000 
CL(17:1/14:0/18:1/16:1)‐H  0.001  ±  0.000 
CL(17:1/16:1/16:1/16:1)‐H  0.001  ±  0.000 
CL(18:1/16:0/16:0/16:0)‐H  0.001  ±  0.000 
CL(18:1/16:0/16:0/16:1)‐H  0.008  ±  0.001 
CL(14:0/18:1/16:1/18:1)‐H  0.020  ±  0.004 
CL(16:1/16:1/16:1/18:1)‐H  0.037  ±  0.009 
CL(18:2/16:1/16:1/16:1)‐H  0.009  ±  0.002 
CL(18:4/18:1/14:0/16:1)‐H  0.002  ±  0.000 
CL(18:4/16:1/16:1/16:1)‐H  0.002  ±  0.000 
CL(15:0/16:0/18:1/18:1)‐H  0.001  ±  0.000 
CL(17:1/16:1/18:1/16:0)‐H  0.002  ±  0.000 
CL(17:1/16:1/18:1/16:1)‐H  0.005  ±  0.001 
CL(17:1/16:1/18:2/16:1)‐H  0.001  ±  0.000 
CL(18:1/16:0/16:0/18:1)‐H  0.017  ±  0.003 
CL(18:1/16:0/16:1/18:1)‐H  0.026  ±  0.005 
CL(18:1/16:1/16:0/18:2)‐H  0.078  ±  0.018 
CL(68:4)‐2H  0.002  ±  0.000 
CL(18:2/16:1/18:1/16:1)‐H  0.038  ±  0.007 
CL(14:0/16:0/18:1/20:4)‐H  0.002  ±  0.000 
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CL(18:2/16:1/16:1/18:2)‐H  0.005  ±  0.001 
CL(16:1/16:1/20:3/16:1)‐H  0.003  ±  0.001 
CL(14:0/20:4/18:1/16:1)‐H  0.004  ±  0.001 
CL(20:4/16:1/16:1/16:1)‐H  0.002  ±  0.001 
CL(18:4/16:1/18:2/16:1)‐H  0.002  ±  0.000 
CL(17:0/16:0/18:1/18:1)‐H  0.001  ±  0.000 
CL(17:1/16:0/18:1/18:1)‐H  0.003  ±  0.000 
CL(17:1/16:1/18:1/18:1)‐H  0.008  ±  0.001 
CL(17:1/16:1/18:2/18:1)‐H  0.005  ±  0.001 
CL(17:1/16:1/18:2/18:2)‐H  0.001  ±  0.000 
CL(17:1/16:1/20:4/16:1)‐H  0.001  ±  0.000 
CL(18:1/16:0/18:0/18:0)‐H  0.006  ±  0.001 
CL(18:1/16:0/18:0/18:1)‐H  0.003  ±  0.001 
CL(18:1/16:0/18:1/18:1)‐H  0.015  ±  0.003 
CL(18:1/16:1/18:1/18:1)‐H  0.059  ±  0.010 
CL(18:2/18:1/16:1/18:1)‐H  0.067  ±  0.013 
CL(20:4/16:0/18:1/16:0)‐H  0.004  ±  0.001 
CL(18:2/16:1/18:1/18:2)‐H  0.019  ±  0.003 
CL(20:4/16:0/16:1/18:1)‐H  0.006  ±  0.001 
CL(18:2/16:1/18:2/18:2)‐H  0.003  ±  0.000 
CL(20:4/16:1/18:1/16:1)‐H  0.006  ±  0.001 
CL(20:4/16:1/16:1/18:1)‐H  0.013  ±  0.002 
CL(18:2/16:1/16:1/20:4)‐H  0.001  ±  0.000 
CL(18:4/18:2/18:1/16:1)‐H  0.008  ±  0.001 
CL(20:5/16:1/16:1/18:2)‐H  0.001  ±  0.000 
CL(17:0/18:1/18:1/18:1)‐H  0.001  ±  0.000 
CL(17:1/18:1/18:1/18:1)‐H  0.004  ±  0.001 
CL(17:1/18:1/18:1/18:2)‐H  0.005  ±  0.001 
CL(17:1/18:1/18:2/18:2)‐H  0.001  ±  0.000 
CL(17:1/20:4/16:1/18:1)‐H  0.002  ±  0.000 
CL(17:1/16:1/18:2/20:4)‐H  0.001  ±  0.000 
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CL(18:2/16:1/16:1/22:6)‐H  0.001  ±  0.000 
CL(18:1/18:0/18:0/18:1)‐H  0.012  ±  0.002 
CL(18:1/18:0/18:1/18:1)‐H  0.002  ±  0.000 
CL(18:1/18:1/18:1/18:1)‐H  0.013  ±  0.003 
CL(18:2/18:1/18:1/18:1)‐H  0.029  ±  0.005 
CL(18:1/16:0/18:1/20:3)‐H  0.001  ±  0.000 
CL(18:2/18:1/18:1/18:2)‐H  0.023  ±  0.004 
CL(20:4/16:0/18:1/18:1)‐H  0.004  ±  0.001 
CL(18:2/16:1/20:3/18:1)‐H  0.008  ±  0.001 
CL(18:2/18:2/18:2/18:1)‐H  0.008  ±  0.001 
CL(20:4/18:1/16:1/18:1)‐H  0.012  ±  0.002 
CL(18:2/18:2/18:2/18:2)‐H  0.004  ±  0.002 
CL(18:2/18:1/20:4/16:1)‐H  0.012  ±  0.002 
CL(18:2/16:1/16:1/22:5)‐H  0.002  ±  0.000 
CL(20:5/18:1/16:1/18:2)‐H  0.005  ±  0.001 
CL(19:1/18:1/18:1/18:1)‐H  0.000  ±  0.000 
CL(19:1/18:1/18:1/18:2)‐H  0.001  ±  0.000 
CL(19:1/18:1/18:2/18:2)‐H  0.001  ±  0.000 
CL(17:1/18:1/20:4/18:1)‐H  0.001  ±  0.000 
CL(17:1/18:1/18:2/20:4)‐H  0.001  ±  0.000 
CL(18:1/18:0/18:0/20:0)‐H  0.019  ±  0.003 
CL(22:5/16:1/18:2/18:2)‐H  0.002  ±  0.000 
CL(18:2/16:1/20:4/20:4)‐H  0.001  ±  0.000 
CL(22:2/16:1/18:0/18:1)‐H  0.006  ±  0.001 
CL(20:4/18:0/18:0/18:1)‐H  0.000  ±  0.000 
CL(18:2/18:1/18:2/20:1)‐H  0.002  ±  0.000 
CL(18:1/18:1/20:3/18:1)‐H  0.001  ±  0.000 
CL(18:2/18:1/20:3/18:1)‐H  0.003  ±  0.001 
CL(20:4/18:1/18:1/18:1)‐H  0.004  ±  0.001 
CL(18:2/16:1/18:1/22:4)‐H  0.001  ±  0.000 
CL(18:2/18:1/20:3/18:2)‐H  0.004  ±  0.001 
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CL(18:1/18:1/18:2/20:4)‐H  0.006  ±  0.001 
CL(18:2/18:1/20:4/18:2)‐H  0.005  ±  0.001 
CL(23:1/16:0/18:0/18:1)‐H  0.003  ±  0.000 
CL(18:2/18:2/18:2/22:5)‐H  0.000  ±  0.000 
CL(22:3/18:0/18:0/18:1)‐H  0.005  ±  0.000 
CL(20:4/18:0/18:1/20:0)‐H  0.011  ±  0.002 
CL(22:5/18:0/18:0/18:1)‐H  0.002  ±  0.001 
CL(22:6/18:1/18:1/18:1)‐H  0.001  ±  0.000 
CL(23:0/18:0/18:0/18:1)‐H  0.002  ±  0.001 
CL(22:3/18:0/18:0/20:4)‐H  0.008  ±  0.001 
CL(21:0/18:0/18:0/22:6)‐H  0.004  ±  0.001 
CL(22:3/18:0/18:0/22:5)‐H  0.002  ±  0.000 
CL(23:0/18:0/18:0/22:4)‐H  0.002  ±  0.000 
Table 20: Diacylglycerols in treated 143B cells 
Lipid Ion  Diacylglycerol 
DG(16:0/14:0)+NH4  0.027  ±  0.002 
DG(16:1/14:0)+NH4  0.005  ±  0.001 
DG(16:0/16:0)+NH4  0.124  ±  0.017 
DG(18:1/14:0)+NH4  0.150  ±  0.004 
DG(16:1/16:1)+NH4  0.003  ±  0.002 
DG(16:0/17:0)+NH4  0.002  ±  0.000 
DG(17:1/16:0)+NH4  0.014  ±  0.002 
DG(18:0/16:0)+NH4  0.072  ±  0.017 
DG(16:0/18:1)+NH4  0.745  ±  0.077 
DG(16:1/18:1)+NH4  0.106  ±  0.005 
DG(17:0/18:1)+NH4  0.005  ±  0.001 
DG(17:1/18:1)+NH4  0.014  ±  0.002 
DG(18:0/18:0)+NH4  0.006  ±  0.001 
DG(18:0/18:1)+NH4  0.247  ±  0.039 
DG(18:1/18:1)+NH4  0.486  ±  0.055 
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DG(18:1/18:2)+NH4  0.039  ±  0.005 
DG(16:0/20:4)+NH4  0.022  ±  0.001 
DG(19:1/18:1)+NH4  0.007  ±  0.000 
DG(16:0/22:1)+NH4  0.017  ±  0.004 
DG(20:1/18:1)+NH4  0.054  ±  0.007 
DG(18:1/20:2)+NH4  0.021  ±  0.002 
DG(18:0/20:3)+NH4  0.014  ±  0.002 
DG(18:1/20:3)+NH4  0.012  ±  0.003 
DG(16:0/22:4)+NH4  0.010  ±  0.002 
DG(18:0/20:4)+NH4  0.089  ±  0.007 
DG(18:1/20:4)+NH4  0.038  ±  0.003 
DG(16:0/22:6)+NH4  0.023  ±  0.002 
DG(16:1/22:6)+NH4  0.005  ±  0.001 
DG(26:0/14:0)+NH4  0.005  ±  0.001 
DG(16:0/24:1)+NH4  0.009  ±  0.003 
DG(18:1/22:1)+NH4  0.012  ±  0.003 
DG(18:0/22:4)+NH4  0.007  ±  0.001 
DG(18:0/22:5)+NH4  0.021  ±  0.002 
DG(18:1/22:5)+NH4  0.012  ±  0.002 
DG(18:0/22:6)+NH4  0.013  ±  0.002 
DG(18:1/22:6)+NH4  0.021  ±  0.001 
DG(26:0/16:0)+NH4  0.019  ±  0.005 
DG(26:1/16:0)+NH4  0.020  ±  0.006 
DG(18:1/24:1)+NH4  0.018  ±  0.004 
DG(27:1/16:0)+NH4  0.002  ±  0.000 
DG(28:0/16:0)+NH4  0.004  ±  0.001 
DG(28:1/16:0)+NH4  0.031  ±  0.010 
DG(26:1/18:1)+NH4  0.039  ±  0.011 
DG(27:1/18:1)+NH4  0.003  ±  0.001 
DG(30:1/16:0)+NH4  0.008  ±  0.004 
DG(28:1/18:1)+NH4  0.010  ±  0.003 
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DG(30:1/18:1)+NH4  0.007  ±  0.001 
 





LPC(12:0)+H  0.000  ±  0.000 
LPC(14:0)+H  0.000  ±  0.000 
LPC(15:0)+H  0.001  ±  0.000 
LPC(16:0)+H  0.004  ±  0.000 
LPC(16:0e)+H  0.002  ±  0.000 
LPC(16:0p)+H  0.001  ±  0.000 
LPC(16:1)+H  0.000  ±  0.000 
LPC(17:1)+H  0.000  ±  0.000 
LPC(18:0)+H  0.005  ±  0.001 
LPC(18:0e)+H  0.001  ±  0.000 
LPC(18:0p)+H  0.001  ±  0.000 
LPC(18:1)+H  0.003  ±  0.000 
LPC(18:1p)+H  0.000  ±  0.000 
LPC(18:2)+H  0.000  ±  0.000 
LPC(19:0)+H  0.000  ±  0.000 
LPC(19:1)+H  0.000  ±  0.000 
LPC(20:0)+H  0.000  ±  0.000 
LPC(20:0e)+H  0.000  ±  0.000 
LPC(20:0p)+H  0.001  ±  0.000 
LPC(20:1)+H  0.001  ±  0.000 
LPC(20:3)+H  0.000  ±  0.000 
LPC(20:4)+H  0.000  ±  0.000 
LPC(22:0)+H  0.000  ±  0.000 
LPC(22:1)+H  0.000  ±  0.000 
LPC(22:5)+H  0.000  ±  0.000 
LPC(22:6)+H  0.000  ±  0.000 
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LPC(24:0)+H  0.001  ±  0.000 
LPC(24:1)+H  0.001  ±  0.000 
LPC(26:0)+H  0.005  ±  0.001 
LPC(26:1)+H  0.002  ±  0.000 
LPC(28:0)+H  0.008  ±  0.002 
LPC(28:1)+H  0.002  ±  0.000 
 





PC(18:2p/8:0)+H  0.000  ±  0.000 
PC(28:0)+H  0.132  ±  0.028 
PC(14:0p/14:0)+H  0.001  ±  0.000 
PC(16:0/13:0)+H  0.004  ±  0.001 
PC(11:0/18:1)+H  0.025  ±  0.006 
PC(30:0)+H  0.580  ±  0.082 
PC(30:0e)+H  0.181  ±  0.032 
PC(30:0p)+H  0.032  ±  0.004 
PC(30:1)+H  0.240  ±  0.068 
PC(16:0/14:1)+H  0.003  ±  0.000 
PC(14:0p/16:1)+H  0.002  ±  0.000 
PC(31:0)+H  0.062  ±  0.010 
PC(31:1)+H  0.038  ±  0.009 
PC(32:0)+H  0.318  ±  0.017 
PC(32:0e)+H  0.332  ±  0.043 
PC(16:0p/16:0)+H  0.336  ±  0.070 
PC(32:1)+H  1.650  ±  0.181 
PC(16:0/16:1)+H  0.009  ±  0.001 
PC(32:1p)+H  0.051  ±  0.007 
PC(32:2)+H  0.074  ±  0.012 
PC(18:1/14:1)+H  0.005  ±  0.001 
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PC(14:0/18:3)+H  0.005  ±  0.001 
PC(17:1/16:0)+H  0.255  ±  0.030 
PC(15:0/18:1)+H  0.119  ±  0.022 
PC(17:1/16:1)+H  0.031  ±  0.007 
PC(20:0/14:0)+H  0.000  ±  0.000 
PC(34:0)+H  0.153  ±  0.019 
PC(34:0e)+H  0.128  ±  0.015 
PC(34:1)+H  2.077  ±  0.190 
PC(34:1e)+H  0.811  ±  0.103 
PC(18:1p/16:0)+H  0.066  ±  0.010 
PC(16:0p/18:1)+H  0.120  ±  0.021 
PC(34:2)+H  0.748  ±  0.140 
PC(16:1/18:1)+H  0.003  ±  0.001 
PC(34:2e)+H  0.067  ±  0.008 
PC(16:1p/18:1)+H  0.012  ±  0.002 
PC(34:3)+H  0.058  ±  0.015 
PC(34:4)+H  0.013  ±  0.002 
PC(17:0/18:1)+H  0.045  ±  0.003 
PC(35:1)+H  0.104  ±  0.017 
PC(17:1/18:1)+H  0.130  ±  0.027 
PC(35:2)+H  0.035  ±  0.005 
PC(15:0/20:3)+H  0.012  ±  0.003 
PC(36:0e)+H  0.010  ±  0.002 
PC(36:1)+H  0.918  ±  0.121 
PC(36:1e)+H  0.224  ±  0.045 
PC(20:1p/16:0)+H  0.053  ±  0.006 
PC(18:1p/18:0)+H  0.034  ±  0.009 
PC(18:1/18:1)+H  1.272  ±  0.227 
PC(18:2p/18:0)+H  0.022  ±  0.003 
PC(36:2p)+H  0.030  ±  0.004 
PC(14:0p/22:2)+H  0.004  ±  0.001 
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PC(36:3)+H  0.293  ±  0.028 
PC(18:2p/18:1)+H  0.102  ±  0.012 
PC(36:4)+H  0.158  ±  0.018 
PC(18:4/18:0)+H  0.013  ±  0.004 
PC(16:0p/20:4)+H  0.018  ±  0.002 
PC(14:0p/22:4)+H  0.000  ±  0.000 
PC(36:5)+H  0.030  ±  0.006 
PC(14:0/22:6)+H  0.001  ±  0.000 
PC(16:0/21:1)+H  0.022  ±  0.004 
PC(19:1/18:1)+H  0.065  ±  0.012 
PC(15:0/22:4)+H  0.010  ±  0.001 
PC(20:0/18:1)+H  0.000  ±  0.000 
PC(38:1e)+H  0.028  ±  0.006 
PC(38:2)+H  0.221  ±  0.038 
PC(38:3)+H  0.080  ±  0.010 
PC(38:4)+H  0.102  ±  0.013 
PC(38:4e)+H  0.032  ±  0.003 
PC(38:4p)+H  0.066  ±  0.009 
PC(38:5)+H  0.183  ±  0.020 
PC(16:0e/22:5)+H  0.008  ±  0.000 
PC(38:6)+H  0.097  ±  0.015 
PC(38:7)+H  0.021  ±  0.003 
PC(18:1/21:0)+H  0.003  ±  0.001 
PC(18:1/21:1)+H  0.003  ±  0.001 
PC(40:0e)+H  0.002  ±  0.000 
PC(40:1)+H  0.029  ±  0.006 
PC(40:2)+H  0.056  ±  0.010 
PC(40:3)+H  0.015  ±  0.002 
PC(26:1/14:3)+H  0.000  ±  0.000 
PC(40:4)+H  0.017  ±  0.001 
PC(18:0/22:5)+H  0.037  ±  0.006 
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PC(40:6)+H  0.045  ±  0.005 
PC(40:7)+H  0.097  ±  0.013 
PC(40:8)+H  0.021  ±  0.003 
PC(18:1/23:0)+H  0.002  ±  0.001 
PC(18:1/23:1)+H  0.002  ±  0.000 
PC(20:4/21:1)+H  0.001  ±  0.000 
PC(42:0)+H  0.015  ±  0.005 
PC(42:1)+H  0.032  ±  0.007 
PC(42:2)+H  0.054  ±  0.011 
PC(42:3)+H  0.016  ±  0.003 
PC(27:0/16:0)+H  0.001  ±  0.000 
PC(44:1)+H  0.039  ±  0.009 
PC(44:2)+H  0.060  ±  0.013 
PC(44:3)+H  0.019  ±  0.006 
PC(27:0/18:1)+H  0.002  ±  0.001 
PC(46:1)+H  0.017  ±  0.003 
PC(46:2)+H  0.020  ±  0.005 
PC(46:4)+H  0.004  ±  0.001 
PC(46:5)+H  0.006  ±  0.001 
PC(48:2)+H  0.007  ±  0.002 
 





LPE(16:0)‐H  0.001  ±  0.000 
LPE(18:1)‐H  0.002  ±  0.000 
LPE(20:4)‐H  0.001  ±  0.000 
LPE(24:0)‐H  0.004  ±  0.001 
LPE(26:1)‐H  0.001  ±  0.000 







PE(16:0/14:0)+H  0.026  ±  0.001 
PE(30:1)+H  0.013  ±  0.002 
PE(16:0p/14:1)+H  0.003  ±  0.001 
PE(16:0/16:0)+H  0.051  ±  0.007 
PE(16:0p/16:0)+H  0.010  ±  0.002 
PE(16:0/16:1)+H  0.368  ±  0.066 
PE(16:0p/16:1)+H  0.173  ±  0.024 
PE(16:1/16:1)+H  0.026  ±  0.005 
PE(16:0p/17:1)+H  0.024  ±  0.003 
PE(18:0p/16:0)+H  0.011  ±  0.003 
PE(16:0/18:1)+H  1.975  ±  0.175 
PE(16:0e/18:1)+H  0.049  ±  0.006 
PE(16:0p/18:1)+H  0.898  ±  0.148 
PE(16:1/18:1)+H  0.546  ±  0.071 
PE(18:1p/16:1)+H  0.065  ±  0.010 
PE(16:0p/18:2)+H  0.066  ±  0.007 
PE(16:1/18:2)+H  0.025  ±  0.012 
PE(16:0p/18:3)+H  0.006  ±  0.001 
PE(14:0/20:4)+H  0.006  ±  0.001 
PE(16:0p/19:1)+H  0.028  ±  0.004 
PE(17:1/18:1)+H  0.078  ±  0.010 
PE(18:0/18:1)+H  1.726  ±  0.244 
PE(18:0p/18:1)+H  0.417  ±  0.081 
PE(18:1/18:1)+H  2.064  ±  0.226 
PE(18:1p/18:1)+H  0.242  ±  0.042 
PE(18:0p/18:2)+H  0.100  ±  0.014 
PE(18:1/18:2)+H  0.271  ±  0.034 
PE(36:3)+H  0.028  ±  0.004 
PE(16:0p/20:3)+H  0.170  ±  0.022 
PE(16:0/20:4)+H  0.432  ±  0.040 
PE(16:0p/20:4)+H  1.134  ±  0.557 
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PE(16:1/20:4)+H  0.027  ±  0.005 
PE(16:0/20:5)+H  0.029  ±  0.004 
PE(16:0p/20:5)+H  0.150  ±  0.012 
PE(16:1/20:5)+H  0.002  ±  0.000 
PE(16:0p/22:1)+H  0.062  ±  0.012 
PE(18:1p/20:1)+H  0.025  ±  0.007 
PE(18:0/20:3)+H  0.175  ±  0.034 
PE(18:0p/20:3)+H  0.095  ±  0.018 
PE(18:0/20:4)+H  1.917  ±  0.199 
PE(16:0p/22:4)+H  0.269  ±  0.030 
PE(18:0p/20:4)+H  0.699  ±  0.079 
PE(18:0/20:5)+H  0.173  ±  0.020 
PE(16:0p/22:5)+H  1.171  ±  0.110 
PE(18:0p/20:5)+H  0.127  ±  0.022 
PE(16:0/22:6)+H  0.112  ±  0.004 
PE(18:1p/20:5)+H  0.041  ±  0.002 
PE(16:1/22:6)+H  0.015  ±  0.003 
PE(17:0/22:6)+H  0.014  ±  0.002 
PE(18:0p/22:1)+H  0.011  ±  0.007 
PE(18:0p/22:2)+H  0.014  ±  0.002 
PE(18:0p/22:3)+H  0.011  ±  0.002 
PE(18:0/22:4)+H  0.150  ±  0.013 
PE(18:0p/22:4)+H  0.077  ±  0.009 
PE(18:0/22:5)+H  0.318  ±  0.032 
PE(18:0p/22:5)+H  0.290  ±  0.027 
PE(18:0/22:6)+H  0.514  ±  0.012 
PE(18:1p/22:5)+H  0.138  ±  0.010 
PE(18:1/22:6)+H  0.244  ±  0.018 
PE(18:1/24:0)+H  0.050  ±  0.008 
PE(22:0/20:4)+H  0.009  ±  0.002 
PE(20:0p/22:5)+H  0.014  ±  0.002 
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PE(26:0/18:1)+H  0.030  ±  0.006 
PE(24:0/20:4)+H  0.028  ±  0.008 
PE(24:1/20:4)+H  0.029  ±  0.005 
PE(26:1/20:4)+H  0.016  ±  0.002 
 





PI(16:0/16:1)‐H  0.050  ±  0.014 
PI(18:1/14:1)‐H  0.004  ±  0.001 
PI(17:1/16:0)‐H  0.007  ±  0.002 
PI(18:0/16:0)‐H  0.013  ±  0.002 
PI(16:0/18:1)‐H  0.819  ±  0.111 
PI(16:0e/18:1)‐H  0.009  ±  0.001 
PI(16:1/18:2)‐H  0.003  ±  0.001 
PI(17:0/18:1)‐H  0.011  ±  0.002 
PI(17:1/18:1)‐H  0.018  ±  0.006 
PI(17:0/18:2)‐H  0.004  ±  0.000 
PI(18:0/18:1)‐H  0.037  ±  0.009 
PI(18:0p/18:1)‐H  0.003  ±  0.002 
PI(18:1/18:1)‐H  1.542  ±  0.302 
PI(16:0/20:4)‐H  0.119  ±  0.017 
PI(16:0e/20:4)‐H  0.004  ±  0.001 
PI(16:1/20:4)‐H  0.002  ±  0.001 
PI(19:1/18:0)‐H  0.016  ±  0.003 
PI(17:0/20:4)‐H  0.018  ±  0.003 
PI(18:0/20:1)‐H  0.030  ±  0.006 
PI(18:1/20:3)‐H  0.059  ±  0.013 
PI(18:0/20:4)‐H  2.162  ±  0.342 
PI(18:0e/20:4)‐H  0.006  ±  0.001 
PI(18:0p/20:4)‐H  0.008  ±  0.002 
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PI(19:1/20:3)‐H  0.007  ±  0.004 
PI(19:0/20:4)‐H  0.005  ±  0.001 
PI(19:1/20:4)‐H  0.007  ±  0.001 
PI(18:0/22:1)‐H  0.004  ±  0.001 
PI(18:1/22:1)‐H  0.006  ±  0.002 
PI(18:0/22:3)‐H  0.032  ±  0.006 
PI(20:0/20:3)‐H  0.001  ±  0.000 
PI(20:0/20:4)‐H  0.005  ±  0.001 
PI(18:0e/22:5)‐H  0.002  ±  0.000 
PI(20:3/20:4)‐H  0.001  ±  0.000 
PI(18:0/24:2)‐H  0.003  ±  0.001 
PI(18:1/24:2)‐H  0.002  ±  0.001 
PI(22:5/20:4)‐H  0.001  ±  0.000 
PI(26:1/18:0)‐H  0.002  ±  0.001 
 





PG(16:1/14:0)‐H  0.001  ±  0.000 
PG(16:0/16:0)‐H  0.006  ±  0.001 
PG(16:0/16:1)‐H  0.007  ±  0.002 
PG(16:1/16:1)‐H  0.001  ±  0.000 
PG(16:0/18:1)‐H  0.124  ±  0.008 
PG(16:1/18:1)‐H  0.012  ±  0.002 
PG(19:1/16:0)‐H  0.003  ±  0.001 
PG(18:0/18:1)‐H  0.051  ±  0.008 
PG(18:1/18:1)‐H  0.161  ±  0.031 
PG(18:1/18:2)‐H  0.003  ±  0.001 
PG(20:1/18:1)‐H  0.005  ±  0.001 
PG(18:1/20:2)‐H  0.010  ±  0.002 
PG(16:0/22:6)‐H  0.009  ±  0.002 
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PG(16:1/22:6)‐H  0.003  ±  0.001 
PG(18:1/22:5)‐H  0.007  ±  0.002 
PG(18:1/22:6)‐H  0.087  ±  0.018 
PG(18:2/22:6)‐H  0.003  ±  0.000 
PG(42:9)‐H  0.002  ±  0.000 
PG(22:5/22:6)‐H  0.002  ±  0.000 
PG(22:6/22:6)‐H  0.014  ±  0.002 
 





PS(16:0/14:0)‐H  0.002  ±  0.000 
PS(16:0/16:1)‐H  0.063  ±  0.015 
PS(18:0/16:0)‐H  0.004  ±  0.001 
PS(16:0/18:1)‐H  0.387  ±  0.020 
PS(16:0e/18:1)‐H  0.014  ±  0.003 
PS(16:1/18:1)‐H  0.043  ±  0.005 
PS(17:1/18:1)‐H  0.010  ±  0.002 
PS(18:0e/18:1)‐H  0.026  ±  0.006 
PS(18:1/18:2)‐H  0.016  ±  0.001 
PS(16:0/20:4)‐H  0.009  ±  0.001 
PS(19:0/18:1)‐H  0.045  ±  0.008 
PS(17:0/20:4)‐H  0.002  ±  0.000 
PS(18:0/20:1)‐H  0.063  ±  0.014 
PS(18:0/20:2)‐H  0.042  ±  0.007 
PS(18:0/20:3)‐H  0.084  ±  0.010 
PS(18:1/20:2)‐H  0.053  ±  0.004 
PS(18:0/20:4)‐H  0.036  ±  0.002 
PS(18:1/20:3)‐H  0.006  ±  0.001 
PS(18:1/20:4)‐H  0.016  ±  0.003 
PS(18:0/20:5)‐H  0.008  ±  0.001 
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PS(18:1/21:0)‐H  0.012  ±  0.002 
PS(19:0/20:3)‐H  0.005  ±  0.001 
PS(17:0/22:5)‐H  0.004  ±  0.001 
PS(18:1/22:1)‐H  0.020  ±  0.003 
PS(18:0/22:5)‐H  0.013  ±  0.002 
PS(18:1/22:5)‐H  0.028  ±  0.005 
PS(20:3/20:3)‐H  0.003  ±  0.000 
PS(18:1/22:6)‐H  0.018  ±  0.004 
PS(18:1/24:1)‐H  0.006  ±  0.001 
PS(20:0/22:4)‐H  0.002  ±  0.000 
PS(20:0/22:6)‐H  0.023  ±  0.005 
PS(25:0/18:1)‐H  0.002  ±  0.000 
PS(26:0/18:1)‐H  0.016  ±  0.002 
PS(26:1/18:1)‐H  0.023  ±  0.004 
PS(26:1/18:2)‐H  0.005  ±  0.001 
PS(24:0/20:3)‐H  0.016  ±  0.002 
PS(24:1/20:3)‐H  0.002  ±  0.000 
PS(24:0/20:4)‐H  0.008  ±  0.001 
PS(28:0/18:1)‐H  0.001  ±  0.000 
PS(28:1/18:1)‐H  0.009  ±  0.002 
 





SM(d30:1)+H  0.001  ±  0.000 
SM(d31:1)+H  0.002  ±  0.000 
SM(d32:0)+H  0.050  ±  0.013 
SM(d32:1)+H  0.151  ±  0.024 
SM(d32:2)+H  0.003  ±  0.000 
SM(d33:1)+H  0.139  ±  0.029 
SM(d33:2)+H  0.001  ±  0.000 
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SM(d34:0)+H  1.051  ±  0.140 
SM(d34:1)+H  2.946  ±  0.303 
SM(d34:2)+H  0.254  ±  0.040 
SM(d34:3)+H  0.003  ±  0.001 
SM(d34:4)+H  0.023  ±  0.003 
SM(d35:1)+H  0.037  ±  0.005 
SM(d35:4)+H  0.014  ±  0.002 
SM(d36:0)+H  0.034  ±  0.008 
SM(d36:1)+H  0.047  ±  0.003 
SM(d36:2)+H  0.023  ±  0.005 
SM(d18:2/18:1)+H  0.011  ±  0.001 
SM(d36:5)+H  0.024  ±  0.003 
SM(d38:1)+H  0.024  ±  0.003 
SM(d38:5)+H  0.007  ±  0.001 
SM(d39:6)+H  0.004  ±  0.001 
SM(d40:0)+H  0.031  ±  0.007 
SM(d40:1)+H  0.245  ±  0.035 
SM(d40:2)+H  0.048  ±  0.006 
SM(d41:1)+H  0.038  ±  0.007 
SM(d41:2)+H  0.053  ±  0.009 
SM(d42:0)+H  0.040  ±  0.008 
SM(d42:1)+H  0.735  ±  0.122 
SM(d18:1/24:1)+H  1.300  ±  0.151 
SM(d18:0/24:2)+H  0.015  ±  0.003 
SM(d18:1/24:2)+H  0.002  ±  0.000 
SM(d42:3)+H  0.177  ±  0.022 
SM(d18:2/24:1)+H  0.003  ±  0.001 
SM(d42:4)+H  0.023  ±  0.002 
SM(d42:5)+H  0.002  ±  0.000 
SM(d43:1)+H  0.011  ±  0.002 
SM(d43:2)+H  0.017  ±  0.003 
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SM(d18:1/25:3)+H  0.004  ±  0.001 
SM(d43:4)+H  0.006  ±  0.000 
SM(d43:5)+H  0.004  ±  0.000 
SM(d44:0)+H  0.003  ±  0.001 
SM(d44:1)+H  0.029  ±  0.006 
SM(d44:2)+H  0.065  ±  0.012 
SM(d44:3)+H  0.022  ±  0.006 
SM(d18:0/26:3)+H  0.004  ±  0.001 
SM(d18:2/26:2)+H  0.022  ±  0.005 
SM(d18:1/26:3)+H  0.080  ±  0.008 
SM(d18:1/26:4)+H  0.083  ±  0.004 
SM(d44:6)+H  0.005  ±  0.000 
SM(d18:1/28:0)+H  0.004  ±  0.000 
SM(d46:4)+H  0.003  ±  0.001 
SM(d46:5)+H  0.006  ±  0.001 
SM(d48:2)+H  0.007  ±  0.001 
SM(d54:3)+H  0.005  ±  0.000 









TG(16:0/12:0/14:0)+NH4  0.013  ±  0.004 
TG(16:1/12:0/14:0)+NH4  0.002  ±  0.001 
TG(16:0/14:0/14:0)+NH4  0.051  ±  0.016 
TG(18:0e/12:0/14:0)+NH4  0.012  ±  0.003 
TG(16:0/14:0/14:1)+NH4  0.038  ±  0.013 
TG(15:0/14:0/16:0)+NH4  0.005  ±  0.002 
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TG(16:0/14:0/16:0)+NH4  0.162  ±  0.082 
TG(16:0e/14:0/16:0)+NH4  0.058  ±  0.013 
TG(16:0/14:0/16:1)+NH4  0.246  ±  0.065 
TG(16:0e/14:0/16:1)+NH4  0.026  ±  0.005 
TG(16:1/14:0/16:1)+NH4  0.052  ±  0.013 
TG(15:0/16:0/16:0)+NH4  0.023  ±  0.008 
TG(15:0/15:0/17:1)+NH4  0.028  ±  0.004 
TG(16:1/14:0/17:1)+NH4  0.005  ±  0.001 
TG(16:0/16:0/16:0)+NH4  0.387  ±  0.065 
TG(16:0e/16:0/16:0)+NH4  0.155  ±  0.024 
TG(16:0/14:0/18:1)+NH4  0.930  ±  0.132 
TG(18:0e/14:0/16:1)+NH4  0.160  ±  0.032 
TG(16:1/14:0/18:1)+NH4  0.366  ±  0.086 
TG(16:0e/16:1/16:1)+NH4  0.028  ±  0.006 
TG(16:1/16:1/16:1)+NH4  0.033  ±  0.009 
TG(16:0/16:0/17:0)+NH4  0.015  ±  0.003 
TG(16:0/16:0/17:1)+NH4  0.088  ±  0.007 
TG(16:0/16:1/17:1)+NH4  0.047  ±  0.008 
TG(16:1/16:1/17:1)+NH4  0.007  ±  0.002 
TG(18:0/16:0/16:0)+NH4  0.318  ±  0.056 
TG(18:0e/16:0/16:0)+NH4  0.130  ±  0.027 
TG(18:0p/16:0/16:0)+NH4  0.471  ±  0.075 
TG(16:0/16:0/18:1)+NH4  1.553  ±  0.229 
TG(18:1p/16:0/16:0)+NH4  0.117  ±  0.057 
TG(16:0/16:1/18:1)+NH4  1.252  ±  0.156 
TG(16:1/16:1/18:1)+NH4  0.223  ±  0.045 
TG(16:1/16:1/18:2)+NH4  0.016  ±  0.004 
TG(16:0/14:0/20:4)+NH4  0.008  ±  0.001 
TG(18:0/16:0/17:0)+NH4  0.011  ±  0.002 
TG(16:0/17:0/18:1)+NH4  0.044  ±  0.008 
TG(16:0/17:1/18:1)+NH4  0.152  ±  0.019 
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TG(16:1/17:1/18:1)+NH4  0.031  ±  0.003 
TG(18:0/16:0/18:0)+NH4  0.116  ±  0.025 
TG(20:0p/16:0/16:0)+NH4  0.322  ±  0.054 
TG(18:0/16:0/18:1)+NH4  1.105  ±  0.169 
TG(16:0/18:1/18:1)+NH4  2.362  ±  0.336 
TG(16:0e/18:1/18:1)+NH4  0.342  ±  0.050 
TG(18:0p/16:1/18:1)+NH4  0.073  ±  0.011 
TG(16:1/18:1/18:1)+NH4  0.758  ±  0.101 
TG(16:1/18:1/18:2)+NH4  0.087  ±  0.008 
TG(16:0/16:0/20:4)+NH4  0.026  ±  0.005 
TG(18:1/14:0/20:4)+NH4  0.008  ±  0.002 
TG(19:1/16:0/18:0)+NH4  0.049  ±  0.011 
TG(17:0/18:1/18:1)+NH4  0.140  ±  0.023 
TG(18:1/17:1/18:1)+NH4  0.079  ±  0.010 
TG(18:1/17:1/18:2)+NH4  0.011  ±  0.001 
TG(18:0/16:0/20:0)+NH4  0.026  ±  0.007 
TG(16:0e/16:0/22:0)+NH4  0.016  ±  0.003 
TG(18:0/18:0/18:1)+NH4  0.267  ±  0.061 
TG(16:0e/16:0/22:1)+NH4  0.078  ±  0.015 
TG(18:0/18:1/18:1)+NH4  1.112  ±  0.175 
TG(18:0e/18:1/18:1)+NH4  0.151  ±  0.026 
TG(18:0p/18:1/18:1)+NH4  0.083  ±  0.013 
TG(18:1/18:1/18:1)+NH4  1.257  ±  0.187 
TG(16:0e/18:1/20:3)+NH4  0.032  ±  0.001 
TG(16:1/18:1/20:4)+NH4  0.038  ±  0.007 
TG(16:0/16:0/22:6)+NH4  0.024  ±  0.003 
TG(16:0/16:1/22:6)+NH4  0.014  ±  0.005 
TG(16:1/16:1/22:6)+NH4  0.004  ±  0.001 
TG(18:0/18:1/19:0)+NH4  0.018  ±  0.005 
TG(19:1/18:0/18:1)+NH4  0.045  ±  0.007 
TG(19:1/18:1/18:1)+NH4  0.054  ±  0.011 
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TG(19:1/18:1/18:2)+NH4  0.017  ±  0.001 
TG(26:0/14:0/16:0)+NH4  0.031  ±  0.009 
TG(26:1/14:0/16:0)+NH4  0.116  ±  0.035 
TG(16:0e/16:0/24:1)+NH4  0.064  ±  0.012 
TG(18:1p/19:0/19:0)+NH4  0.062  ±  0.012 
TG(16:0/18:1/22:1)+NH4  0.246  ±  0.049 
TG(20:0p/18:1/18:1)+NH4  0.039  ±  0.010 
TG(20:1/18:1/18:1)+NH4  0.339  ±  0.055 
TG(18:1/18:1/20:2)+NH4  0.140  ±  0.028 
TG(16:0e/18:1/22:5)+NH4  0.058  ±  0.008 
TG(16:1/18:1/22:5)+NH4  0.041  ±  0.006 
TG(16:0/18:1/22:6)+NH4  0.066  ±  0.007 
TG(16:0e/18:1/22:6)+NH4  0.043  ±  0.006 
TG(16:1/18:1/22:6)+NH4  0.023  ±  0.003 
TG(25:0/16:0/16:1)+NH4  0.012  ±  0.003 
TG(25:1/16:0/16:1)+NH4  0.022  ±  0.004 
TG(18:1/18:1/21:1)+NH4  0.019  ±  0.002 
TG(26:0/16:0/16:0)+NH4  0.051  ±  0.012 
TG(18:0e/16:0/24:0)+NH4  0.020  ±  0.004 
TG(26:1/16:0/16:0)+NH4  0.167  ±  0.041 
TG(18:0e/16:0/24:1)+NH4  0.052  ±  0.007 
TG(16:0/18:1/24:1)+NH4  0.248  ±  0.061 
TG(16:0e/18:1/24:1)+NH4  0.056  ±  0.011 
TG(18:0p/18:1/22:1)+NH4  0.024  ±  0.005 
TG(18:1/18:1/22:1)+NH4  0.142  ±  0.026 
TG(18:0/18:1/22:3)+NH4  0.048  ±  0.010 
TG(18:1/18:1/22:3)+NH4  0.034  ±  0.004 
TG(18:1/18:1/22:4)+NH4  0.064  ±  0.024 
TG(18:1/18:1/22:6)+NH4  0.055  ±  0.005 
TG(18:1/18:2/22:6)+NH4  0.009  ±  0.001 
TG(27:0/16:0/16:0)+NH4  0.003  ±  0.001 
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TG(27:1/16:0/16:0)+NH4  0.018  ±  0.005 
TG(25:1/16:0/18:1)+NH4  0.024  ±  0.007 
TG(18:1/18:1/23:1)+NH4  0.014  ±  0.003 
TG(26:0/16:0/18:0)+NH4  0.029  ±  0.006 
TG(26:0/16:0/18:1)+NH4  0.218  ±  0.050 
TG(18:1/20:4/22:6)+NH4  0.006  ±  0.001 
TG(26:1/16:0/18:1)+NH4  0.302  ±  0.070 
TG(18:1/18:1/24:1)+NH4  0.199  ±  0.042 
TG(18:1/18:1/24:2)+NH4  0.039  ±  0.008 
TG(20:0/18:1/22:4)+NH4  0.014  ±  0.004 
TG(20:1/18:1/22:5)+NH4  0.028  ±  0.004 
TG(20:1/18:1/22:6)+NH4  0.010  ±  0.002 
TG(29:1/16:0/16:0)+NH4  0.012  ±  0.003 
TG(27:1/16:0/18:1)+NH4  0.025  ±  0.006 
TG(25:1/18:1/18:1)+NH4  0.016  ±  0.005 
TG(28:0/16:0/18:0)+NH4  0.006  ±  0.001 
TG(26:0/18:0/18:1)+NH4  0.091  ±  0.021 
TG(18:1/22:5/22:6)+NH4  0.004  ±  0.000 
TG(26:1/18:0/18:1)+NH4  0.260  ±  0.065 
TG(26:1/18:1/18:1)+NH4  0.178  ±  0.041 
TG(26:1/18:1/18:2)+NH4  0.045  ±  0.010 
TG(18:1/20:3/24:1)+NH4  0.015  ±  0.003 
TG(29:0/16:0/18:1)+NH4  0.005  ±  0.001 
TG(29:1/16:0/18:1)+NH4  0.014  ±  0.004 
TG(27:1/18:1/18:1)+NH4  0.009  ±  0.003 
TG(30:0/16:0/18:1)+NH4  0.022  ±  0.008 
TG(28:0/18:1/18:1)+NH4  0.079  ±  0.018 
TG(20:0e/22:1/22:1)+NH4  0.012  ±  0.003 
TG(28:1/18:1/18:1)+NH4  0.075  ±  0.020 
TG(26:1/18:1/20:2)+NH4  0.019  ±  0.005 
TG(26:1/18:1/20:3)+NH4  0.006  ±  0.002 
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TG(29:1/18:0/18:1)+NH4  0.006  ±  0.002 
TG(29:1/18:1/18:1)+NH4  0.006  ±  0.001 
TG(26:0/16:0/24:1)+NH4  0.015  ±  0.004 
TG(30:0/18:1/18:1)+NH4  0.033  ±  0.010 
TG(30:1/18:1/18:1)+NH4  0.032  ±  0.008 
TG(26:1/18:1/22:6)+NH4  0.003  ±  0.000 
TG(26:0/18:1/24:0)+NH4  0.008  ±  0.002 
TG(26:0/18:1/24:1)+NH4  0.025  ±  0.006 
TG(26:1/18:1/24:1)+NH4  0.024  ±  0.006 
TG(27:1/18:1/24:0)+NH4  0.002  ±  0.001 
TG(27:1/18:1/24:1)+NH4  0.002  ±  0.001 
TG(28:0/18:1/24:0)+NH4  0.004  ±  0.001 
TG(28:1/18:1/24:0)+NH4  0.014  ±  0.004 
TG(26:1/20:1/24:1)+NH4  0.014  ±  0.004 
TG(28:1/18:1/24:2)+NH4  0.004  ±  0.001 
TG(30:1/18:1/24:1)+NH4  0.005  ±  0.001 
 





PA(18:0/16:0)‐H  0.004  ±  0.001 
PA(16:0/18:1)‐H  0.012  ±  0.001 









MG(32:0)+H  0.034  ±  0.000 
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MG(34:0)+H  0.030  ±  0.007 
MG(34:1)+H  0.087  ±  0.010 
MG(36:0)+H  0.003  ±  0.001 
MG(36:1)+H  0.018  ±  0.003 
MG(38:0)+H  0.003  ±  0.001 
 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































APPENDIX E: SUPPLEMENTARY INFORMATION ASSOCIATED WITH CHAPTER 
V: ANTI-TUMORIGENIC PROPERTIES OF OMEGA-3 ENDOCANNABINOID 
EPOXIDES 
 
Supplementary Figure 1: endocannabinoids detected in normal lungs and lungs with OS tumor:  
Figure shows the levels of endocannabinoids and endocannabinoid epoxides in lungs of nude mice 




pmol/g  7,8- 10,11- 13,14- 16,17- 19,20 DHEA EPEA Anandamide 
normal 
lungs 




0 670.97 2393.41 4382.93 51947.03 57211.73 2755.32 235592.78 
error 
(normal) 
0 339.36 230.39 421.43 2042.16 2449.697 196.20 9427.26 
error 
(tumor) 
0 447.27 879.65 1395.30 12721.57 3613.3 821.65 63203.15 
 
 
Supplementary figure 2: endocannabinoids detected in k7m2 murine osteosarcoma cells 
Figure shows the levels of endocannabinoid epoxides in K7M2 murine osteosarcoma cell lines 














Supplementary figure 3: CTB assay all compounds 

















Table 1: Apoptosis assay with parent compounds 


















Table 2: Apoptosis assay HOS cells with Cb1 and cb2 antagonists 




















Table 3: Apoptosis assay 143B cells with Cb1 and cb2 antagonists 




















Table 4: Apoptosis assay MG63 cells with Cb1 and cb2 antagonists 




















Supplementary figure 4: Scratch assay 143B cells 













Supplementary figure 5: Scratch assay MG63 cells 











Supplementary figure 6: Scratch assay HOS cells 











Supplementary figure 7: sEH hydrolysis of amide modified derivatives 












Supplementary figure 8: CTB assay with HUVEC cells 
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Supplementary figure 9: PCR of cannabinoid receptors in cell lines 
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Supplementary Figure 10: Presto Tango assay showing receptor activation of cannabinoid 
receptors 1 and 2 (CNR1 and CNR2) 
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